line,predictions
"Further, the crude hexane and bioactive fraction extracts induced apoptosis in the MDA-MB-231 TNBC cells, like the reference drug cisplatin (17.44%, 17.26% and 20.25%, respectively) compared to untreated cells. ","Further,/O Further,/O the/O crude/O hexane/O hexane/O hexane/O and/O bioactive/O bioactive/O fraction/O extracts/O extracts/O induced/O apoptosis/O apoptosis/O apoptosis/O in/O the/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O TNBC/O TNBC/O cells,/O cells,/O like/O the/O reference/O drug/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O (17.44%,/O (17.44%,/O (17.44%,/O (17.44%,/O (17.44%,/O (17.44%,/O 17.26%/O 17.26%/O 17.26%/O 17.26%/O and/O 20.25%,/O 20.25%,/O 20.25%,/O 20.25%,/O 20.25%,/O respectively)/O respectively)/O compared/O to/O untreated/O untreated/O untreated/O cells./O cells./O"
"Caspase 3 activities confirmed the induction of apoptosis in both cisplatin and the plant crude extracts, while caspase 8 and 9 activities confirmed the activation of both the intrinsic and extrinsic apoptosis pathways. ","Caspase/O Caspase/O Caspase/O Caspase/O 3/O activities/O confirmed/O the/O induction/O of/O apoptosis/O apoptosis/O apoptosis/O in/O both/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O the/O plant/O crude/O extracts,/O extracts,/O extracts,/O while/O caspase/O caspase/O caspase/O 8/O and/O 9/O activities/O confirmed/O the/O activation/O of/O both/O the/O intrinsic/O and/O extrinsic/O extrinsic/O extrinsic/O extrinsic/O apoptosis/O apoptosis/O apoptosis/O pathways./O pathways./O"
"The cells were treated with plant crude extract at 7.8125, 15.625, 31.25, 62.5, 125 and 250 μg/mL and cisplatin (Sigma Aldrich, USA) at 3 μg/mL (as the reference drug). ","The/O cells/O were/O treated/O with/O plant/O crude/O extract/O at/O 7.8125,/O 7.8125,/O 7.8125,/O 7.8125,/O 7.8125,/O 15.625,/O 15.625,/O 15.625,/O 15.625,/O 31.25,/O 31.25,/O 31.25,/O 31.25,/O 62.5,/O 62.5,/O 62.5,/O 62.5,/O 125/O and/O 250/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O and/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O (Sigma/O (Sigma/O Aldrich,/O Aldrich,/O Aldrich,/O Aldrich,/O USA)/O USA)/O at/O 3/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O (as/O (as/O the/O reference/O drug)./O drug)./O drug)./O"
The Annexin V-FITC/Propidium Iodide (PI) apoptosis assay was conducted on MDA-MB 231 TNBC cells that were seeded in 24-well plates at a density of 2.5 × 10⁵  cells/well. ,The/O Annexin/O Annexin/O V-FITC/Propidium/O V-FITC/Propidium/O V-FITC/Propidium/O V-FITC/Propidium/O V-FITC/Propidium/O V-FITC/Propidium/O V-FITC/Propidium/O V-FITC/Propidium/O V-FITC/Propidium/O Iodide/O Iodide/O Iodide/O (PI)/O (PI)/O (PI)/O (PI)/O apoptosis/O apoptosis/O apoptosis/O assay/O assay/O was/O conducted/O on/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O TNBC/O TNBC/O cells/O that/O were/O seeded/O in/O 24-well/O 24-well/O 24-well/O plates/O at/O a/O density/O of/O 2.5/O 2.5/O 2.5/O ×/O 10⁵/O 10⁵/O cells/well./O cells/well./O cells/well./O cells/well./O
"Afterwards, the cells were treated with cisplatin (10 μM/3 μg/mL) and the plant crude extract at their respective IC  values for 48 h. ","Afterwards,/O Afterwards,/O the/O cells/O were/O treated/O with/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O (10/O (10/O μM/3/O μM/3/O μM/3/O μM/3/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O and/O the/O plant/O crude/O extract/O at/O their/O respective/O IC/O IC/O values/O for/O 48/O h./O h./O"
"To measure the activities of Caspase 3, 8, and 9, cells were treated with plant crude extract (IC  values) and cisplatin (3 μg/mL) for 48 h. ","To/O measure/O the/O activities/O of/O Caspase/O Caspase/O Caspase/O Caspase/O 3,/O 3,/O 8,/O 8,/O and/O 9,/O 9,/O cells/O were/O treated/O with/O plant/O crude/O extract/O (IC/O (IC/O (IC/O values)/O values)/O and/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O (3/O (3/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O for/O 48/O h./O h./O"
"Untreated cells (MDA-MB 231), cells treated with the reference drug (cisplatin, 3 μg/mL), and cells treated with   (IC ) were added to the chambers.","Untreated/O Untreated/O Untreated/O cells/O (MDA-MB/O (MDA-MB/O (MDA-MB/O (MDA-MB/O (MDA-MB/O 231),/O 231),/O 231),/O cells/O treated/O with/O the/O reference/O drug/O (cisplatin,/O (cisplatin,/B-CellLine (cisplatin,/O (cisplatin,/O (cisplatin,/O (cisplatin,/O (cisplatin,/O 3/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O and/O cells/O treated/O with/O (IC/O (IC/O (IC/O )/O were/O added/O to/O the/O chambers./O chambers./O"
"The fifth step included stepwise titrations of the uncoupler carbonyl cyanide m-chlorophenylhydrazone CCCP (U) (0.5 μM) to determine noncoupled CI-linked respiration, corresponding to electron transfer system capacity (ETS capacity) with CI-linked substrates.","The/O fifth/O step/O included/O stepwise/O stepwise/O titrations/O titrations/O titrations/O of/O the/O uncoupler/O uncoupler/O uncoupler/O uncoupler/O carbonyl/O carbonyl/O cyanide/O cyanide/O cyanide/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O CCCP/O CCCP/O (U)/O (U)/O (U)/O (0.5/O (0.5/O (0.5/O (0.5/O μM)/O μM)/O μM)/O to/O determine/O noncoupled/O noncoupled/O noncoupled/O noncoupled/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O respiration,/O respiration,/O respiration,/O corresponding/O to/O electron/O transfer/O system/O capacity/O (ETS/O (ETS/O (ETS/O capacity)/O capacity)/O with/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O substrates./O substrates./O"
"Results  crude extract and bioactive fractions against MDA-MB 231 cells An initial pre-screen of the cytotoxic effect of   leaf crude extract against the MDA-MB 231 TNBC cells was done.   leaf crude extract was screened at 250 μg/mL, while cisplatin (reference drug) was screened at 3 μg/mL. ","Results/O crude/O extract/O and/O bioactive/O bioactive/O fractions/O fractions/O against/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O cells/O An/O initial/O pre-screen/O pre-screen/O pre-screen/O of/O the/O cytotoxic/O cytotoxic/O cytotoxic/O cytotoxic/O cytotoxic/O effect/O of/O leaf/O crude/O extract/O against/O the/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O TNBC/O TNBC/O cells/O was/O done./O done./O leaf/O crude/O extract/O was/O screened/O at/O 250/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O while/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O (reference/O (reference/O drug)/O drug)/O was/O screened/O at/O 3/O μg/mL./O μg/mL./O μg/mL./O μg/mL./O μg/mL./O μg/mL./O"
"The plant crude extract showed growth inhibition of 83.40% when screened against MDA-MB 231 cells compared to cisplatin, which showed 78.97% growth inhibition (Fig.  A and Supplementary Fig.  ).","The/O plant/O crude/O extract/O showed/O growth/O inhibition/O inhibition/O of/O 83.40%/O 83.40%/O 83.40%/O 83.40%/O when/O screened/O against/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O cells/O compared/O to/O cisplatin,/B-CellLine cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O which/O showed/O 78.97%/O 78.97%/O 78.97%/O 78.97%/O growth/O inhibition/O inhibition/O (Fig./O (Fig./O (Fig./O (Fig./O A/O and/O Supplementary/O Supplementary/O Supplementary/O Supplementary/O Fig./O Fig./O Fig./O )./O )./O"
"The plant crude extract was screened at concentration range of 7.8125, 15.625, 31.25, 62.5, 125 and 250 μg/mL, while cisplatin was assessed across the concentration range of 0.9375, 1.875, 3.75, 7.5, 15, and 30 μg/mL (Fig.  C and Supplementary Table  ). ","The/O plant/O crude/O extract/O was/O screened/O at/O concentration/O range/O of/O 7.8125,/O 7.8125,/O 7.8125,/O 7.8125,/O 7.8125,/O 15.625,/O 15.625,/O 15.625,/O 15.625,/O 31.25,/O 31.25,/O 31.25,/O 31.25,/O 62.5,/O 62.5,/O 62.5,/O 62.5,/O 125/O and/O 250/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O while/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O was/O assessed/O across/O the/O concentration/O range/O of/O 0.9375,/O 0.9375,/O 0.9375,/O 0.9375,/O 0.9375,/O 1.875,/O 1.875,/O 1.875,/O 1.875,/O 1.875,/O 3.75,/O 3.75,/O 3.75,/O 3.75,/O 7.5,/O 7.5,/O 7.5,/O 7.5,/O 15,/O 15,/O and/O 30/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O (Fig./O (Fig./O (Fig./O (Fig./O C/O and/O Supplementary/O Supplementary/O Supplementary/O Supplementary/O Table/O )./O )./O"
The results indicate that cisplatin was more potent than the crude extract in inhibiting the proliferation of MDA-MB-231 TNBC cells. ,The/O results/O indicate/O that/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O was/O more/O potent/O than/O the/O crude/O extract/O in/O inhibiting/O inhibiting/O inhibiting/O the/O proliferation/O of/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O TNBC/O TNBC/O cells./O cells./O
"1  leaf crude extract, bioactive fractions and cisplatin as reference drug against TNBC. ( A ) Initial cytotoxicity screen of   leaf crude extract against MDA-MB 231 TNBC cells. ( B ) Cytotoxic activity of   and cisplatin against Vero cells line; ( C ) Dose-response curves were constructed to assess the cytotoxicity of   and cisplatin against MDA-MB 231 TNBC cells; ( D ) IC  of the crude leave extracts of  E racemosus ; ( E ). ","1/O leaf/O crude/O extract,/O extract,/O bioactive/O bioactive/O fractions/O fractions/O and/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O as/O reference/O drug/O against/O TNBC./O TNBC./O TNBC./O (/O A/O )/O Initial/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O screen/O of/O leaf/O crude/O extract/O against/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O TNBC/O TNBC/O cells./O cells./O (/O B/O )/O Cytotoxic/O Cytotoxic/O Cytotoxic/O Cytotoxic/O Cytotoxic/O activity/O of/O and/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O against/O Vero/O Vero/O cells/O line;/O line;/O (/O C/O )/O Dose-response/O Dose-response/O Dose-response/O Dose-response/O curves/O were/O constructed/O to/O assess/O the/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O of/O and/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O against/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O TNBC/O TNBC/O cells;/O cells;/O (/O D/O )/O IC/O IC/O of/O the/O crude/O leave/O extracts/O extracts/O of/O E/O racemosus/O racemosus/O racemosus/O ;/O (/O E/O )./O )./O"
"Initial cytotoxicity screen of   bioactive fraction extracts against MDA-MB 231 TNBC cells; ( F ) Cytotoxic activity of the selected bioactive fractions of   (SF2) and cisplatin against Vero cells lines; ( G ) Dose-response curves of the 80% ethyl acetate and 20% hexane of   fraction extract and cisplatin against MDA-MB 231 TNBC ( H  of the crude leave extracts SF2. Results represent the mean ± SD of three technical and biological replicates Full size image The six fractions of   leaf crude extracts (Supplementary Table  ) were also screened against the TNBC cells at concentrations ranging from 62.5 to 250 μg/mL, cisplatin was screened at 3 μg/mL. ","Initial/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O screen/O of/O bioactive/O bioactive/O fraction/O extracts/O extracts/O against/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O TNBC/O TNBC/O cells;/O cells;/O (/O F/O )/O Cytotoxic/O Cytotoxic/O Cytotoxic/O Cytotoxic/O Cytotoxic/O activity/O of/O the/O selected/O bioactive/O bioactive/O fractions/O fractions/O of/O (SF2)/O (SF2)/O (SF2)/O (SF2)/O and/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O against/O Vero/O Vero/O cells/O lines;/O lines;/O (/O G/O )/O Dose-response/O Dose-response/O Dose-response/O Dose-response/O curves/O of/O the/O 80%/O 80%/O ethyl/O ethyl/O acetate/O acetate/O and/O 20%/O 20%/O hexane/O hexane/O hexane/O of/O fraction/O extract/O and/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O against/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O TNBC/O TNBC/O (/O H/O of/O the/O crude/O leave/O extracts/O extracts/O SF2./O SF2./O SF2./O Results/O represent/O the/O mean/O ±/O SD/O of/O three/O technical/O and/O biological/O replicates/O replicates/O Full/O size/O image/O The/O six/O fractions/O fractions/O of/O leaf/O crude/O extracts/O extracts/O (Supplementary/O (Supplementary/O (Supplementary/O (Supplementary/O (Supplementary/O Table/O )/O were/O also/O screened/O against/O the/O TNBC/O TNBC/O cells/O at/O concentrations/O ranging/O from/O 62.5/O 62.5/O 62.5/O to/O 250/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O was/O screened/O at/O 3/O μg/mL./O μg/mL./O μg/mL./O μg/mL./O μg/mL./O μg/mL./O"
"Once again, cisplatin showed a lower IC  value of 2.106 ± 0.09 μg/mL, as was observed with the plant crude extract (Fig.  G-H and Supplementary Table ","Once/O again,/O again,/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O showed/O a/O lower/O IC/O IC/O value/O of/O 2.106/O 2.106/O 2.106/O ±/O 0.09/O 0.09/O 0.09/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O as/O was/O observed/O with/O the/O plant/O crude/O extract/O (Fig./O (Fig./O (Fig./O (Fig./O G-H/O G-H/O G-H/O and/O Supplementary/O Supplementary/O Supplementary/O Supplementary/O Table/O"
Determination of mode of cell death using annexin-V and propidium iodide (PI) staining The mode of cell death in response to treatments with   leaf crude extract and cisplatin was evaluated using the Annexin-V/PI kit from Invitrogen (ThermoFisher Scientific) via flow cytometry. ,Determination/O Determination/O Determination/O of/O mode/O of/O cell/O death/O using/O annexin-V/O annexin-V/O annexin-V/O annexin-V/O annexin-V/O and/O propidium/O propidium/O propidium/O iodide/O iodide/O iodide/O (PI)/O (PI)/O (PI)/O (PI)/O staining/O staining/O The/O mode/O of/O cell/O death/O in/O response/O to/O treatments/O with/O leaf/O crude/O extract/O and/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O was/O evaluated/O using/O the/O Annexin-V/PI/O Annexin-V/PI/O Annexin-V/PI/O Annexin-V/PI/O Annexin-V/PI/O Annexin-V/PI/O Annexin-V/PI/O kit/O from/O Invitrogen/O Invitrogen/O Invitrogen/O Invitrogen/O (ThermoFisher/O (ThermoFisher/O (ThermoFisher/O (ThermoFisher/O (ThermoFisher/O (ThermoFisher/O (ThermoFisher/O Scientific)/O Scientific)/O via/O flow/O cytometry./O cytometry./O cytometry./O cytometry./O cytometry./O
The study’s findings specifically demonstrated that the condition screened   leaf crude extracts induced a similar increase in apoptosis as cisplatin. ,The/O study’s/O study’s/O study’s/O findings/O specifically/O demonstrated/O that/O the/O condition/O screened/O leaf/O crude/O extracts/O extracts/O induced/O a/O similar/O increase/O in/O apoptosis/O apoptosis/O apoptosis/O as/O cisplatin./B-CellLine cisplatin./O cisplatin./O cisplatin./O cisplatin./O cisplatin./O
"However, a higher percentage of necrosis was observed compared to cisplatin and the untreated control.","However,/O However,/O a/O higher/O percentage/O of/O necrosis/O necrosis/O necrosis/O was/O observed/O compared/O to/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O the/O untreated/O untreated/O untreated/O control./O control./O"
4 to  3 μg/mL cisplatin and 12.84 ug/mL   at a concentration of 12.84 ug/mL for 48 h. ,4/O to/O 3/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O 12.84/O 12.84/O 12.84/O ug/mL/O ug/mL/O ug/mL/O ug/mL/O ug/mL/O at/O a/O concentration/O of/O 12.84/O 12.84/O 12.84/O ug/mL/O ug/mL/O ug/mL/O ug/mL/O ug/mL/O for/O 48/O h./O h./O
"5  leaf crude extract, bioactive fraction and cisplatin. ( ) Caspases 3 activity of the hexane crude leaves extract of   and cisplatin; ( ) Caspases 8 activity of the hexane crude leaves extract of  ) Caspases 9 activity of the hexane crude leaves extract of  ) Caspases 3 activity of the bioactive fraction (SF2) of   leaf crude extracts; ( ) Caspases 8 activity of the bioactive fraction (SF2); ( ) Caspases 9 activities of the bioactive fraction (SF2). ","5/O leaf/O crude/O extract,/O extract,/O bioactive/O bioactive/O fraction/O and/O cisplatin./O cisplatin./O cisplatin./O cisplatin./O cisplatin./O cisplatin./O (/O )/O Caspases/O Caspases/O Caspases/O Caspases/O 3/O activity/O of/O the/O hexane/O hexane/O hexane/O crude/O leaves/O extract/O of/O and/O cisplatin;/O cisplatin;/O cisplatin;/O cisplatin;/O cisplatin;/O cisplatin;/O (/O )/O Caspases/O Caspases/O Caspases/O Caspases/O 8/O activity/O of/O the/O hexane/O hexane/O hexane/O crude/O leaves/O extract/O of/O )/O Caspases/O Caspases/O Caspases/O Caspases/O 9/O activity/O of/O the/O hexane/O hexane/O hexane/O crude/O leaves/O extract/O of/O )/O Caspases/O Caspases/O Caspases/O Caspases/O 3/O activity/O of/O the/O bioactive/O bioactive/O fraction/O (SF2)/O (SF2)/O (SF2)/O (SF2)/O of/O leaf/O crude/O extracts;/O extracts;/O extracts;/O (/O )/O Caspases/O Caspases/O Caspases/O Caspases/O 8/O activity/O of/O the/O bioactive/O bioactive/O fraction/O (SF2);/O (SF2);/O (SF2);/O (SF2);/O (SF2);/O (/O )/O Caspases/O Caspases/O Caspases/O Caspases/O 9/O activities/O of/O the/O bioactive/O bioactive/O fraction/O (SF2)./O (SF2)./O (SF2)./O (SF2)./O (SF2)./O"
"The  -values were calculated using the two-tailed student t-test The results suggest   leaves crude extract significantly influences the activity of caspase 8, a pivotal player in the extrinsic apoptotic pathways.   leaves crude extract induced a 0.20-fold increase, while cisplatin showed a slight increase of 0.03-fold in caspase 8 activity compared to the control (1.00-fold) (Fig.  B). ","The/O -values/O -values/O were/O calculated/O using/O the/O two-tailed/O two-tailed/O two-tailed/O student/O t-test/O t-test/O t-test/O The/O results/O suggest/O leaves/O crude/O extract/O significantly/O influences/O the/O activity/O of/O caspase/O caspase/O caspase/O 8,/O 8,/O a/O pivotal/O player/O in/O the/O extrinsic/O extrinsic/O extrinsic/O extrinsic/O apoptotic/O apoptotic/O apoptotic/O apoptotic/O pathways./O pathways./O leaves/O crude/O extract/O induced/O a/O 0.20-fold/O 0.20-fold/O 0.20-fold/O 0.20-fold/O 0.20-fold/O increase,/O increase,/O while/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O showed/O a/O slight/O increase/O of/O 0.03-fold/O 0.03-fold/O 0.03-fold/O 0.03-fold/O 0.03-fold/O in/O caspase/O caspase/O caspase/O 8/O activity/O compared/O to/O the/O control/O (1.00-fold)/O (1.00-fold)/O (1.00-fold)/O (1.00-fold)/O (1.00-fold)/O (1.00-fold)/O (1.00-fold)/O (Fig./O (Fig./O (Fig./O (Fig./O B)./O B)./O B)./O"
"Interestingly,   leaf crude extracts also showed higher caspase 9 activity 0.09-fold when compared to cisplatin and the untreated control, which showed 0.02 and 1.00-fold, respectively (Fig.  C). ","Interestingly,/O Interestingly,/O Interestingly,/O leaf/O crude/O extracts/O extracts/O also/O showed/O higher/O caspase/O caspase/O caspase/O 9/O activity/O 0.09-fold/O 0.09-fold/O 0.09-fold/O 0.09-fold/O 0.09-fold/O when/O compared/O to/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O the/O untreated/O untreated/O untreated/O control,/O control,/O which/O showed/O 0.02/O 0.02/O 0.02/O and/O 1.00-fold,/O 1.00-fold,/O 1.00-fold,/O 1.00-fold,/O 1.00-fold,/O 1.00-fold,/O respectively/O (Fig./O (Fig./O (Fig./O (Fig./O C)./O C)./O C)./O"
"Conversely, cisplatin-treated cells exhibit increased levels of compensatory glycolysis and post-2-DG acidification (650.31 and 242.78 pmol/min, respectively) and a decreased level of basal glycolysis (277.78 pmol/min) in MDA-MB 231 TNBC cells relative to untreated cells (Fig.  A-D). ","Conversely,/O Conversely,/O cisplatin-treated/B-CellLine cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O exhibit/O increased/O levels/O of/O compensatory/O compensatory/O compensatory/O compensatory/O glycolysis/O glycolysis/O glycolysis/O glycolysis/O and/O post-2-DG/O post-2-DG/O post-2-DG/O post-2-DG/O post-2-DG/O post-2-DG/O acidification/O acidification/O (650.31/O (650.31/O (650.31/O (650.31/O and/O 242.78/O 242.78/O 242.78/O pmol/min,/O pmol/min,/O pmol/min,/O pmol/min,/O pmol/min,/O respectively)/O respectively)/O and/O a/O decreased/O level/O of/O basal/O glycolysis/O glycolysis/O glycolysis/O glycolysis/O (277.78/O (277.78/O (277.78/O (277.78/O (277.78/O pmol/min)/O pmol/min)/O pmol/min)/O pmol/min)/O pmol/min)/O in/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O TNBC/O TNBC/O cells/O relative/O to/O untreated/O untreated/O untreated/O cells/O (Fig./O (Fig./O (Fig./O (Fig./O A-D)./O A-D)./O A-D)./O A-D)./O A-D)./O"
"Interestingly, this phenomenon contrasts with the effects of cisplatin treatment, where compensatory glycolysis is similarly elevated but basal glycolysis is reduced. ","Interestingly,/O Interestingly,/O Interestingly,/O this/O phenomenon/O contrasts/O with/O the/O effects/O of/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O treatment,/O treatment,/O where/O compensatory/O compensatory/O compensatory/O compensatory/O glycolysis/O glycolysis/O glycolysis/O glycolysis/O is/O similarly/O elevated/O but/O basal/O glycolysis/O glycolysis/O glycolysis/O glycolysis/O is/O reduced./O reduced./O"
6  leaf crude extracts and cisplatin on MDA-MB TNBC cells. ,6/O leaf/O crude/O extracts/O extracts/O and/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O on/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O TNBC/O TNBC/O cells./O cells./O
"An increase in routine respiration (RO) in cells treated with cisplatin (29.15 pmol·s − 1 ·mL ) compared to untreated cells (10.65 pmol·s ) was observed, and cells treated with   leaf crude extracts showed an elevated level of routine respiration (20.46 pmol·s ). ","An/O increase/O in/O routine/O respiration/O respiration/O (RO)/O (RO)/O (RO)/O (RO)/O in/O cells/O treated/O with/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O (29.15/O (29.15/O (29.15/O (29.15/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O −/O 1/O ·mL/O ·mL/O ·mL/O )/O compared/O to/O untreated/O untreated/O untreated/O cells/O (10.65/O (10.65/O (10.65/O (10.65/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O )/O was/O observed,/O observed,/O and/O cells/O treated/O with/O leaf/O crude/O extracts/O extracts/O showed/O an/O elevated/O level/O of/O routine/O respiration/O respiration/O (20.46/O (20.46/O (20.46/O (20.46/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O )./O )./O"
"Both treatment groups demonstrated significantly higher leak respiration (LR) compared to untreated cells (control), with cisplatin-treated cells (64.06 pmol·s ) and   leaf crude extract treated cells (67.77 pmol·s ) showing a considerable elevation in leak respiration, whereas untreated cells recorded a relatively lower value (17.75 pmol·s","Both/O treatment/O groups/O demonstrated/O significantly/O higher/O leak/O respiration/O respiration/O (LR)/O (LR)/O (LR)/O (LR)/O compared/O to/O untreated/O untreated/O untreated/O cells/O (control),/O (control),/O (control),/O (control),/O with/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O (64.06/O (64.06/O (64.06/O (64.06/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O )/O and/O leaf/O crude/O extract/O treated/O cells/O (67.77/O (67.77/O (67.77/O (67.77/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O )/O showing/O a/O considerable/O elevation/O in/O leak/O respiration,/O respiration,/O respiration,/O whereas/O untreated/O untreated/O untreated/O cells/O recorded/O a/O relatively/O lower/O value/O (17.75/O (17.75/O (17.75/O (17.75/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O"
"In addition, Cytochrome-C (Cyt-C) expression was increased in both cisplatin and   leaf crude extract treated cells (34.29 pmol·s  and 32.30 pmol·s  respectively). ","In/O addition,/O addition,/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O expression/O was/O increased/O in/O both/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O leaf/O crude/O extract/O treated/O cells/O (34.29/O (34.29/O (34.29/O (34.29/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O and/O 32.30/O 32.30/O 32.30/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O respectively)./O respectively)./O respectively)./O"
"Interestingly, Complex-II linked respiration (C-II) demonstrated increased levels in cisplatin-treated cells (37.61 pmol·s ), further emphasising the alterations in mitochondrial activity.","Interestingly,/O Interestingly,/O Interestingly,/O Complex-II/O Complex-II/O Complex-II/O linked/O respiration/O respiration/O (C-II)/O (C-II)/O (C-II)/O (C-II)/O (C-II)/O demonstrated/O increased/O levels/O in/O cisplatin-treated/B-CellLine cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O (37.61/O (37.61/O (37.61/O (37.61/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O ),/O ),/O further/O emphasising/O emphasising/O the/O alterations/O in/O mitochondrial/O activity./O activity./O"
"The results of the glycerophosphate dehydrogenase flux showed an increase in both treatment groups, with cisplatin-treated cells (37.98 pmol·s ) showing the most pronounced effect ( , 26.18 pmol·s ). ","The/O results/O of/O the/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O flux/O showed/O an/O increase/O in/O both/O treatment/O groups,/O groups,/O with/O cisplatin-treated/B-CellLine cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O (37.98/O (37.98/O (37.98/O (37.98/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O )/O showing/O the/O most/O pronounced/O effect/O (/O ,/O 26.18/O 26.18/O 26.18/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O )./O )./O"
"Complex-IV (C-IV) showed increased activity in the cisplatin-treated cells (90.55 pmol·s ), while   leaf crude extract (51.71 pmol·s ) showed a moderate effect when compared to the untreated cells (66.52 pmol·s ). ","Complex-IV/O Complex-IV/O Complex-IV/O (C-IV)/O (C-IV)/O (C-IV)/O (C-IV)/O (C-IV)/O showed/O increased/O activity/O in/O the/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O (90.55/O (90.55/O (90.55/O (90.55/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O ),/O ),/O while/O leaf/O crude/O extract/O (51.71/O (51.71/O (51.71/O (51.71/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O )/O showed/O a/O moderate/O effect/O when/O compared/O to/O the/O untreated/O untreated/O untreated/O cells/O (66.52/O (66.52/O (66.52/O (66.52/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O )./O )./O"
"These findings suggest a complex interplay between cisplatin,   leaf crude extract, and mitochondrial activity within MDA-MB 231 TNBC cells (Fig.  ). ","These/O findings/O suggest/O a/O complex/O interplay/O interplay/O between/O cisplatin,/B-CellLine cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O leaf/O crude/O extract,/O extract,/O and/O mitochondrial/O activity/O within/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O TNBC/O TNBC/O cells/O (Fig./O (Fig./O (Fig./O (Fig./O )./O )./O"
"In the presence of cisplatin and   leaves crude extract, the P/E ratio showed a slight decrease of 0.93 ± 0.85 and 0.89 ± 0.60, respectively, implying a possible effect on the efficiency of mitochondrial oxidative phosphorylation. ","In/O the/O presence/O of/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O leaves/O crude/O extract,/O extract,/O the/O P/E/O P/E/O P/E/O ratio/O showed/O a/O slight/O decrease/O of/O 0.93/O 0.93/O 0.93/O ±/O 0.85/O 0.85/O 0.85/O and/O 0.89/O 0.89/O 0.89/O ±/O 0.60,/O 0.60,/O 0.60,/O 0.60,/O respectively,/O respectively,/O implying/O a/O possible/O effect/O on/O the/O efficiency/O of/O mitochondrial/O oxidative/O oxidative/O oxidative/O oxidative/O phosphorylation./O phosphorylation./O phosphorylation./O phosphorylation./O phosphorylation./O phosphorylation./O"
"An MTT assay was used to evaluate the impact of these isolated phytochemicals on cell viability across multiple cell lines, including MCF-7 (breast cancer), A549 lung cancer, HepG2 liver cancer, and normal HEK 293 cell lines. ","An/O MTT/O MTT/O assay/O assay/O was/O used/O to/O evaluate/O the/O impact/O of/O these/O isolated/O phytochemicals/O phytochemicals/O phytochemicals/O phytochemicals/O phytochemicals/O on/O cell/O viability/O viability/O across/O multiple/O cell/O lines,/O lines,/O including/O MCF-7/B-CellLine MCF-7/O MCF-7/O MCF-7/O (breast/O (breast/O cancer),/O cancer),/O cancer),/O A549/B-CellLine A549/O A549/O A549/O lung/O cancer,/O cancer,/O HepG2/O HepG2/O HepG2/O HepG2/O liver/O cancer,/O cancer,/O and/O normal/O HEK/O HEK/O HEK/O 293/O 293/O cell/O lines./O lines./O"
"Here, Nthambeleni, 2008 [ ] investigated the potential of crude extracts derived from  Eriocephalus tenuifolius E. tenuifolius , which belongs to the same botanical family and genus as  ) and its isolated compounds against a panel of human cell lines, including renal (TK10), melanoma (UACC62) and breast (MCF 7) cancer cell lines. ","Here,/O Here,/O Nthambeleni,/O Nthambeleni,/O Nthambeleni,/O Nthambeleni,/O Nthambeleni,/O 2008/O [/O ]/O investigated/O the/O potential/O of/O crude/O extracts/O extracts/O derived/O from/O Eriocephalus/O Eriocephalus/O Eriocephalus/O Eriocephalus/O Eriocephalus/O tenuifolius/O tenuifolius/O tenuifolius/O tenuifolius/O E./O E./O tenuifolius/O tenuifolius/O tenuifolius/O tenuifolius/O ,/O which/O belongs/O to/O the/O same/O botanical/O family/O and/O genus/O as/O )/O and/O its/O isolated/O compounds/O against/O a/O panel/O of/O human/O cell/O lines,/O lines,/O including/O renal/O renal/O (TK10),/O (TK10),/B-CellLine (TK10),/O (TK10),/O (TK10),/O (TK10),/O melanoma/O melanoma/O melanoma/O (UACC62)/O (UACC62)/O (UACC62)/O (UACC62)/O (UACC62)/O (UACC62)/O (UACC62)/O and/O breast/O (MCF/O (MCF/B-CellLine (MCF/O 7)/O 7)/O cancer/O cell/O lines./O lines./O"
"In comparison, the control drug cisplatin, at a concentration of 3 μg/mL, demonstrated a higher growth inhibition rate of 62.55% against Vero cells (Fig.  ). ","In/O comparison,/O comparison,/O the/O control/O drug/O cisplatin,/B-CellLine cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O at/O a/O concentration/O of/O 3/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O μg/mL,/O demonstrated/O a/O higher/O growth/O inhibition/O inhibition/O rate/O of/O 62.55%/O 62.55%/O 62.55%/O 62.55%/O against/O Vero/O Vero/O cells/O (Fig./O (Fig./O (Fig./O (Fig./O )./O )./O"
"In the current study, the administration of cisplatin (3 μg/mL) exhibited a significant increase in both early (20.25 ± 1.43) and late apoptosis (7.29 ± 0.89) within TNBC cells, thereby emphasising its effectiveness in promoting programmed cell death. ","In/O the/O current/O study,/O study,/O the/O administration/O of/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O (3/O (3/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O exhibited/O a/O significant/O increase/O in/O both/O early/O (20.25/O (20.25/O (20.25/O (20.25/O ±/O 1.43)/O 1.43)/O 1.43)/O 1.43)/O and/O late/O apoptosis/O apoptosis/O apoptosis/O (7.29/O (7.29/O (7.29/O (7.29/O ±/O 0.89)/O 0.89)/O 0.89)/O 0.89)/O within/O TNBC/O TNBC/O cells,/O cells,/O thereby/O emphasising/O emphasising/O its/O effectiveness/O in/O promoting/O programmed/O cell/O death./O death./O"
"The noteworthy role of   fraction and cisplatin in enhancing the incidence of necrosis (8.24 ± 1.12, 3.06 ± 1.76 and 0.89 ± 1.02, respectively) necessitates attention (Figs.  ). ","The/O noteworthy/O role/O of/O fraction/O and/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O in/O enhancing/O the/O incidence/O of/O necrosis/O necrosis/O necrosis/O (8.24/O (8.24/O (8.24/O (8.24/O ±/O 1.12,/O 1.12,/O 1.12,/O 1.12,/O 3.06/O 3.06/O 3.06/O ±/O 1.76/O 1.76/O 1.76/O and/O 0.89/O 0.89/O 0.89/O ±/O 1.02,/O 1.02,/O 1.02,/O 1.02,/O respectively)/O respectively)/O necessitates/O necessitates/O necessitates/O necessitates/O attention/O (Figs./O (Figs./O (Figs./O (Figs./O )./O )./O"
"The current study investigated the activity of caspase-3, caspase-8, and caspase-9 in MDA-MB 231 TNBC cells when treated with   leaf crude extracts, fraction SF2 and cisplatin (Fig.  A-F). ","The/O current/O study/O investigated/O the/O activity/O of/O caspase-3,/O caspase-3,/O caspase-3,/O caspase-3,/O caspase-3,/O caspase-3,/O caspase-8,/O caspase-8,/O caspase-8,/O caspase-8,/O caspase-8,/O caspase-8,/O and/O caspase-9/O caspase-9/O caspase-9/O caspase-9/O caspase-9/O in/O MDA-MB/O MDA-MB/O MDA-MB/O MDA-MB/O 231/O TNBC/O TNBC/O cells/O when/O treated/O with/O leaf/O crude/O extracts,/O extracts,/O extracts,/O fraction/O SF2/O SF2/O and/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O (Fig./O (Fig./O (Fig./O (Fig./O A-F)./O A-F)./O A-F)./O A-F)./O A-F)./O"
"In comparison, the control group maintained a baseline caspase-3 activity level of 1.00, and cisplatin showed similar activity as the control. ","In/O comparison,/O comparison,/O the/O control/O group/O maintained/O a/O baseline/O baseline/O caspase-3/O caspase-3/O caspase-3/O caspase-3/O caspase-3/O activity/O level/O of/O 1.00,/O 1.00,/O 1.00,/O 1.00,/O and/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O showed/O similar/O activity/O as/O the/O control./O control./O"
The present study’s findings highlight the dynamic alterations in cellular respiration and mitochondrial function in MDA-MB-231 TNBC cells following treatment with   leaf crude extract and cisplatin (Fig.  ). ,The/O present/O study’s/O study’s/O study’s/O findings/O highlight/O the/O dynamic/O alterations/O in/O cellular/O respiration/O respiration/O and/O mitochondrial/O function/O in/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O TNBC/O TNBC/O cells/O following/O treatment/O with/O leaf/O crude/O extract/O and/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O (Fig./O (Fig./O (Fig./O (Fig./O )./O )./O
"Firstly, the substantial increase in routine respiration observed in cisplatin-treated cells signifies a heightened basal metabolic activity, which might be attributed to the cellular response to cisplatin-induced stress. ","Firstly,/O Firstly,/O Firstly,/O the/O substantial/O increase/O in/O routine/O respiration/O respiration/O observed/O in/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O signifies/O signifies/O a/O heightened/O basal/O metabolic/O activity,/O activity,/O which/O might/O be/O attributed/O to/O the/O cellular/O response/O to/O cisplatin-induced/O cisplatin-induced/O cisplatin-induced/O cisplatin-induced/O cisplatin-induced/O cisplatin-induced/O cisplatin-induced/O stress./O stress./O"
"Moreover, the results involving Glycerophosphate dehydrogenase activity showed substantial increases in both treatment groups, particularly in cisplatin-treated cells, suggesting a metabolic shift influenced by the treatments. ","Moreover,/O Moreover,/O the/O results/O involving/O Glycerophosphate/O Glycerophosphate/O Glycerophosphate/O Glycerophosphate/O Glycerophosphate/O Glycerophosphate/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O activity/O showed/O substantial/O increases/O in/O both/O treatment/O groups,/O groups,/O particularly/O in/O cisplatin-treated/B-CellLine cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells,/O cells,/O suggesting/O a/O metabolic/O shift/O influenced/O by/O the/O treatments./O treatments./O"
"Notably, Complex-IV activity exhibited an increase in cisplatin-treated cells, while   leaf crude extract treatment displayed a moderate effect, suggesting distinct responses in mitochondrial respiration between the two treatments. ","Notably,/O Notably,/O Notably,/O Complex-IV/O Complex-IV/O Complex-IV/O activity/O exhibited/O an/O increase/O in/O cisplatin-treated/B-CellLine cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells,/O cells,/O while/O leaf/O crude/O extract/O treatment/O displayed/O a/O moderate/O effect,/O effect,/O suggesting/O distinct/O responses/O in/O mitochondrial/O respiration/O respiration/O between/O the/O two/O treatments./O treatments./O"
"The fifth step included stepwise titrations of the uncoupler carbonyl cyanide m-chlorophenylhydrazone CCCP (U) (0.5 μM) to determine noncoupled CI-linked respiration, corresponding to electron transfer system capacity (ETS capacity) with CI-linked substrates.","The/O fifth/O step/O included/O stepwise/O stepwise/O titrations/O titrations/O titrations/O of/O the/O uncoupler/O uncoupler/O uncoupler/O uncoupler/O carbonyl/O carbonyl/O cyanide/O cyanide/O cyanide/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O CCCP/O CCCP/O (U)/O (U)/O (U)/O (0.5/O (0.5/O (0.5/O (0.5/O μM)/O μM)/O μM)/O to/O determine/O noncoupled/O noncoupled/O noncoupled/O noncoupled/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O respiration,/O respiration,/O respiration,/O corresponding/O to/O electron/O transfer/O system/O capacity/O (ETS/O (ETS/O (ETS/O capacity)/O capacity)/O with/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O substrates./O substrates./O"
"The fifth step included stepwise titrations of the uncoupler carbonyl cyanide m-chlorophenylhydrazone CCCP (U) (0.5 μM) to determine noncoupled CI-linked respiration, corresponding to electron transfer system capacity (ETS capacity) with CI-linked substrates.","The/O fifth/O step/O included/O stepwise/O stepwise/O titrations/O titrations/O titrations/O of/O the/O uncoupler/O uncoupler/O uncoupler/O uncoupler/O carbonyl/O carbonyl/O cyanide/O cyanide/O cyanide/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O CCCP/O CCCP/O (U)/O (U)/O (U)/O (0.5/O (0.5/O (0.5/O (0.5/O μM)/O μM)/O μM)/O to/O determine/O noncoupled/O noncoupled/O noncoupled/O noncoupled/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O respiration,/O respiration,/O respiration,/O corresponding/O to/O electron/O transfer/O system/O capacity/O (ETS/O (ETS/O (ETS/O capacity)/O capacity)/O with/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O substrates./O substrates./O"
"The fifth step included stepwise titrations of the uncoupler carbonyl cyanide m-chlorophenylhydrazone CCCP (U) (0.5 μM) to determine noncoupled CI-linked respiration, corresponding to electron transfer system capacity (ETS capacity) with CI-linked substrates.","The/O fifth/O step/O included/O stepwise/O stepwise/O titrations/O titrations/O titrations/O of/O the/O uncoupler/O uncoupler/O uncoupler/O uncoupler/O carbonyl/O carbonyl/O cyanide/O cyanide/O cyanide/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O CCCP/O CCCP/O (U)/O (U)/O (U)/O (0.5/O (0.5/O (0.5/O (0.5/O μM)/O μM)/O μM)/O to/O determine/O noncoupled/O noncoupled/O noncoupled/O noncoupled/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O respiration,/O respiration,/O respiration,/O corresponding/O to/O electron/O transfer/O system/O capacity/O (ETS/O (ETS/O (ETS/O capacity)/O capacity)/O with/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O substrates./O substrates./O"
"The fifth step included stepwise titrations of the uncoupler carbonyl cyanide m-chlorophenylhydrazone CCCP (U) (0.5 μM) to determine noncoupled CI-linked respiration, corresponding to electron transfer system capacity (ETS capacity) with CI-linked substrates.","The/O fifth/O step/O included/O stepwise/O stepwise/O titrations/O titrations/O titrations/O of/O the/O uncoupler/O uncoupler/O uncoupler/O uncoupler/O carbonyl/O carbonyl/O cyanide/O cyanide/O cyanide/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O m-chlorophenylhydrazone/O CCCP/O CCCP/O (U)/O (U)/O (U)/O (0.5/O (0.5/O (0.5/O (0.5/O μM)/O μM)/O μM)/O to/O determine/O noncoupled/O noncoupled/O noncoupled/O noncoupled/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O respiration,/O respiration,/O respiration,/O corresponding/O to/O electron/O transfer/O system/O capacity/O (ETS/O (ETS/O (ETS/O capacity)/O capacity)/O with/O CI-linked/B-CellLine CI-linked/O CI-linked/O CI-linked/O substrates./O substrates./O"
"In addition, Cytochrome-C (Cyt-C) expression was increased in both cisplatin and ","In/O addition,/O addition,/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O expression/O was/O increased/O in/O both/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O"
"The results of the glycerophosphate dehydrogenase flux showed an increase in both treatment groups, with cisplatin-treated cells (37.98 pmol·s","The/O results/O of/O the/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O flux/O showed/O an/O increase/O in/O both/O treatment/O groups,/O groups,/O with/O cisplatin-treated/B-CellLine cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O (37.98/O (37.98/O (37.98/O (37.98/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O"
"In addition, Cytochrome-C (Cyt-C) expression was increased in both cisplatin and ","In/O addition,/O addition,/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O expression/O was/O increased/O in/O both/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O"
"The results of the glycerophosphate dehydrogenase flux showed an increase in both treatment groups, with cisplatin-treated cells (37.98 pmol·s","The/O results/O of/O the/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O flux/O showed/O an/O increase/O in/O both/O treatment/O groups,/O groups,/O with/O cisplatin-treated/B-CellLine cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O (37.98/O (37.98/O (37.98/O (37.98/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O"
"In addition, Cytochrome-C (Cyt-C) expression was increased in both cisplatin and ","In/O addition,/O addition,/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O expression/O was/O increased/O in/O both/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O"
"The results of the glycerophosphate dehydrogenase flux showed an increase in both treatment groups, with cisplatin-treated cells (37.98 pmol·s","The/O results/O of/O the/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O flux/O showed/O an/O increase/O in/O both/O treatment/O groups,/O groups,/O with/O cisplatin-treated/B-CellLine cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O (37.98/O (37.98/O (37.98/O (37.98/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O"
"In addition, Cytochrome-C (Cyt-C) expression was increased in both cisplatin and ","In/O addition,/O addition,/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O Cytochrome-C/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O (Cyt-C)/O expression/O was/O increased/O in/O both/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O and/O"
"The results of the glycerophosphate dehydrogenase flux showed an increase in both treatment groups, with cisplatin-treated cells (37.98 pmol·s","The/O results/O of/O the/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O glycerophosphate/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O dehydrogenase/O flux/O showed/O an/O increase/O in/O both/O treatment/O groups,/O groups,/O with/O cisplatin-treated/B-CellLine cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cisplatin-treated/O cells/O (37.98/O (37.98/O (37.98/O (37.98/O pmol·s/O pmol·s/O pmol·s/O pmol·s/O"
MCF7 cell line was from the laboratory of Dr. ,MCF7/B-CellLine MCF7/O MCF7/O cell/O line/O was/O from/O the/O laboratory/O of/O Dr./O Dr./O
The SUM44PE cell line was purchased from BioIVT (Catalog: HUMANSUM-0003016). ,The/O SUM44PE/B-CellLine SUM44PE/B-CellLine SUM44PE/B-CellLine SUM44PE/O SUM44PE/O cell/O line/O was/O purchased/O from/O BioIVT/O BioIVT/O BioIVT/O BioIVT/O BioIVT/O (Catalog:/O (Catalog:/O (Catalog:/O (Catalog:/O HUMANSUM-0003016)./O HUMANSUM-0003016)./O HUMANSUM-0003016)./O HUMANSUM-0003016)./O HUMANSUM-0003016)./O HUMANSUM-0003016)./O HUMANSUM-0003016)./O HUMANSUM-0003016)./O HUMANSUM-0003016)./O HUMANSUM-0003016)./O HUMANSUM-0003016)./O
"Dulbecco’s modified Eagle’s medium (DMEM) with high glucose (Hyclone #SH30081.01) was supplemented with 10% fetal bovine serum (FBS, Omega Scientific #FB-01) and 1% Pen Strep Glutamine (PSG, Life Technologies #10378-016) to prepare the complete media for MCF7 cell culturing. ","Dulbecco’s/O Dulbecco’s/O Dulbecco’s/O Dulbecco’s/O Dulbecco’s/O Dulbecco’s/O modified/O Eagle’s/O Eagle’s/O Eagle’s/O medium/O (DMEM)/O (DMEM)/O (DMEM)/O (DMEM)/O (DMEM)/O with/O high/O glucose/O (Hyclone/O (Hyclone/O (Hyclone/O (Hyclone/O (Hyclone/O #SH30081.01)/O #SH30081.01)/O #SH30081.01)/O #SH30081.01)/O #SH30081.01)/O #SH30081.01)/O #SH30081.01)/O #SH30081.01)/O #SH30081.01)/O was/O supplemented/O with/O 10%/O 10%/O fetal/O fetal/O bovine/O bovine/O bovine/O serum/O (FBS,/O (FBS,/O (FBS,/O (FBS,/O Omega/O Scientific/O #FB-01)/O #FB-01)/O #FB-01)/O #FB-01)/O #FB-01)/O #FB-01)/O and/O 1%/O 1%/O Pen/O Strep/O Strep/O Strep/O Glutamine/O Glutamine/O Glutamine/O (PSG,/O (PSG,/O (PSG,/O (PSG,/O Life/O Technologies/O #10378-016)/O #10378-016)/O #10378-016)/O #10378-016)/O #10378-016)/O #10378-016)/O #10378-016)/O #10378-016)/O to/O prepare/O the/O complete/O media/O for/O MCF7/B-CellLine MCF7/O MCF7/O cell/O culturing./O culturing./O culturing./O"
"Ham’s F-12 (Life Technologies #11765054) was supplemented with 1 g/L Bovine Serum Albumin (BSA, Sigma Aldrich #A8806), 5 mM of Ethanolamine (Sigma Aldrich #E0135), 10 mM of HEPES (Sigma Aldrich H3375), 1 μg/mL of Hydrocortisone (Sigma Aldrich #H4001), 5 μg/mL of Insulin (Sigma Aldrich #I9278), 50 nM of Sodium Selenite (Sigma Aldrich #S9133), 5 μg/mL of apo-Transferrin (Sigma Aldrich #T2252), 10 nM of Triiodo Thyronine (T3, Sigma Aldrich #T5516), and 2% FBS to prepare the complete media for the SUM44PE cell line. ","Ham’s/O Ham’s/O Ham’s/O F-12/O F-12/O F-12/O (Life/O (Life/O Technologies/O #11765054)/O #11765054)/O #11765054)/O #11765054)/O #11765054)/O #11765054)/O #11765054)/O was/O supplemented/O with/O 1/O g/L/O g/L/O g/L/O Bovine/O Bovine/O Bovine/O Serum/O Serum/O Albumin/O Albumin/O (BSA,/O (BSA,/O (BSA,/O (BSA,/O Sigma/O Aldrich/O Aldrich/O Aldrich/O #A8806),/O #A8806),/O #A8806),/O #A8806),/O #A8806),/O #A8806),/O #A8806),/O 5/O mM/O mM/O of/O Ethanolamine/O Ethanolamine/O Ethanolamine/O (Sigma/O (Sigma/O Aldrich/O Aldrich/O Aldrich/O #E0135),/O #E0135),/O #E0135),/O #E0135),/O #E0135),/O #E0135),/O 10/O mM/O mM/O of/O HEPES/O HEPES/O HEPES/O (Sigma/O (Sigma/O Aldrich/O Aldrich/O Aldrich/O H3375),/O H3375),/O H3375),/O H3375),/O H3375),/O 1/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O of/O Hydrocortisone/O Hydrocortisone/O Hydrocortisone/O Hydrocortisone/O Hydrocortisone/O (Sigma/O (Sigma/O Aldrich/O Aldrich/O Aldrich/O #H4001),/O #H4001),/O #H4001),/O #H4001),/O #H4001),/O #H4001),/O 5/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O of/O Insulin/O Insulin/O Insulin/O (Sigma/O (Sigma/O Aldrich/O Aldrich/O Aldrich/O #I9278),/O #I9278),/O #I9278),/O #I9278),/O #I9278),/O #I9278),/O #I9278),/O 50/O nM/O nM/O of/O Sodium/O Sodium/O Selenite/O Selenite/O Selenite/O (Sigma/O (Sigma/O Aldrich/O Aldrich/O Aldrich/O #S9133),/O #S9133),/O #S9133),/O #S9133),/O #S9133),/O #S9133),/O #S9133),/O 5/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O of/O apo-Transferrin/O apo-Transferrin/O apo-Transferrin/O apo-Transferrin/O apo-Transferrin/O (Sigma/O (Sigma/O Aldrich/O Aldrich/O Aldrich/O #T2252),/O #T2252),/O #T2252),/O #T2252),/O #T2252),/O #T2252),/O #T2252),/O 10/O nM/O nM/O of/O Triiodo/O Triiodo/O Triiodo/O Thyronine/O Thyronine/O Thyronine/O Thyronine/O (T3,/O (T3,/O (T3,/O (T3,/O Sigma/O Aldrich/O Aldrich/O Aldrich/O #T5516),/O #T5516),/O #T5516),/O #T5516),/O #T5516),/O #T5516),/O and/O 2%/O 2%/O FBS/O FBS/O to/O prepare/O the/O complete/O media/O for/O the/O SUM44PE/O SUM44PE/O SUM44PE/O SUM44PE/O SUM44PE/O cell/O line./O line./O"
"DfAd-GFP or Ad-GFP were added to the cells (day 1) and incubated at 37 °C and 5% CO . GFP fluorescence intensities were measured using a Tecan F PLEX Infinite 200 Pro microplate reader (Tecan Group Ltd., Männedorf, Switzerland) on day 4 for human primary breast cancer cells, MCF7, SUM44PE, and MDA-MB-231 cells.","DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O or/O Ad-GFP/O Ad-GFP/O Ad-GFP/O Ad-GFP/O were/O added/O to/O the/O cells/O (day/O (day/O 1)/O 1)/O and/O incubated/O incubated/O incubated/O incubated/O at/O 37/O °C/O and/O 5%/O 5%/O CO/O ./O GFP/O GFP/O fluorescence/O fluorescence/O fluorescence/O intensities/O intensities/O intensities/O were/O measured/O using/O a/O Tecan/O Tecan/O F/O PLEX/O PLEX/O PLEX/O Infinite/O 200/O Pro/O microplate/O microplate/O reader/O (Tecan/O (Tecan/O (Tecan/O Group/O Ltd.,/O Ltd.,/O Ltd.,/O Männedorf,/O Männedorf,/O Männedorf,/O Männedorf,/O Männedorf,/O Switzerland)/O Switzerland)/O on/O day/O 4/O for/O human/O primary/O breast/O cancer/O cells,/O cells,/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O SUM44PE,/B-CellLine SUM44PE,/B-CellLine SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O and/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O cells./O cells./O"
"3 ) CAR IHC of MCF7 shows negative CAR expression in membrane and cytoplasm. ( ) CAR IHC of SUM44PE shows negative CAR expression in membrane and punctate cytoplasmic expression. ( ) CAR IHC of MDA-MB-231 show positive CAR expression in membrane and some cytoplasmic expression. ( ) Transduction efficiency of MCF7, a CAR-negative IDC cell line. ( ) Transduction efficiency of SUM44PE, a membrane CAR-negative ILC cell line. ( ) Transduction efficiency of MDA-MB-231, a membrane CAR-positive IDC cell line. ","3/O )/O CAR/O CAR/O IHC/O IHC/O of/O MCF7/B-CellLine MCF7/O MCF7/O shows/O negative/O CAR/O CAR/O expression/O in/O membrane/O and/O cytoplasm./O cytoplasm./O cytoplasm./O cytoplasm./O cytoplasm./O cytoplasm./O (/O )/O CAR/O CAR/O IHC/O IHC/O of/O SUM44PE/O SUM44PE/O SUM44PE/O SUM44PE/O SUM44PE/O shows/O negative/O CAR/O CAR/O expression/O in/O membrane/O and/O punctate/O punctate/O punctate/O cytoplasmic/O cytoplasmic/O cytoplasmic/O cytoplasmic/O cytoplasmic/O expression./O expression./O (/O )/O CAR/O CAR/O IHC/O IHC/O of/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O show/O positive/O CAR/O CAR/O expression/O in/O membrane/O and/O some/O cytoplasmic/O cytoplasmic/O cytoplasmic/O cytoplasmic/O cytoplasmic/O expression./O expression./O (/O )/O Transduction/O Transduction/O efficiency/O of/O MCF7,/O MCF7,/O MCF7,/O MCF7,/O a/O CAR-negative/O CAR-negative/O CAR-negative/O CAR-negative/O IDC/O IDC/O cell/O line./O line./O (/O )/O Transduction/O Transduction/O efficiency/O of/O SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O a/O membrane/O CAR-negative/O CAR-negative/O CAR-negative/O CAR-negative/O ILC/O ILC/O cell/O line./O line./O (/O )/O Transduction/O Transduction/O efficiency/O of/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O a/O membrane/O CAR-positive/O CAR-positive/O CAR-positive/O CAR-positive/O IDC/O IDC/O cell/O line./O line./O"
Error bars are standard error of the mean (SEM) ,Error/O Error/O Error/O bars/O are/O standard/O error/O of/O the/O mean/O (SEM)/O (SEM)/O (SEM)/O (SEM)/O
"The cell lines used were MCF7, a CAR-negative IDC cell line, MDA-MB-231, a high-CAR IDC cell line and SUM44PE is an ILC cell line. ","The/O cell/O lines/O used/O were/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O a/O CAR-negative/O CAR-negative/O CAR-negative/O CAR-negative/O IDC/O IDC/O cell/O line,/O line,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O a/O high-CAR/O high-CAR/O high-CAR/O high-CAR/O IDC/O IDC/O cell/O line/O and/O SUM44PE/B-CellLine SUM44PE/B-CellLine SUM44PE/O SUM44PE/O SUM44PE/O is/O an/O ILC/O ILC/O cell/O line./O line./O"
CAR IHC staining reveals no CAR expression in either the membrane or cytoplasm in MCF7 (Fig.  A). ,CAR/O CAR/O IHC/O IHC/O staining/O staining/O reveals/O no/O CAR/O CAR/O expression/O in/O either/O the/O membrane/O or/O cytoplasm/O cytoplasm/O cytoplasm/O cytoplasm/O cytoplasm/O in/O MCF7/B-CellLine MCF7/O MCF7/O (Fig./O (Fig./O (Fig./O (Fig./O A)./O A)./O A)./O
CAR expression is dot-like in the cytoplasm of SUM44PE similar to that observed in human ILC tissue specimens (Fig.  B). ,CAR/O CAR/O expression/O is/O dot-like/O dot-like/O dot-like/O in/O the/O cytoplasm/O cytoplasm/O cytoplasm/O cytoplasm/O cytoplasm/O of/O SUM44PE/B-CellLine SUM44PE/B-CellLine SUM44PE/O SUM44PE/O SUM44PE/O similar/O to/O that/O observed/O in/O human/O ILC/O ILC/O tissue/O specimens/O (Fig./O (Fig./O (Fig./O (Fig./O B)./O B)./O B)./O
"To model how DfAd and Ad transduce IDC and ILC tumor cells, MCF7, SUM44PE, and MDA-MB-231 cells were transduced by DfAd-GFP and Ad-GFP. ","To/O model/O how/O DfAd/O DfAd/O DfAd/O DfAd/O and/O Ad/O transduce/O transduce/O transduce/O IDC/O IDC/O and/O ILC/O ILC/O tumor/O cells,/O cells,/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O SUM44PE,/B-CellLine SUM44PE,/B-CellLine SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O and/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O cells/O were/O transduced/O transduced/O by/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O and/O Ad-GFP./O Ad-GFP./O Ad-GFP./O Ad-GFP./O Ad-GFP./O"
MCF7 cells treated with DfAd-GFP at MOI 100 demonstrated 17-times higher transduction efficiency compared to cells treated by Ad-GFP at the same MOI (Fig.  D). ,MCF7/B-CellLine MCF7/O MCF7/O cells/O treated/O with/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O at/O MOI/O MOI/O MOI/O 100/O demonstrated/O 17-times/O 17-times/O 17-times/O higher/O transduction/O transduction/O efficiency/O compared/O to/O cells/O treated/O by/O Ad-GFP/O Ad-GFP/O Ad-GFP/O Ad-GFP/O at/O the/O same/O MOI/O MOI/O MOI/O (Fig./O (Fig./O (Fig./O (Fig./O D)./O D)./O D)./O
SUM44PE cells treated with DfAd-GFP at MOI 50 demonstrated 4-fold higher transduction efficiency compared to cells treated by Ad-GFP at the same MOI (Fig.  E). ,SUM44PE/B-CellLine SUM44PE/B-CellLine SUM44PE/O SUM44PE/O SUM44PE/O cells/O treated/O with/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O at/O MOI/O MOI/O MOI/O 50/O demonstrated/O 4-fold/O 4-fold/O 4-fold/O higher/O transduction/O transduction/O efficiency/O compared/O to/O cells/O treated/O by/O Ad-GFP/O Ad-GFP/O Ad-GFP/O Ad-GFP/O at/O the/O same/O MOI/O MOI/O MOI/O (Fig./O (Fig./O (Fig./O (Fig./O E)./O E)./O E)./O
"CAR Expression (  = 3 in Low and   = 2 in High), *  < 0.05, ns = not significant. ( ) The transduction efficiency of primary human tumor sample ID 0.029 when transduced with DfAd-GFP versus Ad-GFP at multiple MOI.   = 3. ( ) The transduction efficiency of primary human tumor sample ID 0.030 when transduced with DfAd-GFP versus Ad-GFP at multiple MOI.   = 3. Of the five reported tumor samples, 0.029 and 0.030 were the only two samples that yielded sufficient cells to measure transduction efficiency at multiple MOIs. ( ) CAR IHC staining of an IDC tumor that shows CAR staining intensity < 1+. ( ) CAR IHC staining of an IDC tumor that shows very high CAR staining intensity 3+. Error bars are SEM Transduction of human primary IDC tumor cells To model how DfAd and Ad transduce primary human breast tumors, human breast tumor samples were homogenized into single cells and transduced with DfAd-GFP and Ad-GFP. ","CAR/O CAR/O Expression/O Expression/O (/O =/O 3/O in/O Low/O and/O =/O 2/O in/O High),/O High),/O High),/O */O </O 0.05,/O 0.05,/O 0.05,/O 0.05,/O ns/O ns/O =/O not/O significant./O significant./O (/O )/O The/O transduction/O transduction/O efficiency/O of/O primary/O human/O tumor/O sample/O ID/O 0.029/O 0.029/O 0.029/O 0.029/O when/O transduced/O transduced/O with/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O versus/O Ad-GFP/O Ad-GFP/O Ad-GFP/O Ad-GFP/O at/O multiple/O MOI./O MOI./O MOI./O MOI./O =/O 3./O 3./O (/O )/O The/O transduction/O transduction/O efficiency/O of/O primary/O human/O tumor/O sample/O ID/O 0.030/O 0.030/O 0.030/O 0.030/O when/O transduced/O transduced/O with/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O versus/O Ad-GFP/O Ad-GFP/O Ad-GFP/O Ad-GFP/O at/O multiple/O MOI./O MOI./O MOI./O MOI./O =/O 3./O 3./O Of/O the/O five/O reported/O tumor/O samples,/O samples,/O 0.029/O 0.029/O 0.029/O 0.029/O and/O 0.030/O 0.030/O 0.030/O 0.030/O were/O the/O only/O two/O samples/O that/O yielded/O sufficient/O cells/O to/O measure/O transduction/O transduction/O efficiency/O at/O multiple/O MOIs./O MOIs./O MOIs./O MOIs./O MOIs./O (/O )/O CAR/O CAR/O IHC/O IHC/O staining/O staining/O of/O an/O IDC/O IDC/O tumor/O that/O shows/O CAR/O CAR/O staining/O staining/O intensity/O </O 1+./O 1+./O 1+./O (/O )/O CAR/O CAR/O IHC/O IHC/O staining/O staining/O of/O an/O IDC/O IDC/O tumor/O that/O shows/O very/O high/O CAR/O CAR/O staining/O staining/O intensity/O 3+./O 3+./O 3+./O Error/O Error/O Error/O bars/O are/O SEM/O SEM/O Transduction/O Transduction/O of/O human/O primary/O IDC/O IDC/O tumor/O cells/O To/O model/O how/O DfAd/O DfAd/O DfAd/O DfAd/O and/O Ad/O transduce/O transduce/O transduce/O primary/O human/O breast/O tumors,/O tumors,/O human/O breast/O tumor/O samples/O were/O homogenized/O homogenized/O homogenized/O homogenized/O into/O single/O cells/O and/O transduced/O transduced/O with/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O and/O Ad-GFP./O Ad-GFP./O Ad-GFP./O Ad-GFP./O Ad-GFP./O"
"Using cell lines MCF7 and MDA-MB-231 to model IDC with no CAR expression and high membrane CAR expression, respectively, we show that liposome encapsulation (DfAd-GFP) increases adenoviral transduction efficiency up to 17-fold in CAR negative cells. ","Using/O cell/O lines/O MCF7/B-CellLine MCF7/O MCF7/O and/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O to/O model/O IDC/O IDC/O with/O no/O CAR/O CAR/O expression/O and/O high/O membrane/O CAR/O CAR/O expression,/O expression,/O respectively,/O respectively,/O we/O show/O that/O liposome/O liposome/O liposome/O encapsulation/O encapsulation/O encapsulation/O encapsulation/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O increases/O adenoviral/O adenoviral/O adenoviral/O adenoviral/O transduction/O transduction/O efficiency/O up/O to/O 17-fold/O 17-fold/O 17-fold/O in/O CAR/O CAR/O negative/O cells./O cells./O"
"Our experiments using SUM44PE, an ILC cell line, showed 4-fold enhanced transduction efficiency using DfAd-GFP compared to Ad-GFP, indicating that liposome enhanced transduction is more efficient in ILC tumor cells than receptor-based Ad transduction through CAR. ","Our/O experiments/O using/O SUM44PE,/B-CellLine SUM44PE,/B-CellLine SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O an/O ILC/O ILC/O cell/O line,/O line,/O showed/O 4-fold/O 4-fold/O 4-fold/O enhanced/O transduction/O transduction/O efficiency/O using/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O compared/O to/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O indicating/O that/O liposome/O liposome/O liposome/O enhanced/O transduction/O transduction/O is/O more/O efficient/O in/O ILC/O ILC/O tumor/O cells/O than/O receptor-based/O receptor-based/O receptor-based/O Ad/O transduction/O transduction/O through/O CAR./O CAR./O CAR./O"
"2020;10:590643. Engstrøm MJ, Opdahl S, Vatten LJ, Haugen OA, Bofin AM. ","2020;10:590643./O 2020;10:590643./O 2020;10:590643./O 2020;10:590643./O 2020;10:590643./O 2020;10:590643./O 2020;10:590643./O 2020;10:590643./O 2020;10:590643./O Engstrøm/O Engstrøm/O Engstrøm/O Engstrøm/O Engstrøm/O MJ,/O MJ,/O MJ,/O Opdahl/O Opdahl/O Opdahl/O S,/O S,/O Vatten/O Vatten/O Vatten/O LJ,/O LJ,/O LJ,/O Haugen/O Haugen/O OA,/O OA,/O OA,/O Bofin/O Bofin/O AM./O AM./O"
Multiple treatment cycles of liposome-encapsulated adenoviral RIP-TK gene therapy effectively ablate human pancreatic cancer cells in SCID mice. ,Multiple/O treatment/O cycles/O of/O liposome-encapsulated/O liposome-encapsulated/O liposome-encapsulated/O liposome-encapsulated/O liposome-encapsulated/O liposome-encapsulated/O liposome-encapsulated/O liposome-encapsulated/O adenoviral/O adenoviral/O adenoviral/O adenoviral/O RIP-TK/O RIP-TK/O RIP-TK/O RIP-TK/O RIP-TK/O gene/O therapy/O effectively/O ablate/O ablate/O ablate/O human/O pancreatic/O pancreatic/O pancreatic/O cancer/O cells/O in/O SCID/O SCID/O mice./O mice./O
"Using cell lines MCF7 and MDA-MB-231 to model IDC with no CAR expression and high membrane CAR expression, respectively, we show that liposome encapsulation (DfAd-GFP) increases adenoviral transduction efficiency up to 17-fold in CAR negative cells. ","Using/O cell/O lines/O MCF7/B-CellLine MCF7/O MCF7/O and/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O to/O model/O IDC/O IDC/O with/O no/O CAR/O CAR/O expression/O and/O high/O membrane/O CAR/O CAR/O expression,/O expression,/O respectively,/O respectively,/O we/O show/O that/O liposome/O liposome/O liposome/O encapsulation/O encapsulation/O encapsulation/O encapsulation/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O increases/O adenoviral/O adenoviral/O adenoviral/O adenoviral/O transduction/O transduction/O efficiency/O up/O to/O 17-fold/O 17-fold/O 17-fold/O in/O CAR/O CAR/O negative/O cells./O cells./O"
"Our experiments using SUM44PE, an ILC cell line, showed 4-fold enhanced transduction efficiency using DfAd-GFP compared to Ad-GFP, indicating that liposome enhanced transduction is more efficient in ILC tumor cells than receptor-based Ad transduction through CAR. ","Our/O experiments/O using/O SUM44PE,/B-CellLine SUM44PE,/B-CellLine SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O an/O ILC/O ILC/O cell/O line,/O line,/O showed/O 4-fold/O 4-fold/O 4-fold/O enhanced/O transduction/O transduction/O efficiency/O using/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O compared/O to/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O indicating/O that/O liposome/O liposome/O liposome/O enhanced/O transduction/O transduction/O is/O more/O efficient/O in/O ILC/O ILC/O tumor/O cells/O than/O receptor-based/O receptor-based/O receptor-based/O Ad/O transduction/O transduction/O through/O CAR./O CAR./O CAR./O"
"Using cell lines MCF7 and MDA-MB-231 to model IDC with no CAR expression and high membrane CAR expression, respectively, we show that liposome encapsulation (DfAd-GFP) increases adenoviral transduction efficiency up to 17-fold in CAR negative cells. ","Using/O cell/O lines/O MCF7/B-CellLine MCF7/O MCF7/O and/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O to/O model/O IDC/O IDC/O with/O no/O CAR/O CAR/O expression/O and/O high/O membrane/O CAR/O CAR/O expression,/O expression,/O respectively,/O respectively,/O we/O show/O that/O liposome/O liposome/O liposome/O encapsulation/O encapsulation/O encapsulation/O encapsulation/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O increases/O adenoviral/O adenoviral/O adenoviral/O adenoviral/O transduction/O transduction/O efficiency/O up/O to/O 17-fold/O 17-fold/O 17-fold/O in/O CAR/O CAR/O negative/O cells./O cells./O"
"Our experiments using SUM44PE, an ILC cell line, showed 4-fold enhanced transduction efficiency using DfAd-GFP compared to Ad-GFP, indicating that liposome enhanced transduction is more efficient in ILC tumor cells than receptor-based Ad transduction through CAR. ","Our/O experiments/O using/O SUM44PE,/B-CellLine SUM44PE,/B-CellLine SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O an/O ILC/O ILC/O cell/O line,/O line,/O showed/O 4-fold/O 4-fold/O 4-fold/O enhanced/O transduction/O transduction/O efficiency/O using/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O compared/O to/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O indicating/O that/O liposome/O liposome/O liposome/O enhanced/O transduction/O transduction/O is/O more/O efficient/O in/O ILC/O ILC/O tumor/O cells/O than/O receptor-based/O receptor-based/O receptor-based/O Ad/O transduction/O transduction/O through/O CAR./O CAR./O CAR./O"
"Using cell lines MCF7 and MDA-MB-231 to model IDC with no CAR expression and high membrane CAR expression, respectively, we show that liposome encapsulation (DfAd-GFP) increases adenoviral transduction efficiency up to 17-fold in CAR negative cells. ","Using/O cell/O lines/O MCF7/B-CellLine MCF7/O MCF7/O and/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O to/O model/O IDC/O IDC/O with/O no/O CAR/O CAR/O expression/O and/O high/O membrane/O CAR/O CAR/O expression,/O expression,/O respectively,/O respectively,/O we/O show/O that/O liposome/O liposome/O liposome/O encapsulation/O encapsulation/O encapsulation/O encapsulation/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O increases/O adenoviral/O adenoviral/O adenoviral/O adenoviral/O transduction/O transduction/O efficiency/O up/O to/O 17-fold/O 17-fold/O 17-fold/O in/O CAR/O CAR/O negative/O cells./O cells./O"
"Our experiments using SUM44PE, an ILC cell line, showed 4-fold enhanced transduction efficiency using DfAd-GFP compared to Ad-GFP, indicating that liposome enhanced transduction is more efficient in ILC tumor cells than receptor-based Ad transduction through CAR. ","Our/O experiments/O using/O SUM44PE,/B-CellLine SUM44PE,/B-CellLine SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O an/O ILC/O ILC/O cell/O line,/O line,/O showed/O 4-fold/O 4-fold/O 4-fold/O enhanced/O transduction/O transduction/O efficiency/O using/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O compared/O to/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O indicating/O that/O liposome/O liposome/O liposome/O enhanced/O transduction/O transduction/O is/O more/O efficient/O in/O ILC/O ILC/O tumor/O cells/O than/O receptor-based/O receptor-based/O receptor-based/O Ad/O transduction/O transduction/O through/O CAR./O CAR./O CAR./O"
"Using cell lines MCF7 and MDA-MB-231 to model IDC with no CAR expression and high membrane CAR expression, respectively, we show that liposome encapsulation (DfAd-GFP) increases adenoviral transduction efficiency up to 17-fold in CAR negative cells. ","Using/O cell/O lines/O MCF7/B-CellLine MCF7/O MCF7/O and/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O to/O model/O IDC/O IDC/O with/O no/O CAR/O CAR/O expression/O and/O high/O membrane/O CAR/O CAR/O expression,/O expression,/O respectively,/O respectively,/O we/O show/O that/O liposome/O liposome/O liposome/O encapsulation/O encapsulation/O encapsulation/O encapsulation/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O (DfAd-GFP)/O increases/O adenoviral/O adenoviral/O adenoviral/O adenoviral/O transduction/O transduction/O efficiency/O up/O to/O 17-fold/O 17-fold/O 17-fold/O in/O CAR/O CAR/O negative/O cells./O cells./O"
"Our experiments using SUM44PE, an ILC cell line, showed 4-fold enhanced transduction efficiency using DfAd-GFP compared to Ad-GFP, indicating that liposome enhanced transduction is more efficient in ILC tumor cells than receptor-based Ad transduction through CAR. ","Our/O experiments/O using/O SUM44PE,/B-CellLine SUM44PE,/B-CellLine SUM44PE,/O SUM44PE,/O SUM44PE,/O SUM44PE,/O an/O ILC/O ILC/O cell/O line,/O line,/O showed/O 4-fold/O 4-fold/O 4-fold/O enhanced/O transduction/O transduction/O efficiency/O using/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O DfAd-GFP/O compared/O to/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O Ad-GFP,/O indicating/O that/O liposome/O liposome/O liposome/O enhanced/O transduction/O transduction/O is/O more/O efficient/O in/O ILC/O ILC/O tumor/O cells/O than/O receptor-based/O receptor-based/O receptor-based/O Ad/O transduction/O transduction/O through/O CAR./O CAR./O CAR./O"
"55 (33–80) ECOG performance status  0–1ⁱⁱⁱ (83.5)  ⩾2⁲⁲ (16.5) HER2 expression  IHC 2+ and FISH+ 24 (18.0)  IHC 3+ 109 (82.0) HR status  Negative 62 (46.6)  Positive 71 (53.4) Ki-67 level  ⩽20% 22 (16.5)  >20% 96 (72.2)  NA 15 (11.3) Surgery 25 (18.8)  Yes 108 (81.2) Radiotherapy 75 (56.4) 58 (43.6) DFI (month)  ⩽12⁲⁵ (18.8)  >12⁸⁳ (62.4)  De novo IV stage Previous trastuzumab treatment  Neoadjuvant therapy period 29 (21.8)  Adjuvant therapy period 46 (34.6)  Metastatic disease period 68 (51.1) Previous anti-HER2 treatment  Pertuzumab 38 (28.6)  Pyrotinib 72 (54.1)  Lapatinib  Other TKIs 7 (5.3)  Angiogenesis inhibitors 5 (3.8)  TDM1  DS-8201⁵ (3.8)  RC-48⁸ (6.0)  Other ADCs 9 (6.8) Metastatic sites  Lymph node 81 (60.9)  Liver 50 (37.6)  Lung 73 (54.9)  Bone 57 (42.9)  Brain 31 (23.3)  Others 30 (22.6) Visceral metastases 26 (19.5) 107 (80.5) Treatment lines  1 line 19 (14.3)  2 lines 36 (27.1)  3 lines  4 lines  ⩾5 lines 27 (20.3) ADC, antibody–drug conjugate; DFI, disease-free interval; FISH, Fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hazard ratios; IHC, immunohistochemical; TKI, tyrosine kinase inhibitor.","55/O (33–80)/O (33–80)/O (33–80)/O (33–80)/O (33–80)/O ECOG/O ECOG/O ECOG/O performance/O status/O 0–1ⁱⁱⁱ/O 0–1ⁱⁱⁱ/O 0–1ⁱⁱⁱ/O 0–1ⁱⁱⁱ/O 0–1ⁱⁱⁱ/O 0–1ⁱⁱⁱ/O (83.5)/O (83.5)/O (83.5)/O (83.5)/O (83.5)/O ⩾2⁲⁲/O (16.5)/O (16.5)/O (16.5)/O (16.5)/O (16.5)/O HER2/O HER2/O HER2/O expression/O IHC/O IHC/O 2+/O 2+/O and/O FISH+/O FISH+/O FISH+/O FISH+/O 24/O (18.0)/O (18.0)/O (18.0)/O (18.0)/O (18.0)/O IHC/O IHC/O 3+/O 3+/O 109/O (82.0)/O (82.0)/O (82.0)/O (82.0)/O (82.0)/O HR/O HR/O status/O Negative/O Negative/O Negative/O 62/O (46.6)/O (46.6)/O (46.6)/O (46.6)/O (46.6)/O Positive/O Positive/O 71/O (53.4)/O (53.4)/O (53.4)/O (53.4)/O (53.4)/O Ki-67/O Ki-67/O Ki-67/O level/O ⩽20%/O ⩽20%/O 22/O (16.5)/O (16.5)/O (16.5)/O (16.5)/O (16.5)/O >20%/O >20%/O >20%/O 96/O (72.2)/O (72.2)/O (72.2)/O (72.2)/O (72.2)/O NA/O NA/O 15/O (11.3)/O (11.3)/O (11.3)/O (11.3)/O (11.3)/O Surgery/O 25/O (18.8)/O (18.8)/O (18.8)/O (18.8)/O (18.8)/O Yes/O 108/O (81.2)/O (81.2)/O (81.2)/O (81.2)/O (81.2)/O Radiotherapy/O Radiotherapy/O Radiotherapy/O Radiotherapy/O 75/O (56.4)/O (56.4)/O (56.4)/O (56.4)/O (56.4)/O 58/O (43.6)/O (43.6)/O (43.6)/O (43.6)/O (43.6)/O DFI/O DFI/O (month)/O (month)/O (month)/O ⩽12⁲⁵/O (18.8)/O (18.8)/O (18.8)/O (18.8)/O (18.8)/O >12⁸⁳/O >12⁸⁳/O (62.4)/O (62.4)/O (62.4)/O (62.4)/O (62.4)/O De/O novo/O novo/O IV/O stage/O Previous/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O treatment/O Neoadjuvant/O Neoadjuvant/O Neoadjuvant/O Neoadjuvant/O therapy/O period/O 29/O (21.8)/O (21.8)/O (21.8)/O (21.8)/O (21.8)/O Adjuvant/O Adjuvant/O Adjuvant/O therapy/O period/O 46/O (34.6)/O (34.6)/O (34.6)/O (34.6)/O (34.6)/O Metastatic/O Metastatic/O Metastatic/O disease/O period/O 68/O (51.1)/O (51.1)/O (51.1)/O (51.1)/O (51.1)/O Previous/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O treatment/O Pertuzumab/O Pertuzumab/O Pertuzumab/O Pertuzumab/O Pertuzumab/O 38/O (28.6)/O (28.6)/O (28.6)/O (28.6)/O (28.6)/O Pyrotinib/O Pyrotinib/O Pyrotinib/O Pyrotinib/O Pyrotinib/O 72/O (54.1)/O (54.1)/O (54.1)/O (54.1)/O (54.1)/O Lapatinib/O Lapatinib/O Lapatinib/O Lapatinib/O Other/O TKIs/O TKIs/O TKIs/O TKIs/O 7/O (5.3)/O (5.3)/O (5.3)/O (5.3)/O (5.3)/O Angiogenesis/O Angiogenesis/O Angiogenesis/O inhibitors/O inhibitors/O 5/O (3.8)/O (3.8)/O (3.8)/O (3.8)/O (3.8)/O TDM1/O TDM1/O TDM1/O DS-8201⁵/O DS-8201⁵/O DS-8201⁵/O DS-8201⁵/O DS-8201⁵/O (3.8)/O (3.8)/O (3.8)/O (3.8)/O (3.8)/O RC-48⁸/O RC-48⁸/O RC-48⁸/O RC-48⁸/O (6.0)/O (6.0)/O (6.0)/O (6.0)/O (6.0)/O Other/O ADCs/O ADCs/O 9/O (6.8)/O (6.8)/O (6.8)/O (6.8)/O (6.8)/O Metastatic/O Metastatic/O Metastatic/O sites/O Lymph/O Lymph/O node/O 81/O (60.9)/O (60.9)/O (60.9)/O (60.9)/O (60.9)/O Liver/O Liver/O 50/O (37.6)/O (37.6)/O (37.6)/O (37.6)/O (37.6)/O Lung/O Lung/O 73/O (54.9)/O (54.9)/O (54.9)/O (54.9)/O (54.9)/O Bone/O 57/O (42.9)/O (42.9)/O (42.9)/O (42.9)/O (42.9)/O Brain/O 31/O (23.3)/O (23.3)/O (23.3)/O (23.3)/O (23.3)/O Others/O 30/O (22.6)/O (22.6)/O (22.6)/O (22.6)/O (22.6)/O Visceral/O Visceral/O Visceral/O Visceral/O metastases/O metastases/O metastases/O 26/O (19.5)/O (19.5)/O (19.5)/O (19.5)/O (19.5)/O 107/O (80.5)/O (80.5)/O (80.5)/O (80.5)/O (80.5)/O Treatment/O lines/O 1/O line/O 19/O (14.3)/O (14.3)/O (14.3)/O (14.3)/O (14.3)/O 2/O lines/O 36/O (27.1)/O (27.1)/O (27.1)/O (27.1)/O (27.1)/O 3/O lines/O 4/O lines/O ⩾5/O lines/O 27/O (20.3)/O (20.3)/O (20.3)/O (20.3)/O (20.3)/O ADC,/O ADC,/O ADC,/O antibody–drug/O antibody–drug/O antibody–drug/O antibody–drug/O conjugate;/O conjugate;/O conjugate;/O conjugate;/O DFI,/O DFI,/O DFI,/O disease-free/O disease-free/O disease-free/O interval;/O interval;/O FISH,/O FISH,/O FISH,/O FISH,/O Fluorescence/O Fluorescence/O Fluorescence/O Fluorescence/O in/O situ/O situ/O hybridization;/O hybridization;/O hybridization;/O HER2,/O HER2,/O HER2,/O HER2,/O human/O epidermal/O epidermal/O epidermal/O epidermal/O growth/O factor/O receptor/O 2;/O 2;/O HR,/O HR,/O HR,/O hazard/O ratios;/O ratios;/O IHC,/O IHC,/O IHC,/O immunohistochemical;/O immunohistochemical;/O immunohistochemical;/O immunohistochemical;/O immunohistochemical;/O immunohistochemical;/O immunohistochemical;/O TKI,/O TKI,/O TKI,/O TKI,/O tyrosine/O tyrosine/O tyrosine/O tyrosine/O kinase/O inhibitor./O inhibitor./O"
"Statistical analysis Statistical analysis was performed using SPSS 26.0 (IBM Corporation, Armonk, NY, USA) and R Studio (version 4.1.2, RStudio, PBC, Boston, MA, USA). ","Statistical/O analysis/O Statistical/O analysis/O was/O performed/O using/O SPSS/O SPSS/O 26.0/O 26.0/O 26.0/O (IBM/O (IBM/O Corporation,/O Corporation,/O Armonk,/O Armonk,/O Armonk,/O Armonk,/O NY,/O NY,/O USA)/O USA)/O and/O R/O Studio/O (version/O (version/O 4.1.2,/O 4.1.2,/O 4.1.2,/O 4.1.2,/O 4.1.2,/O 4.1.2,/O RStudio,/O RStudio,/O RStudio,/O RStudio,/O PBC,/O PBC,/O PBC,/O Boston,/O Boston,/O MA,/O MA,/O USA)./O USA)./O USA)./O"
"The results showed that the first-line treatment group had a mPFS of 14.0 months (95% CI: 10.2–17.8), while the second-line treatment group had a mPFS of 15.0 months (95% CI: 4.4–25.6;  Supplemental Figure S1(G) ","The/O results/O showed/O that/O the/O first-line/O first-line/O first-line/O treatment/O group/O had/O a/O mPFS/O mPFS/O mPFS/O of/O 14.0/O 14.0/O 14.0/O months/O (95%/O (95%/O (95%/O CI:/B-CellLine CI:/O CI:/O 10.2–17.8),/O 10.2–17.8),/O 10.2–17.8),/O 10.2–17.8),/O 10.2–17.8),/O 10.2–17.8),/O 10.2–17.8),/O 10.2–17.8),/O 10.2–17.8),/O while/O the/O second-line/O second-line/O second-line/O treatment/O group/O had/O a/O mPFS/O mPFS/O mPFS/O of/O 15.0/O 15.0/O 15.0/O months/O (95%/O (95%/O (95%/O CI:/B-CellLine CI:/O CI:/O 4.4–25.6;/O 4.4–25.6;/O 4.4–25.6;/O 4.4–25.6;/O 4.4–25.6;/O 4.4–25.6;/O 4.4–25.6;/O 4.4–25.6;/O Supplemental/O Supplemental/O Supplemental/O Supplemental/O Figure/O S1(G)/O S1(G)/O S1(G)/O S1(G)/O S1(G)/O"
"Further analysis of multivariate demonstrated that patients with a history of HER2-TKIs treatment had a worse PFS (HR 2.829, 95% CI 1.265–6.328,   = 0.011). ","Further/O analysis/O of/O multivariate/O multivariate/O multivariate/O demonstrated/O that/O patients/O with/O a/O history/O of/O HER2-TKIs/O HER2-TKIs/O HER2-TKIs/O HER2-TKIs/O HER2-TKIs/O HER2-TKIs/O HER2-TKIs/O HER2-TKIs/O treatment/O had/O a/O worse/O PFS/O PFS/O (HR/O (HR/O (HR/O 2.829,/O 2.829,/O 2.829,/O 2.829,/O 2.829,/O 95%/O 95%/O CI/B-CellLine CI/O 1.265–6.328,/O 1.265–6.328,/O 1.265–6.328,/O 1.265–6.328,/O 1.265–6.328,/O 1.265–6.328,/O 1.265–6.328,/O 1.265–6.328,/O 1.265–6.328,/O =/O 0.011)./O 0.011)./O 0.011)./O 0.011)./O 0.011)./O 0.011)./O"
Items 95% CI Age  <50 —    ⩾50⁰.790⁰.503–1.241⁰.307  0–1  ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064 0.706⁰.403–1.235⁰.222 0.818⁰.539–1.243⁰.348 Ki-67 expression 0.854⁰.486–1.502⁰.854 0.744⁰.347–1.595⁰.744 0.677⁰.398–1.152⁰.151 1.524⁰.994–2.338⁰.055  ⩽12  >12ⁱ.265⁰.725–2.208⁰.408 1.766⁰.888–3.511⁰.105 Liver metastasis 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220 Lung metastasis 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943 Bone metastasis 1.281⁰.843–1.946⁰.246 Brain metastasis 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794 Lymph nodes metastasis 1.358⁰.877–2.103⁰.171 Visceral metastasis 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456 Number of metastasis sites before inetetamab  1  ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376 Number of inetetamab therapy lines  1–2 lines  3–4 lines 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704  Neoadjuvant therapy period (no vs yes) ,Items/O Items/O 95%/O 95%/O CI/O CI/O Age/O <50/O <50/O —/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O ⩾50⁰.790⁰.503–1.241⁰.307/O 0–1/O 0–1/O 0–1/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O ⩾2⁲.309ⁱ.353–3.939⁰.002ⁱ.850⁰.964–3.553⁰.064/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.706⁰.403–1.235⁰.222/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O 0.818⁰.539–1.243⁰.348/O Ki-67/O Ki-67/O Ki-67/O expression/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.854⁰.486–1.502⁰.854/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.744⁰.347–1.595⁰.744/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 0.677⁰.398–1.152⁰.151/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O 1.524⁰.994–2.338⁰.055/O ⩽12/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O >12ⁱ.265⁰.725–2.208⁰.408/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O 1.766⁰.888–3.511⁰.105/O Liver/O Liver/O metastasis/O metastasis/O metastasis/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O 1.751ⁱ.145–2.678⁰.010ⁱ.383⁰.824–2.322⁰.220/O Lung/O Lung/O metastasis/O metastasis/O metastasis/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O 1.550ⁱ.007–2.385⁰.046⁰.978⁰.532–1.799⁰.943/O Bone/O metastasis/O metastasis/O metastasis/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O 1.281⁰.843–1.946⁰.246/O Brain/O metastasis/O metastasis/O metastasis/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O 1.693ⁱ.061–2.701⁰.027⁰.932⁰.550–1.581⁰.794/O Lymph/O Lymph/O nodes/O metastasis/O metastasis/O metastasis/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O 1.358⁰.877–2.103⁰.171/O Visceral/O Visceral/O Visceral/O Visceral/O metastasis/O metastasis/O metastasis/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O 2.391ⁱ.270–4.504⁰.007ⁱ.401⁰.578–3.398⁰.456/O Number/O of/O metastasis/O metastasis/O metastasis/O sites/O before/O inetetamab/O inetetamab/O inetetamab/O inetetamab/O 1/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O ⩾2⁲.361ⁱ.283–4.342⁰.006ⁱ.379⁰.676–2.814⁰.376/O Number/O of/O inetetamab/O inetetamab/O inetetamab/O inetetamab/O therapy/O lines/O 1–2/O 1–2/O 1–2/O lines/O 3–4/O 3–4/O 3–4/O lines/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 1.919ⁱ.162–3.167⁰.011⁰.661⁰.282–1.552⁰.342/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O 3.816⁲.135–6.822⁰.000⁰.824⁰.303–2.243⁰.704/O Neoadjuvant/O Neoadjuvant/O Neoadjuvant/O Neoadjuvant/O
"In addition, some patients also received treatment with ADCs, including Trastuzumab emtansine (T-DM1) (11.3%), Trastuzumab deruxtecan (DS-8201) (3.8%), Disitamab Vedotin (RC-48) (6.0%), and other ADCs (6.8%). ","In/O addition,/O addition,/O some/O patients/O also/O received/O treatment/O with/O ADCs,/O ADCs,/O ADCs,/O including/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O emtansine/O emtansine/O emtansine/O emtansine/O (T-DM1)/O (T-DM1)/O (T-DM1)/O (T-DM1)/O (T-DM1)/O (T-DM1)/O (T-DM1)/O (11.3%),/O (11.3%),/O (11.3%),/O (11.3%),/O (11.3%),/O (11.3%),/O (11.3%),/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O deruxtecan/O deruxtecan/O deruxtecan/O deruxtecan/O (DS-8201)/O (DS-8201)/O (DS-8201)/O (DS-8201)/O (DS-8201)/O (DS-8201)/O (3.8%),/O (3.8%),/O (3.8%),/O (3.8%),/O (3.8%),/O (3.8%),/O (3.8%),/O Disitamab/O Disitamab/O Disitamab/O Disitamab/O Vedotin/O Vedotin/O Vedotin/O Vedotin/O (RC-48)/O (RC-48)/O (RC-48)/O (RC-48)/O (RC-48)/O (6.0%),/O (6.0%),/O (6.0%),/O (6.0%),/O (6.0%),/O (6.0%),/O (6.0%),/O and/O other/O ADCs/O ADCs/O (6.8%)./O (6.8%)./O (6.8%)./O (6.8%)./O (6.8%)./O (6.8%)./O (6.8%)./O"
"Similarly, findings from the 2023 ESMO meeting even revealed that 77 patients with HER2-positive MBC treated with inetetamab in combination with pyrotinib and vinorelbine had an mPFS of up to 10.03 months (95% CI 6.66–13.41 months) and had an ORR of 62.3% (48/77) and a clinical benefit rate (CBR) of 77.9% (60/77).","Similarly,/O Similarly,/O findings/O from/O the/O 2023/O 2023/O ESMO/O ESMO/O ESMO/O meeting/O even/O revealed/O that/O 77/O patients/O with/O HER2-positive/O HER2-positive/O HER2-positive/O HER2-positive/O HER2-positive/O MBC/O MBC/O treated/O with/O inetetamab/O inetetamab/O inetetamab/O inetetamab/O in/O combination/O with/O pyrotinib/O pyrotinib/O pyrotinib/O pyrotinib/O pyrotinib/O and/O vinorelbine/O vinorelbine/O vinorelbine/O vinorelbine/O had/O an/O mPFS/O mPFS/O mPFS/O of/O up/O to/O 10.03/O 10.03/O 10.03/O months/O (95%/O (95%/O (95%/O CI/B-CellLine CI/O 6.66–13.41/O 6.66–13.41/O 6.66–13.41/O 6.66–13.41/O 6.66–13.41/O 6.66–13.41/O 6.66–13.41/O months)/O months)/O and/O had/O an/O ORR/O ORR/O of/O 62.3%/O 62.3%/O 62.3%/O 62.3%/O (48/77)/O (48/77)/O (48/77)/O (48/77)/O (48/77)/O and/O a/O clinical/O benefit/O rate/O (CBR)/O (CBR)/O (CBR)/O (CBR)/O of/O 77.9%/O 77.9%/O 77.9%/O 77.9%/O (60/77)./O (60/77)./O (60/77)./O (60/77)./O (60/77)./O (60/77)./O"
"References 1.  Siegel RL, Giaquinto AN, Jemal AN. ","References/O References/O 1./O 1./O Siegel/O Siegel/O RL,/O RL,/O RL,/O Giaquinto/O Giaquinto/O Giaquinto/O Giaquinto/O AN,/O AN,/O Jemal/O Jemal/O AN./O AN./O"
"Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma. ","Inetetamab,/O Inetetamab,/O Inetetamab,/O Inetetamab,/O Inetetamab,/O a/O novel/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O monoclonal/O monoclonal/O monoclonal/O monoclonal/O antibody,/O antibody,/O antibody,/O exhibits/O potent/O synergistic/O synergistic/O synergistic/O synergistic/O anticancer/O anticancer/O anticancer/O effects/O with/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O by/O inducing/O inducing/O pyroptosis/O pyroptosis/O pyroptosis/O pyroptosis/O in/O lung/O adenocarcinoma./O adenocarcinoma./O adenocarcinoma./O adenocarcinoma./O adenocarcinoma./O adenocarcinoma./O"
"After that, the cells were washed with PBS for three times and incubated with 100 μL serum-free medium containing 10 μL CCK-8 for 1 h. ","After/O that,/O that,/O the/O cells/O were/O washed/O with/O PBS/O for/O three/O times/O and/O incubated/O incubated/O incubated/O incubated/O with/O 100/O μL/O μL/O serum-free/O serum-free/O serum-free/O medium/O containing/O 10/O μL/O μL/O CCK-8/O CCK-8/O CCK-8/O CCK-8/O for/O 1/O h./O h./O"
"References 1.  Siegel RL, Miller KD, Fuchs HE, et al. ","References/O References/O 1./O 1./O Siegel/O Siegel/O RL,/O RL,/O RL,/O Miller/O KD,/O KD,/O KD,/O Fuchs/O Fuchs/O HE,/O HE,/O HE,/O et/O al./O al./O"
"J Control Release . 2024;371:204–215. doi:10.1016/j.jconrel.2024.05.045ⁱ⁸.  Odda AH, Cheang TY, Alesary HF, et al. ","J/O Control/O Release/O ./O 2024;371:204–215./O 2024;371:204–215./O 2024;371:204–215./O 2024;371:204–215./O 2024;371:204–215./O 2024;371:204–215./O 2024;371:204–215./O 2024;371:204–215./O 2024;371:204–215./O 2024;371:204–215./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O doi:10.1016/j.jconrel.2024.05.045ⁱ⁸./O Odda/O Odda/O AH,/O AH,/O AH,/O Cheang/O Cheang/O Cheang/O TY,/O TY,/O TY,/O Alesary/O Alesary/O Alesary/O HF,/O HF,/O HF,/O et/O al./O al./O"
Carbosilane dendrimers loaded with siRNA targeting Nrf2 as a tool to overcome cisplatin chemoresistance in bladder cancer cells. ,Carbosilane/O Carbosilane/O Carbosilane/O Carbosilane/O dendrimers/O dendrimers/O dendrimers/O dendrimers/O loaded/O with/O siRNA/O siRNA/O targeting/O Nrf2/O Nrf2/O Nrf2/O as/O a/O tool/O to/O overcome/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O chemoresistance/O chemoresistance/O chemoresistance/O chemoresistance/O chemoresistance/O in/O bladder/O cancer/O cells./O cells./O
"Ultrason Sonochem . 2021;79:105769. doi:10.1016/j.ultsonch.2021.105769⁲⁹.  Fan CH, Lin YT, Ho YJ, et al. ","Ultrason/O Ultrason/O Sonochem/O Sonochem/O Sonochem/O ./O 2021;79:105769./O 2021;79:105769./O 2021;79:105769./O 2021;79:105769./O 2021;79:105769./O 2021;79:105769./O 2021;79:105769./O 2021;79:105769./O 2021;79:105769./O 2021;79:105769./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O doi:10.1016/j.ultsonch.2021.105769⁲⁹./O Fan/O CH,/O CH,/O Lin/O YT,/O YT,/O YT,/O Ho/O YJ,/O YJ,/O YJ,/O et/O al./O al./O"
A laser-activated multifunctional targeted nanoagent for imaging and gene therapy in a mouse xenograft model with retinoblastoma Y79 cells. ,A/O laser-activated/O laser-activated/O laser-activated/O multifunctional/O multifunctional/O multifunctional/O targeted/O nanoagent/O nanoagent/O nanoagent/O nanoagent/O for/O imaging/O and/O gene/O therapy/O in/O a/O mouse/O xenograft/O xenograft/O xenograft/O xenograft/O model/O with/O retinoblastoma/O retinoblastoma/O retinoblastoma/O retinoblastoma/O Y79/B-CellLine Y79/O Y79/O cells./O cells./O
"Materials and Methods Cell Culture and Drugs The TNBC cell lines, HCC1937 and SUM149PT, were acquired from ATCC (VA, USA) and Asterand Bioscience (MI, USA), respectively. ","Materials/O and/O Methods/O Methods/O Cell/O Culture/O and/O Drugs/O The/O TNBC/O TNBC/O cell/O lines,/O lines,/O HCC1937/B-CellLine HCC1937/O HCC1937/O HCC1937/O and/O SUM149PT,/B-CellLine SUM149PT,/B-CellLine SUM149PT,/O SUM149PT,/O SUM149PT,/O SUM149PT,/O SUM149PT,/O were/O acquired/O from/O ATCC/O ATCC/O (VA,/O (VA,/O (VA,/O USA)/O USA)/O and/O Asterand/O Asterand/O Asterand/O Bioscience/O Bioscience/O Bioscience/O Bioscience/O (MI,/O (MI,/O (MI,/O USA),/O USA),/O USA),/O respectively./O respectively./O"
HCC1937 cells were cultured in RPMI-1640 culture medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. ,HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O cells/O were/O cultured/O cultured/O in/O RPMI-1640/O RPMI-1640/O RPMI-1640/O RPMI-1640/O RPMI-1640/O culture/O medium/O supplemented/O with/O 10%/O 10%/O fetal/O fetal/O bovine/O bovine/O bovine/O serum/O and/O 1%/O 1%/O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O
"The SUM149PT cells were maintained in Ham’s F-12 medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, 5μg/mL insulin, and 1 μg/mL hydrocortisone. ","The/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O were/O maintained/O in/O Ham’s/O Ham’s/O Ham’s/O F-12/O F-12/O F-12/O medium/O supplemented/O with/O 10%/O 10%/O fetal/O fetal/O bovine/O bovine/O bovine/O serum,/O serum,/O 1%/O 1%/O penicillin/streptomycin,/O penicillin/streptomycin,/O penicillin/streptomycin,/O penicillin/streptomycin,/O penicillin/streptomycin,/O penicillin/streptomycin,/O penicillin/streptomycin,/O penicillin/streptomycin,/O penicillin/streptomycin,/O penicillin/streptomycin,/O 5μg/mL/O 5μg/mL/O 5μg/mL/O 5μg/mL/O 5μg/mL/O 5μg/mL/O insulin,/O insulin,/O and/O 1/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O hydrocortisone./O hydrocortisone./O hydrocortisone./O hydrocortisone./O hydrocortisone./O hydrocortisone./O"
The U2OS osteosarcoma cells were acquired from ATCC and were cultured in DMEM medium with 10% fetal bovine serum and 1% penicillin/streptomycin. ,The/O U2OS/B-CellLine U2OS/O osteosarcoma/O osteosarcoma/O osteosarcoma/O osteosarcoma/O osteosarcoma/O cells/O were/O acquired/O from/O ATCC/O ATCC/O and/O were/O cultured/O cultured/O in/O DMEM/O DMEM/O DMEM/O medium/O with/O 10%/O 10%/O fetal/O fetal/O bovine/O bovine/O bovine/O serum/O and/O 1%/O 1%/O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O penicillin/streptomycin./O
Cell Viability and Drug Synergy Assay The HCC1937 and SUM149PT cells were transfected with PARG or c-Myc si-RNA (as described subsequently) or treated with COH34 or IU1-248 alone or in combination for 3 d. ,Cell/O Viability/O Viability/O and/O Drug/O Synergy/O Synergy/O Synergy/O Assay/O Assay/O The/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O were/O transfected/O transfected/O with/O PARG/O PARG/O PARG/O or/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O si-RNA/O si-RNA/O si-RNA/O (as/O (as/O described/O subsequently)/O subsequently)/O or/O treated/O with/O COH34/O COH34/O COH34/O or/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O alone/O or/O in/O combination/O for/O 3/O d./O d./O
The combined effects were analyzed using the Calcusyn software V2.0 to determine the combination index (CI).,The/O combined/O effects/O were/O analyzed/O using/O the/O Calcusyn/O Calcusyn/O Calcusyn/O software/O V2.0/O V2.0/O V2.0/O V2.0/O to/O determine/O the/O combination/O index/O (CI)./O (CI)./B-CellLine (CI)./O (CI)./O (CI)./O
33  CI < 1 indicates synergism. ,33/O CI/B-CellLine CI/O </O 1/O indicates/O synergism./O synergism./O synergism./O synergism./O synergism./O
HCC1937 and SUM149PT TNBC cell lines harboring BRCA1 silencing mutations and resistant to PARP inhibitors were selected.,HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O TNBC/O TNBC/O cell/O lines/O harboring/O harboring/O BRCA1/O BRCA1/O BRCA1/O silencing/O silencing/O silencing/O mutations/O and/O resistant/O to/O PARP/O PARP/O inhibitors/O inhibitors/O were/O selected./O selected./O
"HCC1937 and SUM149PT TNBC cell lines were further treated with the PARG-specific inhibitor, COH34. 15  Treatment with COH34 suppressed cell survival ( Figure 1C D ) and attenuated clonogenic proliferation ( Figure 1E ) in both TNBC cell lines in a concentration-dependent manner. ","HCC1937/B-CellLine HCC1937/O HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O TNBC/O TNBC/O cell/O lines/O were/O further/O treated/O with/O the/O PARG-specific/O PARG-specific/O PARG-specific/O PARG-specific/O PARG-specific/O inhibitor,/O inhibitor,/O COH34./O COH34./O COH34./O COH34./O 15/O Treatment/O with/O COH34/O COH34/O COH34/O suppressed/O cell/O survival/O (/O Figure/O 1C/O 1C/O D/O )/O and/O attenuated/O attenuated/O attenuated/O clonogenic/O clonogenic/O clonogenic/O proliferation/O (/O Figure/O 1E/O 1E/O )/O in/O both/O TNBC/O TNBC/O cell/O lines/O in/O a/O concentration-dependent/O concentration-dependent/O concentration-dependent/O manner./O manner./O"
Figure 1 A ) The relative cell survival was examined by CCK8 assay for HCC1937 cells ( ) and SUM149PT cells ( ) transfected with si-NC or si-PARG. ,Figure/O 1/O A/O )/O The/O relative/O cell/O survival/O was/O examined/O by/O CCK8/O CCK8/O CCK8/O assay/O assay/O for/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O cells/O (/O )/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O (/O )/O transfected/O transfected/O with/O si-NC/O si-NC/O si-NC/O or/O si-PARG./O si-PARG./O si-PARG./O si-PARG./O si-PARG./O si-PARG./O
PARG protein levels of Western blot analysis are shown. β-Actin was used as a loading control. ( C ) The relative cell survival was examined by CCK8 assay for HCC1937 ( ) and SUM149PT ( ) cells treated with COH34 at different concentrations. ( E ). ,PARG/O PARG/O PARG/O protein/O levels/O of/O Western/O blot/O blot/O analysis/O are/O shown./O shown./O β-Actin/O β-Actin/O β-Actin/O β-Actin/O was/O used/O as/O a/O loading/O control./O control./O (/O C/O )/O The/O relative/O cell/O survival/O was/O examined/O by/O CCK8/B-CellLine CCK8/O CCK8/O assay/O assay/O for/O HCC1937/B-CellLine HCC1937/O HCC1937/O HCC1937/O (/O )/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O (/O )/O cells/O treated/O with/O COH34/O COH34/O COH34/O at/O different/O concentrations./O concentrations./O (/O E/O )./O )./O
Long-term relative cell viability was measured by crystal violet assay for HCC1937 and SUM149PT cells treated with COH34 at different concentrations.,Long-term/O Long-term/O Long-term/O relative/O cell/O viability/O viability/O was/O measured/O by/O crystal/O violet/O assay/O assay/O for/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O treated/O with/O COH34/O COH34/O COH34/O at/O different/O concentrations./O concentrations./O
"The combination treatment exerted more prominent cytotoxic effects at varying concentrations against BRCA1-mutant, PARPi-resistant HCC1937 and SUM149PT cells ( Figure 2A ). ","The/O combination/O treatment/O exerted/O exerted/O exerted/O more/O prominent/O cytotoxic/O cytotoxic/O cytotoxic/O cytotoxic/O cytotoxic/O effects/O at/O varying/O concentrations/O against/O BRCA1-mutant,/O BRCA1-mutant,/O BRCA1-mutant,/O BRCA1-mutant,/O BRCA1-mutant,/O BRCA1-mutant,/O PARPi-resistant/O PARPi-resistant/O PARPi-resistant/O PARPi-resistant/O PARPi-resistant/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O (/O Figure/O 2A/O 2A/O )./O )./O"
"Similarly, knockdown of USP14 with siRNA sensitized HCC1937 and SUM149PT cells to PARGi COH34, as analyzed by the cell viability assay ( Figure 2C ). ","Similarly,/O Similarly,/O knockdown/O knockdown/O of/O USP14/O USP14/O USP14/O with/O siRNA/O siRNA/O sensitized/O sensitized/O sensitized/O sensitized/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O to/O PARGi/O PARGi/O PARGi/O PARGi/O COH34,/O COH34,/O COH34,/O COH34,/O as/O analyzed/O by/O the/O cell/O viability/O viability/O assay/O assay/O (/O Figure/O 2C/O 2C/O )./O )./O"
The relative cell survival was examined by CCK8 assay for HCC1937 and SUM149PT cells treated with different concentrations of COH34 and IU1-248 for 72 h. ,The/O relative/O cell/O survival/O was/O examined/O by/O CCK8/B-CellLine CCK8/O CCK8/O assay/O assay/O for/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O treated/O with/O different/O concentrations/O of/O COH34/O COH34/O COH34/O and/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O for/O 72/O h./O h./O
Long-term relative cell viability was measured by crystal violet assay for HCC1937 and SUM149PT cells treated with 2.5 μM COH34 and 5 μM IU1-248 as single-agents or in combination for 6 days. ( ). ,Long-term/O Long-term/O Long-term/O relative/O cell/O viability/O viability/O was/O measured/O by/O crystal/O violet/O assay/O assay/O for/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O treated/O with/O 2.5/O 2.5/O 2.5/O μM/O μM/O COH34/O COH34/O COH34/O and/O 5/O μM/O μM/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O as/O single-agents/O single-agents/O single-agents/O or/O in/O combination/O for/O 6/O days./O days./O (/O )./O )./O
Relative cell survival was examined by CCK8 assay for HCC1937 cells and SUM149PT cells transfected with si-NC or si-USP14. Cells were treated with or without 2.5 μM COH34 for 72 h. ,Relative/O Relative/O cell/O survival/O was/O examined/O by/O CCK8/O CCK8/O CCK8/O assay/O assay/O for/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O cells/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O transfected/O transfected/O with/O si-NC/O si-NC/O si-NC/O or/O si-USP14./O si-USP14./O si-USP14./O si-USP14./O si-USP14./O si-USP14./O Cells/O Cells/O were/O treated/O with/O or/O without/O 2.5/O 2.5/O 2.5/O μM/O μM/O COH34/O COH34/O COH34/O for/O 72/O h./O h./O
Flow cytometric apoptosis analysis of HCC1937 and SUM149PT cells following 2.5 μM COH34 and 5 μM IU1-248 as single-agents or in combination for 48 h. ( B-D ).,Flow/O cytometric/O cytometric/O cytometric/O apoptosis/O apoptosis/O apoptosis/O analysis/O of/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O following/O 2.5/O 2.5/O 2.5/O μM/O μM/O COH34/O COH34/O COH34/O and/O 5/O μM/O μM/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O as/O single-agents/O single-agents/O single-agents/O or/O in/O combination/O for/O 48/O h./O h./O (/O B-D/O B-D/O B-D/O )./O )./O
"U2OS osteosarcoma cells are frequently used to study DNA damage responses, and U2OS reporter assay models have been established.","U2OS/O U2OS/O osteosarcoma/O osteosarcoma/O osteosarcoma/O osteosarcoma/O osteosarcoma/O cells/O are/O frequently/O used/O to/O study/O DNA/O damage/O responses,/O responses,/O and/O U2OS/O U2OS/O reporter/O assay/O assay/O models/O have/O been/O established./O established./O"
39  The present study directly analyzed changes in HR and NHEJ repair efficiencies in response to COH34/IU1-248 treatment in U2OS cells. ,39/O The/O present/O study/O directly/O analyzed/O changes/O in/O HR/O HR/O and/O NHEJ/O NHEJ/O NHEJ/O repair/O efficiencies/O efficiencies/O efficiencies/O efficiencies/O in/O response/O to/O COH34/IU1-248/O COH34/IU1-248/O COH34/IU1-248/O COH34/IU1-248/O COH34/IU1-248/O COH34/IU1-248/O COH34/IU1-248/O COH34/IU1-248/O COH34/IU1-248/O treatment/O in/O U2OS/B-CellLine U2OS/O cells./O cells./O
The U2OS cells were transiently transfected with si-BRCA1 to induce BRCA1 defects. ,The/O U2OS/B-CellLine U2OS/O cells/O were/O transiently/O transiently/O transiently/O transfected/O transfected/O with/O si-BRCA1/O si-BRCA1/O si-BRCA1/O si-BRCA1/O si-BRCA1/O to/O induce/O BRCA1/O BRCA1/O BRCA1/O defects./O defects./O
"As determined using HR and NHEJ reporter assays, the combination treatment significantly increased the NHEJ activity in BRCA1-mutant U2OS cells, whereas COH34 or IU1-248 used alone moderately induced NHEJ activity ( Figure 3C ). ","As/O determined/O using/O HR/O HR/O and/O NHEJ/O NHEJ/O NHEJ/O reporter/O assays,/O assays,/O assays,/O the/O combination/O treatment/O significantly/O increased/O the/O NHEJ/O NHEJ/O NHEJ/O activity/O in/O BRCA1-mutant/O BRCA1-mutant/O BRCA1-mutant/O BRCA1-mutant/O BRCA1-mutant/O U2OS/B-CellLine U2OS/O cells,/O cells,/O whereas/O COH34/O COH34/O COH34/O or/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O used/O alone/O moderately/O induced/O NHEJ/O NHEJ/O NHEJ/O activity/O (/O Figure/O 3C/O 3C/O )./O )./O"
Figure 3 ) Representative images of immunofluorescent staining for γH2AX ( ) and 53BP1 ( ) in HCC1937 and SUM149PT cells following 1.25 μM COH34 and 2.5 μM IU1-248 as single-agents or in combination for 48 h. ,Figure/O 3/O )/O Representative/O images/O of/O immunofluorescent/O immunofluorescent/O immunofluorescent/O immunofluorescent/O immunofluorescent/O immunofluorescent/O immunofluorescent/O staining/O staining/O for/O γH2AX/O γH2AX/O γH2AX/O γH2AX/O γH2AX/O (/O )/O and/O 53BP1/O 53BP1/O 53BP1/O 53BP1/O (/O )/O in/O HCC1937/B-CellLine HCC1937/O HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O following/O 1.25/O 1.25/O 1.25/O μM/O μM/O COH34/O COH34/O COH34/O and/O 2.5/O 2.5/O 2.5/O μM/O μM/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O as/O single-agents/O single-agents/O single-agents/O or/O in/O combination/O for/O 48/O h./O h./O
Cells with more than five γH2AX or 53BP1 foci were identified as positive. ( ) NHEJ ( ) and HR ( ) activities in U2OS cells following si-BRCA1 transfection and treatment of 1.25 μM COH34 and 2.5 μM IU1-248 as single-agents or in combination for 48 h were determined by the percentages of EGFP cells in the NHEJ and HR reporter assays. ,Cells/O Cells/O with/O more/O than/O five/O γH2AX/O γH2AX/O γH2AX/O γH2AX/O γH2AX/O or/O 53BP1/O 53BP1/O 53BP1/O 53BP1/O foci/O foci/O foci/O were/O identified/O as/O positive./O positive./O (/O )/O NHEJ/O NHEJ/O NHEJ/O (/O )/O and/O HR/O HR/O (/O )/O activities/O in/O U2OS/O U2OS/O cells/O following/O si-BRCA1/O si-BRCA1/O si-BRCA1/O si-BRCA1/O si-BRCA1/O transfection/O transfection/O transfection/O and/O treatment/O of/O 1.25/O 1.25/O 1.25/O μM/O μM/O COH34/O COH34/O COH34/O and/O 2.5/O 2.5/O 2.5/O μM/O μM/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O as/O single-agents/O single-agents/O single-agents/O or/O in/O combination/O for/O 48/O h/O were/O determined/O by/O the/O percentages/O percentages/O of/O EGFP/O EGFP/O EGFP/O cells/O in/O the/O NHEJ/O NHEJ/O NHEJ/O and/O HR/O HR/O reporter/O assays./O assays./O assays./O
HCC1937 and SUM149PT cells with silenced Ku70 expression exhibited a weakened response to the combination of PARGi and USP14i ( ). ,HCC1937/B-CellLine HCC1937/O HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O with/O silenced/O silenced/O Ku70/B-CellLine Ku70/O expression/O exhibited/O a/O weakened/O response/O to/O the/O combination/O of/O PARGi/O PARGi/O PARGi/O PARGi/O and/O USP14i/O USP14i/O USP14i/O USP14i/O (/O )./O )./O
Ku70 knockdown abrogated this synergistic inhibitory effect on the viability of HCC1937 and SUM149PT cells ( Figure 4C ). ,Ku70/O Ku70/O knockdown/O knockdown/O abrogated/O abrogated/O abrogated/O this/O synergistic/O synergistic/O synergistic/O synergistic/O inhibitory/O inhibitory/O effect/O on/O the/O viability/O viability/O of/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O (/O Figure/O 4C/O 4C/O )./O )./O
Figure 4 ) Long-term relative cell viability was measured by crystal violet assay for HCC1937 ( ) cells. ,Figure/O 4/O )/O Long-term/O Long-term/O Long-term/O relative/O cell/O viability/O viability/O was/O measured/O by/O crystal/O violet/O assay/O assay/O for/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O (/O )/O cells./O cells./O
Cells were transfected with si-NC or si-Ku70 and treated with 2.5 μM COH34 and 5 μM IU1-248 as single-agents or in combination for 6 (SUM149PT) or 7 (HCC1937) days. ,Cells/O Cells/O were/O transfected/O transfected/O with/O si-NC/O si-NC/O si-NC/O or/O si-Ku70/O si-Ku70/O si-Ku70/B-CellLine si-Ku70/O and/O treated/O with/O 2.5/O 2.5/O 2.5/O μM/O μM/O COH34/O COH34/O COH34/O and/O 5/O μM/O μM/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O as/O single-agents/O single-agents/O single-agents/O or/O in/O combination/O for/O 6/O (SUM149PT)/O (SUM149PT)/B-CellLine (SUM149PT)/B-CellLine (SUM149PT)/O (SUM149PT)/O (SUM149PT)/O (SUM149PT)/O (SUM149PT)/O or/O 7/O (HCC1937)/O (HCC1937)/B-CellLine (HCC1937)/O (HCC1937)/O (HCC1937)/O (HCC1937)/O days./O days./O
Ku70 protein levels of Western blot analysis are shown. β-Actin was used as a loading control. ( ) and ( ) The synergistic effect of concomitant PARG and USP14 inhibition in HCC1937 ( ) cells with or without Ku70-knockdown was measured by CCK8 assay after 72 h treatment.,Ku70/O Ku70/O protein/O levels/O of/O Western/O blot/O blot/O analysis/O are/O shown./O shown./O β-Actin/O β-Actin/O β-Actin/O β-Actin/O was/O used/O as/O a/O loading/O control./O control./O (/O )/O and/O (/O )/O The/O synergistic/O synergistic/O synergistic/O synergistic/O effect/O of/O concomitant/O concomitant/O concomitant/O concomitant/O PARG/O PARG/O PARG/O and/O USP14/O USP14/O USP14/O inhibition/O inhibition/O in/O HCC1937/B-CellLine HCC1937/O HCC1937/O HCC1937/O (/O )/O cells/O with/O or/O without/O Ku70-knockdown/O Ku70-knockdown/O Ku70-knockdown/O Ku70-knockdown/O Ku70-knockdown/O was/O measured/O by/O CCK8/O CCK8/O CCK8/O assay/O assay/O after/O 72/O h/O treatment./O treatment./O
"Western blotting analysis revealed that IU1-248, used alone or in combination with COH34, significantly suppressed c-Myc expression in both HCC1937 and SUM149PT cells ( Figure 5A ). ","Western/O blotting/O blotting/O blotting/O analysis/O revealed/O that/O IU1-248,/O IU1-248,/O IU1-248,/O IU1-248,/O IU1-248,/O IU1-248,/O used/O alone/O or/O in/O combination/O with/O COH34,/O COH34,/O COH34,/O COH34,/O significantly/O suppressed/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O expression/O in/O both/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O (/O Figure/O 5A/O 5A/O )./O )./O"
"The knockdown of c-Myc using siRNA sensitized HCC1937 and SUM149PT cells to COH34, as determined using a cell viability assay ( Figure 5B ). ","The/O knockdown/O knockdown/O of/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O using/O siRNA/O siRNA/O sensitized/O sensitized/O sensitized/O sensitized/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O to/O COH34,/O COH34,/O COH34,/O COH34,/O as/O determined/O using/O a/O cell/O viability/O viability/O assay/O assay/O (/O Figure/O 5B/O 5B/O )./O )./O"
"Conversely, ectopic expression of c-Myc abrogated the synergistic cytotoxic effects of IU1-248/COH34 in HCC1937 cells ( Figure 5D ). ","Conversely,/O Conversely,/O ectopic/O ectopic/O ectopic/O ectopic/O expression/O of/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O abrogated/O abrogated/O abrogated/O the/O synergistic/O synergistic/O synergistic/O synergistic/O cytotoxic/O cytotoxic/O cytotoxic/O cytotoxic/O cytotoxic/O effects/O of/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O in/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O cells/O (/O Figure/O 5D/O 5D/O )./O )./O"
"Further molecular mechanistic analysis revealed that, compared with observations in the control cells, the HCC1937 cells with c-Myc ectopic expression exhibited an attenuated accumulation of γH2AX foci in response to IU1-248/COH34 combined treatment ( Figure 5E ). ","Further/O molecular/O mechanistic/O mechanistic/O mechanistic/O analysis/O revealed/O that,/O that,/O compared/O with/O observations/O in/O the/O control/O cells,/O cells,/O the/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O cells/O with/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O ectopic/O ectopic/O ectopic/O ectopic/O expression/O exhibited/O an/O attenuated/O attenuated/O attenuated/O accumulation/O of/O γH2AX/O γH2AX/O γH2AX/O γH2AX/O γH2AX/O foci/O foci/O foci/O in/O response/O to/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O IU1-248/COH34/O combined/O treatment/O (/O Figure/O 5E/O 5E/O )./O )./O"
"Accordingly, the BRCA1-interfered U2OS cells overexpressing c-Myc also showed downregulated NHEJ activity after the combined treatment ( Figure 5F ). ","Accordingly,/O Accordingly,/O the/O BRCA1-interfered/O BRCA1-interfered/O BRCA1-interfered/O BRCA1-interfered/O BRCA1-interfered/O BRCA1-interfered/O U2OS/B-CellLine U2OS/O cells/O overexpressing/O overexpressing/O overexpressing/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O also/O showed/O downregulated/O downregulated/O downregulated/O downregulated/O NHEJ/O NHEJ/O NHEJ/O activity/O after/O the/O combined/O treatment/O (/O Figure/O 5F/O 5F/O )./O )./O"
Western blot analysis of c-Myc in HCC1937 and SUM149PT cells upon treatment with 2.5 μM COH34 and 5 μM IU1-248 as single-agents or in combination for 24 h. β-Actin was used as a loading control. ( ) transfected with si-NC or si-c-Myc. ,Western/O blot/O blot/O analysis/O of/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O in/O HCC1937/B-CellLine HCC1937/O HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O cells/O upon/O treatment/O with/O 2.5/O 2.5/O 2.5/O μM/O μM/O COH34/O COH34/O COH34/O and/O 5/O μM/O μM/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O as/O single-agents/O single-agents/O single-agents/O or/O in/O combination/O for/O 24/O h./O h./O β-Actin/O β-Actin/O β-Actin/O β-Actin/O was/O used/O as/O a/O loading/O control./O control./O (/O )/O transfected/O transfected/O with/O si-NC/O si-NC/O si-NC/O or/O si-c-Myc./O si-c-Myc./O si-c-Myc./O si-c-Myc./O si-c-Myc./O si-c-Myc./O si-c-Myc./O
The relative cell survival of HCC1937 cells with or without c-Myc overexpression was measured by CCK8 assay after treatment with 2.5 μM COH34 and 5 μM IU1-248 as single-agents or in combination for 72 h. ,The/O relative/O cell/O survival/O of/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O cells/O with/O or/O without/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O overexpression/O overexpression/O overexpression/O overexpression/O was/O measured/O by/O CCK8/B-CellLine CCK8/O CCK8/O assay/O assay/O after/O treatment/O with/O 2.5/O 2.5/O 2.5/O μM/O μM/O COH34/O COH34/O COH34/O and/O 5/O μM/O μM/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O as/O single-agents/O single-agents/O single-agents/O or/O in/O combination/O for/O 72/O h./O h./O
Representative images of immunofluorescent staining for γH2AX in HCC1937 cells with or without c-Myc overexpression. ,Representative/O images/O of/O immunofluorescent/O immunofluorescent/O immunofluorescent/O immunofluorescent/O immunofluorescent/O immunofluorescent/O immunofluorescent/O staining/O staining/O for/O γH2AX/O γH2AX/O γH2AX/O γH2AX/O γH2AX/O in/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O cells/O with/O or/O without/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O overexpression./O overexpression./O overexpression./O overexpression./O overexpression./O
NHEJ activity in U2OS cells with or without c-Myc overexpression following si-BRCA1 transfection and treatment of 1.25 μM COH34 and 2.5 μM IU1-248 as single-agents or in combination for 48 h were determined by the percentages of EGFP cells in the NHEJ reporter assay. ,NHEJ/O NHEJ/O NHEJ/O activity/O in/O U2OS/B-CellLine U2OS/O cells/O with/O or/O without/O c-Myc/O c-Myc/O c-Myc/O c-Myc/O overexpression/O overexpression/O overexpression/O overexpression/O following/O si-BRCA1/O si-BRCA1/O si-BRCA1/O si-BRCA1/O si-BRCA1/O transfection/O transfection/O transfection/O and/O treatment/O of/O 1.25/O 1.25/O 1.25/O μM/O μM/O COH34/O COH34/O COH34/O and/O 2.5/O 2.5/O 2.5/O μM/O μM/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O as/O single-agents/O single-agents/O single-agents/O or/O in/O combination/O for/O 48/O h/O were/O determined/O by/O the/O percentages/O percentages/O of/O EGFP/O EGFP/O EGFP/O cells/O in/O the/O NHEJ/O NHEJ/O NHEJ/O reporter/O assay./O assay./O assay./O
"43  Notably, the present study demonstrates for the first time, to the best of our knowledge, that the combined use of COH34 and IU1-248 significantly inhibits cell survival and proliferation and promotes the apoptosis in BRCA1-mutant, PARP inhibitor-resistant HCC1937 and SUM149PT TNBC cells. ","43/O Notably,/O Notably,/O Notably,/O the/O present/O study/O demonstrates/O for/O the/O first/O time,/O time,/O to/O the/O best/O of/O our/O knowledge,/O knowledge,/O that/O the/O combined/O use/O of/O COH34/O COH34/O COH34/O and/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O significantly/O inhibits/O inhibits/O inhibits/O cell/O survival/O and/O proliferation/O and/O promotes/O the/O apoptosis/O apoptosis/O apoptosis/O in/O BRCA1-mutant,/O BRCA1-mutant,/O BRCA1-mutant,/O BRCA1-mutant,/O BRCA1-mutant,/O BRCA1-mutant,/O PARP/O PARP/O inhibitor-resistant/O inhibitor-resistant/O inhibitor-resistant/O HCC1937/B-CellLine HCC1937/O HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O TNBC/O TNBC/O cells./O cells./O"
"Compared with observations when each treatment agent was used alone, the combined use of COH34 and IU1-248 had more notable therapeutic efficacy against HCC1937 and SUM149PT TNBC cells. ","Compared/O with/O observations/O when/O each/O treatment/O agent/O was/O used/O alone,/O alone,/O the/O combined/O use/O of/O COH34/O COH34/O COH34/O and/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O IU1-248/O had/O more/O notable/O therapeutic/O efficacy/O against/O HCC1937/B-CellLine HCC1937/B-CellLine HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O TNBC/O TNBC/O cells./O cells./O"
"32  In the present study, although increased 53BP1 (activating NHEJ and inhibiting HR of DNA DSBs) foci were observed in response to USP14i treatment in BRCA1-mutant HCC1937 and SUM149PT TNBC cells, it was found that neither USP14i alone nor in combination with PARGi altered the HR activity in BRCA1-depleted U2OS cells. ","32/O In/O the/O present/O study,/O study,/O although/O increased/O 53BP1/O 53BP1/O 53BP1/O 53BP1/O (activating/O (activating/O (activating/O NHEJ/O NHEJ/O NHEJ/O and/O inhibiting/O inhibiting/O inhibiting/O HR/O HR/O of/O DNA/O DSBs)/O DSBs)/O DSBs)/O DSBs)/O foci/O foci/O foci/O were/O observed/O in/O response/O to/O USP14i/O USP14i/O USP14i/O USP14i/O treatment/O in/O BRCA1-mutant/O BRCA1-mutant/O BRCA1-mutant/O BRCA1-mutant/O BRCA1-mutant/O HCC1937/B-CellLine HCC1937/O HCC1937/O HCC1937/O and/O SUM149PT/B-CellLine SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O SUM149PT/O TNBC/O TNBC/O cells,/O cells,/O it/O was/O found/O that/O neither/O USP14i/O USP14i/O USP14i/O USP14i/O alone/O nor/O in/O combination/O with/O PARGi/O PARGi/O PARGi/O PARGi/O altered/O the/O HR/O HR/O activity/O in/O BRCA1-depleted/O BRCA1-depleted/O BRCA1-depleted/O BRCA1-depleted/O BRCA1-depleted/O U2OS/B-CellLine U2OS/O cells./O cells./O"
"Curr Top Microbiol Immunol . 2006;302:169–203. doi:10.1007/3-540-32952-8_7 49.  Li Z, Owonikoko TK, Sun SY, et al. c-Myc suppression of DNA double-strand break repair. ","Curr/O Curr/O Curr/O Top/O Microbiol/O Microbiol/O Microbiol/O Immunol/O Immunol/O Immunol/O Immunol/O ./O 2006;302:169–203./O 2006;302:169–203./O 2006;302:169–203./O 2006;302:169–203./O 2006;302:169–203./O 2006;302:169–203./O 2006;302:169–203./O 2006;302:169–203./O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O doi:10.1007/3-540-32952-8_7/O 49./O 49./O Li/O Z,/O Z,/O Owonikoko/O Owonikoko/O Owonikoko/O Owonikoko/O TK,/O TK,/O TK,/O Sun/O SY,/O SY,/O SY,/O et/O al./O al./O c-Myc/O c-Myc/O c-Myc/O c-Myc/O suppression/O of/O DNA/O double-strand/O double-strand/O double-strand/O break/O repair./O repair./O"
"KGaA The complex tumor microenvironment constitutes a variety of barriers to prevent nanoparticles (NPs) delivery and results in extremely low accumulation of nanomedicines in solid tumors.  Here, a newly developed size-changeable collagenase-modified polymer micelle is employed to enhance the penetration and retention of nanomedicine in deep tumor tissue.  The TCPPB micelle is first formed by self-assembly of maleimide-terminated poly(ethylene glycol)-block-poly(β-amino ester) (MAL-PEG-PBAE) and succinic anhydride-modified cisplatin-conjugated poly(ε-caprolactone)-block-poly(ethylene oxide)-triphenylphosphonium (CDDP-PCL-PEO-TPP).  Next, Col-TCPPB NPs are prepd. through a ""click"" chem. combination of thiolated collagenase and maleimide groups on TCPPB micelle.  Finally, biocompatible chondroitin sulfate (CS) is coated to obtain CS/Col-TCPPB NPs for avoiding collagenase inactivation in blood circulation.  In tumor acidic microenvironment, the hydrophobic PBAE segments of the resultant micelles become hydrophilic, leading to a dissocn. and subsequent dissoln. of partial collagenase-contg. components (Col-PEG-PBAE) from NPs.  The dissolved Col-PEG-PBAE promotes the digestion of collagen fibers in tumor tissue like a scavenger, which enhances the NPs penetration.  Simultaneously, the increased hydrophilicity of residual Col-PEG-PBAE in the micellar matrix causes an expansion of the NPs, resulting in an enhanced intratumoral retention.  In tumor cells, the NPs target to release the cisplatin drugs into mitochondria, achieving an excellent anticancer efficacy.","KGaA/O KGaA/O KGaA/O KGaA/O The/O complex/O tumor/O microenvironment/O microenvironment/O microenvironment/O microenvironment/O microenvironment/O constitutes/O a/O variety/O of/O barriers/O to/O prevent/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O (NPs)/O (NPs)/O (NPs)/O (NPs)/O delivery/O and/O results/O in/O extremely/O low/O accumulation/O of/O nanomedicines/O nanomedicines/O nanomedicines/O nanomedicines/O nanomedicines/O in/O solid/O tumors./O tumors./O Here,/O Here,/O a/O newly/O developed/O size-changeable/O size-changeable/O size-changeable/O size-changeable/O collagenase-modified/O collagenase-modified/O collagenase-modified/O collagenase-modified/O collagenase-modified/O collagenase-modified/O polymer/O micelle/O micelle/O is/O employed/O to/O enhance/O the/O penetration/O and/O retention/O of/O nanomedicine/O nanomedicine/O nanomedicine/O nanomedicine/O nanomedicine/O in/O deep/O tumor/O tissue./O tissue./O The/O TCPPB/O TCPPB/O TCPPB/O TCPPB/O micelle/O micelle/O is/O first/O formed/O by/O self-assembly/O self-assembly/O self-assembly/O of/O maleimide-terminated/O maleimide-terminated/O maleimide-terminated/O maleimide-terminated/O maleimide-terminated/O poly(ethylene/O poly(ethylene/O poly(ethylene/O poly(ethylene/O poly(ethylene/O poly(ethylene/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O glycol)-block-poly(β-amino/O ester)/O ester)/O ester)/O (MAL-PEG-PBAE)/O (MAL-PEG-PBAE)/O (MAL-PEG-PBAE)/O (MAL-PEG-PBAE)/O (MAL-PEG-PBAE)/O (MAL-PEG-PBAE)/O (MAL-PEG-PBAE)/O (MAL-PEG-PBAE)/O (MAL-PEG-PBAE)/O (MAL-PEG-PBAE)/O and/O succinic/O succinic/O succinic/O anhydride-modified/O anhydride-modified/O anhydride-modified/O anhydride-modified/O anhydride-modified/O anhydride-modified/O cisplatin-conjugated/O cisplatin-conjugated/O cisplatin-conjugated/O cisplatin-conjugated/O cisplatin-conjugated/O cisplatin-conjugated/O cisplatin-conjugated/O cisplatin-conjugated/O cisplatin-conjugated/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O poly(ε-caprolactone)-block-poly(ethylene/O oxide)-triphenylphosphonium/O oxide)-triphenylphosphonium/O oxide)-triphenylphosphonium/O oxide)-triphenylphosphonium/O oxide)-triphenylphosphonium/O oxide)-triphenylphosphonium/O oxide)-triphenylphosphonium/O oxide)-triphenylphosphonium/O oxide)-triphenylphosphonium/O oxide)-triphenylphosphonium/O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O (CDDP-PCL-PEO-TPP)./O Next,/O Next,/O Col-TCPPB/O Col-TCPPB/O Col-TCPPB/O Col-TCPPB/O Col-TCPPB/O Col-TCPPB/O NPs/O NPs/O are/O prepd./O prepd./O prepd./O prepd./O through/O a/O ""click""/O ""click""/O ""click""/O chem./O chem./O chem./O combination/O of/O thiolated/O thiolated/O thiolated/O collagenase/O collagenase/O collagenase/O collagenase/O and/O maleimide/O maleimide/O maleimide/O groups/O on/O TCPPB/O TCPPB/O TCPPB/O TCPPB/O micelle./O micelle./O micelle./O Finally,/O Finally,/O biocompatible/O biocompatible/O biocompatible/O biocompatible/O chondroitin/O chondroitin/O chondroitin/O chondroitin/O sulfate/O sulfate/O sulfate/O (CS)/O (CS)/O (CS)/O is/O coated/O to/O obtain/O CS/Col-TCPPB/O CS/Col-TCPPB/O CS/Col-TCPPB/O CS/Col-TCPPB/O CS/Col-TCPPB/O CS/Col-TCPPB/O CS/Col-TCPPB/O CS/Col-TCPPB/O NPs/O NPs/O for/O avoiding/O collagenase/O collagenase/O collagenase/O collagenase/O inactivation/O inactivation/O inactivation/O in/O blood/O circulation./O circulation./O In/O tumor/O acidic/O microenvironment,/O microenvironment,/O microenvironment,/O microenvironment,/O microenvironment,/O microenvironment,/O the/O hydrophobic/O hydrophobic/O hydrophobic/O PBAE/O PBAE/O segments/O of/O the/O resultant/O resultant/O micelles/O micelles/O become/O hydrophilic,/O hydrophilic,/O hydrophilic,/O hydrophilic,/O hydrophilic,/O leading/O to/O a/O dissocn./O dissocn./O dissocn./O dissocn./O dissocn./O and/O subsequent/O dissoln./O dissoln./O dissoln./O dissoln./O of/O partial/O collagenase-contg./O collagenase-contg./O collagenase-contg./O collagenase-contg./O collagenase-contg./O collagenase-contg./O collagenase-contg./O collagenase-contg./O collagenase-contg./O components/O (Col-PEG-PBAE)/O (Col-PEG-PBAE)/O (Col-PEG-PBAE)/O (Col-PEG-PBAE)/O (Col-PEG-PBAE)/O (Col-PEG-PBAE)/O (Col-PEG-PBAE)/O (Col-PEG-PBAE)/O (Col-PEG-PBAE)/O from/O NPs./O NPs./O NPs./O The/O dissolved/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O promotes/O the/O digestion/O digestion/O digestion/O of/O collagen/O collagen/O collagen/O fibers/O in/O tumor/O tissue/O like/O a/O scavenger,/O scavenger,/O scavenger,/O scavenger,/O scavenger,/O which/O enhances/O enhances/O the/O NPs/O NPs/O penetration./O penetration./O Simultaneously,/O Simultaneously,/O Simultaneously,/O Simultaneously,/O Simultaneously,/O Simultaneously,/O the/O increased/O hydrophilicity/O hydrophilicity/O hydrophilicity/O hydrophilicity/O of/O residual/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O Col-PEG-PBAE/O in/O the/O micellar/O micellar/O matrix/O causes/O an/O expansion/O of/O the/O NPs,/O NPs,/O NPs,/O resulting/O in/O an/O enhanced/O intratumoral/O intratumoral/O intratumoral/O intratumoral/O retention./O retention./O In/O tumor/O cells,/O cells,/O the/O NPs/O NPs/O target/O to/O release/O the/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O drugs/O into/O mitochondria,/O mitochondria,/O mitochondria,/O mitochondria,/O mitochondria,/O achieving/O an/O excellent/O anticancer/O anticancer/O anticancer/O efficacy./O efficacy./O"
";  A NIR light triggered disintegratable nanoplatform for enhanced penetration and chemotherapy in deep tumor tissues Biomaterials 245 119840                 10.1016/j.biomaterials.2020.119840⁲⁲ Xiong, Xiang; Xu, Zeng; Huang, Huabei; Wang, Yi; Zhao, Jingya; Guo, Xing; Zhou, Shaobing BIMADU 0142-9612 Poor penetration and resultant low accumulation of nanomedicines in deep tumor tissues greatly reduce the chemotherapeutic efficiency.  How to maximize the tumor accumulation is still a great challenge in the development of nanocarriers.  Here, we developed a cyclic Arg-Gly-Asp-Phe-Lys peptide (cRGD) modified and near-IR (NIR) light triggered disintegratable liposomal nanoplatform (PAM/Pt@IcLipo), where photosensitizer indocyanine green (ICG) was loaded in the out layer and polyamindoamine (PAMAM) dendrimers grafting cisplatin prodrug (PAM/Pt) were encapsulated inside.  The cRGD ligands render the liposomes to target αvβ3 integrin receptors overexpressed by vascular endothelial cells in tumor tissues.  Long blood circulation can be achieved owing to the relative large size (∼162 nm) of the liposomes.  When irradiated by NIR light locally at tumor site, ICG heating detonated the thermosensitive liposomes to release the small sized PAM/Pt nanoparticles (∼8.6 nm), which were capable of penetrating into the deep tumor tissue.  The in vivo results also showed that the PAM/Pt@IcLipo could significantly improve the penetration of cisplatin drug in deep tumor tissues under NIR light irradn., resulting in an excellent antitumor activity.  This nanoplatform solved the dilemma of long blood circulation of large sized nanoparticles and deep penetration of small sized nanoparticles, opening up a new strategy in the development of nanomedicines for cancer therapy.",";/O A/O NIR/O NIR/O light/O triggered/O disintegratable/O disintegratable/O disintegratable/O disintegratable/O disintegratable/O nanoplatform/O nanoplatform/O nanoplatform/O nanoplatform/O nanoplatform/O for/O enhanced/O penetration/O and/O chemotherapy/O chemotherapy/O chemotherapy/O in/O deep/O tumor/O tissues/O Biomaterials/O Biomaterials/O Biomaterials/O Biomaterials/O Biomaterials/O 245/O 119840/O 119840/O 119840/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O 10.1016/j.biomaterials.2020.119840⁲⁲/O Xiong,/O Xiong,/O Xiong,/O Xiang;/O Xiang;/O Xiang;/O Xu,/O Xu,/O Zeng;/O Zeng;/O Zeng;/O Huang,/O Huang,/O Huabei;/O Huabei;/O Huabei;/O Huabei;/O Wang,/O Wang,/O Yi;/O Yi;/O Zhao,/O Zhao,/O Jingya;/O Jingya;/O Jingya;/O Guo,/O Guo,/O Xing;/O Xing;/O Xing;/O Zhou,/O Zhou,/O Shaobing/O Shaobing/O Shaobing/O BIMADU/O BIMADU/O BIMADU/O BIMADU/O 0142-9612/O 0142-9612/O 0142-9612/O 0142-9612/O 0142-9612/O Poor/O penetration/O and/O resultant/O resultant/O low/O accumulation/O of/O nanomedicines/O nanomedicines/O nanomedicines/O nanomedicines/O nanomedicines/O in/O deep/O tumor/O tissues/O greatly/O reduce/O the/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O efficiency./O efficiency./O How/O to/O maximize/O maximize/O maximize/O the/O tumor/O accumulation/O is/O still/O a/O great/O challenge/O in/O the/O development/O of/O nanocarriers./O nanocarriers./O nanocarriers./O nanocarriers./O nanocarriers./O nanocarriers./O Here,/O Here,/O we/O developed/O a/O cyclic/O cyclic/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O Arg-Gly-Asp-Phe-Lys/O peptide/O peptide/O (cRGD)/O (cRGD)/O (cRGD)/O (cRGD)/O (cRGD)/O (cRGD)/O modified/O and/O near-IR/O near-IR/O near-IR/O near-IR/O (NIR)/O (NIR)/O (NIR)/O (NIR)/O light/O triggered/O disintegratable/O disintegratable/O disintegratable/O disintegratable/O disintegratable/O liposomal/O liposomal/O liposomal/O nanoplatform/O nanoplatform/O nanoplatform/O nanoplatform/O nanoplatform/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O (PAM/Pt@IcLipo),/O where/O photosensitizer/O photosensitizer/O photosensitizer/O photosensitizer/O indocyanine/O indocyanine/O indocyanine/O indocyanine/O indocyanine/O green/O (ICG)/O (ICG)/O (ICG)/O (ICG)/O (ICG)/O was/O loaded/O in/O the/O out/O layer/O and/O polyamindoamine/O polyamindoamine/O polyamindoamine/O polyamindoamine/O polyamindoamine/O (PAMAM)/O (PAMAM)/O (PAMAM)/O (PAMAM)/O (PAMAM)/O dendrimers/O dendrimers/O dendrimers/O dendrimers/O grafting/O grafting/O grafting/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O prodrug/O prodrug/O prodrug/O (PAM/Pt)/O (PAM/Pt)/O (PAM/Pt)/O (PAM/Pt)/O (PAM/Pt)/O (PAM/Pt)/O (PAM/Pt)/O were/O encapsulated/O encapsulated/O encapsulated/O encapsulated/O inside./O inside./O The/O cRGD/O cRGD/O cRGD/O cRGD/O ligands/O ligands/O ligands/O render/O the/O liposomes/O liposomes/O liposomes/O to/O target/O αvβ3/O αvβ3/O αvβ3/O αvβ3/O integrin/O integrin/O integrin/O integrin/O receptors/O overexpressed/O overexpressed/O overexpressed/O by/O vascular/O endothelial/O endothelial/O endothelial/O endothelial/O cells/O in/O tumor/O tissues./O tissues./O Long/O blood/O circulation/O can/O be/O achieved/O owing/O to/O the/O relative/O large/O size/O (∼162/O (∼162/O nm)/O nm)/O of/O the/O liposomes./O liposomes./O liposomes./O liposomes./O When/O irradiated/O irradiated/O irradiated/O irradiated/O by/O NIR/O NIR/O light/O locally/O at/O tumor/O site,/O site,/O ICG/O ICG/O ICG/O heating/O detonated/O detonated/O detonated/O the/O thermosensitive/O thermosensitive/O thermosensitive/O thermosensitive/O thermosensitive/O liposomes/O liposomes/O liposomes/O to/O release/O the/O small/O sized/O PAM/Pt/O PAM/Pt/O PAM/Pt/O PAM/Pt/O PAM/Pt/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O (∼8.6/O (∼8.6/O (∼8.6/O (∼8.6/O nm),/O nm),/O nm),/O which/O were/O capable/O of/O penetrating/O into/O the/O deep/O tumor/O tissue./O tissue./O The/O in/O vivo/O vivo/O results/O also/O showed/O that/O the/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O PAM/Pt@IcLipo/O could/O significantly/O improve/O the/O penetration/O of/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O drug/O in/O deep/O tumor/O tissues/O under/O NIR/O NIR/O light/O irradn.,/O irradn.,/O irradn.,/O irradn.,/O irradn.,/O resulting/O in/O an/O excellent/O antitumor/O antitumor/O antitumor/O activity./O activity./O This/O nanoplatform/O nanoplatform/O nanoplatform/O nanoplatform/O nanoplatform/O solved/O the/O dilemma/O dilemma/O of/O long/O blood/O circulation/O of/O large/O sized/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O and/O deep/O penetration/O of/O small/O sized/O nanoparticles,/O nanoparticles,/O nanoparticles,/O nanoparticles,/O nanoparticles,/O nanoparticles,/O opening/O up/O a/O new/O strategy/O in/O the/O development/O of/O nanomedicines/O nanomedicines/O nanomedicines/O nanomedicines/O nanomedicines/O for/O cancer/O therapy./O therapy./O"
"Hyaluronic acid controls the uptake pathway and intracellular trafficking of an octaarginine-modified gene vector in CD44 positive- and CD44 negative-cells 2015 52 198                 10.1016/j.biomaterials.2015.02.027⁳⁷ Yamada, Yuma; Hashida, Masahiro; Harashima, Hideyoshi 189-198 The cellular uptake pathway for a gene vector is an important factor in transgene expression.  We previously constructed an original gene vector, multifunctional envelope-type nano device (MEND).  The use of octaarginine (R8), a cell-penetrating peptide dramatically enhanced the transfection activity of the MEND since efficient cellular uptake via macropinocytosis, while the R8 should overcome its poor cell selectivity.  Here we prepd. an R8-MEND equipped with GALA (a peptide for endosomal escape) (R8/GALA-MEND) coated with hyaluronic acid (HA) (HA-R8/GALA-MEND), a natural ligand for cancer cells overexpressing CD44.  We investigated the cellular uptake pathway of the HA-R8/GALA-MEND and the R8/GALA-MEND using HCT116 cells overexpressing CD44.  Both carriers were taken up by cells mainly via macropinocytosis, whereas only the HA-R8/GALA-MEND was partially internalized into cells via a CD44-mediated pathway.  Investigation of transgene expression showed that the HA-R8/GALA-MEND had a high transfection activity in HCT116 cells via both macropinocytotic and CD44-mediated pathways.  On the other hand, the value for the HA-R8/GALA-MEND was significantly decreased compared with the value for the R8/GALA-MEND in NIH3T3 cells (CD44-neg. cells).  These findings indicate that the HA-coating controls the intracellular pathway for R8-modified nanocarriers, and that a CD44-mediated pathway is an important route for transgene expression.","Hyaluronic/O Hyaluronic/O Hyaluronic/O Hyaluronic/O acid/O controls/O the/O uptake/O uptake/O pathway/O and/O intracellular/O intracellular/O intracellular/O trafficking/O of/O an/O octaarginine-modified/O octaarginine-modified/O octaarginine-modified/O octaarginine-modified/O octaarginine-modified/O octaarginine-modified/O octaarginine-modified/O gene/O vector/O in/O CD44/O CD44/O positive-/O positive-/O and/O CD44/O CD44/O negative-cells/O negative-cells/O negative-cells/O 2015/O 52/O 198/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O 10.1016/j.biomaterials.2015.02.027⁳⁷/O Yamada,/O Yamada,/O Yamada,/O Yuma;/O Yuma;/O Yuma;/O Hashida,/O Hashida,/O Hashida,/O Hashida,/O Masahiro;/O Masahiro;/O Masahiro;/O Masahiro;/O Harashima,/O Harashima,/O Harashima,/O Hideyoshi/O Hideyoshi/O Hideyoshi/O 189-198/O 189-198/O 189-198/O The/O cellular/O uptake/O uptake/O pathway/O for/O a/O gene/O vector/O is/O an/O important/O factor/O in/O transgene/O transgene/O expression./O expression./O We/O previously/O constructed/O an/O original/O gene/O vector,/O vector,/O multifunctional/O multifunctional/O multifunctional/O envelope-type/O envelope-type/O envelope-type/O nano/O nano/O device/O (MEND)./O (MEND)./O (MEND)./O (MEND)./O (MEND)./O The/O use/O of/O octaarginine/O octaarginine/O octaarginine/O octaarginine/O octaarginine/O (R8),/O (R8),/O (R8),/O (R8),/O (R8),/O a/O cell-penetrating/O cell-penetrating/O cell-penetrating/O peptide/O peptide/O dramatically/O enhanced/O the/O transfection/O transfection/O transfection/O activity/O of/O the/O MEND/O MEND/O since/O efficient/O cellular/O uptake/O uptake/O via/O macropinocytosis,/O macropinocytosis,/O macropinocytosis,/O macropinocytosis,/O macropinocytosis,/O macropinocytosis,/O while/O the/O R8/O R8/O should/O overcome/O its/O poor/O cell/O selectivity./O selectivity./O selectivity./O Here/O we/O prepd./O prepd./O prepd./O prepd./O an/O R8-MEND/O R8-MEND/O R8-MEND/O R8-MEND/O R8-MEND/O equipped/O with/O GALA/O GALA/O (a/O (a/O peptide/O peptide/O for/O endosomal/O endosomal/O endosomal/O escape)/O escape)/O (R8/GALA-MEND)/O (R8/GALA-MEND)/O (R8/GALA-MEND)/O (R8/GALA-MEND)/O (R8/GALA-MEND)/O (R8/GALA-MEND)/O (R8/GALA-MEND)/O (R8/GALA-MEND)/O (R8/GALA-MEND)/O (R8/GALA-MEND)/O coated/O with/O hyaluronic/O hyaluronic/O hyaluronic/O hyaluronic/O acid/O (HA)/O (HA)/O (HA)/O (HA)/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O (HA-R8/GALA-MEND),/O a/O natural/O ligand/O ligand/O ligand/O for/O cancer/O cells/O overexpressing/O overexpressing/O overexpressing/O CD44./O CD44./O CD44./O We/O investigated/O the/O cellular/O uptake/O uptake/O pathway/O of/O the/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O and/O the/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O using/O HCT116/O HCT116/O HCT116/O HCT116/O cells/O overexpressing/O overexpressing/O overexpressing/O CD44./O CD44./O CD44./O Both/O carriers/O were/O taken/O up/O by/O cells/O mainly/O via/O macropinocytosis,/O macropinocytosis,/O macropinocytosis,/O macropinocytosis,/O macropinocytosis,/O macropinocytosis,/O whereas/O only/O the/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O was/O partially/O internalized/O internalized/O into/O cells/O via/O a/O CD44-mediated/O CD44-mediated/O CD44-mediated/O CD44-mediated/O pathway./O pathway./O Investigation/O of/O transgene/O transgene/O expression/O showed/O that/O the/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O had/O a/O high/O transfection/O transfection/O transfection/O activity/O in/O HCT116/O HCT116/O HCT116/O HCT116/O cells/O via/O both/O macropinocytotic/O macropinocytotic/O macropinocytotic/O macropinocytotic/O macropinocytotic/O macropinocytotic/O and/O CD44-mediated/O CD44-mediated/O CD44-mediated/O CD44-mediated/O pathways./O pathways./O On/O the/O other/O hand,/O hand,/O the/O value/O for/O the/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O HA-R8/GALA-MEND/O was/O significantly/O decreased/O compared/O with/O the/O value/O for/O the/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O R8/GALA-MEND/O in/O NIH3T3/O NIH3T3/O NIH3T3/O NIH3T3/O NIH3T3/O NIH3T3/O cells/O (CD44-neg./O (CD44-neg./O (CD44-neg./O (CD44-neg./O (CD44-neg./O (CD44-neg./O (CD44-neg./O cells)./O cells)./O cells)./O These/O findings/O indicate/O that/O the/O HA-coating/O HA-coating/O HA-coating/O HA-coating/O controls/O the/O intracellular/O intracellular/O intracellular/O pathway/O for/O R8-modified/O R8-modified/O R8-modified/O R8-modified/O nanocarriers,/O nanocarriers,/O nanocarriers,/O nanocarriers,/O nanocarriers,/O nanocarriers,/O and/O that/O a/O CD44-mediated/O CD44-mediated/O CD44-mediated/O CD44-mediated/O pathway/O is/O an/O important/O route/O for/O transgene/O transgene/O expression./O expression./O"
"For apoptosis assays, 4T1 cells (1 × 10⁵  cells/well) were incubated with PBS, DOX, HA-DOX NPs, or HA-DOX-JSK NPs (DOX 16 μg/mL) for 24 h. ","For/O apoptosis/O apoptosis/O apoptosis/O assays,/O assays,/O assays,/O 4T1/O 4T1/O 4T1/O cells/O (1/O (1/O ×/O 10⁵/O 10⁵/O cells/well)/O cells/well)/O cells/well)/O cells/well)/O were/O incubated/O incubated/O incubated/O incubated/O with/O PBS,/O PBS,/O DOX,/O DOX,/O DOX,/O HA-DOX/O HA-DOX/O HA-DOX/O HA-DOX/O HA-DOX/O NPs,/O NPs,/O NPs,/O or/O HA-DOX-JSK/O HA-DOX-JSK/O HA-DOX-JSK/O HA-DOX-JSK/O HA-DOX-JSK/O HA-DOX-JSK/O HA-DOX-JSK/O HA-DOX-JSK/O HA-DOX-JSK/O NPs/O NPs/O (DOX/O (DOX/O (DOX/O 16/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O for/O 24/O h./O h./O"
"Curcumin loaded poly (lactic-co-glycolic) acid nanofiber for the treatment of carcinoma Colloids Surf., B 117 128 134                 10.1016/j.colsurfb.2014.02.020⁳⁷ Sampath, Malathi; Lakra, Rachita; Korrapati, PurnaSai; Sengottuvelan, Balasubramanian Colloids and Surfaces, B: Biointerfaces 128-134 CSBBEQ 0927-7765 Poly (DL-lactic-co-glycolic) acid [PLGA] copolymers with different ratios (78/22, 68/32 and 61/39) and mol. wt. (15,400, 11,000 and 10,000 Da) were synthesized and characterized by 1H NMR, FTIR, GPC and TGA-DTA studies.  Curcumin loaded PLGA with the size of 100-300 nm were obtained by electrospinning in which no visible aggregation obsd. on the surface.  The diam. of CPNF (61/39) nanofiber obtained from the topog. imaging by AFM is 160 ± 10 nm.  The water contact angle measurements indicate that an increase in GA content results in increase in the hydrophilicity of the PLGA copolymer.  The in vitro release profile and release kinetics from the CPNF demonstrated a sustained release of curcumin from CPNF.  The release profile follows Korsmeyer-Peppas model suggesting a combination of surface drug dissoln. and non-Fickian diffusion as a major drug release mechanism.  The effect of CPNF on cell viability was assessed by the MTT (3-[4,5-dimethylthiazol-2-yl] ","Curcumin/O Curcumin/O Curcumin/O Curcumin/O loaded/O poly/O poly/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O (lactic-co-glycolic)/O acid/O nanofiber/O nanofiber/O nanofiber/O nanofiber/O for/O the/O treatment/O of/O carcinoma/O carcinoma/O carcinoma/O Colloids/O Colloids/O Colloids/O Surf.,/O Surf.,/O Surf.,/O Surf.,/O B/O 117/O 128/O 134/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O 10.1016/j.colsurfb.2014.02.020⁳⁷/O Sampath,/O Sampath,/O Sampath,/O Malathi;/O Malathi;/O Malathi;/O Malathi;/O Lakra,/O Lakra,/O Lakra,/O Rachita;/O Rachita;/O Rachita;/O Rachita;/O Korrapati,/O Korrapati,/O Korrapati,/O Korrapati,/O Korrapati,/O PurnaSai;/O PurnaSai;/O PurnaSai;/O PurnaSai;/O PurnaSai;/O PurnaSai;/O Sengottuvelan,/O Sengottuvelan,/O Sengottuvelan,/O Sengottuvelan,/O Sengottuvelan,/O Sengottuvelan,/O Balasubramanian/O Balasubramanian/O Balasubramanian/O Balasubramanian/O Balasubramanian/O Colloids/O Colloids/O Colloids/O and/O Surfaces,/O Surfaces,/O Surfaces,/O B:/O B:/O Biointerfaces/O Biointerfaces/O Biointerfaces/O Biointerfaces/O Biointerfaces/O Biointerfaces/O 128-134/O 128-134/O 128-134/O CSBBEQ/O CSBBEQ/O CSBBEQ/O CSBBEQ/O 0927-7765/O 0927-7765/O 0927-7765/O 0927-7765/O 0927-7765/O Poly/O Poly/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O (DL-lactic-co-glycolic)/O acid/O [PLGA]/O [PLGA]/O [PLGA]/O [PLGA]/O [PLGA]/O copolymers/O copolymers/O copolymers/O with/O different/O ratios/O (78/22,/O (78/22,/O (78/22,/O (78/22,/O (78/22,/O 68/32/O 68/32/O 68/32/O and/O 61/39)/O 61/39)/O 61/39)/O 61/39)/O and/O mol./O mol./O mol./O wt./O wt./O wt./O (15,400,/O (15,400,/O (15,400,/O (15,400,/O (15,400,/O 11,000/O 11,000/O 11,000/O and/O 10,000/O 10,000/O 10,000/O Da)/O Da)/O were/O synthesized/O and/O characterized/O by/O 1H/O 1H/O NMR,/O NMR,/O NMR,/O FTIR,/O FTIR,/O FTIR,/O FTIR,/O GPC/O GPC/O and/O TGA-DTA/O TGA-DTA/O TGA-DTA/O TGA-DTA/O TGA-DTA/O studies./O studies./O Curcumin/O Curcumin/O Curcumin/O Curcumin/O loaded/O PLGA/O PLGA/O PLGA/O with/O the/O size/O of/O 100-300/O 100-300/O 100-300/O nm/O were/O obtained/O by/O electrospinning/O electrospinning/O electrospinning/O electrospinning/O in/O which/O no/O visible/O aggregation/O aggregation/O aggregation/O obsd./O obsd./O obsd./O obsd./O on/O the/O surface./O surface./O The/O diam./O diam./O diam./O of/O CPNF/O CPNF/O (61/39)/O (61/39)/O (61/39)/O (61/39)/O (61/39)/O nanofiber/O nanofiber/O nanofiber/O nanofiber/O obtained/O from/O the/O topog./O topog./O topog./O imaging/O by/O AFM/O AFM/O is/O 160/O ±/O 10/O nm./O nm./O The/O water/O contact/O angle/O measurements/O indicate/O that/O an/O increase/O in/O GA/O content/O results/O in/O increase/O in/O the/O hydrophilicity/O hydrophilicity/O hydrophilicity/O hydrophilicity/O of/O the/O PLGA/O PLGA/O PLGA/O copolymer./O copolymer./O copolymer./O copolymer./O The/O in/O vitro/O vitro/O vitro/O release/O profile/O and/O release/O kinetics/O kinetics/O from/O the/O CPNF/O CPNF/O demonstrated/O a/O sustained/O release/O of/O curcumin/O curcumin/O curcumin/O curcumin/O from/O CPNF./O CPNF./O CPNF./O The/O release/O profile/O follows/O Korsmeyer-Peppas/O Korsmeyer-Peppas/O Korsmeyer-Peppas/O Korsmeyer-Peppas/O Korsmeyer-Peppas/O Korsmeyer-Peppas/O Korsmeyer-Peppas/O model/O suggesting/O a/O combination/O of/O surface/O drug/O dissoln./O dissoln./O dissoln./O dissoln./O and/O non-Fickian/O non-Fickian/O non-Fickian/O non-Fickian/O non-Fickian/O diffusion/O as/O a/O major/O drug/O release/O mechanism./O mechanism./O The/O effect/O of/O CPNF/O CPNF/O on/O cell/O viability/O viability/O was/O assessed/O by/O the/O MTT/O MTT/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O (3-[4,5-dimethylthiazol-2-yl]/O"
"2,5-diphenyltetrazolium bromide) assay to examine the cytotoxic effect of released curcumin on A431 cells in vitro.","2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O 2,5-diphenyltetrazolium/O bromide)/O bromide)/O bromide)/O bromide)/O assay/O assay/O to/O examine/O the/O cytotoxic/O cytotoxic/O cytotoxic/O cytotoxic/O cytotoxic/O effect/O of/O released/O curcumin/O curcumin/O curcumin/O curcumin/O on/O A431/B-CellLine A431/O A431/O cells/O in/O vitro./O vitro./O vitro./O vitro./O"
"CMEJAJ 1385-8947 In the present work, novel dual drug loaded - anionic graphene oxide/cationic polyethyleneimine/poly anionic dextran sulfate (GO/PEI/DS) was synthesized by a layer-by-layer self-assembly technique for transdermal anti-cancer drug delivery.  Doxorubicin (DOX) was loaded onto folic acid conjugated graphene oxide (GO) and methotrexate (MTX) was loaded onto dextran sulfate (DS).  The drug carrier was characterized by fourier transform IR spectroscopy, x-ray diffraction spectroscopy, dynamic light scattering anal., SEM, at. force microscopy, transmission electron microscopy, zeta-potential anal., drug loading and encapsulation efficiency, equil. swelling studies, in vitro drug release studies, hemocompatibility assays, in vitro cytotoxicity assay, skin irritation studies, ex vivo skin permeation studies and in vivo pharmacokinetic studies.  The cytotoxicity of synthesized materials was evaluated against MCF-7 breast cancer cells using an MTT assay and apoptosis assay.  The synergistic effect of DOX and MTX to inhibit the growth of cancer cells was also confirmed.  The final dual drug-loaded carrier showed a cell viability of 36.38% towards MCF-7 cancer cells while it showed a cell viability of >87.65% towards normal L929 cell lines.  The in vivo pharmacokinetic studies in Wistar rats through oral and transdermal routes of administration, the transdermal route of administration of dual drug-loaded material provided a sustained and prolonged drug existence in the blood circulation system.  The mean residence time of drugs in the bloodstream via oral administration was 83.98 ± 3.71 h, while that of the transdermal route of administration was 149.62 ± 6.11 h.  The results revealed that the synthesized dual drug-loaded material showed a good pH-dependent controlled and sustained release profile for both DOX and MTX via the transdermal route of administration in comparison with oral delivery.","CMEJAJ/O CMEJAJ/O CMEJAJ/O CMEJAJ/O CMEJAJ/O 1385-8947/O 1385-8947/O 1385-8947/O 1385-8947/O 1385-8947/O In/O the/O present/O work,/O work,/O novel/O dual/O drug/O loaded/O -/O anionic/O anionic/O anionic/O graphene/O graphene/O oxide/cationic/O oxide/cationic/O oxide/cationic/O oxide/cationic/O oxide/cationic/O polyethyleneimine/poly/O polyethyleneimine/poly/O polyethyleneimine/poly/O polyethyleneimine/poly/O polyethyleneimine/poly/O polyethyleneimine/poly/O polyethyleneimine/poly/O polyethyleneimine/poly/O polyethyleneimine/poly/O polyethyleneimine/poly/O anionic/O anionic/O anionic/O dextran/O dextran/O dextran/O dextran/O sulfate/O sulfate/O sulfate/O (GO/PEI/DS)/O (GO/PEI/DS)/O (GO/PEI/DS)/O (GO/PEI/DS)/O (GO/PEI/DS)/O (GO/PEI/DS)/O (GO/PEI/DS)/O (GO/PEI/DS)/O was/O synthesized/O by/O a/O layer-by-layer/O layer-by-layer/O layer-by-layer/O layer-by-layer/O layer-by-layer/O self-assembly/O self-assembly/O self-assembly/O technique/O for/O transdermal/O transdermal/O transdermal/O anti-cancer/O anti-cancer/O anti-cancer/O drug/O delivery./O delivery./O Doxorubicin/O Doxorubicin/O Doxorubicin/O Doxorubicin/O Doxorubicin/O (DOX)/O (DOX)/O (DOX)/O (DOX)/O was/O loaded/O onto/O folic/O folic/O acid/O conjugated/O conjugated/O conjugated/O graphene/O graphene/O oxide/O (GO)/O (GO)/O (GO)/O and/O methotrexate/O methotrexate/O methotrexate/O methotrexate/O methotrexate/O (MTX)/O (MTX)/O (MTX)/O (MTX)/O (MTX)/O was/O loaded/O onto/O dextran/O dextran/O dextran/O dextran/O sulfate/O sulfate/O sulfate/O (DS)./O (DS)./O (DS)./O (DS)./O The/O drug/O carrier/O was/O characterized/O by/O fourier/O fourier/O transform/O IR/O IR/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O x-ray/O x-ray/O x-ray/O diffraction/O diffraction/O diffraction/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O dynamic/O light/O scattering/O anal.,/O anal.,/O anal.,/O SEM,/O SEM,/O SEM,/O at./O at./O force/O microscopy,/O microscopy,/O microscopy,/O microscopy,/O transmission/O electron/O microscopy,/O microscopy,/O microscopy,/O microscopy,/O zeta-potential/O zeta-potential/O zeta-potential/O zeta-potential/O anal.,/O anal.,/O anal.,/O drug/O loading/O and/O encapsulation/O encapsulation/O encapsulation/O encapsulation/O efficiency,/O efficiency,/O equil./O equil./O equil./O equil./O swelling/O studies,/O studies,/O in/O vitro/O vitro/O vitro/O drug/O release/O studies,/O studies,/O hemocompatibility/O hemocompatibility/O hemocompatibility/O hemocompatibility/O hemocompatibility/O hemocompatibility/O assays,/O assays,/O assays,/O in/O vitro/O vitro/O vitro/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O assay,/O assay,/O assay,/O skin/O irritation/O studies,/O studies,/O ex/O vivo/O vivo/O skin/O permeation/O permeation/O permeation/O studies/O and/O in/O vivo/O vivo/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O studies./O studies./O The/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O of/O synthesized/O materials/O was/O evaluated/O against/O MCF-7/O MCF-7/O MCF-7/O MCF-7/O breast/O cancer/O cells/O using/O an/O MTT/O MTT/O assay/O assay/O and/O apoptosis/O apoptosis/O apoptosis/O assay./O assay./O assay./O The/O synergistic/O synergistic/O synergistic/O synergistic/O effect/O of/O DOX/O DOX/O and/O MTX/O MTX/O MTX/O to/O inhibit/O inhibit/O the/O growth/O of/O cancer/O cells/O was/O also/O confirmed./O confirmed./O The/O final/O dual/O drug-loaded/O drug-loaded/O drug-loaded/O carrier/O showed/O a/O cell/O viability/O viability/O of/O 36.38%/O 36.38%/O 36.38%/O 36.38%/O towards/O MCF-7/O MCF-7/O MCF-7/O MCF-7/O cancer/O cells/O while/O it/O showed/O a/O cell/O viability/O viability/O of/O >87.65%/O >87.65%/O >87.65%/O >87.65%/O >87.65%/O towards/O normal/O L929/O L929/O L929/O cell/O lines./O lines./O The/O in/O vivo/O vivo/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O studies/O in/O Wistar/O Wistar/O Wistar/O rats/O through/O oral/O and/O transdermal/O transdermal/O transdermal/O routes/O of/O administration,/O administration,/O the/O transdermal/O transdermal/O transdermal/O route/O of/O administration/O of/O dual/O drug-loaded/O drug-loaded/O drug-loaded/O material/O provided/O a/O sustained/O and/O prolonged/O drug/O existence/O in/O the/O blood/O circulation/O system./O system./O The/O mean/O residence/O time/O of/O drugs/O in/O the/O bloodstream/O bloodstream/O via/O oral/O administration/O was/O 83.98/O 83.98/O 83.98/O ±/O 3.71/O 3.71/O 3.71/O h,/O h,/O while/O that/O of/O the/O transdermal/O transdermal/O transdermal/O route/O of/O administration/O was/O 149.62/O 149.62/O 149.62/O ±/O 6.11/O 6.11/O 6.11/O h./O h./O The/O results/O revealed/O that/O the/O synthesized/O dual/O drug-loaded/O drug-loaded/O drug-loaded/O material/O showed/O a/O good/O pH-dependent/O pH-dependent/O pH-dependent/O controlled/O and/O sustained/O release/O profile/O for/O both/O DOX/O DOX/O and/O MTX/O MTX/O MTX/O via/O the/O transdermal/O transdermal/O transdermal/O route/O of/O administration/O in/O comparison/O with/O oral/O delivery./O delivery./O"
"175                 10.1016/j.ijbiomac.2013.03.058⁵⁵ Adsorbent for hydroquinone removal based on graphene oxide functionalized with magnetic cyclodextrin-chitosan Li, Leilei; Fan, Lulu; Sun, Min; Qiu, Huamin; Li, Xiangjun; Duan, Huimin; Luo, Chuannan 169-175 IJBMDR 0141-8130 Magnetic cyclodextrin-chitosan/graphene oxide (CCGO) with high surface area was synthesized via a simple chem. bonding method.  The characteristics results of FTIR, SEM, TEM and XRD showed that CCGO was prepd.  The large satn. magnetization (22.35 emu/g) of the synthesized nanoparticles allows fast sepn. of the CCGO from liq. suspension.  These composites could efficiently remove hydroquinone from simulated wastewater with a facile subsequent solid-liq. sepn. because of their large area, abundant hydroxyl and amino groups with handy operation, and hydrophobicity.  The hydroquinone removal process was found to obey the Freundlich adsorption model and its kinetics followed pseudo-second-order rate equation.  The hydroquinone removal mechanism of CCGO might be attributed to the electrostatic adsorption of hydroquinone in the form of neg. charged hydroquinone by pos. charged chitosan, accompanying hydroquinone absorbed by cavities of the cyclodextrin, and forming hydrogen bonds between hydroquinone and the hydroxyl groups on the surface of CCGO.  The used CCGO could be recovered with ethanol.  This study provides a promising nanostructured adsorbent with easy sepn. property for heavy metal ions removal.","175/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O 10.1016/j.ijbiomac.2013.03.058⁵⁵/O Adsorbent/O Adsorbent/O Adsorbent/O for/O hydroquinone/O hydroquinone/O hydroquinone/O hydroquinone/O removal/O based/O on/O graphene/O graphene/O oxide/O functionalized/O functionalized/O with/O magnetic/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O cyclodextrin-chitosan/O Li,/O Li,/O Leilei;/O Leilei;/O Leilei;/O Leilei;/O Fan,/O Fan,/O Lulu;/O Lulu;/O Sun,/O Sun,/O Min;/O Min;/O Qiu,/O Qiu,/O Qiu,/O Huamin;/O Huamin;/O Huamin;/O Huamin;/O Li,/O Li,/O Xiangjun;/O Xiangjun;/O Xiangjun;/O Xiangjun;/O Duan,/O Duan,/O Duan,/O Huimin;/O Huimin;/O Huimin;/O Luo,/O Luo,/O Luo,/O Chuannan/O Chuannan/O Chuannan/O 169-175/O 169-175/O 169-175/O IJBMDR/O IJBMDR/O IJBMDR/O IJBMDR/O 0141-8130/O 0141-8130/O 0141-8130/O 0141-8130/O 0141-8130/O Magnetic/O Magnetic/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O cyclodextrin-chitosan/graphene/O oxide/O (CCGO)/O (CCGO)/O (CCGO)/O (CCGO)/O (CCGO)/O with/O high/O surface/O area/O was/O synthesized/O via/O a/O simple/O chem./O chem./O chem./O bonding/O method./O method./O The/O characteristics/O results/O of/O FTIR,/O FTIR,/O FTIR,/O FTIR,/O SEM,/O SEM,/O SEM,/O TEM/O TEM/O and/O XRD/O XRD/O showed/O that/O CCGO/O CCGO/O CCGO/O was/O prepd./O prepd./O prepd./O prepd./O The/O large/O satn./O satn./O satn./O magnetization/O magnetization/O (22.35/O (22.35/O (22.35/O (22.35/O emu/g)/O emu/g)/O emu/g)/O emu/g)/O emu/g)/O of/O the/O synthesized/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O allows/O fast/O sepn./O sepn./O sepn./O sepn./O of/O the/O CCGO/O CCGO/O CCGO/O from/O liq./O liq./O liq./O suspension./O suspension./O These/O composites/O composites/O could/O efficiently/O remove/O hydroquinone/O hydroquinone/O hydroquinone/O hydroquinone/O from/O simulated/O wastewater/O wastewater/O with/O a/O facile/O facile/O facile/O subsequent/O solid-liq./O solid-liq./O solid-liq./O solid-liq./O solid-liq./O sepn./O sepn./O sepn./O sepn./O because/O of/O their/O large/O area,/O area,/O abundant/O hydroxyl/O hydroxyl/O hydroxyl/O hydroxyl/O and/O amino/O groups/O with/O handy/O operation,/O operation,/O and/O hydrophobicity./O hydrophobicity./O hydrophobicity./O hydrophobicity./O hydrophobicity./O The/O hydroquinone/O hydroquinone/O hydroquinone/O hydroquinone/O removal/O process/O was/O found/O to/O obey/O the/O Freundlich/O Freundlich/O Freundlich/O Freundlich/O adsorption/O adsorption/O adsorption/O model/O and/O its/O kinetics/O kinetics/O followed/O pseudo-second-order/O pseudo-second-order/O pseudo-second-order/O pseudo-second-order/O pseudo-second-order/O rate/O equation./O equation./O The/O hydroquinone/O hydroquinone/O hydroquinone/O hydroquinone/O removal/O mechanism/O of/O CCGO/O CCGO/O CCGO/O might/O be/O attributed/O to/O the/O electrostatic/O electrostatic/O adsorption/O adsorption/O adsorption/O of/O hydroquinone/O hydroquinone/O hydroquinone/O hydroquinone/O in/O the/O form/O of/O neg./O neg./O neg./O charged/O hydroquinone/O hydroquinone/O hydroquinone/O hydroquinone/O by/O pos./O pos./O pos./O charged/O chitosan,/O chitosan,/O chitosan,/O chitosan,/O accompanying/O hydroquinone/O hydroquinone/O hydroquinone/O hydroquinone/O absorbed/O by/O cavities/O cavities/O cavities/O of/O the/O cyclodextrin,/O cyclodextrin,/O cyclodextrin,/O cyclodextrin,/O cyclodextrin,/O cyclodextrin,/O cyclodextrin,/O cyclodextrin,/O cyclodextrin,/O and/O forming/O hydrogen/O bonds/O between/O hydroquinone/O hydroquinone/O hydroquinone/O hydroquinone/O and/O the/O hydroxyl/O hydroxyl/O hydroxyl/O hydroxyl/O groups/O on/O the/O surface/O of/O CCGO./O CCGO./O CCGO./O CCGO./O The/O used/O CCGO/O CCGO/O CCGO/O could/O be/O recovered/O with/O ethanol./O ethanol./O This/O study/O provides/O a/O promising/O nanostructured/O nanostructured/O nanostructured/O nanostructured/O adsorbent/O adsorbent/O adsorbent/O with/O easy/O sepn./O sepn./O sepn./O sepn./O property/O for/O heavy/O metal/O ions/O removal./O removal./O"
"The doxorubicin-loaded carrier was characterized by Fourier transform infrared (FTIR) spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, ultraviolet–visible (UV–vis) spectroscopy, zeta potential analysis, dynamic light scattering (DLS), scanning electron microscopy (SEM), and transmission electron microscopy (TEM). ","The/O doxorubicin-loaded/O doxorubicin-loaded/O doxorubicin-loaded/O doxorubicin-loaded/O doxorubicin-loaded/O doxorubicin-loaded/O doxorubicin-loaded/O carrier/O was/O characterized/O by/O Fourier/O Fourier/O transform/O infrared/O (FTIR)/O (FTIR)/O (FTIR)/O (FTIR)/O (FTIR)/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O nuclear/O magnetic/O resonance/O (NMR)/O (NMR)/O (NMR)/O (NMR)/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O ultraviolet–visible/O ultraviolet–visible/O ultraviolet–visible/O ultraviolet–visible/O ultraviolet–visible/O (UV–vis)/O (UV–vis)/O (UV–vis)/O (UV–vis)/O (UV–vis)/O (UV–vis)/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O zeta/O zeta/O potential/O analysis,/O analysis,/O dynamic/O light/O scattering/O (DLS),/O (DLS),/O (DLS),/O (DLS),/O (DLS),/O scanning/O electron/O microscopy/O microscopy/O microscopy/O (SEM),/O (SEM),/O (SEM),/O (SEM),/O (SEM),/O and/O transmission/O electron/O microscopy/O microscopy/O microscopy/O (TEM)./O (TEM)./O (TEM)./O (TEM)./O (TEM)./O"
3.1.5.  Scanning Electron Microscopy (SEM) ,3.1.5./O 3.1.5./O 3.1.5./O 3.1.5./O 3.1.5./O 3.1.5./O Scanning/O Scanning/O Scanning/O Electron/O Electron/O Electron/O Microscopy/O Microscopy/O Microscopy/O (SEM)/O (SEM)/O (SEM)/O (SEM)/O
"The size of the drug-loaded final material was determined by DLS, SEM, and TEM analytical methods as 135.8 ± 2.2 nm, in the range of the nano level, which shows its efficacy toward drug loading capacity and active drug delivery. ","The/O size/O of/O the/O drug-loaded/O drug-loaded/O drug-loaded/O final/O material/O was/O determined/O by/O DLS,/O DLS,/O DLS,/O SEM,/O SEM,/O SEM,/O and/O TEM/O TEM/O analytical/O methods/O as/O 135.8/O 135.8/O 135.8/O ±/O 2.2/O 2.2/O 2.2/O nm,/O nm,/O in/O the/O range/O of/O the/O nano/O nano/O level,/O level,/O which/O shows/O its/O efficacy/O toward/O drug/O loading/O capacity/O and/O active/O drug/O delivery./O delivery./O"
"All error bars show +/−SEM, *** P  < 0.001, ****  < 0.0001. Full size image In addition to previously identified genes involved in cytokine responses [ ], we identified the gene  Cbfβ  among our most significantly enriched sgRNA. ","All/O error/O bars/O show/O +/−SEM,/O +/−SEM,/O +/−SEM,/O +/−SEM,/O +/−SEM,/O +/−SEM,/O ***/O ***/O ***/O P/O </O 0.001,/O 0.001,/O 0.001,/O 0.001,/O 0.001,/O ****/O ****/O ****/O ****/O </O 0.0001./O 0.0001./O 0.0001./O 0.0001./O 0.0001./O Full/O size/O image/O In/O addition/O to/O previously/O identified/O genes/O involved/O in/O cytokine/O cytokine/O cytokine/O cytokine/O responses/O [/O ],/O ],/O we/O identified/O the/O gene/O Cbfβ/O Cbfβ/O Cbfβ/O Cbfβ/O among/O our/O most/O significantly/O enriched/O enriched/O enriched/O sgRNA./O sgRNA./O sgRNA./O sgRNA./O"
"WT human breast cancer MCF10A tumour cells [ 8 ], showing common DEGs across all three cell lines. ","WT/O WT/O human/O breast/O cancer/O MCF10A/B-CellLine MCF10A/O MCF10A/O MCF10A/O tumour/O tumour/O cells/O [/O 8/O ],/O ],/O showing/O common/O DEGs/O DEGs/O DEGs/O across/O all/O three/O cell/O lines./O lines./O"
"F G  and   MC38 tumour cells, measured by ICP-MS, unpaired t-test,   vs.   MC38 tumour cells, columns represent replicate samples. *  < 0.05, **  < 0.01, ***  < 0.001. We next investigated the applicability of our results to human cancer by comparing our DEG analyses in mouse MC38 and E0771 cancer cells to a published RNA-seq dataset from wildtype and CBFβ deficient human breast cancer cells (MCF10A) [ ]. ","F/O G/O and/O MC38/O MC38/O tumour/O tumour/O cells,/O cells,/O measured/O by/O ICP-MS,/O ICP-MS,/O ICP-MS,/O ICP-MS,/O ICP-MS,/O unpaired/O unpaired/O unpaired/O t-test,/O t-test,/O t-test,/O t-test,/O vs./O vs./O MC38/O MC38/O tumour/O tumour/O cells,/O cells,/O columns/O represent/O replicate/O replicate/O samples./O samples./O */O </O 0.05,/O 0.05,/O 0.05,/O 0.05,/O **/O **/O </O 0.01,/O 0.01,/O 0.01,/O 0.01,/O ***/O ***/O ***/O </O 0.001./O 0.001./O 0.001./O 0.001./O 0.001./O We/O next/O investigated/O the/O applicability/O applicability/O applicability/O of/O our/O results/O to/O human/O cancer/O by/O comparing/O our/O DEG/O DEG/O analyses/O in/O mouse/O MC38/O MC38/O and/O E0771/O E0771/O E0771/O E0771/O E0771/O cancer/O cells/O to/O a/O published/O RNA-seq/O RNA-seq/O RNA-seq/O RNA-seq/O dataset/O dataset/O from/O wildtype/O wildtype/O and/O CBFβ/O CBFβ/O CBFβ/O deficient/O deficient/O human/O breast/O cancer/O cells/O (MCF10A)/O (MCF10A)/B-CellLine (MCF10A)/O (MCF10A)/O (MCF10A)/O (MCF10A)/O [/O ]./O ]./O"
"All error bars show +/−SEM, *  < 0.01, **** Given that zinc supplementation reduced tumour cell sensitivity to TNF, we next questioned whether sequestering zinc would contrariwise increase tumour cell TNF sensitivity. ","All/O error/O bars/O show/O +/−SEM,/O +/−SEM,/O +/−SEM,/O +/−SEM,/O +/−SEM,/O +/−SEM,/O */O </O 0.01,/O 0.01,/O 0.01,/O 0.01,/O ****/O ****/O ****/O ****/O Given/O that/O zinc/O supplementation/O supplementation/O reduced/O tumour/O tumour/O cell/O sensitivity/O to/O TNF,/O TNF,/O TNF,/O we/O next/O questioned/O whether/O sequestering/O sequestering/O sequestering/O zinc/O would/O contrariwise/O contrariwise/O contrariwise/O contrariwise/O increase/O tumour/O tumour/O cell/O TNF/O TNF/O sensitivity./O sensitivity./O"
"B 2022 5784 5795                 10.1039/D2TB01242A Zwitterionic polymer coated sorafenib-loaded Fe3O4 composite nanoparticles induced ferroptosis for cancer therapy Lin, Jingbo; Zhang, Jiaxin; Wang, Kuang; Guo, Shengdi; Yang, Wuli 30 5784-5795 JMCBDV 2050-7518 Royal Society of Chemistry Ferroptosis, as a form of cell death different from apoptosis, is very promising for the treatment of cancer in nonapoptotic systems.  Since iron is a key component in the induction of ferroptosis in cells, the use of iron-based nanomaterials in treating cancer through ferroptosis is of great significance.  Therefore, in this study, magnetic nanoparticles (MNP) were coated with the zwitterionic polymer poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC), and then loaded with sorafenib (SRF) to obtain drug-loaded composite nanoparticles MNP@PMPC-SRF.  Fe3O4 provided a large no. of ferric/ferrous ions as an iron source, releasing Fe2+ for the regulation of the ferroptosis process and enhancing the effect of the induced cellular ferroptosis on the treatment of colon cancer with SRF.  The zwitterionic polymer PMPC effectively extended the blood circulation time, resulting in an enhanced tumor accumulation of the nanodrug.  MNP@PMPC-SRF exhibited good biocompatibility for in vivo application and showed an excellent tumor inhibitory effect on HCT116 tumor-bearing nude mice.","B/O 2022/O 2022/O 5784/O 5784/O 5784/O 5795/O 5795/O 5795/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O 10.1039/D2TB01242A/O Zwitterionic/O Zwitterionic/O Zwitterionic/O Zwitterionic/O Zwitterionic/O polymer/O coated/O sorafenib-loaded/O sorafenib-loaded/O sorafenib-loaded/O sorafenib-loaded/O sorafenib-loaded/O sorafenib-loaded/O Fe3O4/O Fe3O4/O Fe3O4/O Fe3O4/O composite/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O induced/O ferroptosis/O ferroptosis/O ferroptosis/O ferroptosis/O for/O cancer/O therapy/O Lin,/O Lin,/O Jingbo;/O Jingbo;/O Jingbo;/O Zhang,/O Zhang,/O Jiaxin;/O Jiaxin;/O Jiaxin;/O Jiaxin;/O Wang,/O Wang,/O Kuang;/O Kuang;/O Kuang;/O Guo,/O Guo,/O Shengdi;/O Shengdi;/O Shengdi;/O Shengdi;/O Yang,/O Yang,/O Wuli/O Wuli/O 30/O 5784-5795/O 5784-5795/O 5784-5795/O 5784-5795/O 5784-5795/O 5784-5795/O 5784-5795/O JMCBDV/O JMCBDV/O JMCBDV/O JMCBDV/O JMCBDV/O 2050-7518/O 2050-7518/O 2050-7518/O 2050-7518/O 2050-7518/O Royal/O Society/O of/O Chemistry/O Ferroptosis,/O Ferroptosis,/O Ferroptosis,/O Ferroptosis,/O Ferroptosis,/O as/O a/O form/O of/O cell/O death/O different/O from/O apoptosis,/O apoptosis,/O apoptosis,/O apoptosis,/O is/O very/O promising/O for/O the/O treatment/O of/O cancer/O in/O nonapoptotic/O nonapoptotic/O nonapoptotic/O nonapoptotic/O nonapoptotic/O systems./O systems./O Since/O iron/O is/O a/O key/O component/O in/O the/O induction/O of/O ferroptosis/O ferroptosis/O ferroptosis/O ferroptosis/O in/O cells,/O cells,/O the/O use/O of/O iron-based/O iron-based/O iron-based/O nanomaterials/O nanomaterials/O nanomaterials/O nanomaterials/O nanomaterials/O in/O treating/O cancer/O through/O ferroptosis/O ferroptosis/O ferroptosis/O ferroptosis/O is/O of/O great/O significance./O significance./O Therefore,/O Therefore,/O in/O this/O study,/O study,/O magnetic/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O (MNP)/O (MNP)/O (MNP)/O (MNP)/O were/O coated/O with/O the/O zwitterionic/O zwitterionic/O zwitterionic/O zwitterionic/O zwitterionic/O polymer/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O poly(2-methacryloyloxyethyl/O phosphorylcholine)/O phosphorylcholine)/O phosphorylcholine)/O phosphorylcholine)/O phosphorylcholine)/O phosphorylcholine)/O phosphorylcholine)/O phosphorylcholine)/O (PMPC),/O (PMPC),/O (PMPC),/O (PMPC),/O (PMPC),/O and/O then/O loaded/O with/O sorafenib/O sorafenib/O sorafenib/O sorafenib/O (SRF)/O (SRF)/O (SRF)/O (SRF)/O to/O obtain/O drug-loaded/O drug-loaded/O drug-loaded/O composite/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O nanoparticles/O MNP@PMPC-SRF./O MNP@PMPC-SRF./O MNP@PMPC-SRF./O MNP@PMPC-SRF./O MNP@PMPC-SRF./O MNP@PMPC-SRF./O MNP@PMPC-SRF./O MNP@PMPC-SRF./O MNP@PMPC-SRF./O Fe3O4/O Fe3O4/O Fe3O4/O Fe3O4/O provided/O a/O large/O no./O no./O of/O ferric/ferrous/O ferric/ferrous/O ferric/ferrous/O ferric/ferrous/O ferric/ferrous/O ferric/ferrous/O ferric/ferrous/O ions/O as/O an/O iron/O source,/O source,/O releasing/O Fe2+/O Fe2+/O Fe2+/O for/O the/O regulation/O of/O the/O ferroptosis/O ferroptosis/O ferroptosis/O ferroptosis/O process/O and/O enhancing/O the/O effect/O of/O the/O induced/O cellular/O ferroptosis/O ferroptosis/O ferroptosis/O ferroptosis/O on/O the/O treatment/O of/O colon/O colon/O cancer/O with/O SRF./O SRF./O SRF./O The/O zwitterionic/O zwitterionic/O zwitterionic/O zwitterionic/O zwitterionic/O polymer/O PMPC/O PMPC/O effectively/O extended/O the/O blood/O circulation/O time,/O time,/O resulting/O in/O an/O enhanced/O tumor/O accumulation/O of/O the/O nanodrug./O nanodrug./O nanodrug./O nanodrug./O nanodrug./O MNP@PMPC-SRF/O MNP@PMPC-SRF/O MNP@PMPC-SRF/O MNP@PMPC-SRF/O MNP@PMPC-SRF/O MNP@PMPC-SRF/O MNP@PMPC-SRF/O MNP@PMPC-SRF/O exhibited/O good/O biocompatibility/O biocompatibility/O biocompatibility/O biocompatibility/O biocompatibility/O for/O in/O vivo/O vivo/O application/O and/O showed/O an/O excellent/O tumor/O inhibitory/O inhibitory/O effect/O on/O HCT116/O HCT116/O HCT116/O HCT116/O tumor-bearing/O tumor-bearing/O tumor-bearing/O nude/O mice./O mice./O"
"2017 284 291                 10.1021/acs.nanolett.6b04060 Switching Apoptosis to Ferroptosis: Metal-Organic Network for High-Efficiency Anticancer Therapy Zheng, Di-Wei; Lei, Qi; Zhu, Jing-Yi; Fan, Jin-Xuan; Li, Chu-Xin; Li, Cao; Xu, Zushun; Cheng, Si-Xue; Zhang, Xian-Zheng 284-291 NALEFD 1530-6984 Discovering advanced materials for regulating cell death is of great importance in the development of anticancer therapy.  Herein, by harnessing the recently discovered oxidative stress regulation ability of p53 and the Fenton reaction inducing capability of metal-org. network (MON), MON encapsulated with p53 plasmid (MON-p53) was designed to eradicate cancer cells via ferroptosis/apoptosis hybrid pathway.  After confirming the detailed mechanism of MON-p53 in evoking ferroptosis, we further discovered that MON-p53 mediated a ""bystander effect"" to further sensitize cancer cells toward the MON-p53 induced ferroptosis.  A 75-day anticancer expt. indicated that MON-p53 treatment not only suppressed the tumor growth but also prolonged the life-span of tumor bearing mice.  Owing to its ability to promote intracellular oxidative stress, MON-p53 decreased the blood metastasis, lung metastasis, and liver metastasis.  As a consequence, discovering methods to induce cell ferroptosis would provide a new insight in designing anticancer materials.","2017/O 284/O 284/O 291/O 291/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O 10.1021/acs.nanolett.6b04060/O Switching/O Switching/O Switching/O Apoptosis/O Apoptosis/O Apoptosis/O to/O Ferroptosis:/O Ferroptosis:/O Ferroptosis:/O Ferroptosis:/O Ferroptosis:/O Metal-Organic/O Metal-Organic/O Metal-Organic/O Network/O for/O High-Efficiency/O High-Efficiency/O High-Efficiency/O High-Efficiency/O High-Efficiency/O Anticancer/O Anticancer/O Anticancer/O Therapy/O Zheng,/O Zheng,/O Di-Wei;/O Di-Wei;/O Di-Wei;/O Di-Wei;/O Lei,/O Lei,/O Lei,/O Qi;/O Qi;/O Zhu,/O Zhu,/O Jing-Yi;/O Jing-Yi;/O Jing-Yi;/O Jing-Yi;/O Fan,/O Fan,/O Jin-Xuan;/O Jin-Xuan;/O Jin-Xuan;/O Jin-Xuan;/O Jin-Xuan;/O Li,/O Li,/O Chu-Xin;/O Chu-Xin;/O Chu-Xin;/O Chu-Xin;/O Chu-Xin;/O Li,/O Li,/O Cao;/O Cao;/O Xu,/O Xu,/O Zushun;/O Zushun;/O Zushun;/O Zushun;/O Cheng,/O Cheng,/O Si-Xue;/O Si-Xue;/O Si-Xue;/O Si-Xue;/O Si-Xue;/O Zhang,/O Zhang,/O Xian-Zheng/O Xian-Zheng/O Xian-Zheng/O Xian-Zheng/O 284-291/O 284-291/O 284-291/O 284-291/O 284-291/O NALEFD/O NALEFD/O NALEFD/O NALEFD/O 1530-6984/O 1530-6984/O 1530-6984/O 1530-6984/O 1530-6984/O 1530-6984/O Discovering/O Discovering/O advanced/O materials/O for/O regulating/O cell/O death/O is/O of/O great/O importance/O in/O the/O development/O of/O anticancer/O anticancer/O anticancer/O therapy./O therapy./O Herein,/O Herein,/O Herein,/O by/O harnessing/O harnessing/O the/O recently/O discovered/O oxidative/O oxidative/O oxidative/O oxidative/O stress/O regulation/O ability/O of/O p53/O p53/O and/O the/O Fenton/O Fenton/O reaction/O inducing/O inducing/O capability/O of/O metal-org./O metal-org./O metal-org./O metal-org./O network/O (MON),/O (MON),/O (MON),/O (MON),/O (MON),/O MON/O MON/O encapsulated/O encapsulated/O encapsulated/O encapsulated/O with/O p53/O p53/O plasmid/O plasmid/O plasmid/O plasmid/O (MON-p53)/O (MON-p53)/O (MON-p53)/O (MON-p53)/O (MON-p53)/O (MON-p53)/O (MON-p53)/O was/O designed/O to/O eradicate/O eradicate/O cancer/O cells/O via/O ferroptosis/apoptosis/O ferroptosis/apoptosis/O ferroptosis/apoptosis/O ferroptosis/apoptosis/O ferroptosis/apoptosis/O ferroptosis/apoptosis/O ferroptosis/apoptosis/O ferroptosis/apoptosis/O hybrid/O pathway./O pathway./O After/O confirming/O the/O detailed/O mechanism/O of/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O in/O evoking/O evoking/O ferroptosis,/O ferroptosis,/O ferroptosis,/O ferroptosis,/O ferroptosis,/O we/O further/O discovered/O that/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O mediated/O a/O ""bystander/O ""bystander/O ""bystander/O ""bystander/O effect""/O effect""/O to/O further/O sensitize/O sensitize/O sensitize/O sensitize/O cancer/O cells/O toward/O the/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O induced/O ferroptosis./O ferroptosis./O ferroptosis./O ferroptosis./O ferroptosis./O A/O 75-day/O 75-day/O 75-day/O anticancer/O anticancer/O anticancer/O expt./O expt./O expt./O indicated/O that/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O treatment/O not/O only/O suppressed/O the/O tumor/O growth/O but/O also/O prolonged/O the/O life-span/O life-span/O life-span/O of/O tumor/O bearing/O mice./O mice./O Owing/O Owing/O to/O its/O ability/O to/O promote/O intracellular/O intracellular/O intracellular/O oxidative/O oxidative/O oxidative/O oxidative/O stress,/O stress,/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O MON-p53/O decreased/O the/O blood/O metastasis,/O metastasis,/O metastasis,/O metastasis,/O lung/O metastasis,/O metastasis,/O metastasis,/O metastasis,/O and/O liver/O metastasis./O metastasis./O metastasis./O metastasis./O As/O a/O consequence,/O consequence,/O discovering/O methods/O to/O induce/O cell/O ferroptosis/O ferroptosis/O ferroptosis/O ferroptosis/O would/O provide/O a/O new/O insight/O in/O designing/O anticancer/O anticancer/O anticancer/O materials./O materials./O"
";  Rational design of ROS-responsive nanocarriers for targeted X-ray-induced photodynamic therapy and cascaded chemotherapy of intracranial glioblastoma Nanoscale 14 5054 5067                 10.1039/D2NR00436D Zhang, Beibei; Xue, Rui; Sun, Chunyang 5054-5067 NANOHL 2040-3372 Glioblastoma (GBM) is the most lethal primary intracranial tumor because of its high invasiveness and recurrence.  Therefore, nanocarriers with blood-brain barrier (BBB) penetration and transcranial-controlled drug release and activation are rather attractive options for glioblastoma treatment.  Herein, we designed a multifunctional nanocarrier (T-TKNPVP) that combined targeted X-ray-induced photodynamic therapy (X-PDT) and cascaded reactive oxygen species (ROS)-boosted chemotherapy.  The T-TKNPVP loaded with verteporfin (VP) and paclitaxel (PTX) was self-assembled from an angiopep-2 (Ang) peptide, functionalized Ang-PEG-DSPE and ROS-sensitive PEG-TK-PTX conjugate.  After systemic injection, the T-TKNPVP efficiently crossed the BBB and targeted the GBM cells via receptor-mediated transcytosis.  Upon X-ray irradn., they can generate a certain amt. of ROS, which not only induces X-PDT but also locoregionally activates PTX release and action by cleaving the TK bridged bonds.  As evidenced by 9.4 T MRI and other expts., such nanocarriers offer significant growth inhibition of GBM in situ and prolong the survival times of U87-MG tumor-bearing mice.  Taken together, the designed T-TKNPVP provided an alternative avenue for realizing transcranial X-PDT and X-ray-activated chemotherapy for targeted and locoregional GBM treatment in vivo.",";/O Rational/O Rational/O design/O of/O ROS-responsive/O ROS-responsive/O ROS-responsive/O ROS-responsive/O ROS-responsive/O ROS-responsive/O ROS-responsive/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O for/O targeted/O X-ray-induced/O X-ray-induced/O X-ray-induced/O X-ray-induced/O X-ray-induced/O photodynamic/O photodynamic/O therapy/O and/O cascaded/O cascaded/O cascaded/O chemotherapy/O chemotherapy/O chemotherapy/O of/O intracranial/O intracranial/O intracranial/O intracranial/O intracranial/O glioblastoma/O glioblastoma/O glioblastoma/O glioblastoma/O Nanoscale/O Nanoscale/O Nanoscale/O 14/O 5054/O 5054/O 5054/O 5067/O 5067/O 5067/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O 10.1039/D2NR00436D/O Zhang,/O Zhang,/O Beibei;/O Beibei;/O Beibei;/O Beibei;/O Xue,/O Xue,/O Xue,/O Rui;/O Rui;/O Rui;/O Sun,/O Sun,/O Chunyang/O Chunyang/O 5054-5067/O 5054-5067/O 5054-5067/O 5054-5067/O 5054-5067/O 5054-5067/O 5054-5067/O NANOHL/O NANOHL/O NANOHL/O NANOHL/O 2040-3372/O 2040-3372/O 2040-3372/O 2040-3372/O 2040-3372/O 2040-3372/O Glioblastoma/O Glioblastoma/O Glioblastoma/O Glioblastoma/O (GBM)/O (GBM)/O (GBM)/O (GBM)/O is/O the/O most/O lethal/O primary/O intracranial/O intracranial/O intracranial/O intracranial/O intracranial/O tumor/O because/O of/O its/O high/O invasiveness/O invasiveness/O and/O recurrence./O recurrence./O recurrence./O recurrence./O Therefore,/O Therefore,/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O with/O blood-brain/O blood-brain/O blood-brain/O barrier/O (BBB)/O (BBB)/O (BBB)/O (BBB)/O penetration/O and/O transcranial-controlled/O transcranial-controlled/O transcranial-controlled/O transcranial-controlled/O transcranial-controlled/O transcranial-controlled/O drug/O release/O and/O activation/O are/O rather/O attractive/O options/O for/O glioblastoma/O glioblastoma/O glioblastoma/O glioblastoma/O treatment./O treatment./O Herein,/O Herein,/O Herein,/O we/O designed/O a/O multifunctional/O multifunctional/O multifunctional/O nanocarrier/O nanocarrier/O nanocarrier/O nanocarrier/O (T-TKNPVP)/O (T-TKNPVP)/O (T-TKNPVP)/O (T-TKNPVP)/O (T-TKNPVP)/O (T-TKNPVP)/O (T-TKNPVP)/O (T-TKNPVP)/O that/O combined/O targeted/O X-ray-induced/O X-ray-induced/O X-ray-induced/O X-ray-induced/O X-ray-induced/O photodynamic/O photodynamic/O therapy/O (X-PDT)/O (X-PDT)/O (X-PDT)/O (X-PDT)/O (X-PDT)/O (X-PDT)/O and/O cascaded/O cascaded/O cascaded/O reactive/O oxygen/O species/O (ROS)-boosted/O (ROS)-boosted/O (ROS)-boosted/O (ROS)-boosted/O (ROS)-boosted/O (ROS)-boosted/O (ROS)-boosted/O chemotherapy./O chemotherapy./O chemotherapy./O chemotherapy./O The/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O loaded/O with/O verteporfin/O verteporfin/O verteporfin/O verteporfin/O (VP)/O (VP)/O (VP)/O and/O paclitaxel/O paclitaxel/O paclitaxel/O paclitaxel/O paclitaxel/O (PTX)/O (PTX)/O (PTX)/O (PTX)/O was/O self-assembled/O self-assembled/O self-assembled/O from/O an/O angiopep-2/O angiopep-2/O angiopep-2/O angiopep-2/O angiopep-2/O angiopep-2/O (Ang)/O (Ang)/O (Ang)/O peptide,/O peptide,/O peptide,/O functionalized/O functionalized/O Ang-PEG-DSPE/O Ang-PEG-DSPE/O Ang-PEG-DSPE/O Ang-PEG-DSPE/O Ang-PEG-DSPE/O Ang-PEG-DSPE/O Ang-PEG-DSPE/O Ang-PEG-DSPE/O and/O ROS-sensitive/O ROS-sensitive/O ROS-sensitive/O ROS-sensitive/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O conjugate./O conjugate./O conjugate./O conjugate./O After/O systemic/O injection,/O injection,/O the/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O efficiently/O crossed/O the/O BBB/O BBB/O and/O targeted/O the/O GBM/O GBM/O cells/O via/O receptor-mediated/O receptor-mediated/O receptor-mediated/O transcytosis./O transcytosis./O transcytosis./O transcytosis./O Upon/O X-ray/O X-ray/O X-ray/O irradn.,/O irradn.,/O irradn.,/O irradn.,/O irradn.,/O they/O can/O generate/O a/O certain/O amt./O amt./O amt./O of/O ROS,/O ROS,/O ROS,/O which/O not/O only/O induces/O induces/O X-PDT/O X-PDT/O X-PDT/O X-PDT/O but/O also/O locoregionally/O locoregionally/O locoregionally/O locoregionally/O activates/O activates/O PTX/O PTX/O release/O and/O action/O by/O cleaving/O cleaving/O cleaving/O the/O TK/O TK/O bridged/O bridged/O bonds./O bonds./O As/O evidenced/O by/O 9.4/O 9.4/O 9.4/O T/O MRI/O MRI/O and/O other/O expts.,/O expts.,/O expts.,/O expts.,/O such/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O offer/O significant/O growth/O inhibition/O inhibition/O of/O GBM/O GBM/O in/O situ/O situ/O and/O prolong/O prolong/O the/O survival/O times/O of/O U87-MG/O U87-MG/O U87-MG/O U87-MG/O U87-MG/O tumor-bearing/O tumor-bearing/O tumor-bearing/O mice./O mice./O Taken/O Taken/O together,/O together,/O the/O designed/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O T-TKNPVP/O provided/O an/O alternative/O avenue/O for/O realizing/O transcranial/O transcranial/O transcranial/O transcranial/O X-PDT/O X-PDT/O X-PDT/O X-PDT/O and/O X-ray-activated/O X-ray-activated/O X-ray-activated/O X-ray-activated/O X-ray-activated/O chemotherapy/O chemotherapy/O chemotherapy/O for/O targeted/O and/O locoregional/O locoregional/O locoregional/O locoregional/O GBM/O GBM/O treatment/O in/O vivo./O vivo./O vivo./O"
"To achieve combined chemotherapy and ferroptosis, a nanocarrier ( -Fc) was constructed by using thioketal (TK)-bridged paclitaxel prodrug (PEG-TK-PTX) and ferrocene (Fc)-conjugated PEG-Fc, where DHA was encapsulated by a hydrophobic–hydrophobic interaction. ","To/O achieve/O combined/O chemotherapy/O chemotherapy/O chemotherapy/O and/O ferroptosis,/O ferroptosis,/O ferroptosis,/O ferroptosis,/O ferroptosis,/O a/O nanocarrier/O nanocarrier/O nanocarrier/O nanocarrier/O (/O -Fc)/O -Fc)/O -Fc)/O -Fc)/O was/O constructed/O by/O using/O thioketal/O thioketal/O thioketal/O thioketal/O (TK)-bridged/O (TK)-bridged/O (TK)-bridged/O (TK)-bridged/O (TK)-bridged/O (TK)-bridged/O (TK)-bridged/O paclitaxel/O paclitaxel/O paclitaxel/O paclitaxel/O paclitaxel/O prodrug/O prodrug/O prodrug/O (PEG-TK-PTX)/O (PEG-TK-PTX)/O (PEG-TK-PTX)/O (PEG-TK-PTX)/O (PEG-TK-PTX)/O (PEG-TK-PTX)/O (PEG-TK-PTX)/O (PEG-TK-PTX)/O (PEG-TK-PTX)/O (PEG-TK-PTX)/O and/O ferrocene/O ferrocene/O ferrocene/O ferrocene/O (Fc)-conjugated/O (Fc)-conjugated/O (Fc)-conjugated/O (Fc)-conjugated/O (Fc)-conjugated/O (Fc)-conjugated/O (Fc)-conjugated/O (Fc)-conjugated/O PEG-Fc,/O PEG-Fc,/O PEG-Fc,/O PEG-Fc,/O PEG-Fc,/O PEG-Fc,/O where/O DHA/O DHA/O was/O encapsulated/O encapsulated/O encapsulated/O encapsulated/O by/O a/O hydrophobic–hydrophobic/O hydrophobic–hydrophobic/O hydrophobic–hydrophobic/O hydrophobic–hydrophobic/O hydrophobic–hydrophobic/O hydrophobic–hydrophobic/O hydrophobic–hydrophobic/O interaction./O interaction./O"
"Upon cellular uptake,  -Fc could facilitate PTX release through TK breakage under an excess H  microenvironment. ","Upon/O cellular/O uptake,/O uptake,/O uptake,/O -Fc/O -Fc/O -Fc/O could/O facilitate/O PTX/O PTX/O release/O through/O TK/B-CellLine TK/O breakage/O breakage/O under/O an/O excess/O H/O microenvironment./O microenvironment./O microenvironment./O microenvironment./O microenvironment./O microenvironment./O"
"Moreover, both the chemotherapy-induced reactive oxygen species and the  OH produced from reinforced ferroptosis further stimulated the TK cleavage. ","Moreover,/O Moreover,/O both/O the/O chemotherapy-induced/O chemotherapy-induced/O chemotherapy-induced/O chemotherapy-induced/O chemotherapy-induced/O reactive/O oxygen/O species/O and/O the/O OH/O produced/O from/O reinforced/O ferroptosis/O ferroptosis/O ferroptosis/O ferroptosis/O further/O stimulated/O stimulated/O the/O TK/B-CellLine TK/O cleavage./O cleavage./O cleavage./O cleavage./O"
"(15,16)  Fortunately, traditional chemotherapeutic agents, such as doxorubicin, cisplatin, and paclitaxel (PTX), were found to effectively supply H  for ferroptosis. ","(15,16)/O (15,16)/O (15,16)/O (15,16)/O (15,16)/O Fortunately,/O Fortunately,/O traditional/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O agents,/O agents,/O such/O as/O doxorubicin,/O doxorubicin,/O doxorubicin,/O doxorubicin,/O doxorubicin,/O doxorubicin,/O cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O and/O paclitaxel/O paclitaxel/O paclitaxel/O paclitaxel/O paclitaxel/O (PTX),/O (PTX),/O (PTX),/O (PTX),/O (PTX),/O were/O found/O to/O effectively/O supply/O H/O for/O ferroptosis./O ferroptosis./O ferroptosis./O ferroptosis./O ferroptosis./O"
"(38−40)  Moreover, a series of moieties have been developed for specific ROS-responsive breakage, such as thioketal (TK), arylboronic ester, thioether, and diselenide bonds. ","(38−40)/O (38−40)/O (38−40)/O (38−40)/O (38−40)/O Moreover,/O Moreover,/O a/O series/O of/O moieties/O moieties/O moieties/O moieties/O have/O been/O developed/O for/O specific/O ROS-responsive/O ROS-responsive/O ROS-responsive/O ROS-responsive/O ROS-responsive/O ROS-responsive/O ROS-responsive/O breakage,/O breakage,/O breakage,/O such/O as/O thioketal/O thioketal/O thioketal/O thioketal/O (TK),/O (TK),/B-CellLine (TK),/O (TK),/O (TK),/O arylboronic/O arylboronic/O arylboronic/O arylboronic/O ester,/O ester,/O ester,/O thioether,/O thioether,/O thioether,/O thioether,/O thioether,/O and/O diselenide/O diselenide/O diselenide/O diselenide/O bonds./O bonds./O"
"The PTX was bridged with PEG by ROS-sensitive TK linkage to achieve the control and accelerated payload liberation and function, and the Fc was conjugated with PEG to ensure minimal leakage in the bloodstream. ","The/O PTX/O PTX/O was/O bridged/O bridged/O with/O PEG/O PEG/O by/O ROS-sensitive/O ROS-sensitive/O ROS-sensitive/O ROS-sensitive/O TK/O TK/O linkage/O linkage/O to/O achieve/O the/O control/O and/O accelerated/O payload/O liberation/O and/O function,/O function,/O and/O the/O Fc/O Fc/O was/O conjugated/O conjugated/O conjugated/O with/O PEG/O PEG/O to/O ensure/O minimal/O leakage/O leakage/O in/O the/O bloodstream./O bloodstream./O bloodstream./O"
"Subsequently, the abundant ROS microenvironment stimulated the breakage of the TK linker to boost PTX release for chemotherapy, along with the  -Fc dissociation for DHA liberation. ","Subsequently,/O Subsequently,/O the/O abundant/O ROS/O ROS/O microenvironment/O microenvironment/O microenvironment/O microenvironment/O microenvironment/O stimulated/O stimulated/O the/O breakage/O breakage/O of/O the/O TK/B-CellLine TK/O linker/O linker/O to/O boost/O PTX/O PTX/O release/O for/O chemotherapy,/O chemotherapy,/O chemotherapy,/O chemotherapy,/O along/O with/O the/O -Fc/O -Fc/O -Fc/O dissociation/O dissociation/O dissociation/O for/O DHA/O DHA/O liberation./O liberation./O"
"Although the initial ROS microenvironment was consumed by TK cleavage of  -Fc, it would be supplied continuously in the presence of PTX, DHA, and Fc to further trigger  -Fc dissociation and ROS accumulation. ","Although/O the/O initial/O ROS/O ROS/O microenvironment/O microenvironment/O microenvironment/O microenvironment/O microenvironment/O was/O consumed/O by/O TK/O TK/O cleavage/O cleavage/O cleavage/O of/O -Fc,/O -Fc,/O -Fc,/O -Fc,/O it/O would/O be/O supplied/O continuously/O in/O the/O presence/O of/O PTX,/O PTX,/O PTX,/O DHA,/O DHA,/O DHA,/O and/O Fc/O Fc/O to/O further/O trigger/O -Fc/O -Fc/O -Fc/O dissociation/O dissociation/O dissociation/O and/O ROS/O ROS/O accumulation./O accumulation./O"
"TK linker, PTX-conjugated monomethoxy poly(ethylene glycol) (PEG-TK-PTX,  Figure S1 ), and Fc-conjugated PEG-Fc ( Figure S2 ) were synthesized according to a previous report, respectively. ","TK/O TK/O linker,/O linker,/O linker,/O PTX-conjugated/O PTX-conjugated/O PTX-conjugated/O PTX-conjugated/O PTX-conjugated/O PTX-conjugated/O monomethoxy/O monomethoxy/O monomethoxy/O monomethoxy/O monomethoxy/O poly(ethylene/O poly(ethylene/O poly(ethylene/O poly(ethylene/O poly(ethylene/O poly(ethylene/O glycol)/O glycol)/O glycol)/O glycol)/O glycol)/O (PEG-TK-PTX,/O (PEG-TK-PTX,/O (PEG-TK-PTX,/O (PEG-TK-PTX,/O (PEG-TK-PTX,/O (PEG-TK-PTX,/O (PEG-TK-PTX,/O (PEG-TK-PTX,/O (PEG-TK-PTX,/O (PEG-TK-PTX,/O Figure/O S1/O S1/O ),/O ),/O and/O Fc-conjugated/O Fc-conjugated/O Fc-conjugated/O Fc-conjugated/O Fc-conjugated/O Fc-conjugated/O PEG-Fc/O PEG-Fc/O PEG-Fc/O PEG-Fc/O PEG-Fc/O (/O Figure/O S2/O S2/O )/O were/O synthesized/O according/O to/O a/O previous/O report,/O report,/O respectively./O respectively./O"
"Typically, 10.0 mg of PEG-TK-PTX, 10.0 mg of PEG-Fc, 5.0 mg of PEG-DSPE, and 2.5 mg of DHA (molar ratio, 1.00:1.40:0.56:2.71) were mixed in 3 mL of acetone and then slowly dripped into 10 mL of ddH O under gentle stirring (300 rpm) at 25 °C. ","Typically,/O Typically,/O 10.0/O 10.0/O 10.0/O mg/O of/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O 10.0/O 10.0/O 10.0/O mg/O of/O PEG-Fc,/O PEG-Fc,/O PEG-Fc,/O PEG-Fc,/O PEG-Fc,/O PEG-Fc,/O 5.0/O 5.0/O 5.0/O mg/O of/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O and/O 2.5/O 2.5/O 2.5/O mg/O of/O DHA/O DHA/O (molar/O (molar/O (molar/O ratio,/O ratio,/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O 1.00:1.40:0.56:2.71)/O were/O mixed/O in/O 3/O mL/O mL/O of/O acetone/O acetone/O and/O then/O slowly/O dripped/O into/O 10/O mL/O mL/O of/O ddH/O ddH/O ddH/O O/O under/O gentle/O stirring/O (300/O (300/O rpm)/O rpm)/O at/O 25/O °C./O °C./O"
"According to a comparable procedure, the counterpart nanocarriers without Fc ( ) were fabricated using PEG-TK-PTX, PEG-DSPE, and DHA, and the nanoparticular NP  was prepared using PEG–PTX, PEG-DSPE, and DHA.","According/O to/O a/O comparable/O procedure,/O procedure,/O the/O counterpart/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O without/O Fc/O Fc/O (/O )/O were/O fabricated/O using/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-TK-PTX,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O and/O DHA,/O DHA,/O DHA,/O and/O the/O nanoparticular/O nanoparticular/O nanoparticular/O nanoparticular/O nanoparticular/O NP/O NP/O was/O prepared/O using/O PEG–PTX,/O PEG–PTX,/O PEG–PTX,/O PEG–PTX,/O PEG–PTX,/O PEG–PTX,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O PEG-DSPE,/O and/O DHA./O DHA./O DHA./O"
"The Fe amount in  NP-Fc was determined by inductively coupled plasma mass spectrometry (ICP–MS) as 1.08%. With the help of PEGylation, the average diameters of NP -Fc remained stable in 10 mM PB over 7 days ( As the PTX was conjugated by the ROS-sensitive TK linker, we next studied the PTX release pattern from  -Fc to confirm whether PTX would be specifically liberated under an intracellular H  microenvironment. ","The/O Fe/O amount/O in/O NP-Fc/O NP-Fc/O NP-Fc/O NP-Fc/O NP-Fc/O was/O determined/O by/O inductively/O inductively/O inductively/O coupled/O plasma/O mass/O spectrometry/O spectrometry/O spectrometry/O spectrometry/O (ICP–MS)/O (ICP–MS)/O (ICP–MS)/O (ICP–MS)/O (ICP–MS)/O (ICP–MS)/O as/O 1.08%./O 1.08%./O 1.08%./O 1.08%./O 1.08%./O With/O the/O help/O of/O PEGylation,/O PEGylation,/O PEGylation,/O PEGylation,/O PEGylation,/O the/O average/O diameters/O diameters/O of/O NP/O NP/O -Fc/O -Fc/O -Fc/O remained/O stable/O in/O 10/O mM/O mM/O PB/O PB/O over/O 7/O days/O (/O As/O the/O PTX/O PTX/O was/O conjugated/O conjugated/O conjugated/O by/O the/O ROS-sensitive/O ROS-sensitive/O ROS-sensitive/O ROS-sensitive/O TK/O TK/O linker,/O linker,/O linker,/O we/O next/O studied/O the/O PTX/O PTX/O release/O pattern/O from/O -Fc/O -Fc/O -Fc/O to/O confirm/O whether/O PTX/O PTX/O would/O be/O specifically/O liberated/O under/O an/O intracellular/O intracellular/O intracellular/O H/O microenvironment./O microenvironment./O microenvironment./O microenvironment./O microenvironment./O microenvironment./O"
"Notably, a considerably accelerated PTX release was found in both   (58.00 ± 2.45%) and  -Fc (59.60 ± 1.83%) groups when treated with 10 mM of H , which could be attributed to the ROS-triggered TK breakage, followed by burst PTX release. ","Notably,/O Notably,/O Notably,/O a/O considerably/O accelerated/O PTX/O PTX/O release/O was/O found/O in/O both/O (58.00/O (58.00/O (58.00/O (58.00/O ±/O 2.45%)/O 2.45%)/O 2.45%)/O 2.45%)/O 2.45%)/O and/O -Fc/O -Fc/O -Fc/O (59.60/O (59.60/O (59.60/O (59.60/O ±/O 1.83%)/O 1.83%)/O 1.83%)/O 1.83%)/O 1.83%)/O groups/O when/O treated/O with/O 10/O mM/O mM/O of/O H/O ,/O which/O could/O be/O attributed/O to/O the/O ROS-triggered/O ROS-triggered/O ROS-triggered/O ROS-triggered/O TK/O TK/O breakage,/O breakage,/O breakage,/O followed/O by/O burst/O PTX/O PTX/O release./O release./O"
"To further evaluate the TK cleavage under abundant H  conditions, the 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) method was chosen because the degradation of TK bonds would yield two thiol terminal moieties. ","To/O further/O evaluate/O the/O TK/O TK/O cleavage/O cleavage/O cleavage/O under/O abundant/O H/O conditions,/O conditions,/O the/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O 5,5′-dithiobis(2-nitrobenzoic/O acid)/O acid)/O (DTNB)/O (DTNB)/O (DTNB)/O (DTNB)/O (DTNB)/O (DTNB)/O method/O was/O chosen/O because/O the/O degradation/O of/O TK/O TK/O bonds/O would/O yield/O two/O thiol/O thiol/O terminal/O moieties./O moieties./O moieties./O moieties./O moieties./O"
"As displayed in  Figure S4 , the DTNB absorption at 412 nm of both  NP and  NP-Fc gradually increased with the incubation time, illustrating the continual degradation of TK bonds. ","As/O displayed/O in/O Figure/O S4/O S4/O ,/O the/O DTNB/O DTNB/O DTNB/O DTNB/O absorption/O at/O 412/O 412/O nm/O of/O both/O NP/O NP/O and/O NP-Fc/O NP-Fc/O NP-Fc/O NP-Fc/O NP-Fc/O gradually/O increased/O with/O the/O incubation/O incubation/O incubation/O time,/O time,/O illustrating/O illustrating/O illustrating/O the/O continual/O continual/O continual/O degradation/O of/O TK/O TK/O bonds./O bonds./O"
"Moreover, the peak of PEG and PTX derivatives in gel permeation chromatography ( Figure S5 ) suggested the TK breakage under the H  condition. ","Moreover,/O Moreover,/O the/O peak/O of/O PEG/O PEG/O and/O PTX/O PTX/O derivatives/O in/O gel/O permeation/O permeation/O permeation/O chromatography/O chromatography/O chromatography/O (/O Figure/O S5/O S5/O )/O suggested/O the/O TK/O TK/O breakage/O breakage/O under/O the/O H/O condition./O condition./O"
"Moreover, a sudden burst of encapsulated DHA occurred following TK cleavage and PTX liberation. ","Moreover,/O Moreover,/O a/O sudden/O burst/O of/O encapsulated/O encapsulated/O encapsulated/O encapsulated/O DHA/O DHA/O occurred/O following/O TK/B-CellLine TK/O cleavage/O cleavage/O cleavage/O and/O PTX/O PTX/O liberation./O liberation./O"
"No obvious differences were observed among the three nanocarriers regarding their pharmacokinetic profiles, indicating that the TK linkers of  -Fc had no effects on the blood circulation.","No/O obvious/O differences/O were/O observed/O among/O the/O three/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O nanocarriers/O regarding/O their/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O pharmacokinetic/O profiles,/O profiles,/O indicating/O that/O the/O TK/B-CellLine TK/O linkers/O linkers/O of/O -Fc/O -Fc/O -Fc/O had/O no/O effects/O on/O the/O blood/O circulation./O circulation./O"
"(53)  However, the efficiency of esterification reactions for PEG-TK-PTX and PEG-Fc remains unclear upon scaling up. ","(53)/O (53)/O (53)/O However,/O However,/O the/O efficiency/O of/O esterification/O esterification/O esterification/O reactions/O for/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O and/O PEG-Fc/O PEG-Fc/O PEG-Fc/O PEG-Fc/O PEG-Fc/O remains/O unclear/O upon/O scaling/O scaling/O scaling/O up./O up./O"
"No potential immunogenicity was found for  -Fc in our experiments, indicating the good in vivo biosafety of  -Fc after integrating PEG-TK-PTX and PEG-Fc. ","No/O potential/O immunogenicity/O immunogenicity/O immunogenicity/O immunogenicity/O immunogenicity/O was/O found/O for/O -Fc/O -Fc/O -Fc/O in/O our/O experiments,/O experiments,/O indicating/O the/O good/O in/O vivo/O vivo/O biosafety/O biosafety/O biosafety/O of/O -Fc/O -Fc/O -Fc/O after/O integrating/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O PEG-TK-PTX/O and/O PEG-Fc./O PEG-Fc./O PEG-Fc./O PEG-Fc./O PEG-Fc./O PEG-Fc./O"
"Following preferential navigation to tumor tissues, the TK linker was degraded by excess ROS inside the tumoral cells, and the rapidly released PTX acted as the chemotherapeutic agent. ","Following/O preferential/O preferential/O navigation/O to/O tumor/O tissues,/O tissues,/O the/O TK/O TK/O linker/O linker/O was/O degraded/O degraded/O by/O excess/O ROS/O ROS/O inside/O the/O tumoral/O tumoral/O cells,/O cells,/O and/O the/O rapidly/O released/O PTX/O PTX/O acted/O as/O the/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O chemotherapeutic/O agent./O agent./O"
"Moreover, the chemotherapy-upregulated ROS and  OH generated from the Fenton reaction further stimulated the TK breakage, and the “self-catalytic” loop efficiently worked against tumoral cells. ","Moreover,/O Moreover,/O the/O chemotherapy-upregulated/O chemotherapy-upregulated/O chemotherapy-upregulated/O chemotherapy-upregulated/O chemotherapy-upregulated/O chemotherapy-upregulated/O chemotherapy-upregulated/O chemotherapy-upregulated/O ROS/O ROS/O and/O OH/O generated/O from/O the/O Fenton/O Fenton/O reaction/O further/O stimulated/O stimulated/O the/O TK/B-CellLine TK/O breakage,/O breakage,/O breakage,/O and/O the/O “self-catalytic”/O “self-catalytic”/O “self-catalytic”/O “self-catalytic”/O “self-catalytic”/O “self-catalytic”/O loop/O efficiently/O worked/O against/O tumoral/O tumoral/O cells./O cells./O"
"Cell culture and chemicals used For the study, we purchased three human breast cancer cell lines, namely, T47D, MCF7, and BT474, from the Cell Bank Culture Library of the Chinese Academy of Sciences. ","Cell/O culture/O and/O chemicals/O used/O For/O the/O study,/O study,/O we/O purchased/O three/O human/O breast/O cancer/O cell/O lines,/O lines,/O namely,/O namely,/O T47D,/B-CellLine T47D,/O T47D,/O T47D,/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O and/O BT474,/B-CellLine BT474,/O BT474,/O BT474,/O from/O the/O Cell/O Bank/O Culture/O Library/O of/O the/O Chinese/O Academy/O of/O Sciences./O Sciences./O"
"We obtained MCF10A, human normal breast cells, from the cell bank culture library of the Chinese Academy of Sciences. ","We/O obtained/O MCF10A,/B-CellLine MCF10A,/O MCF10A,/O MCF10A,/O MCF10A,/O human/O normal/O breast/O cells,/O cells,/O from/O the/O cell/O bank/O culture/O library/O of/O the/O Chinese/O Academy/O of/O Sciences./O Sciences./O"
A total of 2×10⁶  stable BT474 cells (two types: LV-shNC control and LV-shTSPAN1) were injected subcutaneously onto the left side of the mice. ,A/O total/O of/O 2×10⁶/O 2×10⁶/O 2×10⁶/O 2×10⁶/O stable/O BT474/B-CellLine BT474/B-CellLine BT474/O cells/O (two/O (two/O types:/O types:/O LV-shNC/O LV-shNC/O LV-shNC/O LV-shNC/O LV-shNC/O LV-shNC/O control/O and/O LV-shTSPAN1)/O LV-shTSPAN1)/O LV-shTSPAN1)/O LV-shTSPAN1)/O LV-shTSPAN1)/O LV-shTSPAN1)/O LV-shTSPAN1)/O LV-shTSPAN1)/O LV-shTSPAN1)/O LV-shTSPAN1)/O were/O injected/O subcutaneously/O subcutaneously/O subcutaneously/O subcutaneously/O onto/O the/O left/O side/O of/O the/O mice./O mice./O
"TSPAN1, tetraspanin 1; BRCA, breast cancer; TCGA, The Cancer Genome Atlas; HR, hazard ratio; CI, confidence interval; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; OS, overall survival; RT-qPCR, quantitative reverse transcription polymerase chain reaction. ","TSPAN1,/O TSPAN1,/O TSPAN1,/O TSPAN1,/O TSPAN1,/O tetraspanin/O tetraspanin/O tetraspanin/O tetraspanin/O 1;/O 1;/O BRCA,/O BRCA,/O BRCA,/O breast/O cancer;/O cancer;/O TCGA,/O TCGA,/O TCGA,/O TCGA,/O The/O Cancer/O Genome/O Genome/O Atlas;/O Atlas;/O HR,/O HR,/O HR,/O hazard/O ratio;/O ratio;/O CI,/B-CellLine CI,/O CI,/O confidence/O interval;/O interval;/O GAPDH,/O GAPDH,/O GAPDH,/O GAPDH,/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O glyceraldehyde-3-phosphate/O dehydrogenase;/O dehydrogenase;/O dehydrogenase;/O dehydrogenase;/O dehydrogenase;/O dehydrogenase;/O OS,/O OS,/O overall/O survival;/O survival;/O RT-qPCR,/O RT-qPCR,/O RT-qPCR,/O RT-qPCR,/O RT-qPCR,/O RT-qPCR,/O RT-qPCR,/O quantitative/O reverse/O transcription/O polymerase/O polymerase/O chain/O reaction./O reaction./O"
The expression of TSPAN1 evaluated through western blotting ( Figure S2A ) and RT-qPCR ( Figure S2B ) in BT474 cancer cell lines with TSPAN1 knockdown. ,The/O expression/O of/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O evaluated/O through/O western/O blotting/O blotting/O blotting/O (/O Figure/O S2A/O S2A/O S2A/O )/O and/O RT-qPCR/O RT-qPCR/O RT-qPCR/O RT-qPCR/O RT-qPCR/O RT-qPCR/O (/O Figure/O S2B/O S2B/O S2B/O )/O in/O BT474/B-CellLine BT474/O BT474/O cancer/O cell/O lines/O with/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O knockdown./O knockdown./O knockdown./O
"Next, we performed the TSPAN1 downregulation experiment in BT474 ( Figure 2B ). ","Next,/O Next,/O we/O performed/O the/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O downregulation/O downregulation/O downregulation/O downregulation/O experiment/O in/O BT474/B-CellLine BT474/O BT474/O (/O Figure/O 2B/O 2B/O )./O )./O"
"After the downregulation of TSPAN1, when compared to the control group, BT474 cells experienced a significant decrease in cell growth (P<0.001,  Figures 2B ) and viability (P<0.001,  Figures 2C ). ","After/O the/O downregulation/O downregulation/O downregulation/O downregulation/O of/O TSPAN1,/O TSPAN1,/O TSPAN1,/O TSPAN1,/O TSPAN1,/O when/O compared/O to/O the/O control/O group,/O group,/O BT474/B-CellLine BT474/O BT474/O cells/O experienced/O a/O significant/O decrease/O in/O cell/O growth/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O Figures/O Figures/O 2B/O 2B/O )/O and/O viability/O viability/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O Figures/O Figures/O 2C/O 2C/O )./O )./O"
"Further, we evaluated tube formation in umbilical vein endothelial human cells, which were co-cultured with the supernatant of BT474 cells to downregulate TSPAN1. Our results showed that the BT474 cell supernatant inhibited endothelial tube formation by downregulating TSPAN1 (P<0.001,  Figure 2E ). ","Further,/O Further,/O we/O evaluated/O tube/O formation/O in/O umbilical/O umbilical/O umbilical/O vein/O endothelial/O endothelial/O endothelial/O endothelial/O human/O cells,/O cells,/O which/O were/O co-cultured/O co-cultured/O co-cultured/O co-cultured/O with/O the/O supernatant/O supernatant/O supernatant/O of/O BT474/B-CellLine BT474/O BT474/O cells/O to/O downregulate/O downregulate/O downregulate/O downregulate/O TSPAN1./O TSPAN1./O TSPAN1./O TSPAN1./O TSPAN1./O Our/O results/O showed/O that/O the/O BT474/B-CellLine BT474/O BT474/O cell/O supernatant/O supernatant/O supernatant/O inhibited/O inhibited/O inhibited/O endothelial/O endothelial/O endothelial/O endothelial/O tube/O formation/O by/O downregulating/O downregulating/O downregulating/O downregulating/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O (P<0.001,/O Figure/O 2E/O 2E/O )./O )./O"
"TSPAN1 and ITGB4 localization within BT474 cells were assessed by fixing cells 24 hours post-transfection, permeabilizing cells, and staining with antibodies specific for TSPAN1 (green) and ITGB4 (red), with DAPI (blue) being used to stain nuclei. ","TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O and/O ITGB4/O ITGB4/O ITGB4/O localization/O localization/O within/O BT474/B-CellLine BT474/O BT474/O cells/O were/O assessed/O by/O fixing/O cells/O 24/O hours/O post-transfection,/O post-transfection,/O post-transfection,/O post-transfection,/O post-transfection,/O post-transfection,/O permeabilizing/O permeabilizing/O permeabilizing/O permeabilizing/O permeabilizing/O cells,/O cells,/O and/O staining/O staining/O with/O antibodies/O specific/O for/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O (green)/O (green)/O (green)/O and/O ITGB4/O ITGB4/O ITGB4/O (red),/O (red),/O (red),/O (red),/O with/O DAPI/O DAPI/O DAPI/O (blue)/O (blue)/O (blue)/O being/O used/O to/O stain/O nuclei./O nuclei./O"
"Levels of MEK1, pMEK1, ERK1/2 and pERK1/2 in BT474 cells in response to TSPAN1 downregulation assessed using western blotting. ","Levels/O Levels/O of/O MEK1,/O MEK1,/O MEK1,/O MEK1,/O pMEK1,/O pMEK1,/O pMEK1,/O pMEK1,/O pMEK1,/O ERK1/2/O ERK1/2/O ERK1/2/O ERK1/2/O ERK1/2/O and/O pERK1/2/O pERK1/2/O pERK1/2/O pERK1/2/O pERK1/2/O pERK1/2/O in/O BT474/B-CellLine BT474/O BT474/O cells/O in/O response/O to/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O downregulation/O downregulation/O downregulation/O downregulation/O assessed/O using/O western/O blotting./O blotting./O blotting./O blotting./O"
"In this study, using the Co-IP assay, we confirmed this mechanism in breast cancer by observing the interaction of TSPAN1 and ITGB4 in BT474 cells ( Figure 3D Immunofluorescence staining of BT474 cells also demonstrated the ability of TSPAN1 (green) and ITGB4 (red) to colocalize each other ( Figure 3E ). ","In/O this/O study,/O study,/O using/O the/O Co-IP/O Co-IP/O Co-IP/O assay,/O assay,/O assay,/O we/O confirmed/O this/O mechanism/O in/O breast/O cancer/O by/O observing/O the/O interaction/O of/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O and/O ITGB4/O ITGB4/O ITGB4/O in/O BT474/B-CellLine BT474/O BT474/O cells/O (/O Figure/O 3D/O Immunofluorescence/O Immunofluorescence/O Immunofluorescence/O Immunofluorescence/O Immunofluorescence/O Immunofluorescence/O Immunofluorescence/O staining/O staining/O of/O BT474/B-CellLine BT474/O BT474/O cells/O also/O demonstrated/O the/O ability/O of/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O (green)/O (green)/O (green)/O and/O ITGB4/O ITGB4/O ITGB4/O (red)/O (red)/O (red)/O to/O colocalize/O colocalize/O colocalize/O colocalize/O each/O other/O (/O Figure/O 3E/O 3E/O )./O )./O"
We tested the TSPAN1-overexpressing cell line using the breast cancer cell line T47D with TSPAN1 overexpression. ,We/O tested/O the/O TSPAN1-overexpressing/O TSPAN1-overexpressing/O TSPAN1-overexpressing/O TSPAN1-overexpressing/O TSPAN1-overexpressing/O TSPAN1-overexpressing/O TSPAN1-overexpressing/O TSPAN1-overexpressing/O cell/O line/O using/O the/O breast/O cancer/O cell/O line/O T47D/B-CellLine T47D/O T47D/O with/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O overexpression./O overexpression./O overexpression./O overexpression./O overexpression./O
Transfection of T47D with the TSPAN1-expressed plasmid enhanced the protein expression of TSPAN1 ( Figure 4D ). ,Transfection/O Transfection/O Transfection/O of/O T47D/B-CellLine T47D/O T47D/O with/O the/O TSPAN1-expressed/O TSPAN1-expressed/O TSPAN1-expressed/O TSPAN1-expressed/O TSPAN1-expressed/O TSPAN1-expressed/O plasmid/O plasmid/O plasmid/O plasmid/O enhanced/O the/O protein/O expression/O of/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O (/O Figure/O 4D/O 4D/O )./O )./O
"Notably, treatment with TSPAN1 resulted in a significant increase in the expression of pERK1/2 in T47D ( ), and treatment with FR180204 reversed these effects ( ). ","Notably,/O Notably,/O Notably,/O treatment/O with/O TSPAN1/O TSPAN1/O TSPAN1/O TSPAN1/O resulted/O in/O a/O significant/O increase/O in/O the/O expression/O of/O pERK1/2/O pERK1/2/B-CellLine pERK1/2/O pERK1/2/O pERK1/2/O pERK1/2/O in/O T47D/B-CellLine T47D/O T47D/O (/O ),/O ),/O and/O treatment/O with/O FR180204/O FR180204/O FR180204/O FR180204/O FR180204/O FR180204/O reversed/O these/O effects/O (/O )./O )./O"
"Although OS data were not mature, a trend favoring Dato-DXd was observed (HR, 0.84 [95% CI, 0.62 to 1.14]). ","Although/O OS/O data/O were/O not/O mature,/O mature,/O a/O trend/O favoring/O favoring/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])./O 1.14])./O 1.14])./O 1.14])./O 1.14])./O 1.14])./O"
"The median PFS by BICR was 6.9 months (95% CI, 5.7 to 7.4) with Dato-DXd versus 4.9 months (95% CI, 4.2 to 5.5) with ICC. ","The/O median/O PFS/O PFS/O by/O BICR/O BICR/O BICR/O was/O 6.9/O 6.9/O 6.9/O months/O (95%/O (95%/O (95%/O CI,/B-CellLine CI,/O CI,/O 5.7/O 5.7/O 5.7/O to/O 7.4)/O 7.4)/O 7.4)/O 7.4)/O with/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O versus/O 4.9/O 4.9/O 4.9/O months/O (95%/O (95%/O (95%/O CI,/B-CellLine CI,/O CI,/O 4.2/O 4.2/O 4.2/O to/O 5.5)/O 5.5)/O 5.5)/O 5.5)/O with/O ICC./O ICC./O"
"PFS by investigator assessment was consistent with PFS by BICR (HR, 0.64 [95% CI, 0.53 to 0.76]; Appendix  Fig A1 ).","PFS/O PFS/O by/O investigator/O assessment/O was/O consistent/O with/O PFS/O PFS/O by/O BICR/O BICR/O BICR/O (HR,/O (HR,/O (HR,/O (HR,/O 0.64/O 0.64/O 0.64/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.53/O 0.53/O 0.53/O to/O 0.76];/O 0.76];/O 0.76];/O 0.76];/O 0.76];/O Appendix/O Appendix/O Appendix/O Appendix/O Fig/O Fig/O A1/O )./O )./O"
"A trend in interim OS data favoring the Dato-DXd arm was observed (HR, 0.84 [95% CI, 0.62 to 1.14]) although OS data were immature at this analysis (maturity, 23.4%; information fraction, 38.5%). ","A/O trend/O in/O interim/O OS/O data/O favoring/O favoring/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O although/O OS/O data/O were/O immature/O immature/O immature/O at/O this/O analysis/O (maturity,/O (maturity,/O (maturity,/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O information/O fraction,/O fraction,/O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O"
"ORR by BICR was improved with Dato-DXd versus ICC (36.4%   22.9%; odds ratio, 1.95 [95% CI, 1.41 to 2.71];  Table 2 ). ","ORR/O ORR/O by/O BICR/O BICR/O BICR/O was/O improved/O with/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O versus/O ICC/O (36.4%/O (36.4%/O (36.4%/O (36.4%/O (36.4%/O 22.9%;/O 22.9%;/O 22.9%;/O 22.9%;/O 22.9%;/O odds/O ratio,/O ratio,/O 1.95/O 1.95/O 1.95/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 1.41/O 1.41/O 1.41/O to/O 2.71];/O 2.71];/O 2.71];/O 2.71];/O 2.71];/O Table/O 2/O )./O )./O"
The median duration of response (95% CI) was 6.7 months (5.6 to 9.8) in the Dato-DXd arm compared with 5.7 months (4.9 to 6.8) in the ICC arm. ,The/O median/O duration/O of/O response/O (95%/O (95%/O (95%/O CI)/B-CellLine CI)/O CI)/O was/O 6.7/O 6.7/O 6.7/O months/O (5.6/O (5.6/O (5.6/O (5.6/O to/O 9.8)/O 9.8)/O 9.8)/O 9.8)/O in/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O compared/O with/O 5.7/O 5.7/O 5.7/O months/O (4.9/O (4.9/O (4.9/O (4.9/O to/O 6.8)/O 6.8)/O 6.8)/O 6.8)/O in/O the/O ICC/O arm./O arm./O
"Variable Confirmed overall response, No. (%) 133 (36.4) 84 (22.9)  Odds ratio (95% CI) ","Variable/O Variable/O Variable/O Confirmed/O Confirmed/O overall/O response,/O response,/O No./O No./O (%)/O (%)/O (%)/O 133/O (36.4)/O (36.4)/O (36.4)/O (36.4)/O (36.4)/O 84/O (22.9)/O (22.9)/O (22.9)/O (22.9)/O (22.9)/O Odds/O Odds/O ratio/O (95%/O (95%/O (95%/O CI)/B-CellLine CI)/O CI)/O"
"1.95 (1.41 to 2.71) Best overall response, No. (%)  Complete response 0  Partial response 131 (35.9)  Stable disease ≥5 weeks 168 (46) 176 (48)  No evidence of disease ≥5 weeks  Progressive disease 58 (15.9) 76 (20.7)  Not evaluable 31 (8.4)   Incomplete postbaseline assessments 28 (7.9)   Stable disease <5 weeks 0⁲ (0.5)   Death Disease control rate at 12 weeks, % 234 (63.8) Median duration of response, months (95% CI) ","1.95/O 1.95/O 1.95/O (1.41/O (1.41/O (1.41/O (1.41/O to/O 2.71)/O 2.71)/O 2.71)/O 2.71)/O Best/O overall/O response,/O response,/O No./O No./O (%)/O (%)/O (%)/O Complete/O response/O 0/O Partial/O Partial/O response/O 131/O (35.9)/O (35.9)/O (35.9)/O (35.9)/O (35.9)/O Stable/O Stable/O disease/O ≥5/O ≥5/O weeks/O 168/O (46)/O (46)/O (46)/O 176/O (48)/O (48)/O (48)/O No/O evidence/O of/O disease/O ≥5/O ≥5/O weeks/O Progressive/O disease/O 58/O (15.9)/O (15.9)/O (15.9)/O (15.9)/O (15.9)/O 76/O (20.7)/O (20.7)/O (20.7)/O (20.7)/O (20.7)/O Not/O evaluable/O evaluable/O evaluable/O evaluable/O 31/O (8.4)/O (8.4)/O (8.4)/O (8.4)/O (8.4)/O Incomplete/O Incomplete/O Incomplete/O Incomplete/O postbaseline/O postbaseline/O postbaseline/O assessments/O 28/O (7.9)/O (7.9)/O (7.9)/O (7.9)/O (7.9)/O Stable/O Stable/O disease/O <5/O <5/O weeks/O 0⁲/O (0.5)/O (0.5)/O (0.5)/O (0.5)/O (0.5)/O Death/O Disease/O control/O rate/O at/O 12/O weeks,/O weeks,/O %/O 234/O (63.8)/O (63.8)/O (63.8)/O (63.8)/O (63.8)/O Median/O Median/O duration/O of/O response,/O response,/O months/O (95%/O (95%/O (95%/O CI)/O CI)/O CI)/O"
"TFST  Events, No. (%) 219 (60) 283 (77.1)  TFST, months, median (95% CI) ","TFST/O TFST/O TFST/O Events,/O Events,/O No./O No./O (%)/O (%)/O (%)/O 219/O (60)/O (60)/O (60)/O 283/O 283/O (77.1)/O (77.1)/O (77.1)/O (77.1)/O (77.1)/O TFST,/O TFST,/O TFST,/O TFST,/O months,/O months,/O median/O (95%/O (95%/O (95%/O CI)/B-CellLine CI)/O CI)/O"
8.2 (7.4 to 8.9) 5 (4.6 to 5.7)  HR (95% CI) ,8.2/O 8.2/O 8.2/O (7.4/O (7.4/O (7.4/O (7.4/O to/O 8.9)/O 8.9)/O 8.9)/O 8.9)/O 5/O (4.6/O (4.6/O (4.6/O (4.6/O to/O 5.7)/O 5.7)/O 5.7)/O 5.7)/O HR/O HR/O (95%/O (95%/O (95%/O CI)/B-CellLine CI)/O CI)/O
"0.53 (0.45 to 0.64) TSST 126 (34.5) 144 (39.2)  TSST, months, median (95% CI) ","0.53/O 0.53/O 0.53/O (0.45/O (0.45/O (0.45/O (0.45/O to/O 0.64)/O 0.64)/O 0.64)/O 0.64)/O TSST/O TSST/O TSST/O 126/O (34.5)/O (34.5)/O (34.5)/O (34.5)/O (34.5)/O 144/O (39.2)/O (39.2)/O (39.2)/O (39.2)/O (39.2)/O TSST,/O TSST,/O TSST,/O TSST,/O months,/O months,/O median/O (95%/O (95%/O (95%/O CI)/B-CellLine CI)/O CI)/O"
"11.5 (10.3 to 13.1) 0.75 (0.59 to 0.96) PFS2 117 (32.1) 121 (33)  PFS2, months, median (95% CI) ","11.5/O 11.5/O 11.5/O (10.3/O (10.3/O (10.3/O (10.3/O to/O 13.1)/O 13.1)/O 13.1)/O 13.1)/O 0.75/O 0.75/O 0.75/O (0.59/O (0.59/O (0.59/O (0.59/O to/O 0.96)/O 0.96)/O 0.96)/O 0.96)/O PFS2/O PFS2/O PFS2/O 117/O (32.1)/O (32.1)/O (32.1)/O (32.1)/O (32.1)/O 121/O (33)/O (33)/O (33)/O PFS2,/O PFS2,/O PFS2,/O PFS2,/O months,/O months,/O median/O (95%/O (95%/O (95%/O CI)/B-CellLine CI)/O CI)/O"
"Ann Oncol  32:1475-1495, 2021 Crossref Google Scholar 2. Burstein HJ, Somerfield MR, Barton DL, et al: Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. ","Ann/O Oncol/O Oncol/O Oncol/O 32:1475-1495,/O 32:1475-1495,/O 32:1475-1495,/O 32:1475-1495,/O 32:1475-1495,/O 32:1475-1495,/O 32:1475-1495,/O 32:1475-1495,/O 2021/O 2021/O Crossref/O Crossref/O Crossref/O Google/O Scholar/O 2./O 2./O Burstein/O Burstein/O Burstein/O HJ,/O HJ,/O HJ,/O Somerfield/O Somerfield/O Somerfield/O MR,/O MR,/O Barton/O DL,/O DL,/O et/O al:/O al:/O Endocrine/O Endocrine/O Endocrine/O treatment/O and/O targeted/O therapy/O for/O hormone/O receptor-positive,/O receptor-positive,/O receptor-positive,/O receptor-positive,/O human/O epidermal/O epidermal/O epidermal/O epidermal/O growth/O factor/O receptor/O 2-negative/O 2-negative/O 2-negative/O metastatic/O metastatic/O breast/O cancer:/O cancer:/O ASCO/O ASCO/O guideline/O guideline/O update./O update./O"
"Nat Rev Clin Oncol  19:681-697, 2022 9. Daiichi Sankyo:  ®  for Injection, for Intravenous Use. ","Nat/O Rev/O Clin/O Clin/O Oncol/O Oncol/O Oncol/O 19:681-697,/O 19:681-697,/O 19:681-697,/O 19:681-697,/O 19:681-697,/O 19:681-697,/O 19:681-697,/O 19:681-697,/O 2022/O 2022/O 9./O 9./O Daiichi/O Daiichi/O Sankyo:/O Sankyo:/O Sankyo:/O Sankyo:/O ®/O for/O Injection,/O Injection,/O Injection,/O for/O Intravenous/O Intravenous/O Intravenous/O Intravenous/O Use./O Use./O"
"A trend in interim OS data favoring the Dato-DXd arm was observed (HR, 0.84 [95% CI, 0.62 to 1.14]) although OS data were immature at this analysis (maturity, 23.4%; information fraction, 38.5%). ","A/O trend/O in/O interim/O OS/O data/O favoring/O favoring/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O although/O OS/O data/O were/O immature/O immature/O immature/O at/O this/O analysis/O (maturity,/O (maturity,/O (maturity,/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O information/O fraction,/O fraction,/O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O"
"A trend in interim OS data favoring the Dato-DXd arm was observed (HR, 0.84 [95% CI, 0.62 to 1.14]) although OS data were immature at this analysis (maturity, 23.4%; information fraction, 38.5%). ","A/O trend/O in/O interim/O OS/O data/O favoring/O favoring/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O although/O OS/O data/O were/O immature/O immature/O immature/O at/O this/O analysis/O (maturity,/O (maturity,/O (maturity,/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O information/O fraction,/O fraction,/O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O"
"A trend in interim OS data favoring the Dato-DXd arm was observed (HR, 0.84 [95% CI, 0.62 to 1.14]) although OS data were immature at this analysis (maturity, 23.4%; information fraction, 38.5%). ","A/O trend/O in/O interim/O OS/O data/O favoring/O favoring/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O although/O OS/O data/O were/O immature/O immature/O immature/O at/O this/O analysis/O (maturity,/O (maturity,/O (maturity,/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O information/O fraction,/O fraction,/O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O"
"A trend in interim OS data favoring the Dato-DXd arm was observed (HR, 0.84 [95% CI, 0.62 to 1.14]) although OS data were immature at this analysis (maturity, 23.4%; information fraction, 38.5%). ","A/O trend/O in/O interim/O OS/O data/O favoring/O favoring/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O although/O OS/O data/O were/O immature/O immature/O immature/O at/O this/O analysis/O (maturity,/O (maturity,/O (maturity,/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O information/O fraction,/O fraction,/O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O"
"A trend in interim OS data favoring the Dato-DXd arm was observed (HR, 0.84 [95% CI, 0.62 to 1.14]) although OS data were immature at this analysis (maturity, 23.4%; information fraction, 38.5%). ","A/O trend/O in/O interim/O OS/O data/O favoring/O favoring/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O although/O OS/O data/O were/O immature/O immature/O immature/O at/O this/O analysis/O (maturity,/O (maturity,/O (maturity,/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O information/O fraction,/O fraction,/O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O"
"A trend in interim OS data favoring the Dato-DXd arm was observed (HR, 0.84 [95% CI, 0.62 to 1.14]) although OS data were immature at this analysis (maturity, 23.4%; information fraction, 38.5%). ","A/O trend/O in/O interim/O OS/O data/O favoring/O favoring/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O although/O OS/O data/O were/O immature/O immature/O immature/O at/O this/O analysis/O (maturity,/O (maturity,/O (maturity,/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O information/O fraction,/O fraction,/O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O"
"A trend in interim OS data favoring the Dato-DXd arm was observed (HR, 0.84 [95% CI, 0.62 to 1.14]) although OS data were immature at this analysis (maturity, 23.4%; information fraction, 38.5%). ","A/O trend/O in/O interim/O OS/O data/O favoring/O favoring/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O although/O OS/O data/O were/O immature/O immature/O immature/O at/O this/O analysis/O (maturity,/O (maturity,/O (maturity,/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O information/O fraction,/O fraction,/O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O"
"A trend in interim OS data favoring the Dato-DXd arm was observed (HR, 0.84 [95% CI, 0.62 to 1.14]) although OS data were immature at this analysis (maturity, 23.4%; information fraction, 38.5%). ","A/O trend/O in/O interim/O OS/O data/O favoring/O favoring/O the/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O Dato-DXd/O arm/O was/O observed/O (HR,/O (HR,/O (HR,/O (HR,/O 0.84/O 0.84/O 0.84/O [95%/O [95%/O [95%/O CI,/B-CellLine CI,/O CI,/O 0.62/O 0.62/O 0.62/O to/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O 1.14])/O although/O OS/O data/O were/O immature/O immature/O immature/O at/O this/O analysis/O (maturity,/O (maturity,/O (maturity,/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O 23.4%;/O information/O fraction,/O fraction,/O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O 38.5%)./O"
"Additionally, Amale  . indicated that AuNP-loaded niosomal formulations show promise as a targeted system to improve anti-tumor activity against A2780 cancer cells. ","Additionally,/O Additionally,/O Amale/O Amale/O ./O indicated/O that/O AuNP-loaded/O AuNP-loaded/O AuNP-loaded/O AuNP-loaded/O niosomal/O niosomal/O niosomal/O formulations/O formulations/O show/O promise/O as/O a/O targeted/O system/O to/O improve/O anti-tumor/O anti-tumor/O anti-tumor/O activity/O against/O A2780/B-CellLine A2780/B-CellLine A2780/O cancer/O cells./O cells./O"
"The synergistic, additive, or antagonistic effects of the AuNPs and miRNA combination were evaluated by calculating the combination index (CI) using the CompuSyn software, as described by Chou and Talalay's method. ","The/O synergistic,/O synergistic,/O synergistic,/O synergistic,/O synergistic,/O additive,/O additive,/O additive,/O or/O antagonistic/O antagonistic/O effects/O of/O the/O AuNPs/O AuNPs/O AuNPs/O and/O miRNA/O miRNA/O combination/O were/O evaluated/O by/O calculating/O the/O combination/O index/O (CI)/O (CI)/B-CellLine (CI)/O (CI)/O using/O the/O CompuSyn/O CompuSyn/O CompuSyn/O CompuSyn/O CompuSyn/O software,/O software,/O as/O described/O by/O Chou/O Chou/O and/O Talalay's/O Talalay's/O Talalay's/O Talalay's/O Talalay's/O method./O method./O"
"Specifically, the CI was derived using the formula: $$\text{CI }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$ where: a = the concentration of AuNPs at the IC25 (25% inhibitory concentration) in the presence of miRNA at concentration b. ","Specifically,/O Specifically,/O the/O CI/B-CellLine CI/O was/O derived/O using/O the/O formula:/O formula:/O $$\text{CI/O $$\text{CI/O $$\text{CI/O $$\text{CI/O $$\text{CI/O $$\text{CI/O $$\text{CI/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O }=\;(\text{a}/\text{A})\;+\;(\text{b}/\text{B})$$/O where:/O where:/O a/O =/O the/O concentration/O of/O AuNPs/O AuNPs/O AuNPs/O at/O the/O IC25/O IC25/O IC25/O (25%/O (25%/O (25%/O inhibitory/O inhibitory/O concentration)/O concentration)/O in/O the/O presence/O of/O miRNA/O miRNA/O at/O concentration/O b./O b./O"
A = the concentration of AuNPs alone required to achieve the IC25. b = the concentration of miRNA alone that produces the IC25. B = the concentration of miRNA alone required to achieve the IC25. The interpretation of the CI value is as follows: CI < 1 indicates a synergistic interaction between the AuNPs and miRNA. ,A/O =/O the/O concentration/O of/O AuNPs/O AuNPs/O AuNPs/O alone/O required/O to/O achieve/O the/O IC25./O IC25./O IC25./O IC25./O b/O =/O the/O concentration/O of/O miRNA/O miRNA/O alone/O that/O produces/O the/O IC25./O IC25./O IC25./O IC25./O B/O =/O the/O concentration/O of/O miRNA/O miRNA/O alone/O required/O to/O achieve/O the/O IC25./O IC25./O IC25./O IC25./O The/O interpretation/O of/O the/O CI/B-CellLine CI/O value/O is/O as/O follows:/O follows:/O CI/B-CellLine CI/O </O 1/O indicates/O a/O synergistic/O synergistic/O synergistic/O synergistic/O interaction/O between/O the/O AuNPs/O AuNPs/O AuNPs/O and/O miRNA./O miRNA./O miRNA./O
CI = 1 indicates an additive interaction. ,CI/B-CellLine CI/O =/O 1/O indicates/O an/O additive/O additive/O interaction./O interaction./O
CI > 1 indicates an antagonistic interaction. ,CI/B-CellLine CI/O >/O 1/O indicates/O an/O antagonistic/O antagonistic/O interaction./O interaction./O
Apoptosis Assay  cells per well was seeded in 6-well plates and incubated for 24 h. ,Apoptosis/O Apoptosis/O Apoptosis/O Assay/O Assay/O cells/O per/O well/O was/O seeded/O in/O 6-well/O 6-well/O 6-well/O plates/O and/O incubated/O incubated/O incubated/O incubated/O for/O 24/O h./O h./O
"7 ) C-PEG-Nio, ( ) C-PEG-Nio/miRNA (1:1), ( ) C-PEG-Nio-AuNPs/miRNA (1:1), ( ) C-PEG-Nio/miRNA(5:1) and ( ) C-PEG-Nio AuNPs/miRNA (5:1) for 48 h is presented in the flowcytometry diagram; apoptosis rate shown in the statistical chart ( F ). ","7/O )/O C-PEG-Nio,/O C-PEG-Nio,/O C-PEG-Nio,/O C-PEG-Nio,/O C-PEG-Nio,/O C-PEG-Nio,/O C-PEG-Nio,/O C-PEG-Nio,/O (/O )/O C-PEG-Nio/miRNA/O C-PEG-Nio/miRNA/O C-PEG-Nio/miRNA/O C-PEG-Nio/miRNA/O C-PEG-Nio/miRNA/O C-PEG-Nio/miRNA/O C-PEG-Nio/miRNA/O C-PEG-Nio/miRNA/O C-PEG-Nio/miRNA/O C-PEG-Nio/miRNA/O (1:1),/O (1:1),/O (1:1),/O (1:1),/O (1:1),/O (1:1),/O (/O )/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O C-PEG-Nio-AuNPs/miRNA/O (1:1),/O (1:1),/O (1:1),/O (1:1),/O (1:1),/O (1:1),/O (/O )/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O C-PEG-Nio/miRNA(5:1)/O and/O (/O )/O C-PEG-Nio/O C-PEG-Nio/O C-PEG-Nio/O C-PEG-Nio/O C-PEG-Nio/O C-PEG-Nio/O C-PEG-Nio/O AuNPs/miRNA/O AuNPs/miRNA/O AuNPs/miRNA/O AuNPs/miRNA/O AuNPs/miRNA/O AuNPs/miRNA/O (5:1)/O (5:1)/O (5:1)/O (5:1)/O (5:1)/O for/O 48/O h/O is/O presented/O in/O the/O flowcytometry/O flowcytometry/O flowcytometry/O flowcytometry/O flowcytometry/O diagram;/O diagram;/O apoptosis/O apoptosis/O apoptosis/O rate/O shown/O in/O the/O statistical/O chart/O (/O F/O )./O )./O"
"Fetal bovine serum (FBS) was purchased from GIBCO LLC. (Grand Island, NY, USA). ","Fetal/O Fetal/O bovine/O bovine/O bovine/O serum/O (FBS)/O (FBS)/O (FBS)/O (FBS)/O was/O purchased/O from/O GIBCO/O GIBCO/O GIBCO/O LLC./O LLC./O (Grand/O (Grand/O Island,/O Island,/O NY,/O NY,/O USA)./O USA)./O USA)./O"
"Cell line and animals The 4T1, A2780 and bEND.3 cells were obtained from the Department of Pathology at the Institute of Medicinal Biotechnology at Peking Union Medical College (PUMC). ","Cell/O line/O and/O animals/O The/O 4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780/B-CellLine A2780/O A2780/O and/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O obtained/O from/O the/O Department/O of/O Pathology/O Pathology/O at/O the/O Institute/O of/O Medicinal/O Medicinal/O Biotechnology/O Biotechnology/O Biotechnology/O Biotechnology/O at/O Peking/O Peking/O Union/O Medical/O College/O (PUMC)./O (PUMC)./O (PUMC)./O (PUMC)./O (PUMC)./O (PUMC)./O"
"The active targeting efficacy of FA-based imaging towards 4T1, A2780, bEND.3 cells were confirmed with CLSM analysis. ","The/O active/O targeting/O efficacy/O of/O FA-based/O FA-based/O FA-based/O imaging/O towards/O 4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/B-CellLine A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O confirmed/O with/O CLSM/O CLSM/O CLSM/O analysis./O analysis./O"
"4T1, A2780, bEND.3 cells were seeded onto coverslips in a 12-well plate at a density of 10 × 10⁴  cells per well and incubated at 37 °C to allow cell attachment. ","4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/O A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O seeded/O onto/O coverslips/O coverslips/O coverslips/O in/O a/O 12-well/O 12-well/O 12-well/O plate/O at/O a/O density/O of/O 10/O ×/O 10⁴/O 10⁴/O cells/O per/O well/O and/O incubated/O incubated/O incubated/O incubated/O at/O 37/O °C/O to/O allow/O cell/O attachment./O attachment./O"
"The cells were then treated with different concentrations of Blank LPs or PEI-FA@Blank LPs for 24 and 48 h, followed by treatment with 200 μL of a serum-free medium containing 10% CCK-8 for 3 h at 37 °C. ","The/O cells/O were/O then/O treated/O with/O different/O concentrations/O of/O Blank/O Blank/O LPs/O LPs/O or/O PEI-FA@Blank/O PEI-FA@Blank/O PEI-FA@Blank/O PEI-FA@Blank/O PEI-FA@Blank/O PEI-FA@Blank/O PEI-FA@Blank/O LPs/O LPs/O for/O 24/O and/O 48/O h,/O h,/O followed/O by/O treatment/O with/O 200/O μL/O μL/O of/O a/O serum-free/O serum-free/O serum-free/O medium/O containing/O 10%/O 10%/O CCK-8/O CCK-8/O CCK-8/O CCK-8/O for/O 3/O h/O at/O 37/O °C./O °C./O"
So we selected ovarian cancer cell line A2780 with high expression of FA receptor and mouse brain microvascular endothelial cell line bEND.3 with relatively low expression of FA receptor to investigate the uptake of FA-modified liposomes. ,So/O we/O selected/O ovarian/O ovarian/O ovarian/O cancer/O cell/O line/O A2780/B-CellLine A2780/B-CellLine A2780/O with/O high/O expression/O of/O FA/O receptor/O and/O mouse/O brain/O microvascular/O microvascular/O microvascular/O endothelial/O endothelial/O endothelial/O endothelial/O cell/O line/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O with/O relatively/O low/O expression/O of/O FA/O receptor/O to/O investigate/O the/O uptake/O uptake/O of/O FA-modified/O FA-modified/O FA-modified/O liposomes./O liposomes./O liposomes./O liposomes./O
"In A2780 cells and 4T1 cell lines, liposome uptake and fluorescence intensity were significantly increased in the group without FA incubation compared with that in the group with FA incubation in advance, indicating that FA modified liposomes could bind specifically to tumor cells with high expression of FA receptor.","In/O A2780/B-CellLine A2780/B-CellLine A2780/O cells/O and/O 4T1/O 4T1/O 4T1/O cell/O lines,/O lines,/O liposome/O liposome/O liposome/O uptake/O uptake/O and/O fluorescence/O fluorescence/O fluorescence/O intensity/O were/O significantly/O increased/O in/O the/O group/O without/O FA/O incubation/O incubation/O incubation/O compared/O with/O that/O in/O the/O group/O with/O FA/O incubation/O incubation/O incubation/O in/O advance,/O advance,/O indicating/O that/O FA/O modified/O liposomes/O liposomes/O liposomes/O could/O bind/O specifically/O to/O tumor/O cells/O with/O high/O expression/O of/O FA/O receptor./O receptor./O"
"3 ) Observation of 4T1 cells after treatment with PEI-FA@IR@TPZ/BMS LPs under irradiation within 30 min (Scale bar: 100 μm). ( ) Cellular uptake and ( ) the mean fluorescence intensity analysis of PEI-FA@IR@TPZ/BMS LPs incubated with 4T1 cells by flow cytometrywithin 30 min. ( ) Cellular uptake behavior of free Cou-6, Cou-6 LPs, PEI@Cou-6 LPs and PEI-FA@Cou-6 LPs incubated with 4T1 cells by CLSM imaging. (Scale bar: 100 μm) ( ) Cellular uptake behavior of PEI-FA@Cou-6 LPs (FA+) and PEI-FA@Cou-6 LPs (FA-) incubated with 4T1, A2780, bEND.3 cells by CLSM imaging. ( ) the mean fluorescence intensity analysis of free Cou-6, Cou-6 LPs, PEI@Cou-6 LPs and PEI-FA@Cou-6 LPs incubated with 4T1 cells by flow cytometry. ( H ) Quantification analysis of PEI-FA@Cou-6 LPs (FA+) and PEI-FA@Cou-6 LPs (FA-) incubated with 4T1 cells by flow cytometry. (Scale bar: 100 μm) ","3/O )/O Observation/O Observation/O Observation/O Observation/O of/O 4T1/O 4T1/O 4T1/O cells/O after/O treatment/O with/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O LPs/O LPs/O under/O irradiation/O irradiation/O irradiation/O within/O 30/O min/O (Scale/O (Scale/O bar:/O bar:/O 100/O μm)./O μm)./O μm)./O μm)./O (/O )/O Cellular/O Cellular/O uptake/O uptake/O and/O (/O )/O the/O mean/O fluorescence/O fluorescence/O fluorescence/O intensity/O analysis/O of/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O PEI-FA@IR@TPZ/BMS/O LPs/O LPs/O incubated/O incubated/O incubated/O incubated/O with/O 4T1/O 4T1/O 4T1/O cells/O by/O flow/O cytometrywithin/O cytometrywithin/O cytometrywithin/O cytometrywithin/O cytometrywithin/O cytometrywithin/O 30/O min./O min./O (/O )/O Cellular/O Cellular/O uptake/O uptake/O behavior/O of/O free/O Cou-6,/O Cou-6,/O Cou-6,/O Cou-6,/O Cou-6,/O Cou-6/O Cou-6/O Cou-6/O Cou-6/O LPs,/O LPs,/O LPs,/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O LPs/O LPs/O and/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O LPs/O LPs/O incubated/O incubated/O incubated/O incubated/O with/O 4T1/O 4T1/O 4T1/O cells/O by/O CLSM/O CLSM/O CLSM/O imaging./O imaging./O (Scale/O (Scale/O bar:/O bar:/O 100/O μm)/O μm)/O μm)/O (/O )/O Cellular/O Cellular/O uptake/O uptake/O behavior/O of/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O LPs/O LPs/O (FA+)/O (FA+)/O (FA+)/O (FA+)/O and/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O LPs/O LPs/O (FA-)/O (FA-)/O (FA-)/O (FA-)/O incubated/O incubated/O incubated/O incubated/O with/O 4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/O A2780,/O A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O by/O CLSM/O CLSM/O CLSM/O imaging./O imaging./O (/O )/O the/O mean/O fluorescence/O fluorescence/O fluorescence/O intensity/O analysis/O of/O free/O Cou-6,/O Cou-6,/O Cou-6,/O Cou-6,/O Cou-6,/O Cou-6/O Cou-6/O Cou-6/O Cou-6/O LPs,/O LPs,/O LPs,/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O PEI@Cou-6/O LPs/O LPs/O and/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O LPs/O LPs/O incubated/O incubated/O incubated/O incubated/O with/O 4T1/O 4T1/O 4T1/O cells/O by/O flow/O cytometry./O cytometry./O cytometry./O cytometry./O cytometry./O (/O H/O )/O Quantification/O Quantification/O Quantification/O analysis/O of/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O LPs/O LPs/O (FA+)/O (FA+)/O (FA+)/O (FA+)/O and/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O PEI-FA@Cou-6/O LPs/O LPs/O (FA-)/O (FA-)/O (FA-)/O (FA-)/O incubated/O incubated/O incubated/O incubated/O with/O 4T1/O 4T1/O 4T1/O cells/O by/O flow/O cytometry./O cytometry./O cytometry./O cytometry./O cytometry./O (Scale/O (Scale/O bar:/O bar:/O 100/O μm)/O μm)/O μm)/O"
The apoptosis ratio of irradiated cells was significantly higher than that of unirradiated cells after 48 h of culture. ,The/O apoptosis/O apoptosis/O apoptosis/O ratio/O of/O irradiated/O irradiated/O irradiated/O irradiated/O cells/O was/O significantly/O higher/O than/O that/O of/O unirradiated/O unirradiated/O unirradiated/O unirradiated/O cells/O after/O 48/O h/O of/O culture./O culture./O
Cell apoptosis assay on 4T1 cells in vitro. ( .  ) The flow cytometry results of 4T1 cells apoptosis and the percentage of early and late apoptosis after the 48 h treatment and near-infrared laser irradiation with different treatments. ( ) Live/dead examination of 4T1 cells subjected to different treatments was conducted using Calcein-AM/PI double staining and observing by inverted fluorescence microscope (Scale bar: 100 μm). ,Cell/O apoptosis/O apoptosis/O apoptosis/O assay/O assay/O on/O 4T1/O 4T1/O 4T1/O cells/O in/O vitro./O vitro./O vitro./O vitro./O (/O ./O )/O The/O flow/O cytometry/O cytometry/O cytometry/O cytometry/O results/O of/O 4T1/O 4T1/O 4T1/O cells/O apoptosis/O apoptosis/O apoptosis/O and/O the/O percentage/O of/O early/O and/O late/O apoptosis/O apoptosis/O apoptosis/O after/O the/O 48/O h/O treatment/O and/O near-infrared/O near-infrared/O near-infrared/O laser/O irradiation/O irradiation/O irradiation/O with/O different/O treatments./O treatments./O (/O )/O Live/dead/O Live/dead/O Live/dead/O examination/O of/O 4T1/O 4T1/O 4T1/O cells/O subjected/O to/O different/O treatments/O was/O conducted/O using/O Calcein-AM/PI/O Calcein-AM/PI/O Calcein-AM/PI/O Calcein-AM/PI/O Calcein-AM/PI/O Calcein-AM/PI/O Calcein-AM/PI/O Calcein-AM/PI/O double/O staining/O staining/O and/O observing/O by/O inverted/O fluorescence/O fluorescence/O fluorescence/O microscope/O microscope/O (Scale/O (Scale/O bar:/O bar:/O 100/O μm)./O μm)./O μm)./O μm)./O
"2015;484:207–17. Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller. ","2015;484:207–17./O 2015;484:207–17./O 2015;484:207–17./O 2015;484:207–17./O 2015;484:207–17./O 2015;484:207–17./O 2015;484:207–17./O 2015;484:207–17./O 2015;484:207–17./O Borst/O Borst/O J,/O J,/O Ahrends/O Ahrends/O Ahrends/O T,/O T,/O Bąbała/O Bąbała/O Bąbała/O Bąbała/O N,/O N,/O Melief/O Melief/O CJM,/O CJM,/O CJM,/O CJM,/O Kastenmüller./O Kastenmüller./O Kastenmüller./O Kastenmüller./O Kastenmüller./O Kastenmüller./O"
"Fetal bovine serum (FBS) was purchased from GIBCO LLC. (Grand Island, NY, USA). ","Fetal/O Fetal/O bovine/O bovine/O bovine/O serum/O (FBS)/O (FBS)/O (FBS)/O (FBS)/O was/O purchased/O from/O GIBCO/O GIBCO/O GIBCO/O LLC./O LLC./O (Grand/O (Grand/O Island,/O Island,/O NY,/O NY,/O USA)./O USA)./O USA)./O"
"The active targeting efficacy of FA-based imaging towards 4T1, A2780, bEND.3 cells were confirmed with CLSM analysis. ","The/O active/O targeting/O efficacy/O of/O FA-based/O FA-based/O FA-based/O imaging/O towards/O 4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/B-CellLine A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O confirmed/O with/O CLSM/O CLSM/O CLSM/O analysis./O analysis./O"
"4T1, A2780, bEND.3 cells were seeded onto coverslips in a 12-well plate at a density of 10 × 10⁴","4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/O A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O seeded/O onto/O coverslips/O coverslips/O coverslips/O in/O a/O 12-well/O 12-well/O 12-well/O plate/O at/O a/O density/O of/O 10/O ×/O 10⁴/O 10⁴/O"
"Fetal bovine serum (FBS) was purchased from GIBCO LLC. (Grand Island, NY, USA). ","Fetal/O Fetal/O bovine/O bovine/O bovine/O serum/O (FBS)/O (FBS)/O (FBS)/O (FBS)/O was/O purchased/O from/O GIBCO/O GIBCO/O GIBCO/O LLC./O LLC./O (Grand/O (Grand/O Island,/O Island,/O NY,/O NY,/O USA)./O USA)./O USA)./O"
"The active targeting efficacy of FA-based imaging towards 4T1, A2780, bEND.3 cells were confirmed with CLSM analysis. ","The/O active/O targeting/O efficacy/O of/O FA-based/O FA-based/O FA-based/O imaging/O towards/O 4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/B-CellLine A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O confirmed/O with/O CLSM/O CLSM/O CLSM/O analysis./O analysis./O"
"4T1, A2780, bEND.3 cells were seeded onto coverslips in a 12-well plate at a density of 10 × 10⁴","4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/O A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O seeded/O onto/O coverslips/O coverslips/O coverslips/O in/O a/O 12-well/O 12-well/O 12-well/O plate/O at/O a/O density/O of/O 10/O ×/O 10⁴/O 10⁴/O"
"Fetal bovine serum (FBS) was purchased from GIBCO LLC. (Grand Island, NY, USA). ","Fetal/O Fetal/O bovine/O bovine/O bovine/O serum/O (FBS)/O (FBS)/O (FBS)/O (FBS)/O was/O purchased/O from/O GIBCO/O GIBCO/O GIBCO/O LLC./O LLC./O (Grand/O (Grand/O Island,/O Island,/O NY,/O NY,/O USA)./O USA)./O USA)./O"
"The active targeting efficacy of FA-based imaging towards 4T1, A2780, bEND.3 cells were confirmed with CLSM analysis. ","The/O active/O targeting/O efficacy/O of/O FA-based/O FA-based/O FA-based/O imaging/O towards/O 4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/B-CellLine A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O confirmed/O with/O CLSM/O CLSM/O CLSM/O analysis./O analysis./O"
"4T1, A2780, bEND.3 cells were seeded onto coverslips in a 12-well plate at a density of 10 × 10⁴","4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/O A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O seeded/O onto/O coverslips/O coverslips/O coverslips/O in/O a/O 12-well/O 12-well/O 12-well/O plate/O at/O a/O density/O of/O 10/O ×/O 10⁴/O 10⁴/O"
"Fetal bovine serum (FBS) was purchased from GIBCO LLC. (Grand Island, NY, USA). ","Fetal/O Fetal/O bovine/O bovine/O bovine/O serum/O (FBS)/O (FBS)/O (FBS)/O (FBS)/O was/O purchased/O from/O GIBCO/O GIBCO/O GIBCO/O LLC./O LLC./O (Grand/O (Grand/O Island,/O Island,/O NY,/O NY,/O USA)./O USA)./O USA)./O"
"The active targeting efficacy of FA-based imaging towards 4T1, A2780, bEND.3 cells were confirmed with CLSM analysis. ","The/O active/O targeting/O efficacy/O of/O FA-based/O FA-based/O FA-based/O imaging/O towards/O 4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/B-CellLine A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O confirmed/O with/O CLSM/O CLSM/O CLSM/O analysis./O analysis./O"
"4T1, A2780, bEND.3 cells were seeded onto coverslips in a 12-well plate at a density of 10 × 10⁴","4T1,/O 4T1,/O 4T1,/O 4T1,/O A2780,/B-CellLine A2780,/O A2780,/O A2780,/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O cells/O were/O seeded/O onto/O coverslips/O coverslips/O coverslips/O in/O a/O 12-well/O 12-well/O 12-well/O plate/O at/O a/O density/O of/O 10/O ×/O 10⁴/O 10⁴/O"
So we selected ovarian cancer cell line A2780 with high expression of FA receptor and mouse brain microvascular endothelial cell line bEND.3 with relatively low expression of FA receptor to investigate the uptake of FA-modified liposomes. ,So/O we/O selected/O ovarian/O ovarian/O ovarian/O cancer/O cell/O line/O A2780/B-CellLine A2780/B-CellLine A2780/O with/O high/O expression/O of/O FA/O receptor/O and/O mouse/O brain/O microvascular/O microvascular/O microvascular/O endothelial/O endothelial/O endothelial/O endothelial/O cell/O line/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O with/O relatively/O low/O expression/O of/O FA/O receptor/O to/O investigate/O the/O uptake/O uptake/O of/O FA-modified/O FA-modified/O FA-modified/O liposomes./O liposomes./O liposomes./O liposomes./O
So we selected ovarian cancer cell line A2780 with high expression of FA receptor and mouse brain microvascular endothelial cell line bEND.3 with relatively low expression of FA receptor to investigate the uptake of FA-modified liposomes. ,So/O we/O selected/O ovarian/O ovarian/O ovarian/O cancer/O cell/O line/O A2780/B-CellLine A2780/B-CellLine A2780/O with/O high/O expression/O of/O FA/O receptor/O and/O mouse/O brain/O microvascular/O microvascular/O microvascular/O endothelial/O endothelial/O endothelial/O endothelial/O cell/O line/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O with/O relatively/O low/O expression/O of/O FA/O receptor/O to/O investigate/O the/O uptake/O uptake/O of/O FA-modified/O FA-modified/O FA-modified/O liposomes./O liposomes./O liposomes./O liposomes./O
So we selected ovarian cancer cell line A2780 with high expression of FA receptor and mouse brain microvascular endothelial cell line bEND.3 with relatively low expression of FA receptor to investigate the uptake of FA-modified liposomes. ,So/O we/O selected/O ovarian/O ovarian/O ovarian/O cancer/O cell/O line/O A2780/B-CellLine A2780/B-CellLine A2780/O with/O high/O expression/O of/O FA/O receptor/O and/O mouse/O brain/O microvascular/O microvascular/O microvascular/O endothelial/O endothelial/O endothelial/O endothelial/O cell/O line/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O with/O relatively/O low/O expression/O of/O FA/O receptor/O to/O investigate/O the/O uptake/O uptake/O of/O FA-modified/O FA-modified/O FA-modified/O liposomes./O liposomes./O liposomes./O liposomes./O
So we selected ovarian cancer cell line A2780 with high expression of FA receptor and mouse brain microvascular endothelial cell line bEND.3 with relatively low expression of FA receptor to investigate the uptake of FA-modified liposomes. ,So/O we/O selected/O ovarian/O ovarian/O ovarian/O cancer/O cell/O line/O A2780/B-CellLine A2780/B-CellLine A2780/O with/O high/O expression/O of/O FA/O receptor/O and/O mouse/O brain/O microvascular/O microvascular/O microvascular/O endothelial/O endothelial/O endothelial/O endothelial/O cell/O line/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O bEND.3/O with/O relatively/O low/O expression/O of/O FA/O receptor/O to/O investigate/O the/O uptake/O uptake/O of/O FA-modified/O FA-modified/O FA-modified/O liposomes./O liposomes./O liposomes./O liposomes./O
"After the preliminary research of our group, merecidin can effectively control the proliferation and aggregation of  Staphylococcus  aureus and  Pseudomonas  aeruginosa by regulating the genes associated with the biofilm, thereby achieving effective control of microorganisms and reducing the harm of bacteria to the body 14 ; In addition, merecidin is able to regulate the MAPK/ERK signaling pathway and inhibit the growth, migration, and invasion of non-small cell lung cancer cells A549 and target MAPK1 to induce autophagy.","After/O the/O preliminary/O research/O of/O our/O group,/O group,/O merecidin/O merecidin/O merecidin/O can/O effectively/O control/O the/O proliferation/O and/O aggregation/O aggregation/O aggregation/O of/O Staphylococcus/O Staphylococcus/O Staphylococcus/O Staphylococcus/O Staphylococcus/O Staphylococcus/O aureus/O aureus/O and/O Pseudomonas/O Pseudomonas/O Pseudomonas/O Pseudomonas/O Pseudomonas/O aeruginosa/O aeruginosa/O aeruginosa/O aeruginosa/O aeruginosa/O by/O regulating/O the/O genes/O associated/O with/O the/O biofilm,/O biofilm,/O biofilm,/O thereby/O achieving/O effective/O control/O of/O microorganisms/O microorganisms/O microorganisms/O microorganisms/O and/O reducing/O the/O harm/O of/O bacteria/O to/O the/O body/O 14/O ;/O In/O addition,/O addition,/O merecidin/O merecidin/O merecidin/O is/O able/O to/O regulate/O the/O MAPK/ERK/O MAPK/ERK/O MAPK/ERK/O MAPK/ERK/O MAPK/ERK/O MAPK/ERK/O signaling/O pathway/O and/O inhibit/O inhibit/O the/O growth,/O growth,/O migration,/O migration,/O and/O invasion/O of/O non-small/O non-small/O non-small/O cell/O lung/O cancer/O cells/O A549/B-CellLine A549/O A549/O A549/O and/O target/O MAPK1/O MAPK1/O MAPK1/O MAPK1/O to/O induce/O autophagy./O autophagy./O autophagy./O autophagy./O"
"Briefly, a total of approximately 5 × 10⁳  cells were seeded in 96-well plates, after merecidin stimulation, 10 μL CCK-8 solution was added to each well and cultivated for 1.5 h. ","Briefly,/O Briefly,/O Briefly,/O Briefly,/O a/O total/O of/O approximately/O 5/O ×/O 10⁳/O cells/O were/O seeded/O in/O 96-well/O 96-well/O 96-well/O plates,/O plates,/O after/O merecidin/O merecidin/O merecidin/O stimulation,/O stimulation,/O 10/O μL/O μL/O CCK-8/O CCK-8/O CCK-8/O CCK-8/O solution/O was/O added/O to/O each/O well/O and/O cultivated/O for/O 1.5/O 1.5/O 1.5/O h./O h./O"
Kuroda   found that the similar peptide FF/CAP18 of members of the endogenous cathelicidin family significantly reduced the proliferation of HCT116 cells with increasing doses.,Kuroda/O Kuroda/O Kuroda/O found/O that/O the/O similar/O peptide/O peptide/O FF/CAP18/O FF/CAP18/O FF/CAP18/O FF/CAP18/O FF/CAP18/O of/O members/O of/O the/O endogenous/O endogenous/O endogenous/O cathelicidin/O cathelicidin/O cathelicidin/O cathelicidin/O family/O significantly/O reduced/O the/O proliferation/O of/O HCT116/B-CellLine HCT116/B-CellLine HCT116/O HCT116/O cells/O with/O increasing/O doses./O doses./O
"31  Patil   found that the antimicrobial peptide Nisin ZP can inhibit A549 cell proliferation through non-membrane lysis pathway, mitochondrial membrane depolarization and increase reactive oxygen species (ROS) production, while significantly inhibiting three-dimensional spheroid growth and cell viability of A549 cells, showing potential therapeutic effects on highly metastatic non-small cell lung cancer.","31/O Patil/O Patil/O found/O that/O the/O antimicrobial/O antimicrobial/O antimicrobial/O antimicrobial/O peptide/O peptide/O Nisin/O Nisin/O ZP/O ZP/O can/O inhibit/O inhibit/O A549/O A549/O A549/O A549/O cell/O proliferation/O through/O non-membrane/O non-membrane/O non-membrane/O lysis/O lysis/O lysis/O pathway,/O pathway,/O mitochondrial/O membrane/O depolarization/O depolarization/O depolarization/O depolarization/O and/O increase/O reactive/O oxygen/O species/O (ROS)/O (ROS)/O (ROS)/O (ROS)/O production,/O production,/O while/O significantly/O inhibiting/O inhibiting/O inhibiting/O three-dimensional/O three-dimensional/O three-dimensional/O spheroid/O spheroid/O spheroid/O growth/O and/O cell/O viability/O viability/O of/O A549/O A549/O A549/O A549/O cells,/O cells,/O showing/O potential/O therapeutic/O effects/O on/O highly/O metastatic/O metastatic/O non-small/O non-small/O non-small/O cell/O lung/O cancer./O cancer./O"
"39  Bankell   found that LL-37 can reduce cell viability and stimulate LDH release in osteoblast MG63 cells, suggesting that LL-37 promotes caspase-independent apoptosis, and this effect appears to be related to plasma membrane permeability of human MG63 cells.","39/O Bankell/O Bankell/O found/O that/O LL-37/O LL-37/O LL-37/O can/O reduce/O cell/O viability/O viability/O and/O stimulate/O LDH/O LDH/O LDH/O release/O in/O osteoblast/O osteoblast/O osteoblast/O osteoblast/O MG63/O MG63/O MG63/O cells,/O cells,/O suggesting/O that/O LL-37/O LL-37/O LL-37/O promotes/O caspase-independent/O caspase-independent/O caspase-independent/O caspase-independent/O caspase-independent/O apoptosis,/O apoptosis,/O apoptosis,/O apoptosis,/O and/O this/O effect/O appears/O to/O be/O related/O to/O plasma/O membrane/O permeability/O permeability/O permeability/O of/O human/O MG63/O MG63/O MG63/O cells./O cells./O"
"References 1.  Sung H, Ferlay J, Siegel RL, et al. ","References/O References/O 1./O 1./O Sung/O H,/O H,/O Ferlay/O Ferlay/O Ferlay/O J,/O J,/O Siegel/O Siegel/O RL,/O RL,/O RL,/O et/O al./O al./O"
"Effect of antimicrobial peptide merecidin on proliferation, apoptosis, migration and invasion of lung cancer A549 cells via ERK /mTOR pathway. ","Effect/O of/O antimicrobial/O antimicrobial/O antimicrobial/O antimicrobial/O peptide/O peptide/O merecidin/O merecidin/O merecidin/O on/O proliferation,/O proliferation,/O apoptosis,/O apoptosis,/O apoptosis,/O apoptosis,/O migration/O and/O invasion/O of/O lung/O cancer/O A549/B-CellLine A549/O A549/O A549/O cells/O via/O ERK/O ERK/O /mTOR/O /mTOR/O /mTOR/O /mTOR/O pathway./O pathway./O"
Antimicrobial peptide merecidin induce autophagy of lung adenocarcinoma A549 cells regulated via MAPK1 [master]. ,Antimicrobial/O Antimicrobial/O Antimicrobial/O Antimicrobial/O peptide/O peptide/O merecidin/O merecidin/O merecidin/O induce/O autophagy/O autophagy/O autophagy/O of/O lung/O adenocarcinoma/O adenocarcinoma/O adenocarcinoma/O adenocarcinoma/O adenocarcinoma/O A549/B-CellLine A549/O A549/B-CellLine A549/O cells/O regulated/O via/O MAPK1/O MAPK1/O MAPK1/O MAPK1/O [master]./O [master]./O [master]./O [master]./O
Calycosin inhibits breast cancer cell migration and invasion by suppressing EMT via BATF/TGF-β1.  Aging (Albany NY) ,Calycosin/O Calycosin/O Calycosin/O Calycosin/O inhibits/O inhibits/O inhibits/O breast/O cancer/O cell/O migration/O and/O invasion/O by/O suppressing/O suppressing/O EMT/O EMT/O via/O BATF/TGF-β1./O BATF/TGF-β1./O BATF/TGF-β1./O BATF/TGF-β1./O BATF/TGF-β1./O BATF/TGF-β1./O BATF/TGF-β1./O BATF/TGF-β1./O BATF/TGF-β1./O BATF/TGF-β1./O Aging/O Aging/O (Albany/O (Albany/O NY)/O NY)/O
"A Multifunctional Platform for Tumor Angiogenesis-Targeted Chemo-Thermal Therapy Using Polydopamine-Coated Gold Nanorods 2016 10404 10417                 10.1021/acsnano.6b06267 Zhang, Lu; Su, Huilan; Cai, Jiali; Cheng, Dengfeng; Ma, Yongjie; Zhang, Jianping; Zhou, Chuanqing; Liu, Shiyuan; Shi, Hongcheng; Zhang, Yingjian; Zhang, Chunfu 10404-10417 Image-guided combined chemo-thermal therapy assists in optimizing treatment time, enhancing therapeutic efficiency, and circumventing side effects.  In the present study, we developed a chemo-photothermal theranostic platform based on polydopamine (PDA)-coated gold nanorods (GNRs).  The PDA coating was thin; however, it significantly suppressed the cytotoxicity of the cetyltrimethylammonium bromide template and allowed high cisplatin loading efficiency, arginine-glycine-aspartic acid (RGD) peptide (c(RGDyC)) conjugation, and chelator-free iodine-125 labeling (RGD-125IPt-PDA@GNRs).  While loaded cisplatin was released in a pH-sensitive manner, labeled 125I was outstandingly stable under biol. conditions.  RGD-125IPt-PDA@GNRs had a high specificity for αvβ3 integrin, and consequently, they could selectively accumulate in tumors, as revealed by single photon emission computed tomog./CT imaging, and in target tumor angiogenic vessels, as shown by high-resoln. photoacoustic imaging.  As RGD-125IPt-PDA@GNRs targets tumor angiogenesis, it is a highly potent tumor therapy.  Combined chemo-photothermal therapy with probes could thoroughly ablate tumors and inhibit tumor relapse via a synergistic antitumor effect.  Our studies demonstrated that RGD-125IPt-PDA@GNRs is a robust platform for image-guided, chemo-thermal tumor therapy with outstanding synergistic tumor killing and relapse inhibition effects.","A/O Multifunctional/O Multifunctional/O Multifunctional/O Platform/O for/O Tumor/O Tumor/O Angiogenesis-Targeted/O Angiogenesis-Targeted/O Angiogenesis-Targeted/O Angiogenesis-Targeted/O Angiogenesis-Targeted/O Angiogenesis-Targeted/O Chemo-Thermal/O Chemo-Thermal/O Chemo-Thermal/O Chemo-Thermal/O Chemo-Thermal/O Chemo-Thermal/O Therapy/O Using/O Polydopamine-Coated/O Polydopamine-Coated/O Polydopamine-Coated/O Polydopamine-Coated/O Polydopamine-Coated/O Polydopamine-Coated/O Polydopamine-Coated/O Gold/O Nanorods/O Nanorods/O Nanorods/O 2016/O 10404/O 10404/O 10404/O 10417/O 10417/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O 10.1021/acsnano.6b06267/O Zhang,/O Zhang,/O Lu;/O Lu;/O Su,/O Su,/O Huilan;/O Huilan;/O Huilan;/O Cai,/O Cai,/O Cai,/O Jiali;/O Jiali;/O Jiali;/O Cheng,/O Cheng,/O Dengfeng;/O Dengfeng;/O Dengfeng;/O Dengfeng;/O Ma,/O Ma,/O Yongjie;/O Yongjie;/O Yongjie;/O Yongjie;/O Zhang,/O Zhang,/O Jianping;/O Jianping;/O Jianping;/O Jianping;/O Zhou,/O Zhou,/O Chuanqing;/O Chuanqing;/O Chuanqing;/O Chuanqing;/O Liu,/O Liu,/O Shiyuan;/O Shiyuan;/O Shiyuan;/O Shi,/O Shi,/O Hongcheng;/O Hongcheng;/O Hongcheng;/O Zhang,/O Zhang,/O Yingjian;/O Yingjian;/O Yingjian;/O Yingjian;/O Zhang,/O Zhang,/O Chunfu/O Chunfu/O 10404-10417/O 10404-10417/O 10404-10417/O 10404-10417/O 10404-10417/O 10404-10417/O Image-guided/O Image-guided/O Image-guided/O combined/O chemo-thermal/O chemo-thermal/O chemo-thermal/O chemo-thermal/O chemo-thermal/O therapy/O assists/O in/O optimizing/O optimizing/O optimizing/O treatment/O time,/O time,/O enhancing/O therapeutic/O efficiency,/O efficiency,/O and/O circumventing/O circumventing/O circumventing/O circumventing/O side/O effects./O effects./O In/O the/O present/O study,/O study,/O we/O developed/O a/O chemo-photothermal/O chemo-photothermal/O chemo-photothermal/O chemo-photothermal/O chemo-photothermal/O chemo-photothermal/O theranostic/O theranostic/O theranostic/O platform/O based/O on/O polydopamine/O polydopamine/O polydopamine/O polydopamine/O polydopamine/O (PDA)-coated/O (PDA)-coated/O (PDA)-coated/O (PDA)-coated/O (PDA)-coated/O (PDA)-coated/O gold/O nanorods/O nanorods/O nanorods/O (GNRs)./O (GNRs)./O (GNRs)./O (GNRs)./O (GNRs)./O (GNRs)./O The/O PDA/O PDA/O coating/O was/O thin;/O thin;/O however,/O however,/O it/O significantly/O suppressed/O the/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O of/O the/O cetyltrimethylammonium/O cetyltrimethylammonium/O cetyltrimethylammonium/O cetyltrimethylammonium/O cetyltrimethylammonium/O cetyltrimethylammonium/O cetyltrimethylammonium/O cetyltrimethylammonium/O bromide/O bromide/O bromide/O template/O and/O allowed/O high/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O loading/O efficiency,/O efficiency,/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O arginine-glycine-aspartic/O acid/O (RGD)/O (RGD)/O (RGD)/O (RGD)/O (RGD)/O peptide/O peptide/O (c(RGDyC))/O (c(RGDyC))/O (c(RGDyC))/O (c(RGDyC))/O (c(RGDyC))/O (c(RGDyC))/O (c(RGDyC))/O (c(RGDyC))/O (c(RGDyC))/O (c(RGDyC))/O conjugation,/O conjugation,/O conjugation,/O conjugation,/O and/O chelator-free/O chelator-free/O chelator-free/O chelator-free/O chelator-free/O iodine-125/O iodine-125/O iodine-125/O iodine-125/O iodine-125/O labeling/O labeling/O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O (RGD-125IPt-PDA@GNRs)./O While/O loaded/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O was/O released/O in/O a/O pH-sensitive/O pH-sensitive/O pH-sensitive/O manner,/O manner,/O labeled/O 125I/O 125I/O was/O outstandingly/O outstandingly/O stable/O under/O biol./O biol./O biol./O conditions./O conditions./O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O had/O a/O high/O specificity/O specificity/O for/O αvβ3/O αvβ3/O αvβ3/O αvβ3/O integrin,/O integrin,/O integrin,/O integrin,/O integrin,/O and/O consequently,/O consequently,/O they/O could/O selectively/O selectively/O accumulate/O accumulate/O accumulate/O accumulate/O in/O tumors,/O tumors,/O as/O revealed/O by/O single/O photon/O photon/O emission/O computed/O computed/O tomog./CT/O tomog./CT/O tomog./CT/O tomog./CT/O tomog./CT/O tomog./CT/O imaging,/O imaging,/O and/O in/O target/O tumor/O angiogenic/O angiogenic/O angiogenic/O vessels,/O vessels,/O as/O shown/O by/O high-resoln./O high-resoln./O high-resoln./O high-resoln./O high-resoln./O high-resoln./O photoacoustic/O photoacoustic/O photoacoustic/O imaging./O imaging./O As/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O targets/O tumor/O angiogenesis,/O angiogenesis,/O angiogenesis,/O angiogenesis,/O it/O is/O a/O highly/O potent/O tumor/O therapy./O therapy./O Combined/O chemo-photothermal/O chemo-photothermal/O chemo-photothermal/O chemo-photothermal/O chemo-photothermal/O chemo-photothermal/O therapy/O with/O probes/O probes/O could/O thoroughly/O ablate/O ablate/O ablate/O tumors/O and/O inhibit/O inhibit/O tumor/O relapse/O relapse/O relapse/O via/O a/O synergistic/O synergistic/O synergistic/O synergistic/O antitumor/O antitumor/O antitumor/O effect./O effect./O Our/O studies/O demonstrated/O that/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O RGD-125IPt-PDA@GNRs/O is/O a/O robust/O platform/O for/O image-guided,/O image-guided,/O image-guided,/O image-guided,/O chemo-thermal/O chemo-thermal/O chemo-thermal/O chemo-thermal/O chemo-thermal/O tumor/O therapy/O with/O outstanding/O"
"Robust Electrografting on Self-Organized 3D Graphene Electrodes 2 1424 1433                 10.1021/acsami.5b10647 Fortgang, Philippe; Tite, Teddy; Barnier, Vincent; Zehani, Nedjla; Maddi, Chiranjeevi; Lagarde, Florence; Loir, Anne-Sophie; Jaffrezic-Renault, Nicole; Donnet, Christophe; Garrelie, Florence; Chaix, Carole 1424-1433 Improving graphene-based electrode fabrication processes and developing robust methods for its functionalization are two key research routes to develop new high-performance electrodes for electrochem. applications.  Here, a self-organized three-dimensional (3D) graphene electrode processed by pulsed laser deposition with thermal annealing is reported.  This substrate shows great performance in electron transfer kinetics regarding ferrocene redox probes in soln.  A robust electrografting strategy for covalently attaching a redox probe onto these graphene electrodes is also reported.  The modification protocol consists of a combination of diazonium salt electrografting and click chem.  An alkyne-terminated Ph ring is 1st electrografted onto the self-organized 3-dimensional graphene electrode by in situ electrochem. redn. of 4-ethynylphenyl diazonium.  Then the ethynylphenyl-modified surface efficiently reacts with the redox probe bearing a terminal azide moiety (2-azidoethyl ferrocene) by CuI-catalyzed alkyne-azide cycloaddn.  The authors' modification strategy applied to 3-dimensional graphene electrodes was analyzed by at. force microscopy, SEM, Raman spectroscopy, cyclic voltammetry, and XPS.  For XPS chem. surface anal., special attention was paid to the distribution and chem. state of Fe and N to highlight the functionalization of the graphene-based substrate by electrochem. grafting a ferrocene deriv.  Dense grafting was obsd., offering 4.9 × 10-10 mol cm-2 surface coverage and showing a stable signal over 22 days.  The electrografting was performed as multilayers, which offers higher ferrocene loading than a dense monolayer on a flat surface.  This work opens highly promising perspectives for the development of self-organized 3-dimensional graphene electrodes with various sensing functionalities.","Robust/O Robust/O Electrografting/O Electrografting/O Electrografting/O Electrografting/O Electrografting/O on/O Self-Organized/O Self-Organized/O Self-Organized/O Self-Organized/O 3D/O Graphene/O Graphene/O Graphene/O Graphene/O Electrodes/O Electrodes/O Electrodes/O Electrodes/O 2/O 1424/O 1424/O 1433/O 1433/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O 10.1021/acsami.5b10647/O Fortgang,/O Fortgang,/O Fortgang,/O Fortgang,/O Philippe;/O Philippe;/O Tite,/O Tite,/O Tite,/O Teddy;/O Teddy;/O Barnier,/O Barnier,/O Barnier,/O Vincent;/O Vincent;/O Zehani,/O Zehani,/O Zehani,/O Zehani,/O Nedjla;/O Nedjla;/O Nedjla;/O Nedjla;/O Maddi,/O Maddi,/O Maddi,/O Chiranjeevi;/O Chiranjeevi;/O Chiranjeevi;/O Chiranjeevi;/O Chiranjeevi;/O Lagarde,/O Lagarde,/O Lagarde,/O Lagarde,/O Florence;/O Florence;/O Loir,/O Loir,/O Loir,/O Anne-Sophie;/O Anne-Sophie;/O Anne-Sophie;/O Anne-Sophie;/O Jaffrezic-Renault,/O Jaffrezic-Renault,/O Jaffrezic-Renault,/O Jaffrezic-Renault,/O Jaffrezic-Renault,/O Jaffrezic-Renault,/O Jaffrezic-Renault,/O Jaffrezic-Renault,/O Nicole;/O Nicole;/O Donnet,/O Donnet,/O Donnet,/O Christophe;/O Christophe;/O Garrelie,/O Garrelie,/O Garrelie,/O Garrelie,/O Garrelie,/O Florence;/O Florence;/O Chaix,/O Chaix,/O Chaix,/O Carole/O 1424-1433/O 1424-1433/O 1424-1433/O 1424-1433/O 1424-1433/O Improving/O Improving/O Improving/O graphene-based/O graphene-based/O graphene-based/O graphene-based/O electrode/O electrode/O fabrication/O fabrication/O processes/O and/O developing/O robust/O methods/O for/O its/O functionalization/O functionalization/O are/O two/O key/O research/O routes/O to/O develop/O new/O high-performance/O high-performance/O high-performance/O electrodes/O electrodes/O for/O electrochem./O electrochem./O electrochem./O electrochem./O applications./O applications./O Here,/O Here,/O a/O self-organized/O self-organized/O self-organized/O three-dimensional/O three-dimensional/O three-dimensional/O (3D)/O (3D)/O (3D)/O graphene/O graphene/O electrode/O electrode/O processed/O by/O pulsed/O laser/O deposition/O with/O thermal/O annealing/O annealing/O annealing/O is/O reported./O reported./O This/O substrate/O shows/O great/O performance/O in/O electron/O transfer/O kinetics/O kinetics/O regarding/O ferrocene/O ferrocene/O ferrocene/O ferrocene/O redox/O redox/O probes/O probes/O in/O soln./O soln./O soln./O A/O robust/O electrografting/O electrografting/O electrografting/O strategy/O for/O covalently/O covalently/O covalently/O attaching/O attaching/O a/O redox/O redox/O probe/O onto/O these/O graphene/O graphene/O electrodes/O electrodes/O is/O also/O reported./O reported./O The/O modification/O protocol/O consists/O of/O a/O combination/O of/O diazonium/O diazonium/O diazonium/O salt/O electrografting/O electrografting/O electrografting/O and/O click/O chem./O chem./O chem./O An/O alkyne-terminated/O alkyne-terminated/O alkyne-terminated/O alkyne-terminated/O alkyne-terminated/O Ph/O ring/O is/O 1st/O electrografted/O electrografted/O electrografted/O onto/O the/O self-organized/O self-organized/O self-organized/O 3-dimensional/O 3-dimensional/O 3-dimensional/O graphene/O graphene/O electrode/O electrode/O by/O in/O situ/O situ/O electrochem./O electrochem./O electrochem./O electrochem./O redn./O redn./O redn./O of/O 4-ethynylphenyl/O 4-ethynylphenyl/O 4-ethynylphenyl/O 4-ethynylphenyl/O 4-ethynylphenyl/O 4-ethynylphenyl/O 4-ethynylphenyl/O 4-ethynylphenyl/O 4-ethynylphenyl/O diazonium./O diazonium./O diazonium./O diazonium./O Then/O the/O ethynylphenyl-modified/O ethynylphenyl-modified/O ethynylphenyl-modified/O ethynylphenyl-modified/O ethynylphenyl-modified/O ethynylphenyl-modified/O ethynylphenyl-modified/O ethynylphenyl-modified/O ethynylphenyl-modified/O surface/O efficiently/O reacts/O reacts/O with/O the/O redox/O redox/O probe/O bearing/O a/O terminal/O azide/O azide/O azide/O moiety/O moiety/O moiety/O (2-azidoethyl/O (2-azidoethyl/O (2-azidoethyl/O (2-azidoethyl/O (2-azidoethyl/O (2-azidoethyl/O (2-azidoethyl/O (2-azidoethyl/O ferrocene)/O ferrocene)/O ferrocene)/O ferrocene)/O ferrocene)/O by/O CuI-catalyzed/O CuI-catalyzed/O CuI-catalyzed/O CuI-catalyzed/O CuI-catalyzed/O CuI-catalyzed/O CuI-catalyzed/O alkyne-azide/O alkyne-azide/O alkyne-azide/O alkyne-azide/O alkyne-azide/O alkyne-azide/O alkyne-azide/O cycloaddn./O cycloaddn./O cycloaddn./O cycloaddn./O cycloaddn./O cycloaddn./O The/O authors'/O authors'/O modification/O strategy/O applied/O to/O 3-dimensional/O 3-dimensional/O 3-dimensional/O graphene/O graphene/O electrodes/O electrodes/O was/O analyzed/O by/O at./O at./O force/O microscopy,/O microscopy,/O microscopy,/O microscopy,/O SEM,/O SEM,/O SEM,/O Raman/O Raman/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O spectroscopy,/O cyclic/O cyclic/O voltammetry,/O voltammetry,/O voltammetry,/O voltammetry,/O and/O XPS./O XPS./O XPS./O For/O XPS/O XPS/O chem./O chem./O chem./O surface/O anal.,/O anal.,/O anal.,/O special/O attention/O was/O paid/O to/O the/O distribution/O and/O chem./O chem./O chem./O state/O of/O Fe/O and/O N/O to/O highlight/O the/O functionalization/O functionalization/O of/O the/O graphene-based/O graphene-based/O graphene-based/O graphene-based/O substrate/O by/O electrochem./O electrochem./O electrochem./O electrochem./O grafting/O grafting/O grafting/O a/O ferrocene/O ferrocene/O ferrocene/O ferrocene/O deriv./O deriv./O deriv./O Dense/O Dense/O grafting/O grafting/O grafting/O was/O obsd.,/O obsd.,/O obsd.,/O obsd.,/O obsd.,/O offering/O 4.9/O 4.9/O 4.9/O ×/O 10-10/O 10-10/O 10-10/O mol/O mol/O cm-2/O cm-2/O cm-2/O surface/O coverage/O and/O showing/O a/O stable/O signal/O over/O 22/O days./O days./O The/O electrografting/O electrografting/O electrografting/O was/O performed/O as/O multilayers,/O multilayers,/O multilayers,/O"
"Lenti-sh RRS1 lentivirus was constructed and employed to downregulate the RRS1 expression in MDA-MB-231 and BT549 cells, which had a high-level expression of RRS1. Subsequently, we assessed the impact of RRS1 downregulation on the proliferation, migration, and invasion of breast cancer cells using CCK-8, apoptosis, and cell cycle by flow cytometry, wound healing test, Transwell migration, and invasion experiments. ","Lenti-sh/O Lenti-sh/O Lenti-sh/O Lenti-sh/O Lenti-sh/O RRS1/O RRS1/O RRS1/O lentivirus/O lentivirus/O lentivirus/O lentivirus/O was/O constructed/O and/O employed/O to/O downregulate/O downregulate/O downregulate/O downregulate/O the/O RRS1/O RRS1/O RRS1/O expression/O in/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O and/O BT549/B-CellLine BT549/O BT549/O BT549/O cells,/O cells,/O which/O had/O a/O high-level/O high-level/O high-level/O expression/O of/O RRS1./O RRS1./O RRS1./O RRS1./O Subsequently,/O Subsequently,/O we/O assessed/O the/O impact/O of/O RRS1/O RRS1/O RRS1/O downregulation/O downregulation/O downregulation/O downregulation/O on/O the/O proliferation,/O proliferation,/O migration,/O migration,/O and/O invasion/O of/O breast/O cancer/O cells/O using/O CCK-8,/O CCK-8,/O CCK-8,/O CCK-8,/O CCK-8,/O apoptosis,/O apoptosis,/O apoptosis,/O apoptosis,/O and/O cell/O cycle/O by/O flow/O cytometry,/O cytometry,/O cytometry,/O cytometry,/O cytometry,/O wound/O healing/O test,/O test,/O Transwell/O Transwell/O migration,/O migration,/O and/O invasion/O experiments./O experiments./O"
Loss-of-function experiment illustrated that the inhibiting of RRS1 expression reduced the rapid proliferation capacity of MDA-MB-231 and BT549 cells and hindered their migration and invasion capabilities (p<0.05). ,Loss-of-function/O Loss-of-function/O Loss-of-function/O Loss-of-function/O Loss-of-function/O experiment/O illustrated/O that/O the/O inhibiting/O inhibiting/O inhibiting/O of/O RRS1/O RRS1/O RRS1/O expression/O reduced/O the/O rapid/O proliferation/O capacity/O of/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O and/O BT549/B-CellLine BT549/O BT549/O BT549/O cells/O and/O hindered/O hindered/O their/O migration/O and/O invasion/O capabilities/O (p<0.05)./O (p<0.05)./O (p<0.05)./O (p<0.05)./O (p<0.05)./O (p<0.05)./O (p<0.05)./O (p<0.05)./O
"Cell lines and cell culture Human BC cell lines (MCF7, MDA-MB-231 and BT-549) and HEK293T were purchased from the Cell Bank at the Chinese Academic of Science. ","Cell/O lines/O and/O cell/O culture/O Human/O BC/O cell/O lines/O (MCF7,/O (MCF7,/B-CellLine (MCF7,/O (MCF7,/O (MCF7,/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O and/O BT-549)/B-CellLine BT-549)/O BT-549)/O BT-549)/O BT-549)/O and/O HEK293T/O HEK293T/O HEK293T/O HEK293T/O HEK293T/O HEK293T/O were/O purchased/O from/O the/O Cell/O Bank/O at/O the/O Chinese/O Academic/O of/O Science./O Science./O"
"Chemoresistant MCF7 cells were developed by stepwise selection in increasing doses of doxorubicin (DOX; MedChemExpress) or paclitaxel (PTX, MedChemExpress) as previously described [ 17 18 ], termed MCF7 DOX  and MCF7 PTX , respectively. ","Chemoresistant/O Chemoresistant/O Chemoresistant/O Chemoresistant/O Chemoresistant/O MCF7/B-CellLine MCF7/O MCF7/O cells/O were/O developed/O by/O stepwise/O stepwise/O selection/O in/O increasing/O doses/O of/O doxorubicin/O doxorubicin/O doxorubicin/O doxorubicin/O doxorubicin/O (DOX;/O (DOX;/O (DOX;/O (DOX;/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O or/O paclitaxel/O paclitaxel/O paclitaxel/O paclitaxel/O paclitaxel/O (PTX,/O (PTX,/O (PTX,/O (PTX,/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O MedChemExpress)/O as/O previously/O described/O [/O 17/O 18/O ],/O ],/O termed/O MCF7/B-CellLine MCF7/O MCF7/O DOX/O DOX/O and/O MCF7/B-CellLine MCF7/O MCF7/O PTX/O PTX/O ,/O respectively./O respectively./O"
"MCF7, MDA-MB-231, MCF7 , MCF7  and HEK293T cells were cultured in Dulbecco's Modified Eagle's Medium (Gibco). ","MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MCF7/B-CellLine MCF7/O MCF7/O ,/O MCF7/B-CellLine MCF7/O MCF7/O and/O HEK293T/O HEK293T/O HEK293T/O HEK293T/O HEK293T/O HEK293T/O cells/O were/O cultured/O cultured/O in/O Dulbecco's/O Dulbecco's/O Dulbecco's/O Dulbecco's/O Dulbecco's/O Dulbecco's/O Modified/O Modified/O Eagle's/O Eagle's/O Eagle's/O Medium/O (Gibco)./O (Gibco)./O (Gibco)./O (Gibco)./O (Gibco)./O (Gibco)./O"
BT549 cells were cultured in RPMI 1640 (Gibco). ,BT549/B-CellLine BT549/B-CellLine BT549/O BT549/O cells/O were/O cultured/O cultured/O in/O RPMI/O RPMI/O RPMI/O 1640/O (Gibco)./O (Gibco)./O (Gibco)./O (Gibco)./O (Gibco)./O (Gibco)./O
"MDA-MB-231, MCF7 and MCF7  cells were infected with above lentivirus. ","MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MCF7/B-CellLine MCF7/O MCF7/O and/O MCF7/B-CellLine MCF7/O MCF7/O cells/O were/O infected/O with/O above/O lentivirus./O lentivirus./O lentivirus./O lentivirus./O lentivirus./O"
"In brief, detached cells (2 × 10⁵ ) were rinsed with ice-cold PBS, and incubated with binding buffer supplemented with APC-conjugated annexin-V (BioLegend Cat# 831603, RRID: AB_2686933) and 7-AAD (BioLegend) for 15 min at RT in the dark. ","In/O brief,/O brief,/O detached/O cells/O (2/O (2/O ×/O 10⁵/O 10⁵/O )/O were/O rinsed/O rinsed/O rinsed/O with/O ice-cold/O ice-cold/O ice-cold/O PBS,/O PBS,/O and/O incubated/O incubated/O incubated/O incubated/O with/O binding/O buffer/O supplemented/O with/O APC-conjugated/O APC-conjugated/O APC-conjugated/O APC-conjugated/O APC-conjugated/O APC-conjugated/O annexin-V/O annexin-V/O annexin-V/O annexin-V/O annexin-V/O (BioLegend/O (BioLegend/O (BioLegend/O (BioLegend/O (BioLegend/O (BioLegend/O Cat#/O Cat#/O 831603,/O 831603,/O 831603,/O 831603,/O 831603,/O RRID:/O RRID:/O RRID:/O RRID:/O AB_2686933)/O AB_2686933)/O AB_2686933)/O AB_2686933)/O AB_2686933)/O AB_2686933)/O AB_2686933)/O and/O 7-AAD/O 7-AAD/O 7-AAD/O 7-AAD/O (BioLegend)/O (BioLegend)/O (BioLegend)/O (BioLegend)/O (BioLegend)/O (BioLegend)/O (BioLegend)/O for/O 15/O min/O at/O RT/O RT/O in/O the/O dark./O dark./O"
"Two-dimensional LC-MS were performed using QE HF-X (Thermofisher Scientific), and glycoproteomics data were analyzed with Glyco-Decipher (v1.0.3) [ 19 IP-based mass spectrometry analysis Immunoprecipitated complexes were separated by SDS-PAGE, and gel pieces were dehydrated with acetonitrile, reduced with DTT, alkylated with IAA and digested with trypsin. ","Two-dimensional/O Two-dimensional/O Two-dimensional/O LC-MS/O LC-MS/O LC-MS/O LC-MS/O were/O performed/O using/O QE/O QE/O HF-X/O HF-X/O HF-X/O HF-X/O (Thermofisher/O (Thermofisher/O (Thermofisher/O (Thermofisher/O (Thermofisher/O (Thermofisher/O Scientific),/O Scientific),/O Scientific),/O and/O glycoproteomics/O glycoproteomics/O glycoproteomics/O glycoproteomics/O glycoproteomics/O glycoproteomics/O glycoproteomics/O data/O were/O analyzed/O with/O Glyco-Decipher/O Glyco-Decipher/O Glyco-Decipher/O Glyco-Decipher/O Glyco-Decipher/O Glyco-Decipher/O Glyco-Decipher/O (v1.0.3)/O (v1.0.3)/O (v1.0.3)/O (v1.0.3)/O (v1.0.3)/O (v1.0.3)/O (v1.0.3)/O (v1.0.3)/O [/O 19/O IP-based/O IP-based/O IP-based/O mass/O spectrometry/O spectrometry/O spectrometry/O spectrometry/O analysis/O Immunoprecipitated/O Immunoprecipitated/O Immunoprecipitated/O Immunoprecipitated/O Immunoprecipitated/O Immunoprecipitated/O Immunoprecipitated/O Immunoprecipitated/O complexes/O were/O separated/O by/O SDS-PAGE,/O SDS-PAGE,/O SDS-PAGE,/O SDS-PAGE,/O SDS-PAGE,/O SDS-PAGE,/O and/O gel/O pieces/O were/O dehydrated/O dehydrated/O dehydrated/O dehydrated/O with/O acetonitrile,/O acetonitrile,/O acetonitrile,/O acetonitrile,/O acetonitrile,/O acetonitrile,/O reduced/O with/O DTT,/O DTT,/O DTT,/O alkylated/O alkylated/O alkylated/O with/O IAA/O IAA/O and/O digested/O digested/O with/O trypsin./O trypsin./O trypsin./O trypsin./O"
"Proximity labelling and identification Annexin A1 and Basu-HA were amplified via PCR, fused and linked to lentiviral overexpression vector pLVX-AcGFP-N1. HEK293T cells were transfected with the constructed plasmid using Lipofectamine 2000 reagent (Thermofisher Scientific), incubated with biotin (50 μM) for 18 h, and confirmed by western blot. ","Proximity/O Proximity/O Proximity/O labelling/O labelling/O and/O identification/O Annexin/O Annexin/O A1/O and/O Basu-HA/O Basu-HA/O Basu-HA/O Basu-HA/O Basu-HA/O were/O amplified/O amplified/O via/O PCR,/O PCR,/O PCR,/O fused/O and/O linked/O to/O lentiviral/O lentiviral/O lentiviral/O lentiviral/O overexpression/O overexpression/O overexpression/O overexpression/O vector/O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O pLVX-AcGFP-N1./O HEK293T/O HEK293T/O HEK293T/O HEK293T/O HEK293T/O HEK293T/O cells/O were/O transfected/O transfected/O with/O the/O constructed/O plasmid/O plasmid/O plasmid/O plasmid/O using/O Lipofectamine/O Lipofectamine/O Lipofectamine/O Lipofectamine/O 2000/O reagent/O reagent/O reagent/O (Thermofisher/O (Thermofisher/O (Thermofisher/O (Thermofisher/O (Thermofisher/O (Thermofisher/O Scientific),/O Scientific),/O Scientific),/O incubated/O incubated/O incubated/O incubated/O with/O biotin/O biotin/O (50/O (50/O μM)/O μM)/O μM)/O for/O 18/O h,/O h,/O and/O confirmed/O by/O western/O blot./O blot./O blot./O"
"Bisecting GlcNAc partially reverse the chemoresistance in BC cells Bisecting GlcNAc levels and MGAT3 expression were significantly reduced in breast cancer cells MDA-MB-231, MCF7, BT-549 and MCF7  response to DOX, PTX or cisplatin in dose- and time-dependent manners ( A&B, S2A-J ), and in MCF7 compared to MCF7  ( ). ","Bisecting/O Bisecting/O Bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O partially/O reverse/O the/O chemoresistance/O chemoresistance/O chemoresistance/O chemoresistance/O chemoresistance/O in/O BC/O cells/O Bisecting/O Bisecting/O Bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O and/O MGAT3/O MGAT3/O MGAT3/O expression/O were/O significantly/O reduced/O in/O breast/O cancer/O cells/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O BT-549/O BT-549/O BT-549/O BT-549/O and/O MCF7/B-CellLine MCF7/O MCF7/O response/O to/O DOX,/O DOX,/O DOX,/O PTX/O PTX/O or/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O cisplatin/O in/O dose-/O dose-/O and/O time-dependent/O time-dependent/O time-dependent/O manners/O (/O A&B,/O A&B,/O A&B,/O A&B,/O S2A-J/O S2A-J/O S2A-J/O S2A-J/O S2A-J/O ),/O ),/O and/O in/O MCF7/B-CellLine MCF7/O MCF7/O compared/O to/O MCF7/B-CellLine MCF7/O MCF7/O (/O )./O )./O"
"To explore the roles of bisecting GlcNAc in BC chemoresistance, we introduced MGAT3 into MDA-MB-231, MCF7 and MCF7  cells (termed as MB231/MGAT3, MCF7/MGAT3 and MCF7 /MGAT3) to enhance bisecting GlcNAc levels ( Fig. ","To/O explore/O the/O roles/O of/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O in/O BC/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O we/O introduced/O MGAT3/O MGAT3/O MGAT3/O into/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MCF7/B-CellLine MCF7/O MCF7/O and/O MCF7/B-CellLine MCF7/O MCF7/O cells/O (termed/O (termed/O as/O MB231/MGAT3,/B-CellLine MB231/MGAT3,/O MB231/MGAT3,/O MB231/MGAT3,/O MB231/MGAT3,/O MB231/MGAT3,/O MB231/MGAT3,/O MB231/MGAT3,/O MCF7/MGAT3/B-CellLine MCF7/MGAT3/O MCF7/MGAT3/O MCF7/MGAT3/O MCF7/MGAT3/O MCF7/MGAT3/O MCF7/MGAT3/O and/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3)/O /MGAT3)/O /MGAT3)/O /MGAT3)/O /MGAT3)/O to/O enhance/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O (/O Fig./O Fig./O Fig./O"
"Similar results were observed in MCF7/MGAT3 and MCF7 /MGAT3 cells following DOX treatment ( I, S3D-F ), accompanied by weakened drug efflux activity ( ). ","Similar/O results/O were/O observed/O in/O MCF7/MGAT3/B-CellLine MCF7/MGAT3/O MCF7/MGAT3/O MCF7/MGAT3/O MCF7/MGAT3/O MCF7/MGAT3/O MCF7/MGAT3/O and/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3/O /MGAT3/O /MGAT3/O /MGAT3/O cells/O following/O DOX/O DOX/O treatment/O (/O I,/O I,/O S3D-F/O S3D-F/O S3D-F/O S3D-F/O S3D-F/O ),/O ),/O accompanied/O by/O weakened/O drug/O efflux/O efflux/O efflux/O activity/O (/O )./O )./O"
"This degradation of MGAT3 was reversed in DOX-exposed MDA-MB-231 and MCF7 cells by the proteasome inhibitor, MG132, but not by the lysosomal inhibitor, chloroquine (Chol) ( B, S4A-C ). ","This/O degradation/O of/O MGAT3/O MGAT3/O MGAT3/O was/O reversed/O in/O DOX-exposed/O DOX-exposed/O DOX-exposed/O DOX-exposed/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O and/O MCF7/B-CellLine MCF7/O MCF7/O cells/O by/O the/O proteasome/O proteasome/O proteasome/O proteasome/O inhibitor,/O inhibitor,/O MG132,/O MG132,/O MG132,/O MG132,/O but/O not/O by/O the/O lysosomal/O lysosomal/O lysosomal/O lysosomal/O inhibitor,/O inhibitor,/O chloroquine/O chloroquine/O chloroquine/O chloroquine/O chloroquine/O (Chol)/O (Chol)/O (Chol)/O (Chol)/O (/O B,/O B,/O S4A-C/O S4A-C/O S4A-C/O S4A-C/O S4A-C/O )./O )./O"
"P-gp was further validated to be modified with bisecting GlcNAc, and was down-regulated in MGAT3 overexpressed MCF7  cells ( ), without significant changes at the mRNA level ( Fig. ","P-gp/O P-gp/O P-gp/O P-gp/O was/O further/O validated/O validated/O to/O be/O modified/O with/O bisecting/O bisecting/O bisecting/O GlcNAc,/O GlcNAc,/O GlcNAc,/O GlcNAc,/O GlcNAc,/O GlcNAc,/O and/O was/O down-regulated/O down-regulated/O down-regulated/O in/O MGAT3/O MGAT3/O MGAT3/O overexpressed/O overexpressed/O overexpressed/O MCF7/B-CellLine MCF7/O MCF7/O cells/O (/O ),/O ),/O without/O significant/O changes/O at/O the/O mRNA/O mRNA/O level/O (/O Fig./O Fig./O Fig./O"
"With the incorporation of azidohomoalanine (AHA), an analog of methionine ( ), the amount of newly synthesized P-gp was nearly equivalent in MCF7  cells, regardless of bisecting GlcNAc levels ( ). ","With/O the/O incorporation/O of/O azidohomoalanine/O azidohomoalanine/O azidohomoalanine/O azidohomoalanine/O azidohomoalanine/O azidohomoalanine/O azidohomoalanine/O (AHA),/O (AHA),/O (AHA),/O (AHA),/O (AHA),/O an/O analog/O of/O methionine/O methionine/O methionine/O methionine/O (/O ),/O ),/O the/O amount/O of/O newly/O synthesized/O P-gp/O P-gp/O P-gp/O P-gp/O was/O nearly/O equivalent/O in/O MCF7/B-CellLine MCF7/O MCF7/O cells,/O cells,/O regardless/O of/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O (/O )./O )./O"
"Furthermore, P-gp levels on the plasma membrane were reduced in MCF7 /MGAT3 cells ( D, S6E ). ","Furthermore,/O Furthermore,/O P-gp/O P-gp/O P-gp/O P-gp/O levels/O on/O the/O plasma/O membrane/O were/O reduced/O in/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3/O /MGAT3/O /MGAT3/O /MGAT3/O cells/O (/O D,/O D,/O S6E/O S6E/O S6E/O )./O )./O"
"Bisecting GlcNAc levels in MCF7, MCF7  cells determined by flow cytometry. (D) ","Bisecting/O Bisecting/O Bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O in/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O MCF7/B-CellLine MCF7/O MCF7/O cells/O determined/O by/O flow/O cytometry./O cytometry./O cytometry./O cytometry./O cytometry./O (D)/O (D)/O (D)/O"
Cell viability (G) and apoptosis (H) assays of parental and MGAT3-overexpressed MDA-MB-231 cells treated with different concentration of DOX for 48 h. (I) ,Cell/O viability/O viability/O (G)/O (G)/O (G)/O and/O apoptosis/O apoptosis/O apoptosis/O (H)/O (H)/O (H)/O assays/O assays/O of/O parental/O and/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O cells/O treated/O with/O different/O concentration/O of/O DOX/O DOX/O for/O 48/O h./O h./O (I)/O (I)/O (I)/O
Cell apoptosis of parental and MGAT3-overexpressing MCF7  cells treated with different concentration of DOX for 48 h. (J) ,Cell/O apoptosis/O apoptosis/O apoptosis/O of/O parental/O and/O MGAT3-overexpressing/O MGAT3-overexpressing/O MGAT3-overexpressing/O MGAT3-overexpressing/O MGAT3-overexpressing/O MGAT3-overexpressing/O MGAT3-overexpressing/O MCF7/B-CellLine MCF7/O MCF7/O cells/O treated/O with/O different/O concentration/O of/O DOX/O DOX/O for/O 48/O h./O h./O (J)/O (J)/O (J)/O
"Parental and MGAT3-overexpressed MCF7  cells were pre-treated with 100 μM DOX for 24 h, and residual DOX in cells were determined following 1 or 2 hours of drug efflux. (K-M) ","Parental/O Parental/O Parental/O and/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MGAT3-overexpressed/O MCF7/B-CellLine MCF7/O MCF7/O cells/O were/O pre-treated/O pre-treated/O pre-treated/O with/O 100/O μM/O μM/O DOX/O DOX/O for/O 24/O h,/O h,/O and/O residual/O DOX/O DOX/O in/O cells/O were/O determined/O following/O 1/O or/O 2/O hours/O of/O drug/O efflux./O efflux./O efflux./O efflux./O (K-M)/O (K-M)/O (K-M)/O (K-M)/O (K-M)/O"
"Using IP-MS, we compared the proteins differentially associated with P-gp in MCF7 /MGAT3 compared to MCF7  cells, and known P-gp interactome from STRING database ( A, S7A-C, Tab. ","Using/O IP-MS,/O IP-MS,/O IP-MS,/O IP-MS,/O we/O compared/O the/O proteins/O differentially/O differentially/O associated/O with/O P-gp/O P-gp/O P-gp/O P-gp/O in/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3/O /MGAT3/O /MGAT3/O /MGAT3/O compared/O to/O MCF7/B-CellLine MCF7/O MCF7/O cells,/O cells,/O and/O known/O P-gp/O P-gp/O P-gp/O P-gp/O interactome/O interactome/O from/O STRING/O STRING/O STRING/O database/O (/O A,/O A,/O S7A-C,/O S7A-C,/O S7A-C,/O S7A-C,/O S7A-C,/O S7A-C,/O Tab./O Tab./O Tab./O"
"S7 ), resulting in an increased apoptosis, followed by suppressed proliferation and cell viability in MCF7  cells with DOX treatment ( ). ","S7/O S7/O ),/O ),/O resulting/O in/O an/O increased/O apoptosis,/O apoptosis,/O apoptosis,/O apoptosis,/O followed/O by/O suppressed/O proliferation/O and/O cell/O viability/O viability/O in/O MCF7/B-CellLine MCF7/O MCF7/O cells/O with/O DOX/O DOX/O treatment/O (/O )./O )./O"
We found that drug resistance of recipient cells MDA-MB-231 was enhanced by soluble components from MCF7 Fig. ,We/O found/O that/O drug/O resistance/O of/O recipient/O cells/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O was/O enhanced/O by/O soluble/O components/O from/O MCF7/B-CellLine MCF7/O MCF7/O Fig./O Fig./O Fig./O
"S8 ), but inhibited by which from MCF7 ). ","S8/O S8/O ),/O ),/O but/O inhibited/O inhibited/O inhibited/O by/O which/O from/O MCF7/B-CellLine MCF7/O MCF7/O )./O )./O"
"We isolated MVs from MCF7 A, S8F&G ), and found that bisecting GlcNAc clearly suppressed MCF7 -MV mediated chemoresistance transmission to recipient cells ( ), but have no effect on secretion, morphology and uptake of MVs ( A, S8H&I  Figure 4  Identification of P-gp as the target protein bearing bisecting GlcNAc.","We/O isolated/O MVs/O MVs/O from/O MCF7/B-CellLine MCF7/O MCF7/O A,/O A,/O S8F&G/O S8F&G/O S8F&G/O S8F&G/O S8F&G/O ),/O ),/O and/O found/O that/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O clearly/O suppressed/O MCF7/B-CellLine MCF7/O MCF7/O -MV/O -MV/O mediated/O chemoresistance/O chemoresistance/O chemoresistance/O chemoresistance/O chemoresistance/O transmission/O to/O recipient/O cells/O (/O ),/O ),/O but/O have/O no/O effect/O on/O secretion,/O secretion,/O secretion,/O morphology/O and/O uptake/O uptake/O of/O MVs/O MVs/O (/O A,/O A,/O S8H&I/O S8H&I/O S8H&I/O S8H&I/O S8H&I/O Figure/O 4/O Identification/O Identification/O Identification/O of/O P-gp/O P-gp/O P-gp/O P-gp/O as/O the/O target/O protein/O bearing/O bisecting/O bisecting/O bisecting/O GlcNAc./O GlcNAc./O GlcNAc./O GlcNAc./O GlcNAc./O GlcNAc./O"
"Representative MS/MS spectrum of P-gp peptide EN # VTMDEIEKAVKEANAYDFIMK with bisecting GlcNAc. #, glycosite. (C) ","Representative/O MS/MS/O MS/MS/O MS/MS/O spectrum/O of/O P-gp/O P-gp/O P-gp/O P-gp/O peptide/O peptide/O EN/O EN/O #/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O VTMDEIEKAVKEANAYDFIMK/O with/O bisecting/O bisecting/O bisecting/O GlcNAc./O GlcNAc./O GlcNAc./O GlcNAc./O GlcNAc./O GlcNAc./O #,/O #,/O glycosite./O glycosite./O glycosite./O glycosite./O glycosite./O (C)/O (C)/O (C)/O"
Expression of P-gp with bisecting GlcNAc in parental and MGAT3 overexpressed MCF7  cells determined by immunoprecipitation. (D) ,Expression/O Expression/O of/O P-gp/O P-gp/O P-gp/O P-gp/O with/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O in/O parental/O and/O MGAT3/O MGAT3/O MGAT3/O overexpressed/O overexpressed/O overexpressed/O MCF7/B-CellLine MCF7/O MCF7/O cells/O determined/O by/O immunoprecipitation./O immunoprecipitation./O immunoprecipitation./O immunoprecipitation./O immunoprecipitation./O immunoprecipitation./O immunoprecipitation./O immunoprecipitation./O immunoprecipitation./O (D)/O (D)/O (D)/O
Membranous P-gp expression in parental and MGAT3 overexpressed MCF7  cells labeled with NHS-LC-biotin. (F) ,Membranous/O Membranous/O Membranous/O Membranous/O P-gp/O P-gp/O P-gp/O P-gp/O expression/O in/O parental/O and/O MGAT3/O MGAT3/O MGAT3/O overexpressed/O overexpressed/O overexpressed/O MCF7/B-CellLine MCF7/O MCF7/O cells/O labeled/O with/O NHS-LC-biotin./O NHS-LC-biotin./O NHS-LC-biotin./O NHS-LC-biotin./O NHS-LC-biotin./O NHS-LC-biotin./O NHS-LC-biotin./O NHS-LC-biotin./O (F)/O (F)/O (F)/O
"Venn diagram exhibiting P-gp interactome from STRING, and proteins differentially associated with P-gp in MCF7  cells. (B) ","Venn/O Venn/O Venn/O diagram/O exhibiting/O P-gp/O P-gp/O P-gp/O P-gp/O interactome/O interactome/O from/O STRING,/O STRING,/O STRING,/O STRING,/O and/O proteins/O differentially/O differentially/O associated/O with/O P-gp/O P-gp/O P-gp/O P-gp/O in/O MCF7/B-CellLine MCF7/O MCF7/O cells./O cells./O (B)/O (B)/O (B)/O"
Co-localization of P-gp and ezrin in parental and MGAT3 overexpressed MCF7  cells. (E) ,Co-localization/O Co-localization/O Co-localization/O Co-localization/O of/O P-gp/O P-gp/O P-gp/O P-gp/O and/O ezrin/O ezrin/O ezrin/O in/O parental/O and/O MGAT3/O MGAT3/O MGAT3/O overexpressed/O overexpressed/O overexpressed/O MCF7/B-CellLine MCF7/O MCF7/O cells./O cells./O (E)/O (E)/O (E)/O
Total expression of P-gp and ezrin in ezrin silenced MCF7  cells. (H) ,Total/O expression/O of/O P-gp/O P-gp/O P-gp/O P-gp/O and/O ezrin/O ezrin/O ezrin/O in/O ezrin/O ezrin/O ezrin/O silenced/O silenced/O MCF7/B-CellLine MCF7/O MCF7/O cells./O cells./O (H)/O (H)/O (H)/O
"Proteomic analysis revealed that P-gp exhibited a significant increase in both cell lysates and MVs of MCF7  compared to MCF7, followed by a decrease in which of MCF7 /MGAT3 compared MCF7 C&D, S9A&B, Tab. ","Proteomic/O Proteomic/O Proteomic/O Proteomic/O analysis/O revealed/O that/O P-gp/O P-gp/O P-gp/O P-gp/O exhibited/O a/O significant/O increase/O in/O both/O cell/O lysates/O lysates/O lysates/O and/O MVs/O MVs/O of/O MCF7/B-CellLine MCF7/O MCF7/O compared/O to/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O followed/O by/O a/O decrease/O in/O which/O of/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3/O /MGAT3/O /MGAT3/O /MGAT3/O compared/O MCF7/B-CellLine MCF7/O MCF7/O C&D,/O C&D,/O C&D,/O C&D,/O S9A&B,/O S9A&B,/O S9A&B,/O S9A&B,/O S9A&B,/O S9A&B,/O Tab./O Tab./O Tab./O"
"Bisecting GlcNAc suppressed P-gp levels in MCF7 /MGAT3-MVs ( ), consequently inhibiting the endocytosis and recycle of P-gp onto plasma membrane of recipient cells ( Fig. ","Bisecting/O Bisecting/O Bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O suppressed/O P-gp/O P-gp/O P-gp/O P-gp/O levels/O in/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3-MVs/O /MGAT3-MVs/O /MGAT3-MVs/O /MGAT3-MVs/O /MGAT3-MVs/O /MGAT3-MVs/O /MGAT3-MVs/O (/O ),/O ),/O consequently/O inhibiting/O inhibiting/O inhibiting/O the/O endocytosis/O endocytosis/O endocytosis/O endocytosis/O and/O recycle/O recycle/O of/O P-gp/O P-gp/O P-gp/O P-gp/O onto/O plasma/O membrane/O of/O recipient/O cells/O (/O Fig./O Fig./O Fig./O"
Morphology of MCF7 -MVs and MCF7 /MGAT3-MVs. (B) ,Morphology/O Morphology/O Morphology/O Morphology/O of/O MCF7/B-CellLine MCF7/O MCF7/O -MVs/O -MVs/O -MVs/O and/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O (B)/O (B)/O (B)/O
Cell apoptosis of recipient cells treated with MCF7 /MGAT3-MVs. (C) ,Cell/O apoptosis/O apoptosis/O apoptosis/O of/O recipient/O cells/O treated/O with/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O (C)/O (C)/O (C)/O
"Venn diagram of proteins showing a broadly increase in cell lysates and MVs of MCF7  compared to MCF7, following by a decrease in which of MCF7 . (D) ","Venn/O Venn/O Venn/O diagram/O of/O proteins/O showing/O a/O broadly/O increase/O in/O cell/O lysates/O lysates/O lysates/O and/O MVs/O MVs/O of/O MCF7/B-CellLine MCF7/O MCF7/O compared/O to/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O following/O by/O a/O decrease/O in/O which/O of/O MCF7/B-CellLine MCF7/O MCF7/O ./O (D)/O (D)/O (D)/O"
"Expression pattern of proteins showing overlapping expression patterns in cell lysates and MVs of MCF7, MCF7 /MGAT3. (E) ","Expression/O Expression/O pattern/O of/O proteins/O showing/O overlapping/O expression/O patterns/O in/O cell/O lysates/O lysates/O lysates/O and/O MVs/O MVs/O of/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3./O /MGAT3./O /MGAT3./O /MGAT3./O /MGAT3./O (E)/O (E)/O (E)/O"
P-gp and its bisecting GlcNAc levels in MCF7 /MGAT3-MVs. (F) ,P-gp/O P-gp/O P-gp/O P-gp/O and/O its/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O in/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O /MGAT3-MVs./O (F)/O (F)/O (F)/O
Interaction between P-gp and VPS4A in MCF7 /MGAT3 cells. (I) ,Interaction/O Interaction/O between/O P-gp/O P-gp/O P-gp/O P-gp/O and/O VPS4A/O VPS4A/O VPS4A/O VPS4A/O in/O MCF7/B-CellLine MCF7/O MCF7/O /MGAT3/O /MGAT3/O /MGAT3/O /MGAT3/O cells./O cells./O (I)/O (I)/O (I)/O
P-gp levels in MVs from VPS4A silenced MCF7  cells.  Figure 7  Effects of bisecting GlcNAc on global and local structure of P-gp.,P-gp/O P-gp/O P-gp/O P-gp/O levels/O in/O MVs/O MVs/O from/O VPS4A/O VPS4A/O VPS4A/O VPS4A/O silenced/O silenced/O MCF7/B-CellLine MCF7/O MCF7/O cells./O cells./O Figure/O 7/O Effects/O of/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O on/O global/O and/O local/O structure/O of/O P-gp./O P-gp./O P-gp./O P-gp./O P-gp./O
"We found that the removal of bisecting GlcNAc at Asn494, rather than the conventional glycosites Asn91, 94 and 99, restored P-gp expression and chemoresistance in MGAT3 overexpressed MCF7  cells, indicating the pivotal role of bisecting GlcNAc at Asn494 in regulating P-gp expression and its ability to confer chemoresistance.","We/O found/O that/O the/O removal/O of/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O at/O Asn494,/O Asn494,/O Asn494,/O Asn494,/O Asn494,/O Asn494,/O rather/O than/O the/O conventional/O glycosites/O glycosites/O glycosites/O glycosites/O Asn91,/O Asn91,/O Asn91,/O Asn91,/O Asn91,/O 94/O and/O 99,/O 99,/O restored/O P-gp/O P-gp/O P-gp/O P-gp/O expression/O and/O chemoresistance/O chemoresistance/O chemoresistance/O chemoresistance/O chemoresistance/O in/O MGAT3/O MGAT3/O MGAT3/O overexpressed/O overexpressed/O overexpressed/O MCF7/B-CellLine MCF7/O MCF7/O cells,/O cells,/O indicating/O the/O pivotal/O role/O of/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O at/O Asn494/O Asn494/O Asn494/O Asn494/O Asn494/O in/O regulating/O P-gp/O P-gp/O P-gp/O P-gp/O expression/O and/O its/O ability/O to/O confer/O confer/O chemoresistance./O chemoresistance./O chemoresistance./O chemoresistance./O chemoresistance./O chemoresistance./O"
"The expression of membranous P-gp and association between P-gp and ezrin were reduced in MCF7  cells with high bisecting GlcNAc levels vice versa,  silencing ezrin impaired the location of P-gp onto membrane and attenuated the chemoresistance. ","The/O expression/O of/O membranous/O membranous/O membranous/O membranous/O P-gp/O P-gp/O P-gp/O P-gp/O and/O association/O between/O P-gp/O P-gp/O P-gp/O P-gp/O and/O ezrin/O ezrin/O ezrin/O were/O reduced/O in/O MCF7/B-CellLine MCF7/O MCF7/O cells/O with/O high/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O vice/O versa,/O versa,/O silencing/O silencing/O silencing/O ezrin/O ezrin/O ezrin/O impaired/O the/O location/O of/O P-gp/O P-gp/O P-gp/O P-gp/O onto/O membrane/O and/O attenuated/O attenuated/O attenuated/O the/O chemoresistance./O chemoresistance./O chemoresistance./O chemoresistance./O chemoresistance./O chemoresistance./O"
et al Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation Drug Resist Updat. ,et/O al/O Mechanisms/O Mechanisms/O Mechanisms/O of/O cisplatin/B-CellLine cisplatin/O cisplatin/O cisplatin/O cisplatin/O resistance/O and/O targeting/O of/O cancer/O stem/O cells:/O cells:/O Adding/O Adding/O glycosylation/O glycosylation/O glycosylation/O glycosylation/O glycosylation/O to/O the/O equation/O Drug/O Resist/O Resist/O Updat./O Updat./O Updat./O Updat./O
"  2023; 299 :103051⁴ⁱ.  Kramer R, Weber TK, Arceci R, Ramchurren N, Kastrinakis WV, Steele G Jr.  ","2023;/O 2023;/O 2023;/O 299/O 299/O :103051⁴ⁱ./O :103051⁴ⁱ./O :103051⁴ⁱ./O :103051⁴ⁱ./O :103051⁴ⁱ./O :103051⁴ⁱ./O :103051⁴ⁱ./O Kramer/O R,/O R,/O Weber/O TK,/O TK,/O TK,/O Arceci/O Arceci/O Arceci/O R,/O R,/O Ramchurren/O Ramchurren/O Ramchurren/O Ramchurren/O N,/O N,/O Kastrinakis/O Kastrinakis/O Kastrinakis/O Kastrinakis/O WV,/O WV,/O WV,/O Steele/O G/O Jr./O Jr./O"
"To explore the roles of bisecting GlcNAc in BC chemoresistance, we introduced MGAT3 into MDA-MB-231, MCF7 and MCF7","To/O explore/O the/O roles/O of/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O in/O BC/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O we/O introduced/O MGAT3/O MGAT3/O MGAT3/O into/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MCF7/B-CellLine MCF7/O MCF7/O and/O MCF7/B-CellLine MCF7/O MCF7/O"
"Bisecting GlcNAc levels in MCF7, MCF7","Bisecting/O Bisecting/O Bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O in/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O MCF7/B-CellLine MCF7/O MCF7/O"
Representative MS/MS spectrum of P-gp peptide EN,Representative/O MS/MS/O MS/MS/O MS/MS/O spectrum/O of/O P-gp/O P-gp/O P-gp/O P-gp/O peptide/O peptide/O EN/O EN/O
"Venn diagram exhibiting P-gp interactome from STRING, and proteins differentially associated with P-gp in MCF7","Venn/O Venn/O Venn/O diagram/O exhibiting/O P-gp/O P-gp/O P-gp/O P-gp/O interactome/O interactome/O from/O STRING,/O STRING,/O STRING,/O STRING,/O and/O proteins/O differentially/O differentially/O associated/O with/O P-gp/O P-gp/O P-gp/O P-gp/O in/O MCF7/B-CellLine MCF7/O MCF7/O"
Morphology of MCF7,Morphology/O Morphology/O Morphology/O Morphology/O of/O MCF7/B-CellLine MCF7/O MCF7/O
"To explore the roles of bisecting GlcNAc in BC chemoresistance, we introduced MGAT3 into MDA-MB-231, MCF7 and MCF7","To/O explore/O the/O roles/O of/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O in/O BC/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O we/O introduced/O MGAT3/O MGAT3/O MGAT3/O into/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MCF7/B-CellLine MCF7/O MCF7/O and/O MCF7/B-CellLine MCF7/O MCF7/O"
"Bisecting GlcNAc levels in MCF7, MCF7","Bisecting/O Bisecting/O Bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O in/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O MCF7/B-CellLine MCF7/O MCF7/O"
Representative MS/MS spectrum of P-gp peptide EN,Representative/O MS/MS/O MS/MS/O MS/MS/O spectrum/O of/O P-gp/O P-gp/O P-gp/O P-gp/O peptide/O peptide/O EN/O EN/O
"Venn diagram exhibiting P-gp interactome from STRING, and proteins differentially associated with P-gp in MCF7","Venn/O Venn/O Venn/O diagram/O exhibiting/O P-gp/O P-gp/O P-gp/O P-gp/O interactome/O interactome/O from/O STRING,/O STRING,/O STRING,/O STRING,/O and/O proteins/O differentially/O differentially/O associated/O with/O P-gp/O P-gp/O P-gp/O P-gp/O in/O MCF7/B-CellLine MCF7/O MCF7/O"
Morphology of MCF7,Morphology/O Morphology/O Morphology/O Morphology/O of/O MCF7/B-CellLine MCF7/O MCF7/O
"To explore the roles of bisecting GlcNAc in BC chemoresistance, we introduced MGAT3 into MDA-MB-231, MCF7 and MCF7","To/O explore/O the/O roles/O of/O bisecting/O bisecting/O bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O in/O BC/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O chemoresistance,/O we/O introduced/O MGAT3/O MGAT3/O MGAT3/O into/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MCF7/B-CellLine MCF7/O MCF7/O and/O MCF7/B-CellLine MCF7/O MCF7/O"
"Bisecting GlcNAc levels in MCF7, MCF7","Bisecting/O Bisecting/O Bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O in/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O MCF7/B-CellLine MCF7/O MCF7/O"
"Bisecting GlcNAc levels in MCF7, MCF7","Bisecting/O Bisecting/O Bisecting/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O GlcNAc/O levels/O in/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O MCF7/B-CellLine MCF7/O MCF7/O"
Representative MS/MS spectrum of P-gp peptide EN,Representative/O MS/MS/O MS/MS/O MS/MS/O spectrum/O of/O P-gp/O P-gp/O P-gp/O P-gp/O peptide/O peptide/O EN/O EN/O
Representative MS/MS spectrum of P-gp peptide EN,Representative/O MS/MS/O MS/MS/O MS/MS/O spectrum/O of/O P-gp/O P-gp/O P-gp/O P-gp/O peptide/O peptide/O EN/O EN/O
"Venn diagram exhibiting P-gp interactome from STRING, and proteins differentially associated with P-gp in MCF7","Venn/O Venn/O Venn/O diagram/O exhibiting/O P-gp/O P-gp/O P-gp/O P-gp/O interactome/O interactome/O from/O STRING,/O STRING,/O STRING,/O STRING,/O and/O proteins/O differentially/O differentially/O associated/O with/O P-gp/O P-gp/O P-gp/O P-gp/O in/O MCF7/B-CellLine MCF7/O MCF7/O"
"Venn diagram exhibiting P-gp interactome from STRING, and proteins differentially associated with P-gp in MCF7","Venn/O Venn/O Venn/O diagram/O exhibiting/O P-gp/O P-gp/O P-gp/O P-gp/O interactome/O interactome/O from/O STRING,/O STRING,/O STRING,/O STRING,/O and/O proteins/O differentially/O differentially/O associated/O with/O P-gp/O P-gp/O P-gp/O P-gp/O in/O MCF7/B-CellLine MCF7/O MCF7/O"
Morphology of MCF7,Morphology/O Morphology/O Morphology/O Morphology/O of/O MCF7/B-CellLine MCF7/O MCF7/O
Morphology of MCF7,Morphology/O Morphology/O Morphology/O Morphology/O of/O MCF7/B-CellLine MCF7/O MCF7/O
The response of SKBR3/HER2+ cells to Lapatinib and Ipatasertib was explored by proteomic profiling of cells exposed to 36 h inhibition with the drugs. ,The/O response/O of/O SKBR3/HER2+/B-CellLine SKBR3/HER2+/B-CellLine SKBR3/HER2+/O SKBR3/HER2+/O SKBR3/HER2+/O SKBR3/HER2+/O SKBR3/HER2+/O SKBR3/HER2+/O cells/O to/O Lapatinib/O Lapatinib/O Lapatinib/O Lapatinib/O and/O Ipatasertib/O Ipatasertib/O Ipatasertib/O Ipatasertib/O Ipatasertib/O was/O explored/O by/O proteomic/O proteomic/O proteomic/O proteomic/O profiling/O profiling/O profiling/O of/O cells/O exposed/O to/O 36/O h/O inhibition/O inhibition/O with/O the/O drugs./O drugs./O
"SKBR3 cells, representative of breast cancer cells overexpressing the HER2 receptor, were purchased from ATCC (Manassas, VA). ","SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells,/O cells,/O representative/O of/O breast/O cancer/O cells/O overexpressing/O overexpressing/O overexpressing/O the/O HER2/O HER2/O HER2/O receptor,/O receptor,/O were/O purchased/O from/O ATCC/O ATCC/O (Manassas,/O (Manassas,/O (Manassas,/O (Manassas,/O (Manassas,/O VA)./O VA)./O VA)./O"
"Cell culture and treatment with drugs SKBR3 stock batches were generated from the original ATCC vial [authenticated by Short Tandem Repeat (STR) analysis] by propagating the cells for ∼3 weeks in McCoy 5A supplemented with FBS (10%) and Normocin-a formulation of three antibiotics active against  , bacteria and fungi, and freezing the cells at −80°C. ","Cell/O culture/O and/O treatment/O with/O drugs/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O stock/O batches/O batches/O were/O generated/O from/O the/O original/O ATCC/O ATCC/O vial/O vial/O [authenticated/O [authenticated/O [authenticated/O by/O Short/O Tandem/O Tandem/O Tandem/O Repeat/O Repeat/O (STR)/O (STR)/O (STR)/O (STR)/O analysis]/O analysis]/O by/O propagating/O propagating/O propagating/O the/O cells/O for/O ∼3/O weeks/O in/O McCoy/O 5A/O 5A/O supplemented/O with/O FBS/O FBS/O (10%)/O (10%)/O (10%)/O (10%)/O and/O Normocin-a/O Normocin-a/O Normocin-a/O Normocin-a/O Normocin-a/O formulation/O of/O three/O antibiotics/O antibiotics/O active/O against/O ,/O bacteria/O and/O fungi,/O fungi,/O and/O freezing/O the/O cells/O at/O −80°C./O −80°C./O −80°C./O −80°C./O −80°C./O"
"For this work, SKBR3 cells retrieved from liquid nitrogen were further propagated for 3–4 weeks and grown in T175 cm  Nunc flasks in a water jacketed CO  (5%) incubator at 37°C, in McCoy’s 5A with FBS (10%). ","For/O this/O work,/O work,/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O retrieved/O from/O liquid/O nitrogen/O were/O further/O propagated/O propagated/O propagated/O for/O 3–4/O 3–4/O 3–4/O weeks/O and/O grown/O in/O T175/O T175/O T175/O cm/O Nunc/O Nunc/O Nunc/O flasks/O flasks/O flasks/O in/O a/O water/O jacketed/O jacketed/O CO/O (5%)/O (5%)/O (5%)/O (5%)/O incubator/O incubator/O incubator/O incubator/O at/O 37°C,/O 37°C,/O 37°C,/O 37°C,/O in/O McCoy’s/O McCoy’s/O McCoy’s/O 5A/O 5A/O with/O FBS/O FBS/O (10%)./O (10%)./O (10%)./O (10%)./O (10%)./O"
"The presence of a peptide was considered validated when the peptide displayed a minimum of five transitions and a dot product (dotp) score >0.9. MS data processing The MS raw files were processed by the Proteome Discoverer 2.5 software package (Thermo Fisher Scientific, Waltham, MA) by using the Sequest HT search engine and a  Homo sapiens  database of 20,399 reviewed, non-redundant UniProt protein sequences (August 2022 download) ( ). ","The/O presence/O of/O a/O peptide/O peptide/O was/O considered/O validated/O validated/O when/O the/O peptide/O peptide/O displayed/O a/O minimum/O of/O five/O transitions/O and/O a/O dot/O product/O (dotp)/O (dotp)/O (dotp)/O (dotp)/O score/O >0.9./O >0.9./O >0.9./O >0.9./O >0.9./O MS/O data/O processing/O The/O MS/O raw/O files/O were/O processed/O by/O the/O Proteome/O Proteome/O Proteome/O Discoverer/O Discoverer/O Discoverer/O 2.5/O 2.5/O 2.5/O software/O package/O (Thermo/O (Thermo/O (Thermo/O (Thermo/O Fisher/O Scientific,/O Scientific,/O Waltham,/O Waltham,/O Waltham,/O MA)/O MA)/O by/O using/O the/O Sequest/O Sequest/O HT/O HT/O search/O engine/O and/O a/O Homo/O Homo/O sapiens/O sapiens/O sapiens/O database/O of/O 20,399/O 20,399/O 20,399/O 20,399/O reviewed,/O reviewed,/O non-redundant/O non-redundant/O non-redundant/O UniProt/O UniProt/O UniProt/O UniProt/O protein/O sequences/O (August/O (August/O 2022/O 2022/O download)/O download)/O (/O )./O )./O"
"The  Processing Workflow  search parameters included the followings: the Spectrum Selector peptide precursor mass range was set to 400–5,000 Da, the Sequest HT node parameters enabled the selection of 6–144 aa length fully tryptic peptides comprising maximum two missed cleavages, ion tolerances were set to 15 ppm for the precursor ion and 0.02 Da for the b/y/a ion fragments, and dynamic modifications were enabled for Met (15.995 Da/oxidation) and Nt (42.011 Da/acetyl) for all samples. ","The/O Processing/O Processing/O Workflow/O Workflow/O search/O parameters/O included/O the/O followings:/O followings:/O followings:/O the/O Spectrum/O Selector/O Selector/O peptide/O peptide/O precursor/O mass/O range/O was/O set/O to/O 400–5,000/O 400–5,000/O 400–5,000/O 400–5,000/O 400–5,000/O Da,/O Da,/O the/O Sequest/O Sequest/O HT/O HT/O node/O parameters/O enabled/O the/O selection/O of/O 6–144/O 6–144/O 6–144/O aa/O aa/O length/O fully/O tryptic/O tryptic/O peptides/O peptides/O peptides/O comprising/O maximum/O two/O missed/O cleavages,/O cleavages,/O cleavages,/O cleavages,/O cleavages,/O ion/O tolerances/O tolerances/O were/O set/O to/O 15/O ppm/O ppm/O for/O the/O precursor/O ion/O and/O 0.02/O 0.02/O 0.02/O Da/O for/O the/O b/y/a/O b/y/a/O b/y/a/O b/y/a/O b/y/a/O ion/O fragments,/O fragments,/O and/O dynamic/O modifications/O were/O enabled/O for/O Met/O (15.995/O (15.995/O (15.995/O (15.995/O (15.995/O Da/oxidation)/O Da/oxidation)/O Da/oxidation)/O Da/oxidation)/O and/O Nt/O Nt/O (42.011/O (42.011/O (42.011/O (42.011/O (42.011/O Da/acetyl)/O Da/acetyl)/O Da/acetyl)/O Da/acetyl)/O Da/acetyl)/O Da/acetyl)/O for/O all/O samples./O samples./O"
"The SKBR3 drug treatment strategy consisted of a multi-step process: (a) cell culture and synchronization in SFM for 24 h; (b) stimulation of control-cells with EGF (10 nM) for 36 h to assess canonical growth; (c) preconditioning of the to-be-drug-treated cells for 15 min with drugs; and (d) treatment of cells with drugs for 36 h, i.e., Lapatinib (10 μM)/EGF (10 nM) or Lapatinib (10 μM)/Ipatasertib (1 μM)/EGF (10 nM) ( Figure 1A ). ","The/O SKBR3/B-CellLine SKBR3/O SKBR3/O drug/O treatment/O strategy/O consisted/O of/O a/O multi-step/O multi-step/O multi-step/O process:/O process:/O (a)/O (a)/O (a)/O cell/O culture/O and/O synchronization/O synchronization/O synchronization/O synchronization/O synchronization/O in/O SFM/O SFM/O for/O 24/O h;/O h;/O (b)/O (b)/O (b)/O stimulation/O of/O control-cells/O control-cells/O control-cells/O with/O EGF/O EGF/O EGF/O (10/O (10/O nM)/O nM)/O nM)/O for/O 36/O h/O to/O assess/O canonical/O growth;/O growth;/O (c)/O (c)/O (c)/O preconditioning/O preconditioning/O preconditioning/O preconditioning/O of/O the/O to-be-drug-treated/O to-be-drug-treated/O to-be-drug-treated/O to-be-drug-treated/O to-be-drug-treated/O to-be-drug-treated/O to-be-drug-treated/O cells/O for/O 15/O min/O with/O drugs;/O drugs;/O and/O (d)/O (d)/O (d)/O treatment/O of/O cells/O with/O drugs/O for/O 36/O h,/O h,/O i.e.,/O i.e.,/O i.e.,/O i.e.,/O i.e.,/O Lapatinib/O Lapatinib/O Lapatinib/O Lapatinib/O (10/O (10/O μM)/EGF/O μM)/EGF/O μM)/EGF/O μM)/EGF/O μM)/EGF/O μM)/EGF/O μM)/EGF/O (10/O (10/O nM)/O nM)/O nM)/O or/O Lapatinib/O Lapatinib/O Lapatinib/O Lapatinib/O (10/O (10/O μM)/Ipatasertib/O μM)/Ipatasertib/O μM)/Ipatasertib/O μM)/Ipatasertib/O μM)/Ipatasertib/O μM)/Ipatasertib/O μM)/Ipatasertib/O μM)/Ipatasertib/O μM)/Ipatasertib/O (1/O (1/O μM)/EGF/O μM)/EGF/O μM)/EGF/O μM)/EGF/O μM)/EGF/O μM)/EGF/O μM)/EGF/O (10/O (10/O nM)/O nM)/O nM)/O (/O Figure/O 1A/O )./O )./O"
"FBS (10%) was added to all cell incubations, as in its absence both drugs induced considerable cell detachment within 24 h of drug treatment indicative of apoptotic behavior. ","FBS/O FBS/O (10%)/O (10%)/O (10%)/O (10%)/O was/O added/O to/O all/O cell/O incubations,/O incubations,/O incubations,/O incubations,/O incubations,/O as/O in/O its/O absence/O both/O drugs/O induced/O considerable/O cell/O detachment/O within/O 24/O h/O of/O drug/O treatment/O indicative/O indicative/O of/O apoptotic/O apoptotic/O apoptotic/O apoptotic/O behavior./O behavior./O"
"Incubation of cells with 10 μM Lapatinib for only 36 h evolved as a good compromise, with FACS measurements indicating a larger proportion of cells in the G1 stage of the cell cycle and with proteomic changes being more clearly defined. ","Incubation/O Incubation/O Incubation/O of/O cells/O with/O 10/O μM/O μM/O Lapatinib/O Lapatinib/O Lapatinib/O Lapatinib/O for/O only/O 36/O h/O evolved/O as/O a/O good/O compromise,/O compromise,/O with/O FACS/O FACS/O measurements/O indicating/O a/O larger/O proportion/O of/O cells/O in/O the/O G1/O G1/O stage/O of/O the/O cell/O cycle/O and/O with/O proteomic/O proteomic/O proteomic/O proteomic/O changes/O being/O more/O clearly/O defined./O defined./O"
"We also considered that the cell cycle of mammalian cells is ∼24 h, with the cellular-pool protein half-life being also ∼24 h ( Shamir et al., 2016 ). ","We/O also/O considered/O that/O the/O cell/O cycle/O of/O mammalian/O mammalian/O mammalian/O cells/O is/O ∼24/O h,/O h,/O with/O the/O cellular-pool/O cellular-pool/O cellular-pool/O protein/O half-life/O half-life/O half-life/O being/O also/O ∼24/O h/O (/O Shamir/O Shamir/O Shamir/O et/O al.,/O al.,/O al.,/O 2016/O )./O )./O"
"As expected, and as also confirmed by FACS, the 36 h exposure to drugs led the cells to a more pronounced G1 cell cycle arrest when compared to the no-drug control, i.e., ∼80% vs ∼60% [Control: 57%–61% G1, 24%–26% S, 4%–11% G2; Lapatinib treatment: 78%–87% G1, 7%–16% S, 2%–10% G1; Lapatinib/Ipatasertib treatment: 78%–81% G1, 6%–11% S, 2%–6% G2)] ( Figure 2L ). ","As/O expected,/O expected,/O and/O as/O also/O confirmed/O by/O FACS,/O FACS,/O FACS,/O the/O 36/O h/O exposure/O to/O drugs/O led/O the/O cells/O to/O a/O more/O pronounced/O G1/O G1/O cell/O cycle/O arrest/O when/O compared/O to/O the/O no-drug/O no-drug/O no-drug/O control,/O control,/O i.e.,/O i.e.,/O i.e.,/O i.e.,/O i.e.,/O ∼80%/O ∼80%/O vs/O ∼60%/O ∼60%/O [Control:/O [Control:/O [Control:/O 57%–61%/O 57%–61%/O 57%–61%/O 57%–61%/O 57%–61%/O G1,/O G1,/O G1,/O 24%–26%/O 24%–26%/O 24%–26%/O 24%–26%/O 24%–26%/O S,/O S,/O 4%–11%/O 4%–11%/O 4%–11%/O 4%–11%/O 4%–11%/O G2;/O G2;/O G2;/O Lapatinib/O Lapatinib/O Lapatinib/O Lapatinib/O treatment:/O treatment:/O 78%–87%/O 78%–87%/O 78%–87%/O 78%–87%/O 78%–87%/O G1,/O G1,/O G1,/O 7%–16%/O 7%–16%/O 7%–16%/O 7%–16%/O 7%–16%/O S,/O S,/O 2%–10%/O 2%–10%/O 2%–10%/O 2%–10%/O 2%–10%/O G1;/O G1;/O G1;/O Lapatinib/Ipatasertib/O Lapatinib/Ipatasertib/O Lapatinib/Ipatasertib/O Lapatinib/Ipatasertib/O Lapatinib/Ipatasertib/O Lapatinib/Ipatasertib/O Lapatinib/Ipatasertib/O Lapatinib/Ipatasertib/O Lapatinib/Ipatasertib/O Lapatinib/Ipatasertib/O treatment:/O treatment:/O 78%–81%/O 78%–81%/O 78%–81%/O 78%–81%/O 78%–81%/O G1,/O G1,/O G1,/O 6%–11%/O 6%–11%/O 6%–11%/O 6%–11%/O 6%–11%/O S,/O S,/O 2%–6%/O 2%–6%/O 2%–6%/O 2%–6%/O 2%–6%/O G2)]/O G2)]/O G2)]/O G2)]/O (/O Figure/O 2L/O 2L/O )./O )./O"
"Anti-proliferative, growth inhibition, or apoptosis cell culture assays were conducted with both drugs in the 1–10 μM concentration range and ∼24–72 h inhibition time, with reported IC50 values for Lapatinib in the range of ∼4–10 μM ( Selleck, 2024 ). ","Anti-proliferative,/O Anti-proliferative,/O Anti-proliferative,/O Anti-proliferative,/O Anti-proliferative,/O Anti-proliferative,/O growth/O inhibition,/O inhibition,/O inhibition,/O or/O apoptosis/O apoptosis/O apoptosis/O cell/O culture/O assays/O assays/O were/O conducted/O with/O both/O drugs/O in/O the/O 1–10/O 1–10/O 1–10/O μM/O μM/O concentration/O range/O and/O ∼24–72/O ∼24–72/O ∼24–72/O h/O inhibition/O inhibition/O time,/O time,/O with/O reported/O IC50/O IC50/O IC50/O values/O for/O Lapatinib/O Lapatinib/O Lapatinib/O Lapatinib/O in/O the/O range/O of/O ∼4–10/O ∼4–10/O ∼4–10/O μM/O μM/O (/O Selleck,/O Selleck,/O Selleck,/O Selleck,/O 2024/O 2024/O )./O )./O"
"Endophilin silencing in SKBR3 cells led to impaired HER2 receptor internalization and reduced downstream signaling in cells treated with Trastuzumab, and reduced cytotoxicity in HER2+ cells treated with TDM-1 ( ). ","Endophilin/O Endophilin/O Endophilin/O Endophilin/O silencing/O silencing/O silencing/O in/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O led/O to/O impaired/O HER2/O HER2/O HER2/O receptor/O internalization/O internalization/O and/O reduced/O downstream/O signaling/O in/O cells/O treated/O with/O Trastuzumab,/O Trastuzumab,/O Trastuzumab,/O Trastuzumab,/O Trastuzumab,/O Trastuzumab,/O Trastuzumab,/O and/O reduced/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O cytotoxicity/O in/O HER2+/O HER2+/O HER2+/O HER2+/O cells/O treated/O with/O TDM-1/O TDM-1/O TDM-1/O TDM-1/O (/O )./O )./O"
"To our knowledge, the downregulation of these proteins by Lapatinib in SKBR3 cells is firstly reported here, providing novel opportunities for future research into the mechanism of action of this drug and its effects on biological processes such as adhesion and migration. ","To/O our/O knowledge,/O knowledge,/O the/O downregulation/O downregulation/O downregulation/O downregulation/O of/O these/O proteins/O by/O Lapatinib/O Lapatinib/O Lapatinib/O Lapatinib/O in/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O is/O firstly/O reported/O here,/O here,/O providing/O novel/O opportunities/O for/O future/O research/O into/O the/O mechanism/O of/O action/O of/O this/O drug/O and/O its/O effects/O on/O biological/O processes/O such/O as/O adhesion/O adhesion/O and/O migration./O migration./O"
"The cell membrane proteome of the SKBR3/her2+ cells and implications for cancer targeted therapies . Blacksburg, VA:  ETDs: Virginia Tech Electronic Theses and Dissertations","The/O cell/O membrane/O proteome/O proteome/O proteome/O of/O the/O SKBR3/her2+/B-CellLine SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O cells/O and/O implications/O for/O cancer/O targeted/O therapies/O therapies/O therapies/O ./O Blacksburg,/O Blacksburg,/O Blacksburg,/O VA:/O VA:/O ETDs:/O ETDs:/O ETDs:/O Virginia/O Tech/O Electronic/O Theses/O Theses/O and/O Dissertations/O Dissertations/O Dissertations/O"
The cell membrane proteome of the SKBR3/her2+ cells and implications for cancer targeted therapies,The/O cell/O membrane/O proteome/O proteome/O proteome/O of/O the/O SKBR3/her2+/B-CellLine SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O cells/O and/O implications/O for/O cancer/O targeted/O therapies/O therapies/O therapies/O
The cell membrane proteome of the SKBR3/her2+ cells and implications for cancer targeted therapies,The/O cell/O membrane/O proteome/O proteome/O proteome/O of/O the/O SKBR3/her2+/B-CellLine SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O cells/O and/O implications/O for/O cancer/O targeted/O therapies/O therapies/O therapies/O
The cell membrane proteome of the SKBR3/her2+ cells and implications for cancer targeted therapies,The/O cell/O membrane/O proteome/O proteome/O proteome/O of/O the/O SKBR3/her2+/B-CellLine SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O cells/O and/O implications/O for/O cancer/O targeted/O therapies/O therapies/O therapies/O
The cell membrane proteome of the SKBR3/her2+ cells and implications for cancer targeted therapies,The/O cell/O membrane/O proteome/O proteome/O proteome/O of/O the/O SKBR3/her2+/B-CellLine SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O cells/O and/O implications/O for/O cancer/O targeted/O therapies/O therapies/O therapies/O
The cell membrane proteome of the SKBR3/her2+ cells and implications for cancer targeted therapies,The/O cell/O membrane/O proteome/O proteome/O proteome/O of/O the/O SKBR3/her2+/B-CellLine SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O cells/O and/O implications/O for/O cancer/O targeted/O therapies/O therapies/O therapies/O
The cell membrane proteome of the SKBR3/her2+ cells and implications for cancer targeted therapies,The/O cell/O membrane/O proteome/O proteome/O proteome/O of/O the/O SKBR3/her2+/B-CellLine SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O cells/O and/O implications/O for/O cancer/O targeted/O therapies/O therapies/O therapies/O
The cell membrane proteome of the SKBR3/her2+ cells and implications for cancer targeted therapies,The/O cell/O membrane/O proteome/O proteome/O proteome/O of/O the/O SKBR3/her2+/B-CellLine SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O SKBR3/her2+/B-CellLine SKBR3/her2+/O SKBR3/her2+/O cells/O and/O implications/O for/O cancer/O targeted/O therapies/O therapies/O therapies/O
"And all medium supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) and 1% penicillin–streptomycin (Beyotime, Shanghai, China).","And/O all/O medium/O supplemented/O with/O 10%/O 10%/O fetal/O fetal/O bovine/O bovine/O bovine/O serum/O (FBS;/O (FBS;/O (FBS;/O (FBS;/O Gibco,/O Gibco,/O Gibco,/O Gibco,/O Grand/O Island,/O Island,/O NY,/O NY,/O USA)/O USA)/O and/O 1%/O 1%/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O (Beyotime,/O (Beyotime,/O (Beyotime,/O (Beyotime,/O (Beyotime,/O Shanghai,/O Shanghai,/O China)./O China)./O China)./O"
"As illustrated by Fig.  e, TNBC anticancer agents commonly used in clinical practice, including paclitaxel, docetaxel, cyclophosphamide, and cisplatin, have been shown to have superior efficacy in high-risk populations.","As/O illustrated/O by/O Fig./O Fig./O Fig./O e,/O e,/O TNBC/O TNBC/O anticancer/O anticancer/O anticancer/O agents/O commonly/O used/O in/O clinical/O practice,/O practice,/O including/O paclitaxel,/O paclitaxel,/O paclitaxel,/O paclitaxel,/O paclitaxel,/O paclitaxel,/O docetaxel,/O docetaxel,/O docetaxel,/O docetaxel,/O docetaxel,/O docetaxel,/O cyclophosphamide,/O cyclophosphamide,/O cyclophosphamide,/O cyclophosphamide,/O cyclophosphamide,/O cyclophosphamide,/O cyclophosphamide,/O cyclophosphamide,/O cyclophosphamide,/O and/O cisplatin,/B-CellLine cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O cisplatin,/O have/O been/O shown/O to/O have/O superior/O efficacy/O in/O high-risk/O high-risk/O high-risk/O populations./O populations./O"
"6  strengthens the CSC traits of TNBC cells. ( ) The qRT-PCR analysis of   mRNA levels in normal mammary epithelial cell lines (MCF10A) and TNBC cell lines (SUM159, CAL-148, MDA-MB-231, and MDA-MB-453). ( ) Western blot analysis of   protein levels in normal mammary epithelial cell lines (MCF10A) and TNBC cell lines (SUM159, CAL-148, MDA-MB-231, and MDA-MB-453). ( )   mRNA expression was successfully inhibited by specific siRNAs (si- -2) compared to the negative control (NC) in MDA-MB-453 and MDA-MB-231. (  protein expression was inhibited by specific siRNAs (si- -2) compared to NC in MDA-MB-453 and MDA-MB-231. ( ) The qRT-PCR analysis shows the mRNA expression of stem-related markers  , and   in si- -2 transfected TNBC cells. ( ) Western blot analysis shows the protein expression of stem-related markers  g ) Representative images of TNBC cell spheres after transfection with NC, si- -1, and si- -2 for 7 days, respectively. ","6/O strengthens/O strengthens/O the/O CSC/O CSC/O traits/O of/O TNBC/O TNBC/O cells./O cells./O (/O )/O The/O qRT-PCR/O qRT-PCR/O qRT-PCR/O qRT-PCR/O qRT-PCR/O analysis/O of/O mRNA/O mRNA/O levels/O in/O normal/O mammary/O mammary/O mammary/O epithelial/O epithelial/O epithelial/O epithelial/O cell/O lines/O (MCF10A)/O (MCF10A)/O (MCF10A)/O (MCF10A)/O (MCF10A)/O (MCF10A)/O and/O TNBC/O TNBC/O cell/O lines/O (SUM159,/O (SUM159,/O (SUM159,/O (SUM159,/O (SUM159,/O (SUM159,/O CAL-148,/O CAL-148,/O CAL-148,/O CAL-148,/O CAL-148,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O and/O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O (/O )/O Western/O blot/O blot/O analysis/O of/O protein/O levels/O in/O normal/O mammary/O mammary/O mammary/O epithelial/O epithelial/O epithelial/O epithelial/O cell/O lines/O (MCF10A)/O (MCF10A)/O (MCF10A)/O (MCF10A)/O (MCF10A)/O (MCF10A)/O and/O TNBC/O TNBC/O cell/O lines/O (SUM159,/O (SUM159,/O (SUM159,/O (SUM159,/O (SUM159,/O (SUM159,/O CAL-148,/O CAL-148,/O CAL-148,/O CAL-148,/O CAL-148,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O and/O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O MDA-MB-453)./O (/O )/O mRNA/O mRNA/O expression/O was/O successfully/O inhibited/O inhibited/O inhibited/O by/O specific/O siRNAs/O siRNAs/O siRNAs/O (si-/O (si-/O (si-/O -2)/O -2)/O -2)/O compared/O to/O the/O negative/O control/O (NC)/O (NC)/O (NC)/O in/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O and/O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O (/O protein/O expression/O was/O inhibited/O inhibited/O inhibited/O by/O specific/O siRNAs/O siRNAs/O siRNAs/O (si-/O (si-/O (si-/O -2)/O -2)/O -2)/O compared/O to/O NC/O in/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O MDA-MB-453/O and/O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O MDA-MB-231./O (/O )/O The/O qRT-PCR/O qRT-PCR/O qRT-PCR/O qRT-PCR/O qRT-PCR/O analysis/O shows/O the/O mRNA/O mRNA/O expression/O of/O stem-related/O stem-related/O stem-related/O markers/O ,/O and/O in/O si-/O si-/O -2/O -2/O transfected/O transfected/O TNBC/O TNBC/O cells./O cells./O (/O )/O Western/O blot/O blot/O analysis/O shows/O the/O protein/O expression/O of/O stem-related/O stem-related/O stem-related/O markers/O g/O )/O Representative/O images/O of/O TNBC/O TNBC/O cell/O spheres/O after/O transfection/O transfection/O transfection/O with/O NC,/O NC,/O si-/O si-/O -1,/O -1,/O -1,/O and/O si-/O si-/O -2/O -2/O for/O 7/O days,/O days,/O respectively./O respectively./O"
Data were presented as means ± SEM. ,Data/O were/O presented/O as/O means/O ±/O SEM./O SEM./O SEM./O
"1998;140(1–2):19–24. Ludwig RL, Bates S, Vousden KH. ","1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O 1998;140(1–2):19–24./O Ludwig/O RL,/O RL,/O RL,/O Bates/O S,/O S,/O Vousden/O Vousden/O Vousden/O KH./O KH./O KH./O"
Apoptosis experiments: 4T1 cells (1 × 10⁵  cells per well) were inoculated into 12-well plates. ,Apoptosis/O Apoptosis/O Apoptosis/O experiments:/O experiments:/O 4T1/O 4T1/O 4T1/O cells/O (1/O (1/O ×/O 10⁵/O 10⁵/O cells/O per/O well)/O well)/O were/O inoculated/O inoculated/O inoculated/O into/O 12-well/O 12-well/O 12-well/O plates./O plates./O
"References Article                            Google Scholar                  Ording AG, Heide-Jørgensen U, Christiansen CF, Nørgaard M, Acquavella J, Sørensen HT. ","References/O References/O Article/O Google/O Scholar/O Ording/O Ording/O AG,/O AG,/O Heide-Jørgensen/O Heide-Jørgensen/O Heide-Jørgensen/O Heide-Jørgensen/O Heide-Jørgensen/O Heide-Jørgensen/O Heide-Jørgensen/O U,/O U,/O Christiansen/O Christiansen/O CF,/O CF,/O Nørgaard/O Nørgaard/O Nørgaard/O Nørgaard/O M,/O M,/O Acquavella/O Acquavella/O Acquavella/O Acquavella/O Acquavella/O J,/O J,/O Sørensen/O Sørensen/O Sørensen/O Sørensen/O HT./O HT./O HT./O"
"  2. Materials and Methods   2.1. Cell Culture 4T1 (CRL-2539, ATCC Manassas, VA, USA), 4T1/luc (CRL-2539-LUC2, ATCC Manassas, VA, USA), MDA-MB-231 (HTB-26, ATCC Manassas, VA, USA) mouse or human triple-negative breast cancer cell lines, or NIH3T3 (CRL-1658, Manassas, VA, USA) mouse fibroblast cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM/Nacalai Tesque, Fushimi city, Kyoto, Japan) (26252-94, Nacalai Tesque, Fushimi city, Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS) (26140079, Thermo Fisher Scientific, Grand Island, NY, USA)) and 1% penicillin–streptomycin (26140079, Thermo Fisher Scientific, Grand Island, NY, USA). ","2./O 2./O Materials/O and/O Methods/O Methods/O 2.1./O 2.1./O 2.1./O 2.1./O Cell/O Culture/O 4T1/O 4T1/O 4T1/O (CRL-2539,/O (CRL-2539,/O (CRL-2539,/O (CRL-2539,/O (CRL-2539,/O (CRL-2539,/O (CRL-2539,/O ATCC/O ATCC/O Manassas,/O Manassas,/O Manassas,/O Manassas,/O VA,/O VA,/O USA),/O USA),/O USA),/O 4T1/luc/O 4T1/luc/O 4T1/luc/O 4T1/luc/O 4T1/luc/O 4T1/luc/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O (CRL-2539-LUC2,/O ATCC/O ATCC/O Manassas,/O Manassas,/O Manassas,/O Manassas,/O VA,/O VA,/O USA),/O USA),/O USA),/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O (HTB-26,/O (HTB-26,/O (HTB-26,/O (HTB-26,/O (HTB-26,/O (HTB-26,/O (HTB-26,/O ATCC/O ATCC/O Manassas,/O Manassas,/O Manassas,/O Manassas,/O VA,/O VA,/O USA)/O USA)/O mouse/O or/O human/O triple-negative/O triple-negative/O triple-negative/O breast/O cancer/O cell/O lines,/O lines,/O or/O NIH3T3/O NIH3T3/O NIH3T3/O NIH3T3/O NIH3T3/O NIH3T3/O (CRL-1658,/O (CRL-1658,/O (CRL-1658,/O (CRL-1658,/O (CRL-1658,/O (CRL-1658,/O (CRL-1658,/O Manassas,/O Manassas,/O Manassas,/O Manassas,/O VA,/O VA,/O USA)/O USA)/O mouse/O fibroblast/O fibroblast/O fibroblast/O cell/O lines/O were/O cultured/O cultured/O in/O Dulbecco’s/O Dulbecco’s/O Dulbecco’s/O Dulbecco’s/O Dulbecco’s/O Dulbecco’s/O modified/O Eagle’s/O Eagle’s/O Eagle’s/O medium/O (DMEM/Nacalai/O (DMEM/Nacalai/O (DMEM/Nacalai/O (DMEM/Nacalai/O (DMEM/Nacalai/O (DMEM/Nacalai/O (DMEM/Nacalai/O (DMEM/Nacalai/O Tesque,/O Tesque,/O Tesque,/O Fushimi/O Fushimi/O Fushimi/O city,/O city,/O Kyoto,/O Kyoto,/O Japan)/O Japan)/O (26252-94,/O (26252-94,/O (26252-94,/O (26252-94,/O (26252-94,/O (26252-94,/O (26252-94,/O Nacalai/O Nacalai/O Nacalai/O Tesque,/O Tesque,/O Tesque,/O Fushimi/O Fushimi/O Fushimi/O city,/O city,/O Kyoto,/O Kyoto,/O Japan)/O Japan)/O supplemented/O with/O 10%/O 10%/O fetal/O fetal/O bovine/O bovine/O bovine/O serum/O (FBS)/O (FBS)/O (FBS)/O (FBS)/O (26140079,/O (26140079,/O (26140079,/O (26140079,/O (26140079,/O (26140079,/O (26140079,/O Thermo/O Thermo/O Thermo/O Fisher/O Scientific,/O Scientific,/O Grand/O Island,/O Island,/O NY,/O NY,/O USA))/O USA))/O USA))/O and/O 1%/O 1%/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O penicillin–streptomycin/O (26140079,/O (26140079,/O (26140079,/O (26140079,/O (26140079,/O (26140079,/O (26140079,/O Thermo/O Thermo/O Thermo/O Fisher/O Scientific,/O Scientific,/O Grand/O Island,/O Island,/O NY,/O NY,/O USA)./O USA)./O USA)./O"
"We used the SuperScript TM  III First-Strand Synthesis System (18080051, Thermo Fisher Scientific, Grand Island, NY, USA) with RNase Inhibitor for synthesizing cDNA, and the Applied Biosystems Viia 7 (Thermo Fisher Scientific, Grand Island, NY, USA) was used for detection following the manufacturer’s instructions. ","We/O used/O the/O SuperScript/O SuperScript/O TM/O TM/O III/O First-Strand/O First-Strand/O First-Strand/O Synthesis/O Synthesis/O Synthesis/O System/O (18080051,/O (18080051,/O (18080051,/O (18080051,/O (18080051,/O Thermo/O Thermo/O Thermo/O Fisher/O Scientific,/O Scientific,/O Grand/O Island,/O Island,/O NY,/O NY,/O USA)/O USA)/O with/O RNase/O RNase/O RNase/O Inhibitor/O Inhibitor/O Inhibitor/O for/O synthesizing/O synthesizing/O synthesizing/O synthesizing/O cDNA,/O cDNA,/O cDNA,/O cDNA,/O and/O the/O Applied/O Biosystems/O Biosystems/O Biosystems/O Biosystems/O Biosystems/O Viia/O Viia/O Viia/O 7/O (Thermo/O (Thermo/O (Thermo/O (Thermo/O Fisher/O Scientific,/O Scientific,/O Grand/O Island,/O Island,/O NY,/O NY,/O USA)/O USA)/O was/O used/O for/O detection/O following/O the/O manufacturer’s/O manufacturer’s/O manufacturer’s/O instructions./O instructions./O"
Combination of trastuzumab with ADAM10 and γ-secretase inhibitors completely blocks p75HER2 production in both BT474 and SKBR3 cells. ,Combination/O Combination/O Combination/O of/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O with/O ADAM10/O ADAM10/O ADAM10/O and/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O inhibitors/O inhibitors/O completely/O blocks/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O production/O in/O both/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O
"Trastuzumab did not inhibit the dimerization and phosphorylation of HER2 in HER2+ BT474 and SKBR3 cells, however, trastuzumab inhibited the proliferation of these cells [ 72 ]. ","Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O did/O not/O inhibit/O inhibit/O the/O dimerization/O dimerization/O dimerization/O and/O phosphorylation/O phosphorylation/O phosphorylation/O phosphorylation/O phosphorylation/O of/O HER2/O HER2/O HER2/O in/O HER2+/O HER2+/O HER2+/O HER2+/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/O SKBR3/O cells,/O cells,/O however,/O however,/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O inhibited/O inhibited/O inhibited/O the/O proliferation/O of/O these/O cells/O [/O 72/O ]./O ]./O"
"  2. Materials and Methods   2.1. Cell Culture and Treatments MCF7, MDA-MB-231, SKBR3, BT474, MCF10, and 293T cell lines were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). ","2./O 2./O Materials/O and/O Methods/O Methods/O 2.1./O 2.1./O 2.1./O 2.1./O Cell/O Culture/O and/O Treatments/O Treatments/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O MDA-MB-231,/O SKBR3,/B-CellLine SKBR3,/O SKBR3,/O SKBR3,/O BT474,/B-CellLine BT474,/O BT474,/O BT474,/O MCF10,/B-CellLine MCF10,/O MCF10,/O MCF10,/O and/O 293T/O 293T/O 293T/O cell/O lines/O were/O purchased/O from/O American/O Type/O Culture/O Collection/O (ATCC;/O (ATCC;/O (ATCC;/O (ATCC;/O Manassas,/O Manassas,/O Manassas,/O Manassas,/O VA,/O VA,/O USA)./O USA)./O USA)./O"
"Here, we examined if trastuzumab binds to HER2-positive breast cancer cell lines including SKBR3, BT474, MCF7, and MDA-MB-231 by double immunofluorescence staining of HER2 and trastuzumab ( Figure 1 ). ","Here,/O Here,/O we/O examined/O if/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O binds/O to/O HER2-positive/O HER2-positive/O HER2-positive/O HER2-positive/O HER2-positive/O breast/O cancer/O cell/O lines/O including/O SKBR3,/B-CellLine SKBR3,/B-CellLine SKBR3,/O SKBR3,/O BT474,/B-CellLine BT474,/O BT474,/O BT474,/O MCF7,/B-CellLine MCF7,/O MCF7,/O MCF7,/O and/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O MDA-MB-231/O by/O double/O immunofluorescence/O immunofluorescence/O immunofluorescence/O immunofluorescence/O immunofluorescence/O immunofluorescence/O immunofluorescence/O staining/O staining/O of/O HER2/O HER2/O HER2/O and/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O (/O Figure/O 1/O )./O )./O"
MCF10A cells that do not express HER2 were used as a negative control. ,MCF10A/B-CellLine MCF10A/O MCF10A/O MCF10A/O cells/O that/O do/O not/O express/O HER2/O HER2/O HER2/O were/O used/O as/O a/O negative/O control./O control./O
"  3.2. Trastuzumab Inhibits Proliferation of HER2-Positive Breast Cancer Cells To investigate whether binding of trastuzumab to HER2 inhibits the proliferation of HER2-positive breast cancer cells, we treated SKBR3 and BT474 cell lines with 10 μg/mL trastuzumab for 5 days and monitored the cell proliferation levels by MTT assay. ","3.2./O 3.2./O 3.2./O 3.2./O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Inhibits/O Inhibits/O Inhibits/O Proliferation/O Proliferation/O Proliferation/O of/O HER2-Positive/O HER2-Positive/O HER2-Positive/O HER2-Positive/O HER2-Positive/O HER2-Positive/O Breast/O Breast/O Breast/O Cancer/O Cells/O Cells/O To/O investigate/O whether/O binding/O of/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O to/O HER2/O HER2/O HER2/O inhibits/O inhibits/O inhibits/O the/O proliferation/O of/O HER2-positive/O HER2-positive/O HER2-positive/O HER2-positive/O HER2-positive/O breast/O cancer/O cells,/O cells,/O we/O treated/O SKBR3/B-CellLine SKBR3/O SKBR3/O and/O BT474/B-CellLine BT474/O BT474/O cell/O lines/O with/O 10/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O for/O 5/O days/O and/O monitored/O the/O cell/O proliferation/O levels/O by/O MTT/O MTT/O assay./O assay./O assay./O"
"Cells treated with non-specific human IgG (10 μg/mL), cell cycle inhibitor vinorelbine (10 μM), and HER2 kinase inhibitor CP-714724 (10 μM) were used as mock control, anti-proliferative control, and HER2 inhibition control, respectively. ","Cells/O Cells/O treated/O with/O non-specific/O non-specific/O non-specific/O human/O IgG/O IgG/O IgG/O (10/O (10/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O cell/O cycle/O inhibitor/O vinorelbine/O vinorelbine/O vinorelbine/O vinorelbine/O (10/O (10/O μM),/O μM),/O μM),/O μM),/O and/O HER2/O HER2/O HER2/O kinase/O inhibitor/O CP-714724/O CP-714724/O CP-714724/B-CellLine CP-714724/B-CellLine CP-714724/O (10/O (10/O μM)/O μM)/O μM)/O were/O used/O as/O mock/O control,/O control,/O anti-proliferative/O anti-proliferative/O anti-proliferative/O anti-proliferative/O anti-proliferative/O control,/O control,/O and/O HER2/O HER2/O HER2/O inhibition/O inhibition/O control,/O control,/O respectively./O respectively./O"
As shown in  Figure 2  trastuzumab ( p  < 0.0001) as well as other HER2-targeting agents CP-714724 (  < 0.0001) and pertuzumab (  < 0.0001) significantly inhibited the proliferation of SKBR3 and BT474 cells but not 293T cells. ,As/O shown/O in/O Figure/O 2/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O (/O p/O </O 0.0001)/O 0.0001)/O 0.0001)/O 0.0001)/O 0.0001)/O as/O well/O as/O other/O HER2-targeting/O HER2-targeting/O HER2-targeting/O HER2-targeting/O HER2-targeting/O agents/O CP-714724/O CP-714724/O CP-714724/B-CellLine CP-714724/O CP-714724/O (/O </O 0.0001)/O 0.0001)/O 0.0001)/O 0.0001)/O 0.0001)/O and/O pertuzumab/O pertuzumab/O pertuzumab/O pertuzumab/O pertuzumab/O (/O </O 0.0001)/O 0.0001)/O 0.0001)/O 0.0001)/O 0.0001)/O significantly/O inhibited/O inhibited/O inhibited/O the/O proliferation/O of/O SKBR3/B-CellLine SKBR3/O SKBR3/O and/O BT474/B-CellLine BT474/O BT474/O cells/O but/O not/O 293T/O 293T/O 293T/O cells./O cells./O
We previously showed that trastuzumab did not inhibit the dimerization and phosphorylation of HER2 in HER2+ BT474 and SKBR3 cells [ ]. ,We/O previously/O showed/O that/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O did/O not/O inhibit/O inhibit/O the/O dimerization/O dimerization/O dimerization/O and/O phosphorylation/O phosphorylation/O phosphorylation/O phosphorylation/O phosphorylation/O of/O HER2/O HER2/O HER2/O in/O HER2+/O HER2+/O HER2+/O HER2+/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O [/O ]./O ]./O
Treatment with trastuzumab significantly decreased levels of both p75HER2 and p95 HER2 in SKBR3 and BT474 cell lines (   3.4. p75HER2 Is Cytosolic and Translocated to Nucleus Our results in   are consistent with a previous report that HER2 is proteolytically cleaved to generate an intracellular p75HER2 [ ]. ,Treatment/O with/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O significantly/O decreased/O levels/O of/O both/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O and/O p95/O p95/O p95/O HER2/O HER2/O HER2/O in/O SKBR3/B-CellLine SKBR3/O SKBR3/O and/O BT474/B-CellLine BT474/O BT474/O cell/O lines/O (/O 3.4./O 3.4./O 3.4./O 3.4./O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O Is/O Cytosolic/O Cytosolic/O Cytosolic/O and/O Translocated/O Translocated/O Translocated/O to/O Nucleus/O Nucleus/O Nucleus/O Nucleus/O Our/O results/O in/O are/O consistent/O with/O a/O previous/O report/O that/O HER2/O HER2/O HER2/O is/O proteolytically/O proteolytically/O proteolytically/O proteolytically/O cleaved/O cleaved/O cleaved/O to/O generate/O an/O intracellular/O intracellular/O intracellular/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O [/O ]./O ]./O
"The homogenates of both BT474 and SKBR3 cells were subcellular fractionated into the plasma membrane (PM), cytosolic (Cyt), and nuclear (Nu) fractions and lysed. ","The/O homogenates/O homogenates/O homogenates/O homogenates/O of/O both/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O were/O subcellular/O subcellular/O fractionated/O fractionated/O into/O the/O plasma/O membrane/O (PM),/O (PM),/O (PM),/O (PM),/O cytosolic/O cytosolic/O cytosolic/O cytosolic/O (Cyt),/O (Cyt),/O (Cyt),/O (Cyt),/O (Cyt),/O and/O nuclear/O (Nu)/O (Nu)/O (Nu)/O (Nu)/O fractions/O fractions/O and/O lysed./O lysed./O lysed./O lysed./O"
"Immunoblotting with anti-HER2 antibody (A2) showed that in both BT474 and SKBR3 cells, the full-length HER2 is only presented in the plasma membrane fraction; p75HER2 is mostly in the nuclear fraction, but also in the cytosolic fraction. ","Immunoblotting/O Immunoblotting/O Immunoblotting/O Immunoblotting/O Immunoblotting/O Immunoblotting/O with/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O antibody/O antibody/O (A2)/O (A2)/O (A2)/O showed/O that/O in/O both/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells,/O cells,/O the/O full-length/O full-length/O full-length/O HER2/O HER2/O HER2/O is/O only/O presented/O in/O the/O plasma/O membrane/O fraction;/O fraction;/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O mostly/O in/O the/O nuclear/O fraction,/O fraction,/O but/O also/O in/O the/O cytosolic/O cytosolic/O cytosolic/O cytosolic/O fraction./O fraction./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
Trastuzumab strongly reduces nuclear HER2 by inhibiting the cleavage of p75HER2.   3.5. Phosphorylation of p75HER2 and the Effects of Trastuzumab We next examined the phosphorylation status of p75HER2 by immunofluorescence in BT474 cells. ,Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O strongly/O reduces/O nuclear/O HER2/O HER2/O HER2/O by/O inhibiting/O inhibiting/O inhibiting/O the/O cleavage/O cleavage/O cleavage/O of/O p75HER2./O p75HER2./O p75HER2./O p75HER2./O p75HER2./O p75HER2./O 3.5./O 3.5./O 3.5./O 3.5./O Phosphorylation/O Phosphorylation/O Phosphorylation/O Phosphorylation/O Phosphorylation/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O and/O the/O Effects/O of/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O Trastuzumab/O We/O next/O examined/O the/O phosphorylation/O phosphorylation/O phosphorylation/O phosphorylation/O phosphorylation/O status/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunofluorescence/O immunofluorescence/O immunofluorescence/O immunofluorescence/O immunofluorescence/O immunofluorescence/O immunofluorescence/O in/O BT474/B-CellLine BT474/O BT474/O cells./O cells./O
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"Moreover, inhibition of γ-secretase increased the level of p95HER2 in BT474 cells ( ), which suggests that p75HER is generated by dual proteolytic cleavage ( ). ","Moreover,/O Moreover,/O inhibition/O inhibition/O of/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O increased/O the/O level/O of/O p95HER2/O p95HER2/O p95HER2/O p95HER2/O p95HER2/O p95HER2/O in/O BT474/B-CellLine BT474/O BT474/O cells/O (/O ),/O ),/O which/O suggests/O that/O p75HER/O p75HER/O p75HER/O p75HER/O is/O generated/O by/O dual/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavage/O cleavage/O cleavage/O (/O )./O )./O"
"The first cleavage generates p95HER2, which is then cleaved by γ-secretase to produce p75HER2. We then examined the effects of ADAM10 inhibitor and trastuzumab on the production of p75HER2. We treated BT474 cells with ADAM10 inhibitor GI254023X, γ-secretase inhibitor RO-4929097, and trastuzumab. ","The/O first/O cleavage/O cleavage/O cleavage/O generates/O p95HER2,/O p95HER2,/O p95HER2,/O p95HER2,/O p95HER2,/O p95HER2,/O p95HER2,/O which/O is/O then/O cleaved/O cleaved/O cleaved/O by/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O to/O produce/O p75HER2./O p75HER2./O p75HER2./O p75HER2./O p75HER2./O p75HER2./O We/O then/O examined/O the/O effects/O of/O ADAM10/O ADAM10/O ADAM10/O inhibitor/O and/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O on/O the/O production/O of/O p75HER2./O p75HER2./O p75HER2./O p75HER2./O p75HER2./O p75HER2./O We/O treated/O BT474/B-CellLine BT474/O BT474/O cells/O with/O ADAM10/O ADAM10/O ADAM10/O inhibitor/O GI254023X,/O GI254023X,/O GI254023X,/O GI254023X,/O GI254023X,/O GI254023X,/O GI254023X,/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O inhibitor/O RO-4929097,/O RO-4929097,/O RO-4929097,/O RO-4929097,/O RO-4929097,/O RO-4929097,/O RO-4929097,/O RO-4929097,/O RO-4929097,/O and/O trastuzumab./O trastuzumab./O trastuzumab./O trastuzumab./O trastuzumab./O trastuzumab./O trastuzumab./O"
"When expressed in MCF7 cells, GFP-tagged p75HER2 is mostly in the nucleus, the full-length HER2 in the PM, and ΔNLSp75HER2 in the cytosol ( Figure 9 ). ","When/O expressed/O in/O MCF7/B-CellLine MCF7/O MCF7/O cells,/O cells,/O GFP-tagged/O GFP-tagged/O GFP-tagged/O GFP-tagged/O GFP-tagged/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O mostly/O in/O the/O nucleus,/O nucleus,/O the/O full-length/O full-length/O full-length/O HER2/O HER2/O HER2/O in/O the/O PM,/O PM,/O and/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O in/O the/O cytosol/O cytosol/O cytosol/O cytosol/O (/O Figure/O 9/O )./O )./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"To test this, we treated BT474 and SKBR3 cells with ADAM10 inhibitor GI254023X and showed that GI254023X not only strongly inhibited the production of p95HER2, but also partially inhibited the production of p75HER2. However, the γ-secretase inhibitor RO-4929097 only blocked the production of p75HER2, not p95HER2 ( ). ","To/O test/O this,/O this,/O we/O treated/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O ADAM10/O ADAM10/O ADAM10/O inhibitor/O GI254023X/O GI254023X/O GI254023X/O GI254023X/O GI254023X/O GI254023X/O and/O showed/O that/O GI254023X/O GI254023X/O GI254023X/O GI254023X/O GI254023X/O GI254023X/O not/O only/O strongly/O inhibited/O inhibited/O inhibited/O the/O production/O of/O p95HER2,/O p95HER2,/O p95HER2,/O p95HER2,/O p95HER2,/O p95HER2,/O p95HER2,/O but/O also/O partially/O inhibited/O inhibited/O inhibited/O the/O production/O of/O p75HER2./O p75HER2./O p75HER2./O p75HER2./O p75HER2./O p75HER2./O However,/O However,/O the/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O inhibitor/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O only/O blocked/O the/O production/O of/O p75HER2,/O p75HER2,/O p75HER2,/O p75HER2,/O p75HER2,/O p75HER2,/O not/O p95HER2/O p95HER2/O p95HER2/O p95HER2/O p95HER2/O p95HER2/O (/O )./O )./O"
"When expressed in MCF7 cells, GFP-tagged p75HER2 is mostly in the nucleus ( ). ","When/O expressed/O in/O MCF7/B-CellLine MCF7/O MCF7/O cells,/O cells,/O GFP-tagged/O GFP-tagged/O GFP-tagged/O GFP-tagged/O GFP-tagged/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O mostly/O in/O the/O nucleus/O (/O )./O )./O"
"Indeed, we showed that applying both ADAM10 inhibitor G1254023X and γ-secretase inhibitor RO-4929097 together with trastuzumab resulted in the complete block of p75HER2 production in both BT474 and SKBR3 cells (","Indeed,/O Indeed,/O we/O showed/O that/O applying/O both/O ADAM10/O ADAM10/O ADAM10/O inhibitor/O G1254023X/O G1254023X/O G1254023X/O G1254023X/B-CellLine G1254023X/O G1254023X/O and/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O inhibitor/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O together/O with/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O resulted/O in/O the/O complete/O block/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O production/O in/O both/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/O SKBR3/O cells/O (/O"
"Binding of trastuzumab to HER2 in two CHO cell lines (CHO-K6 and CHO-K13) expressing HER2, breast cancer cell lines with high HER2 expression levels (SKBR3 and BT474), low HER2 expression levels (MCF7 and MDA-MB-231), and HER2-negative breast cell line (MCF10). ","Binding/O Binding/O of/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O to/O HER2/O HER2/O HER2/O in/O two/O CHO/O CHO/O cell/O lines/O (CHO-K6/O (CHO-K6/O (CHO-K6/O (CHO-K6/O (CHO-K6/O (CHO-K6/O and/O CHO-K13)/O CHO-K13)/O CHO-K13)/O CHO-K13)/O CHO-K13)/O CHO-K13)/O expressing/O HER2,/O HER2,/O HER2,/O HER2,/O breast/O cancer/O cell/O lines/O with/O high/O HER2/O HER2/O HER2/O expression/O levels/O (SKBR3/O (SKBR3/B-CellLine (SKBR3/O (SKBR3/O and/O BT474),/B-CellLine BT474),/O BT474),/O BT474),/O BT474),/O low/O HER2/O HER2/O HER2/O expression/O levels/O (MCF7/O (MCF7/B-CellLine (MCF7/O (MCF7/O and/O MDA-MB-231),/O MDA-MB-231),/O MDA-MB-231),/O MDA-MB-231),/O MDA-MB-231),/O MDA-MB-231),/O MDA-MB-231),/O MDA-MB-231),/O and/O HER2-negative/O HER2-negative/O HER2-negative/O HER2-negative/O HER2-negative/O breast/O cell/O line/O (MCF10)./O (MCF10)./B-CellLine (MCF10)./O (MCF10)./O (MCF10)./O (MCF10)./O"
"SKBR3, BT474, and 293T cells were treated with 10 μg/mL trastuzumab, pertuzumab, or their combination for 5 days, and then the cell proliferation was evaluated by MTT assay (absorbance at 540-nanometer wavelengths). ","SKBR3,/B-CellLine SKBR3,/O SKBR3,/O SKBR3,/O BT474,/B-CellLine BT474,/O BT474,/O BT474,/O and/O 293T/O 293T/O 293T/O cells/O were/O treated/O with/O 10/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O μg/mL/O trastuzumab,/O trastuzumab,/O trastuzumab,/O trastuzumab,/O trastuzumab,/O trastuzumab,/O trastuzumab,/O pertuzumab,/O pertuzumab,/O pertuzumab,/O pertuzumab,/O pertuzumab,/O pertuzumab,/O or/O their/O combination/O for/O 5/O days,/O days,/O and/O then/O the/O cell/O proliferation/O was/O evaluated/O by/O MTT/O MTT/O assay/O assay/O (absorbance/O (absorbance/O (absorbance/O at/O 540-nanometer/O 540-nanometer/O 540-nanometer/O 540-nanometer/O 540-nanometer/O wavelengths)./O wavelengths)./O wavelengths)./O wavelengths)./O"
"Ten micrograms/millilitres human IgG, 10 μM vinorelbine, and 10 μM CP-724714 were used as respectively mock, anti-proliferative, and HER2 inhibitor controls. ****:   < 0.0001. Figure 3.       Proteolytic cleavage of HER2 and its inhibition by trastuzumab ( A ) CHO-HER2 cells were treated with EGF and trastuzumab with various concentrations (0, 0.1, 0.5, 1, 5, and 10 μg/mL), and the cell lysates were immunoblotted with anti-HER2 antibody (A2). ( B ) BT474 and SKBR3 cells were treated with trastuzumab (10 μg/mL) or normal human IgG (μg/mL), and the cell lysates were immunoblotted with anti-HER2 antibody (A2). ( C ) the quantification of the data from ( ). **   < 0.01. Figure 4.       Nuclear localization of p75HER2 and its inhibition by trastuzumab. ( ) Subcellular fractionation to show the nuclear p75HER with or without trastuzumab (10 μg/mL). ","Ten/O micrograms/millilitres/O micrograms/millilitres/O micrograms/millilitres/O micrograms/millilitres/O micrograms/millilitres/O micrograms/millilitres/O micrograms/millilitres/O human/O IgG,/O IgG,/O IgG,/O IgG,/O 10/O μM/O μM/O vinorelbine,/O vinorelbine,/O vinorelbine,/O vinorelbine,/O vinorelbine,/O and/O 10/O μM/O μM/O CP-724714/O CP-724714/O CP-724714/O CP-724714/O CP-724714/O were/O used/O as/O respectively/O mock,/O mock,/O anti-proliferative,/O anti-proliferative,/O anti-proliferative,/O anti-proliferative,/O anti-proliferative,/O anti-proliferative,/O and/O HER2/O HER2/O HER2/O inhibitor/O controls./O controls./O ****:/O ****:/O ****:/O ****:/O ****:/O </O 0.0001./O 0.0001./O 0.0001./O 0.0001./O 0.0001./O Figure/O 3./O 3./O Proteolytic/O Proteolytic/O Proteolytic/O Proteolytic/O cleavage/O cleavage/O cleavage/O of/O HER2/O HER2/O HER2/O and/O its/O inhibition/O inhibition/O by/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O (/O A/O )/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells/O were/O treated/O with/O EGF/O EGF/O EGF/O and/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O with/O various/O concentrations/O (0,/O (0,/O (0,/O 0.1,/O 0.1,/O 0.1,/O 0.1,/O 0.5,/O 0.5,/O 0.5,/O 0.5,/O 1,/O 1,/O 5,/O 5,/O and/O 10/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O μg/mL),/O and/O the/O cell/O lysates/O lysates/O lysates/O were/O immunoblotted/O immunoblotted/O immunoblotted/O immunoblotted/O immunoblotted/O with/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O antibody/O antibody/O (A2)./O (A2)./O (A2)./O (A2)./O (/O B/O )/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/O SKBR3/O cells/O were/O treated/O with/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O (10/O (10/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O or/O normal/O human/O IgG/O IgG/O IgG/O (μg/mL),/O (μg/mL),/O (μg/mL),/O (μg/mL),/O (μg/mL),/O (μg/mL),/O (μg/mL),/O (μg/mL),/O and/O the/O cell/O lysates/O lysates/O lysates/O were/O immunoblotted/O immunoblotted/O immunoblotted/O immunoblotted/O immunoblotted/O with/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O anti-HER2/O antibody/O antibody/O (A2)./O (A2)./O (A2)./O (A2)./O (/O C/O )/O the/O quantification/O quantification/O quantification/O of/O the/O data/O from/O (/O )./O )./O **/O **/O </O 0.01./O 0.01./O 0.01./O 0.01./O Figure/O 4./O 4./O Nuclear/O localization/O localization/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O and/O its/O inhibition/O inhibition/O by/O trastuzumab./O trastuzumab./O trastuzumab./O trastuzumab./O trastuzumab./O trastuzumab./O trastuzumab./O (/O )/O Subcellular/O Subcellular/O fractionation/O fractionation/O to/O show/O the/O nuclear/O p75HER/O p75HER/O p75HER/O p75HER/O with/O or/O without/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O (10/O (10/O μg/mL)./O μg/mL)./O μg/mL)./O μg/mL)./O μg/mL)./O μg/mL)./O μg/mL)./O"
The nuclear localization of HER2 was expressed as the percentage of nuclear intensity out of the total cell intensity. **  Figure 5.       Phosphorylation of p75HER2 and the effects of trastuzumab on BT474 cells were treated with trastuzumab (10 μg/mL) or normal human IgG (10 μg/mL). ,The/O nuclear/O localization/O localization/O of/O HER2/O HER2/O HER2/O was/O expressed/O as/O the/O percentage/O of/O nuclear/O intensity/O out/O of/O the/O total/O cell/O intensity./O intensity./O **/O **/O Figure/O 5./O 5./O Phosphorylation/O Phosphorylation/O Phosphorylation/O Phosphorylation/O Phosphorylation/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O and/O the/O effects/O of/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O on/O BT474/B-CellLine BT474/O BT474/O cells/O were/O treated/O with/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O (10/O (10/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O or/O normal/O human/O IgG/O IgG/O IgG/O (10/O (10/O μg/mL)./O μg/mL)./O μg/mL)./O μg/mL)./O μg/mL)./O μg/mL)./O μg/mL)./O
"Each data point is the average of at least 3 repeats. *:   < 0.1; **:  Figure 8.       Effects of γ-secretase inhibitor RO-cj4929097, ADAM10 inhibitor G1254023X, and trastuzumab on the cleavage of HER2 to produce p75HER2 and p95HER2 in BT474 and SKBR3 cells. *   < 0.1, **  Figure 9.       p75HER2 is mitogenic. ( ) subcellular localization of GFP-tagged p75HER2, HER2, and ΔNLSp75HER2 in MCF-7 cells by fluorescence microscopy. ( ) MDA and MCF-7 cells were transfected with GFP-tagged p75HER2, HER2, and ΔNLSp75HER2. The cell proliferation with or without trastuzumab (10 μg/mL) treatment was revealed by MTT assay. ","Each/O data/O point/O is/O the/O average/O of/O at/O least/O 3/O repeats./O repeats./O *:/O *:/O </O 0.1;/O 0.1;/O 0.1;/O 0.1;/O **:/O **:/O **:/O Figure/O 8./O 8./O Effects/O of/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O inhibitor/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O RO-cj4929097,/O ADAM10/O ADAM10/O ADAM10/O inhibitor/O G1254023X,/O G1254023X,/O G1254023X,/O G1254023X,/O G1254023X,/O G1254023X,/O G1254023X,/O and/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O on/O the/O cleavage/O cleavage/O cleavage/O of/O HER2/O HER2/O HER2/O to/O produce/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O and/O p95HER2/O p95HER2/O p95HER2/O p95HER2/O p95HER2/O p95HER2/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/O SKBR3/O cells./O cells./O */O </O 0.1,/O 0.1,/O 0.1,/O 0.1,/O **/O **/O Figure/O 9./O 9./O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O mitogenic./O mitogenic./O mitogenic./O (/O )/O subcellular/O subcellular/O localization/O localization/O of/O GFP-tagged/O GFP-tagged/O GFP-tagged/O GFP-tagged/O GFP-tagged/O p75HER2,/O p75HER2,/O p75HER2,/O p75HER2,/O p75HER2,/O p75HER2,/O HER2,/O HER2,/O HER2,/O HER2,/O and/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O ΔNLSp75HER2/O in/O MCF-7/O MCF-7/O MCF-7/O MCF-7/O cells/O by/O fluorescence/O fluorescence/O fluorescence/O microscopy./O microscopy./O microscopy./O microscopy./O (/O )/O MDA/O MDA/O and/O MCF-7/O MCF-7/O MCF-7/O MCF-7/O cells/O were/O transfected/O transfected/O with/O GFP-tagged/O GFP-tagged/O GFP-tagged/O GFP-tagged/O GFP-tagged/O p75HER2,/O p75HER2,/O p75HER2,/O p75HER2,/O p75HER2,/O p75HER2,/O HER2,/O HER2,/O HER2,/O HER2,/O and/O ΔNLSp75HER2./O ΔNLSp75HER2./O ΔNLSp75HER2./O ΔNLSp75HER2./O ΔNLSp75HER2./O ΔNLSp75HER2./O ΔNLSp75HER2./O ΔNLSp75HER2./O ΔNLSp75HER2./O The/O cell/O proliferation/O with/O or/O without/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O (10/O (10/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O μg/mL)/O treatment/O was/O revealed/O by/O MTT/O MTT/O assay./O assay./O assay./O"
"Figure 10.       Inhibition of p75HER2 by the combination of GI254023X (5 μM), RO=4929097 (10 μM), and trastuzumab (10 μM) in BT474 and SKBR3 cells. ***,   < 0.001. Disclaimer/Publisher’s Note:  The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). ","Figure/O 10./O 10./O Inhibition/O Inhibition/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O the/O combination/O of/O GI254023X/O GI254023X/O GI254023X/O GI254023X/O GI254023X/O GI254023X/O (5/O (5/O μM),/O μM),/O μM),/O μM),/O RO=4929097/O RO=4929097/O RO=4929097/O RO=4929097/O RO=4929097/O RO=4929097/O RO=4929097/O RO=4929097/O (10/O (10/O μM),/O μM),/O μM),/O μM),/O and/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O trastuzumab/O (10/O (10/O μM)/O μM)/O μM)/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/O SKBR3/O cells./O cells./O ***,/O ***,/O ***,/O ***,/O </O 0.001./O 0.001./O 0.001./O 0.001./O 0.001./O Disclaimer/Publisher’s/O Disclaimer/Publisher’s/O Disclaimer/Publisher’s/O Disclaimer/Publisher’s/O Disclaimer/Publisher’s/O Disclaimer/Publisher’s/O Disclaimer/Publisher’s/O Note:/O Note:/O The/O statements,/O statements,/O opinions/O and/O data/O contained/O in/O all/O publications/O are/O solely/O those/O of/O the/O individual/O author(s)/O author(s)/O author(s)/O author(s)/O and/O contributor(s)/O contributor(s)/O contributor(s)/O contributor(s)/O and/O not/O of/O MDPI/O MDPI/O and/or/O and/or/O and/or/O the/O editor(s)./O editor(s)./O editor(s)./O editor(s)./O editor(s)./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"We stained BT474 and SKBR3 cells with two HER2 antibodies, one specific for the N-terminal HER2 (9G6) and one specific for the C-terminal HER2 (C18). ","We/O stained/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O with/O two/O HER2/O HER2/O HER2/O antibodies,/O antibodies,/O one/O specific/O for/O the/O N-terminal/O N-terminal/O N-terminal/O HER2/O HER2/O HER2/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O (9G6)/O and/O one/O specific/O for/O the/O C-terminal/O C-terminal/O C-terminal/O HER2/O HER2/O HER2/O (C18)./O (C18)./B-CellLine (C18)./O (C18)./O (C18)./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"To determine if HER2 signals through the RIP pathway, we first determined if p75HER2 is generated by two proteolytic cleavages of the full-length HER2. We inhibited γ-secretase in BT474 and SKBR3 cells by the chemical inhibitors RO-4929097 and LY411575 and then examined the production of p75HER2 by immunoblotting. ","To/O determine/O if/O HER2/O HER2/O HER2/O signals/O through/O the/O RIP/O RIP/O pathway,/O pathway,/O we/O first/O determined/O if/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O generated/O by/O two/O proteolytic/O proteolytic/O proteolytic/O proteolytic/O cleavages/O cleavages/O cleavages/O cleavages/O of/O the/O full-length/O full-length/O full-length/O HER2./O HER2./O HER2./O HER2./O We/O inhibited/O inhibited/O inhibited/O γ-secretase/O γ-secretase/O γ-secretase/O γ-secretase/O in/O BT474/B-CellLine BT474/O BT474/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells/O by/O the/O chemical/O inhibitors/O inhibitors/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O RO-4929097/O and/O LY411575/O LY411575/O LY411575/O LY411575/O LY411575/O and/O then/O examined/O the/O production/O of/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O by/O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O immunoblotting./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
"This p75HER2 is present in various cell lines, including CHO-HER2 cells, BT474 cells, and SKBR3 cells. ","This/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O p75HER2/O is/O present/O in/O various/O cell/O lines,/O lines,/O including/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O CHO-HER2/O cells,/O cells,/O BT474/B-CellLine BT474/B-CellLine BT474/O cells,/O cells,/O and/O SKBR3/B-CellLine SKBR3/B-CellLine SKBR3/O cells./O cells./O"
